{"959f0fb1f8856d5883e5b217889821b0928589b7": [["CoV-2 coronavirus, subsequently spread exponentially across the globe.", [["CoV-2 coronavirus", "ORGANISM", 0, 17], ["CoV-2 coronavirus", "SPECIES", 0, 17], ["CoV-2 coronavirus", "SPECIES", 0, 17], ["CoV", "TEST", 0, 3], ["2 coronavirus", "PROBLEM", 4, 17], ["coronavirus", "OBSERVATION", 6, 17], ["spread", "OBSERVATION_MODIFIER", 32, 38], ["exponentially", "OBSERVATION_MODIFIER", 39, 52], ["globe", "ANATOMY", 64, 69]]], ["Both scientists and the general public have been eager to receive any new information about this disease, which has affected and caused the deaths of so many people, especially among the most frail population groups.", [["deaths", "DISEASE", 140, 146], ["people", "ORGANISM", 158, 164], ["people", "SPECIES", 158, 164], ["this disease", "PROBLEM", 92, 104]]]], "151a04d55fe00b5c47927d142d442ebbb45ba7e5": [["a b s t r a c tAcute cough is a major symptom of viral respiratory tract infection and causes excessive morbidity in human populations across the world.", [["respiratory tract", "ANATOMY", 55, 72], ["cough", "DISEASE", 21, 26], ["viral respiratory tract infection", "DISEASE", 49, 82], ["human", "ORGANISM", 117, 122], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 117, 122], ["tAcute cough", "PROBLEM", 14, 26], ["viral respiratory tract infection", "PROBLEM", 49, 82], ["excessive morbidity in human populations", "PROBLEM", 94, 134], ["viral", "OBSERVATION_MODIFIER", 49, 54], ["respiratory tract infection", "OBSERVATION", 55, 82], ["excessive", "OBSERVATION_MODIFIER", 94, 103], ["morbidity", "OBSERVATION", 104, 113]]], ["A wide variety of viruses play a role in the development of cough after acute infection and all of these manifest a similar clinical picture across different age groups.", [["cough", "DISEASE", 60, 65], ["acute infection", "DISEASE", 72, 87], ["A wide variety of viruses", "PROBLEM", 0, 25], ["cough", "PROBLEM", 60, 65], ["acute infection", "PROBLEM", 72, 87], ["wide", "OBSERVATION_MODIFIER", 2, 6], ["viruses", "OBSERVATION", 18, 25], ["cough", "OBSERVATION", 60, 65], ["acute", "OBSERVATION_MODIFIER", 72, 77], ["infection", "OBSERVATION", 78, 87]]], ["Despite the large disease burden surprisingly little is known about the mechanism of acute cough following viral infection.", [["cough", "DISEASE", 91, 96], ["viral infection", "DISEASE", 107, 122], ["the large disease burden", "PROBLEM", 8, 32], ["acute cough", "PROBLEM", 85, 96], ["viral infection", "PROBLEM", 107, 122], ["large", "OBSERVATION_MODIFIER", 12, 17], ["disease", "OBSERVATION", 18, 25], ["acute", "OBSERVATION_MODIFIER", 85, 90], ["cough", "OBSERVATION", 91, 96], ["viral", "OBSERVATION_MODIFIER", 107, 112], ["infection", "OBSERVATION", 113, 122]]], ["Both in vitro and in vivo experiments show that increased production of neuropeptides and leukotrienes mediate cough after viral infection, along with altered expression of neural receptors.", [["neural", "ANATOMY", 173, 179], ["leukotrienes", "CHEMICAL", 90, 102], ["cough", "DISEASE", 111, 116], ["viral infection", "DISEASE", 123, 138], ["leukotrienes", "SIMPLE_CHEMICAL", 90, 102], ["neural receptors", "PROTEIN", 173, 189], ["increased production of neuropeptides", "PROBLEM", 48, 85], ["leukotrienes mediate cough", "PROBLEM", 90, 116], ["viral infection", "PROBLEM", 123, 138], ["altered expression of neural receptors", "PROBLEM", 151, 189], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["viral", "OBSERVATION_MODIFIER", 123, 128], ["infection", "OBSERVATION", 129, 138], ["neural receptors", "OBSERVATION", 173, 189]]], ["Increased airway mucus production is also likely to play a significant role.", [["airway mucus", "ANATOMY", 10, 22], ["airway mucus", "MULTI-TISSUE_STRUCTURE", 10, 22], ["Increased airway mucus production", "PROBLEM", 0, 33], ["airway", "ANATOMY", 10, 16], ["mucus production", "OBSERVATION", 17, 33]]], ["Following the recent development of a mouse model for rhinovirus infection and the establishment of experimental models of rhinovirus challenge in human subjects with both asthma and COPD the field is expanding to translate in vitro research into clinical studies and hopefully eventually into clinical practice.", [["rhinovirus infection", "DISEASE", 54, 74], ["rhinovirus challenge", "DISEASE", 123, 143], ["asthma", "DISEASE", 172, 178], ["COPD", "DISEASE", 183, 187], ["mouse", "ORGANISM", 38, 43], ["rhinovirus", "ORGANISM", 54, 64], ["rhinovirus", "ORGANISM", 123, 133], ["human", "ORGANISM", 147, 152], ["mouse", "SPECIES", 38, 43], ["human", "SPECIES", 147, 152], ["mouse", "SPECIES", 38, 43], ["rhinovirus", "SPECIES", 54, 64], ["human", "SPECIES", 147, 152], ["rhinovirus infection", "PROBLEM", 54, 74], ["rhinovirus challenge", "TREATMENT", 123, 143], ["both asthma", "PROBLEM", 167, 178], ["COPD the field", "PROBLEM", 183, 197], ["clinical studies", "TEST", 247, 263], ["rhinovirus", "OBSERVATION", 54, 64], ["rhinovirus", "OBSERVATION", 123, 133], ["asthma", "OBSERVATION", 172, 178], ["COPD", "OBSERVATION", 183, 187]]], ["Developing a clearer understanding of the mechanisms underlying virus induced cough may lead to more specific and effective therapies.a b s t r a c t\u00d3 2009 Elsevier Ltd.", [["cough", "DISEASE", 78, 83], ["underlying virus induced cough", "PROBLEM", 53, 83], ["virus", "OBSERVATION", 64, 69]]], ["All rights reserved.Common respiratory viral infectionsUpper respiratory tract infection (URTI) is the most common illness for which patients seek medical attention and cough is the most frequent symptom presenting to general practitioners [1] .", [["respiratory viral infections", "DISEASE", 27, 55], ["Upper respiratory tract infection", "DISEASE", 55, 88], ["URTI", "DISEASE", 90, 94], ["cough", "DISEASE", 169, 174], ["tract", "ORGANISM_SUBDIVISION", 73, 78], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141], ["Common respiratory viral infections", "PROBLEM", 20, 55], ["Upper respiratory tract infection", "PROBLEM", 55, 88], ["cough", "PROBLEM", 169, 174], ["respiratory", "ANATOMY", 27, 38], ["viral infections", "OBSERVATION", 39, 55], ["Upper", "ANATOMY_MODIFIER", 55, 60], ["respiratory tract", "ANATOMY", 61, 78], ["infection", "OBSERVATION", 79, 88]]], ["Causing excessive morbidity in human populations across the world, URTI resulted in an estimated 84 million consultations in the United States during one year alone [2] .", [["URTI", "DISEASE", 67, 71], ["human", "ORGANISM", 31, 36], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["excessive morbidity in human populations", "PROBLEM", 8, 48], ["URTI", "PROBLEM", 67, 71], ["excessive", "OBSERVATION_MODIFIER", 8, 17], ["morbidity", "OBSERVATION", 18, 27]]], ["There are no effective anti-viral therapies for most URTIs yet Americans spend US$2.9 billion a year on over the counter cold remedies.", [["URTIs", "DISEASE", 53, 58], ["effective anti-viral therapies", "TREATMENT", 13, 43], ["the counter cold remedies", "TREATMENT", 109, 134], ["no", "UNCERTAINTY", 10, 12], ["effective", "OBSERVATION_MODIFIER", 13, 22], ["anti-viral therapies", "OBSERVATION", 23, 43]]], ["Although generally self limiting, symptoms of cough often persist up to 3 weeks following viral infection [4] .", [["cough", "DISEASE", 46, 51], ["viral infection", "DISEASE", 90, 105], ["symptoms", "PROBLEM", 34, 42], ["cough", "PROBLEM", 46, 51], ["viral infection", "PROBLEM", 90, 105], ["self limiting", "OBSERVATION_MODIFIER", 19, 32], ["cough", "OBSERVATION", 46, 51], ["infection", "OBSERVATION", 96, 105]]], ["Additionally a subgroup of patients can develop a chronic cough with symptoms being more prolonged and lasting months or years.Common respiratory viral infectionsAcute coryza, the common cold, is primarily caused by viruses in the picornavirus and coronavirus families.", [["cough", "DISEASE", 58, 63], ["respiratory viral infections", "DISEASE", 134, 162], ["patients", "ORGANISM", 27, 35], ["coronavirus", "ORGANISM", 248, 259], ["patients", "SPECIES", 27, 35], ["coronavirus", "SPECIES", 248, 259], ["a chronic cough", "PROBLEM", 48, 63], ["symptoms", "PROBLEM", 69, 77], ["Common respiratory viral infections", "PROBLEM", 127, 162], ["Acute coryza", "PROBLEM", 162, 174], ["the common cold", "PROBLEM", 176, 191], ["viruses in the picornavirus", "PROBLEM", 216, 243], ["chronic", "OBSERVATION_MODIFIER", 50, 57], ["cough", "OBSERVATION", 58, 63], ["prolonged", "OBSERVATION_MODIFIER", 89, 98], ["respiratory", "ANATOMY", 134, 145], ["viral infections", "OBSERVATION", 146, 162], ["coryza", "OBSERVATION", 168, 174], ["common cold", "ANATOMY", 180, 191], ["viruses", "OBSERVATION", 216, 223], ["picornavirus", "OBSERVATION", 231, 243]]], ["Many other aetiological agents have been identified, however, including human metapneumovirus (HMPV), parainfluenza, influenza A&B and respiratory syncytial viruses (RSV).", [["human metapneumovirus (HMPV)", "DISEASE", 72, 100], ["parainfluenza", "DISEASE", 102, 115], ["influenza A&B", "DISEASE", 117, 130], ["respiratory syncytial viruses", "DISEASE", 135, 164], ["RSV", "DISEASE", 166, 169], ["human metapneumovirus", "ORGANISM", 72, 93], ["HMPV", "ORGANISM", 95, 99], ["parainfluenza", "ORGANISM", 102, 115], ["influenza A&B", "ORGANISM", 117, 130], ["respiratory syncytial viruses", "ORGANISM", 135, 164], ["RSV", "ORGANISM", 166, 169], ["human", "SPECIES", 72, 77], ["metapneumovirus", "SPECIES", 78, 93], ["parainfluenza", "SPECIES", 102, 115], ["human metapneumovirus", "SPECIES", 72, 93], ["HMPV", "SPECIES", 95, 99], ["respiratory syncytial viruses", "SPECIES", 135, 164], ["RSV", "SPECIES", 166, 169], ["human metapneumovirus (HMPV", "PROBLEM", 72, 99], ["parainfluenza", "PROBLEM", 102, 115], ["influenza", "PROBLEM", 117, 126], ["respiratory syncytial viruses", "PROBLEM", 135, 164], ["respiratory", "ANATOMY", 135, 146], ["syncytial viruses", "OBSERVATION", 147, 164]]], ["Clinically the identification of virus type is of minimal significance as all produce similar symptoms of nasopharyngitis and cough.", [["nasopharyngitis", "DISEASE", 106, 121], ["cough", "DISEASE", 126, 131], ["virus type", "PROBLEM", 33, 43], ["nasopharyngitis", "PROBLEM", 106, 121], ["cough", "PROBLEM", 126, 131], ["virus type", "OBSERVATION", 33, 43], ["minimal", "OBSERVATION_MODIFIER", 50, 57], ["nasopharyngitis", "OBSERVATION", 106, 121], ["cough", "OBSERVATION", 126, 131]]], ["The future development of specific anti-viral therapies however will necessitate accurate viral identification which at present is only performed in a research setting.AgeCough in healthy subjects due to respiratory viral infection is a common symptom in childhood and falls in frequency during adult life.", [["respiratory viral infection", "DISEASE", 204, 231], ["specific anti-viral therapies", "TREATMENT", 26, 55], ["accurate viral identification", "TEST", 81, 110], ["respiratory viral infection", "PROBLEM", 204, 231], ["a common symptom", "PROBLEM", 235, 251], ["anti-viral therapies", "OBSERVATION", 35, 55], ["respiratory", "ANATOMY", 204, 215], ["viral infection", "OBSERVATION", 216, 231]]], ["A prospective study following 197 children during their first year of life aimed to define the aetiology of respiratory tract infections [5] .", [["respiratory tract", "ANATOMY", 108, 125], ["respiratory tract infections", "DISEASE", 108, 136], ["children", "ORGANISM", 34, 42], ["respiratory tract", "ORGANISM_SUBDIVISION", 108, 125], ["children", "SPECIES", 34, 42], ["A prospective study", "TEST", 0, 19], ["respiratory tract infections", "PROBLEM", 108, 136], ["respiratory tract", "ANATOMY", 108, 125]]], ["Weekly symptom recording demonstrated that 62% of infants developed URTI and amongst these a virus was identified in 79% -predominantly rhinoviruses (23%) and coronaviruses (18%).", [["URTI", "DISEASE", 68, 72], ["rhinoviruses", "DISEASE", 136, 148], ["coronaviruses", "DISEASE", 159, 172], ["infants", "ORGANISM", 50, 57], ["rhinoviruses", "ORGANISM", 136, 148], ["coronaviruses", "ORGANISM", 159, 172], ["infants", "SPECIES", 50, 57], ["Weekly symptom recording", "TEST", 0, 24], ["URTI", "PROBLEM", 68, 72], ["a virus", "PROBLEM", 91, 98], ["rhinoviruses", "PROBLEM", 136, 148], ["coronaviruses", "TEST", 159, 172], ["virus", "OBSERVATION", 93, 98], ["predominantly", "OBSERVATION_MODIFIER", 122, 135], ["rhinoviruses", "OBSERVATION", 136, 148]]], ["All 112 infants who had an acute viral infection developed cough, demonstrating the significance of this symptom in childhood.AgeAcute cough in healthy adults is almost exclusively associated with respiratory tract infection.", [["respiratory tract", "ANATOMY", 197, 214], ["viral infection", "DISEASE", 33, 48], ["cough", "DISEASE", 59, 64], ["cough", "DISEASE", 135, 140], ["respiratory tract infection", "DISEASE", 197, 224], ["infants", "ORGANISM", 8, 15], ["respiratory tract", "ORGANISM_SUBDIVISION", 197, 214], ["infants", "SPECIES", 8, 15], ["an acute viral infection", "PROBLEM", 24, 48], ["cough", "PROBLEM", 59, 64], ["this symptom", "PROBLEM", 100, 112], ["AgeAcute cough in healthy adults", "PROBLEM", 126, 158], ["respiratory tract infection", "PROBLEM", 197, 224], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["viral", "OBSERVATION_MODIFIER", 33, 38], ["infection", "OBSERVATION", 39, 48], ["cough", "OBSERVATION", 59, 64], ["cough", "OBSERVATION", 135, 140], ["respiratory tract", "ANATOMY", 197, 214], ["infection", "OBSERVATION", 215, 224]]], ["A gender related difference in both acute and chronic cough has been identified; amongst women the incidence of cough is higher with more presentations to medical care providers and a lower cough threshold to provocation tests [1, 6] .", [["cough", "DISEASE", 54, 59], ["cough", "DISEASE", 112, 117], ["women", "ORGANISM", 89, 94], ["women", "SPECIES", 89, 94], ["both acute and chronic cough", "PROBLEM", 31, 59], ["cough", "PROBLEM", 112, 117], ["a lower cough threshold", "PROBLEM", 182, 205], ["provocation tests", "TEST", 209, 226], ["difference", "OBSERVATION_MODIFIER", 17, 27], ["both", "OBSERVATION_MODIFIER", 31, 35], ["acute", "OBSERVATION_MODIFIER", 36, 41], ["chronic", "OBSERVATION_MODIFIER", 46, 53], ["cough", "OBSERVATION", 54, 59], ["cough", "OBSERVATION", 112, 117]]], ["This has been confirmed with objective cough monitoring [7] and is found in both acute and chronic cough.Asthma exacerbationsUsing sensitive molecular techniques it is possible to detect viruses in the majority of asthma exacerbations.", [["cough", "DISEASE", 99, 104], ["Asthma", "DISEASE", 105, 111], ["asthma", "DISEASE", 214, 220], ["objective cough monitoring", "TEST", 29, 55], ["chronic cough", "PROBLEM", 91, 104], ["Asthma exacerbations", "PROBLEM", 105, 125], ["viruses", "PROBLEM", 187, 194], ["asthma exacerbations", "PROBLEM", 214, 234], ["acute", "OBSERVATION_MODIFIER", 81, 86], ["chronic", "OBSERVATION_MODIFIER", 91, 98], ["cough", "OBSERVATION", 99, 104], ["viruses", "OBSERVATION", 187, 194], ["asthma", "OBSERVATION", 214, 220]]], ["In children 85% of exacerbations were associated with a virus [8] and 75% of exacerbations in adults [9] .", [["exacerbations", "DISEASE", 19, 32], ["exacerbations", "DISEASE", 77, 90], ["children", "ORGANISM", 3, 11], ["children", "SPECIES", 3, 11], ["exacerbations", "PROBLEM", 19, 32], ["a virus", "PROBLEM", 54, 61], ["exacerbations in adults", "PROBLEM", 77, 100], ["exacerbations", "OBSERVATION", 77, 90]]], ["Rhinoviruses are consistently the most frequent virus types detected, found in around two-thirds of cases where a virus is identified.", [["Rhinoviruses", "GENE_OR_GENE_PRODUCT", 0, 12], ["Rhinoviruses", "PROBLEM", 0, 12], ["frequent virus types", "PROBLEM", 39, 59], ["a virus", "PROBLEM", 112, 119], ["most frequent", "OBSERVATION_MODIFIER", 34, 47], ["virus", "OBSERVATION", 48, 53], ["virus", "OBSERVATION", 114, 119]]], ["The exact mechanism through which virus infection triggers exacerbations of airway disease is still unclear, but is likely to represent a constellation of host immune responses and specific viral actions.", [["airway", "ANATOMY", 76, 82], ["infection", "DISEASE", 40, 49], ["airway disease", "DISEASE", 76, 90], ["airway", "MULTI-TISSUE_STRUCTURE", 76, 82], ["virus infection", "PROBLEM", 34, 49], ["airway disease", "PROBLEM", 76, 90], ["host immune responses", "PROBLEM", 155, 176], ["airway", "ANATOMY", 76, 82], ["disease", "OBSERVATION", 83, 90], ["likely to represent", "UNCERTAINTY", 116, 135]]], ["Infection of respiratory epithelium leads to a cascade of pro-inflammatory cytokines which recruit and activate immune cells in the airway.", [["respiratory epithelium", "ANATOMY", 13, 35], ["immune cells", "ANATOMY", 112, 124], ["airway", "ANATOMY", 132, 138], ["respiratory epithelium", "TISSUE", 13, 35], ["immune cells", "CELL", 112, 124], ["airway", "MULTI-TISSUE_STRUCTURE", 132, 138], ["pro-inflammatory cytokines", "PROTEIN", 58, 84], ["immune cells", "CELL_TYPE", 112, 124], ["Infection of respiratory epithelium", "PROBLEM", 0, 35], ["pro-inflammatory cytokines", "PROBLEM", 58, 84], ["activate immune cells in the airway", "PROBLEM", 103, 138], ["respiratory epithelium", "OBSERVATION", 13, 35], ["pro-inflammatory cytokines", "OBSERVATION", 58, 84], ["immune cells", "OBSERVATION", 112, 124], ["airway", "ANATOMY", 132, 138]]], ["Mucus hypersecretion following virus infection is likely to be a key factor in airway obstruction and cough in the aetiology of airway disease exacerbations [10] .Asthma exacerbationsIt has been postulated that asthmatic patients are more susceptible to virus infections, a longitudinal cohort study found that asthmatics were not at an increased risk of developing rhinovirus infection but did develop longer lasting and more severe lower respiratory tract symptoms when infected than healthy controls [9] .Asthma exacerbationsReduced antiviral activity in asthmatic subjects may account for this; a recent study found peripheral blood monocytes from asthmatics exposed to rhinovirus were deficient in production of interferon-gamma (IFN-g) and interleukin-12 (IL-12) compared to normal subjects [11] .", [["Mucus", "ANATOMY", 0, 5], ["airway", "ANATOMY", 79, 85], ["airway", "ANATOMY", 128, 134], ["lower respiratory tract", "ANATOMY", 434, 457], ["peripheral blood monocytes", "ANATOMY", 620, 646], ["Mucus hypersecretion", "DISEASE", 0, 20], ["infection", "DISEASE", 37, 46], ["airway obstruction", "DISEASE", 79, 97], ["cough", "DISEASE", 102, 107], ["airway disease", "DISEASE", 128, 142], ["Asthma", "DISEASE", 163, 169], ["asthmatic", "DISEASE", 211, 220], ["infections", "DISEASE", 260, 270], ["rhinovirus infection", "DISEASE", 366, 386], ["lower respiratory tract symptoms", "DISEASE", 434, 466], ["Asthma", "DISEASE", 508, 514], ["Mucus", "ORGANISM_SUBSTANCE", 0, 5], ["airway", "MULTI-TISSUE_STRUCTURE", 79, 85], ["airway", "MULTI-TISSUE_STRUCTURE", 128, 134], ["patients", "ORGANISM", 221, 229], ["asthmatics", "ORGANISM", 311, 321], ["rhinovirus", "ORGANISM", 366, 376], ["lower", "ORGANISM_SUBDIVISION", 434, 439], ["respiratory tract", "ORGANISM_SUBDIVISION", 440, 457], ["peripheral blood monocytes", "ORGANISM_SUBSTANCE", 620, 646], ["asthmatics", "ORGANISM", 652, 662], ["rhinovirus", "ORGANISM", 674, 684], ["interferon-gamma", "GENE_OR_GENE_PRODUCT", 717, 733], ["IFN-g", "GENE_OR_GENE_PRODUCT", 735, 740], ["interleukin-12", "GENE_OR_GENE_PRODUCT", 746, 760], ["IL-12", "GENE_OR_GENE_PRODUCT", 762, 767], ["peripheral blood monocytes", "CELL_TYPE", 620, 646], ["interferon-gamma", "PROTEIN", 717, 733], ["IFN", "PROTEIN", 735, 738], ["interleukin-12", "PROTEIN", 746, 760], ["IL", "PROTEIN", 762, 764], ["patients", "SPECIES", 221, 229], ["Mucus hypersecretion", "PROBLEM", 0, 20], ["virus infection", "PROBLEM", 31, 46], ["airway obstruction", "PROBLEM", 79, 97], ["cough", "PROBLEM", 102, 107], ["airway disease exacerbations", "PROBLEM", 128, 156], ["Asthma exacerbations", "PROBLEM", 163, 183], ["asthmatic patients", "PROBLEM", 211, 229], ["virus infections", "PROBLEM", 254, 270], ["a longitudinal cohort study", "TEST", 272, 299], ["asthmatics", "PROBLEM", 311, 321], ["developing rhinovirus infection", "PROBLEM", 355, 386], ["more severe lower respiratory tract symptoms", "PROBLEM", 422, 466], ["Asthma exacerbations", "PROBLEM", 508, 528], ["Reduced antiviral activity in asthmatic subjects", "PROBLEM", 528, 576], ["a recent study", "TEST", 599, 613], ["peripheral blood monocytes", "PROBLEM", 620, 646], ["asthmatics", "PROBLEM", 652, 662], ["rhinovirus", "PROBLEM", 674, 684], ["interferon", "TREATMENT", 717, 727], ["IFN", "TEST", 735, 738], ["interleukin", "TEST", 746, 757], ["IL", "TEST", 762, 764], ["hypersecretion", "OBSERVATION", 6, 20], ["likely to be", "UNCERTAINTY", 50, 62], ["airway", "ANATOMY", 79, 85], ["obstruction", "OBSERVATION", 86, 97], ["cough", "OBSERVATION", 102, 107], ["airway", "ANATOMY", 128, 134], ["disease", "OBSERVATION", 135, 142], ["asthmatic", "OBSERVATION", 211, 220], ["asthmatics", "OBSERVATION", 311, 321], ["rhinovirus", "OBSERVATION", 366, 376], ["severe", "OBSERVATION_MODIFIER", 427, 433], ["lower", "OBSERVATION_MODIFIER", 434, 439], ["respiratory tract", "ANATOMY", 440, 457], ["antiviral activity", "OBSERVATION", 536, 554], ["may account for", "UNCERTAINTY", 577, 592], ["peripheral", "ANATOMY_MODIFIER", 620, 630], ["blood monocytes", "ANATOMY", 631, 646], ["rhinovirus", "OBSERVATION", 674, 684]]], ["Following experimental infection deficient induction of Th1 cytokines and IL-10 was demonstrated with augmented induction of Th2 cytokines in asthmatic subjects [12] ; additionally the model demonstrated deficient levels of IFN-l (lambda) in primary bronchial epithelial cells and alveolar macrophages which correlated with the severity of both exacerbation and virus load [13] .COPD exacerbationsThe aetiological role of viruses in exacerbations of COPD is becoming increasingly clear.", [["primary bronchial epithelial cells", "ANATOMY", 242, 276], ["alveolar macrophages", "ANATOMY", 281, 301], ["infection", "DISEASE", 23, 32], ["COPD", "DISEASE", 379, 383], ["COPD", "DISEASE", 450, 454], ["IL-10", "GENE_OR_GENE_PRODUCT", 74, 79], ["IFN-l", "GENE_OR_GENE_PRODUCT", 224, 229], ["lambda", "GENE_OR_GENE_PRODUCT", 231, 237], ["bronchial epithelial cells", "CELL", 250, 276], ["alveolar macrophages", "CELL", 281, 301], ["Th1 cytokines", "PROTEIN", 56, 69], ["IL-10", "PROTEIN", 74, 79], ["Th2 cytokines", "PROTEIN", 125, 138], ["IFN-l (lambda)", "PROTEIN", 224, 238], ["primary bronchial epithelial cells", "CELL_TYPE", 242, 276], ["alveolar macrophages", "CELL_TYPE", 281, 301], ["experimental infection deficient induction", "TREATMENT", 10, 52], ["Th1 cytokines and IL", "TREATMENT", 56, 76], ["Th2 cytokines", "TEST", 125, 138], ["asthmatic subjects", "PROBLEM", 142, 160], ["the model", "TEST", 181, 190], ["deficient levels", "PROBLEM", 204, 220], ["IFN", "TEST", 224, 227], ["primary bronchial epithelial cells", "PROBLEM", 242, 276], ["alveolar macrophages", "PROBLEM", 281, 301], ["both exacerbation", "PROBLEM", 340, 357], ["virus load", "PROBLEM", 362, 372], ["COPD exacerbations", "PROBLEM", 379, 397], ["viruses", "PROBLEM", 422, 429], ["COPD", "PROBLEM", 450, 454], ["infection", "OBSERVATION", 23, 32], ["deficient", "OBSERVATION", 204, 213], ["bronchial", "ANATOMY", 250, 259], ["epithelial cells", "OBSERVATION", 260, 276], ["alveolar macrophages", "OBSERVATION", 281, 301], ["both", "OBSERVATION_MODIFIER", 340, 344], ["exacerbation", "OBSERVATION", 345, 357], ["viruses", "OBSERVATION", 422, 429], ["COPD", "OBSERVATION", 450, 454], ["increasingly", "OBSERVATION_MODIFIER", 467, 479], ["clear", "OBSERVATION", 480, 485]]], ["Infection can be identified in the majority of exacerbations; in one study 78% of exacerbations were associated with infection and these were more severe resulting in greater drops in lung function and prolonged hospitalisation compared to non-infective exacerbations [14] .", [["lung", "ANATOMY", 184, 188], ["Infection", "DISEASE", 0, 9], ["exacerbations", "DISEASE", 82, 95], ["infection", "DISEASE", 117, 126], ["lung", "ORGAN", 184, 188], ["Infection", "PROBLEM", 0, 9], ["exacerbations", "PROBLEM", 47, 60], ["one study", "TEST", 65, 74], ["exacerbations", "PROBLEM", 82, 95], ["infection", "PROBLEM", 117, 126], ["greater drops in lung function", "PROBLEM", 167, 197], ["prolonged hospitalisation", "PROBLEM", 202, 227], ["non-infective exacerbations", "PROBLEM", 240, 267], ["majority", "OBSERVATION_MODIFIER", 35, 43], ["exacerbations", "OBSERVATION", 47, 60], ["infection", "OBSERVATION", 117, 126], ["greater", "OBSERVATION_MODIFIER", 167, 174], ["drops", "OBSERVATION_MODIFIER", 175, 180], ["lung", "ANATOMY", 184, 188]]], ["Viruses are detected in 39-56% of exacerbations [15, 16] but this is likely to represent an underestimate as 65% of subjects reported symptoms of a cold prior to exacerbation [16] .", [["exacerbations", "DISEASE", 34, 47], ["Viruses", "PROBLEM", 0, 7], ["exacerbations", "PROBLEM", 34, 47], ["symptoms", "PROBLEM", 134, 142], ["a cold prior to exacerbation", "PROBLEM", 146, 174], ["likely to represent", "UNCERTAINTY", 69, 88]]], ["Detection rates vary depending on the methods of sample collection and analysis as well as exacerbation severity.", [["sample", "ANATOMY", 49, 55], ["Detection rates", "TEST", 0, 15], ["sample collection", "TEST", 49, 66], ["analysis", "TEST", 71, 79], ["exacerbation severity", "PROBLEM", 91, 112]]], ["Cough is the most common symptom in COPD and this is significantly increased during periods of exacerbation and infection.Seasonal patternsIncidence of viral respiratory tract infections varies throughout the year.", [["respiratory tract", "ANATOMY", 158, 175], ["Cough", "DISEASE", 0, 5], ["COPD", "DISEASE", 36, 40], ["infection", "DISEASE", 112, 121], ["viral respiratory tract infections", "DISEASE", 152, 186], ["tract", "ORGANISM_SUBDIVISION", 170, 175], ["Cough", "PROBLEM", 0, 5], ["COPD", "PROBLEM", 36, 40], ["exacerbation", "PROBLEM", 95, 107], ["infection", "PROBLEM", 112, 121], ["Seasonal patterns", "PROBLEM", 122, 139], ["viral respiratory tract infections", "PROBLEM", 152, 186], ["most common", "OBSERVATION_MODIFIER", 13, 24], ["COPD", "OBSERVATION", 36, 40], ["significantly", "OBSERVATION_MODIFIER", 53, 66], ["increased", "OBSERVATION_MODIFIER", 67, 76], ["exacerbation", "OBSERVATION", 95, 107], ["infection", "OBSERVATION", 112, 121], ["viral", "OBSERVATION_MODIFIER", 152, 157], ["respiratory tract infections", "OBSERVATION", 158, 186]]], ["Healthy individuals frequently develop URTI during early autumn associated with an increased incidence of cough and presentations to medical services.", [["URTI", "DISEASE", 39, 43], ["cough", "DISEASE", 106, 111], ["individuals", "ORGANISM", 8, 19], ["URTI", "PROBLEM", 39, 43], ["cough", "PROBLEM", 106, 111], ["increased", "OBSERVATION_MODIFIER", 83, 92], ["cough", "OBSERVATION", 106, 111]]], ["Epidemiological studies demonstrate the striking impact of seasonal factors on exacerbation frequencies in both asthma and COPD [17] .", [["asthma", "DISEASE", 112, 118], ["COPD", "DISEASE", 123, 127], ["Epidemiological studies", "TEST", 0, 23], ["seasonal factors", "PROBLEM", 59, 75], ["exacerbation frequencies", "PROBLEM", 79, 103], ["both asthma", "PROBLEM", 107, 118], ["COPD", "PROBLEM", 123, 127], ["seasonal factors", "OBSERVATION", 59, 75], ["both", "OBSERVATION_MODIFIER", 107, 111], ["asthma", "OBSERVATION", 112, 118], ["COPD", "OBSERVATION", 123, 127]]], ["Asthma exacerbations in children peak around mid to late September strongly correlating with return to school [17] .", [["Asthma exacerbations", "DISEASE", 0, 20], ["children", "ORGANISM", 24, 32], ["children", "SPECIES", 24, 32], ["Asthma exacerbations", "PROBLEM", 0, 20]]], ["A peak in COPD exacerbations follows in December which is associated with the Christmas holiday season and is seen in every northern hemisphere country studied [17] .", [["COPD", "DISEASE", 10, 14], ["A peak in COPD exacerbations", "PROBLEM", 0, 28], ["peak", "OBSERVATION_MODIFIER", 2, 6], ["COPD", "OBSERVATION_MODIFIER", 10, 14], ["exacerbations", "OBSERVATION", 15, 28]]], ["These trends reflect a complex combination of many causative factors; but the primary cause of exacerbations is respiratory virus infection particularly with rhinovirus.", [["respiratory virus infection", "DISEASE", 112, 139], ["rhinovirus", "ORGANISM", 158, 168], ["many causative factors", "PROBLEM", 46, 68], ["exacerbations", "PROBLEM", 95, 108], ["respiratory virus infection", "PROBLEM", 112, 139], ["rhinovirus", "PROBLEM", 158, 168], ["exacerbations", "OBSERVATION", 95, 108], ["respiratory virus infection", "OBSERVATION", 112, 139], ["rhinovirus", "OBSERVATION", 158, 168]]], ["Peak asthma exacerbations correlate with the highest incidence of rhinovirus infections in the community but the reason for the delay in COPD exacerbations is not clear [8, 15, 17] .Mechanism of virus induced coughRemarkably few studies have directly investigated the mechanism of virus induced cough.", [["asthma exacerbations", "DISEASE", 5, 25], ["rhinovirus infections", "DISEASE", 66, 87], ["COPD", "DISEASE", 137, 141], ["cough", "DISEASE", 295, 300], ["rhinovirus", "ORGANISM", 66, 76], ["Peak asthma exacerbations", "PROBLEM", 0, 25], ["rhinovirus infections", "PROBLEM", 66, 87], ["the delay", "PROBLEM", 124, 133], ["COPD exacerbations", "PROBLEM", 137, 155], ["Mechanism of virus", "PROBLEM", 182, 200], ["virus induced cough", "PROBLEM", 281, 300], ["asthma", "OBSERVATION", 5, 11], ["rhinovirus", "OBSERVATION", 66, 76], ["COPD", "OBSERVATION", 137, 141], ["virus", "OBSERVATION", 195, 200], ["virus", "OBSERVATION", 281, 286], ["cough", "OBSERVATION", 295, 300]]], ["Those which have provided some insight have investigated airway hyper-responsiveness (AHR) rather than cough as an outcome measure.", [["airway", "ANATOMY", 57, 63], ["cough", "DISEASE", 103, 108], ["airway", "MULTI-TISSUE_STRUCTURE", 57, 63], ["airway hyper-responsiveness", "PROBLEM", 57, 84], ["cough", "PROBLEM", 103, 108]]], ["Conversely, studies that have specifically investigated cough have not studied experimental virus infections.Mechanism of virus induced coughCoughing is a physiological response to airway irritation and an important defence mechanism for the respiratory tract.", [["airway", "ANATOMY", 181, 187], ["respiratory tract", "ANATOMY", 242, 259], ["cough", "DISEASE", 56, 61], ["infections", "DISEASE", 98, 108], ["coughCoughing", "DISEASE", 136, 149], ["airway irritation", "DISEASE", 181, 198], ["airway", "MULTI-TISSUE_STRUCTURE", 181, 187], ["respiratory tract", "ORGANISM_SUBDIVISION", 242, 259], ["cough", "PROBLEM", 56, 61], ["experimental virus infections", "PROBLEM", 79, 108], ["virus", "PROBLEM", 122, 127], ["airway irritation", "PROBLEM", 181, 198], ["the respiratory tract", "PROBLEM", 238, 259], ["virus", "OBSERVATION", 122, 127], ["airway", "ANATOMY", 181, 187], ["irritation", "OBSERVATION", 188, 198], ["respiratory tract", "ANATOMY", 242, 259]]], ["Inhibition of the normal host response to viral infection may not necessarily be desirable therefore.", [["viral infection", "DISEASE", 42, 57], ["viral infection", "PROBLEM", 42, 57], ["normal host response", "OBSERVATION", 18, 38], ["viral infection", "OBSERVATION", 42, 57], ["may not necessarily be", "UNCERTAINTY", 58, 80]]], ["However the transmission of virus particles between individuals is enabled by coughing and it is likely that viruses have evolved mechanisms to produce and enhance cough production.Mechanism of virus induced coughThe causes of cough are complex and multi-factorial with many diverse aetiological agents other that infection identified.", [["cough", "DISEASE", 164, 169], ["cough", "DISEASE", 208, 213], ["cough", "DISEASE", 227, 232], ["infection", "DISEASE", 314, 323], ["virus particles", "PROBLEM", 28, 43], ["coughing", "PROBLEM", 78, 86], ["viruses", "PROBLEM", 109, 116], ["enhance cough production", "PROBLEM", 156, 180], ["Mechanism of virus induced cough", "PROBLEM", 181, 213], ["cough", "PROBLEM", 227, 232], ["infection", "PROBLEM", 314, 323], ["virus particles", "OBSERVATION", 28, 43], ["viruses", "OBSERVATION", 109, 116], ["virus", "OBSERVATION", 194, 199], ["cough", "OBSERVATION", 208, 213], ["cough", "OBSERVATION", 227, 232], ["diverse", "OBSERVATION_MODIFIER", 275, 282], ["infection", "OBSERVATION", 314, 323]]], ["Several pathways, mediated via the vagus nerve, activate the central cough generator in the brainstem when stimulated by neurotransmitters in the respiratory tract [18] .", [["vagus nerve", "ANATOMY", 35, 46], ["brainstem", "ANATOMY", 92, 101], ["respiratory tract", "ANATOMY", 146, 163], ["vagus nerve", "MULTI-TISSUE_STRUCTURE", 35, 46], ["brainstem", "ORGAN", 92, 101], ["the central cough generator in the brainstem", "PROBLEM", 57, 101], ["vagus nerve", "ANATOMY", 35, 46], ["central", "OBSERVATION_MODIFIER", 61, 68], ["cough generator", "OBSERVATION", 69, 84], ["brainstem", "ANATOMY", 92, 101], ["respiratory tract", "ANATOMY", 146, 163]]], ["Cough is generated by activation of laryngeal, oesophageal or tracheobronchial receptors in addition to voluntary control.", [["laryngeal", "ANATOMY", 36, 45], ["oesophageal", "ANATOMY", 47, 58], ["tracheobronchial", "ANATOMY", 62, 78], ["Cough", "DISEASE", 0, 5], ["laryngeal", "ORGAN", 36, 45], ["oesophageal", "MULTI-TISSUE_STRUCTURE", 47, 58], ["tracheobronchial", "MULTI-TISSUE_STRUCTURE", 62, 78], ["laryngeal, oesophageal or tracheobronchial receptors", "PROTEIN", 36, 88], ["Cough", "PROBLEM", 0, 5], ["tracheobronchial receptors", "TREATMENT", 62, 88], ["voluntary control", "TREATMENT", 104, 121], ["laryngeal", "ANATOMY", 36, 45], ["oesophageal", "ANATOMY", 47, 58], ["tracheobronchial", "ANATOMY", 62, 78]]], ["Virus infection is just one example where cough may be stimulated via these pathways through both direct and indirect actions.Specific mechanismsVirus infection of the airway epithelium leads to inflammation and cytokine release as the host immune system is activated.", [["airway epithelium", "ANATOMY", 168, 185], ["Virus infection", "DISEASE", 0, 15], ["cough", "DISEASE", 42, 47], ["Virus infection", "DISEASE", 145, 160], ["inflammation", "DISEASE", 195, 207], ["Virus", "ORGANISM", 0, 5], ["Virus", "ORGANISM", 145, 150], ["airway epithelium", "TISSUE", 168, 185], ["cytokine", "PROTEIN", 212, 220], ["Virus infection", "PROBLEM", 0, 15], ["cough", "PROBLEM", 42, 47], ["Virus infection of the airway epithelium", "PROBLEM", 145, 185], ["inflammation", "PROBLEM", 195, 207], ["cytokine release", "TREATMENT", 212, 228], ["infection", "OBSERVATION", 6, 15], ["infection", "OBSERVATION", 151, 160], ["airway", "ANATOMY", 168, 174], ["epithelium", "ANATOMY_MODIFIER", 175, 185], ["inflammation", "OBSERVATION", 195, 207]]], ["Viruses, such as influenza, may be highly pathogenic and cause excessive epithelial cell necrosis and inflammation.", [["epithelial cell", "ANATOMY", 73, 88], ["influenza", "DISEASE", 17, 26], ["necrosis", "DISEASE", 89, 97], ["inflammation", "DISEASE", 102, 114], ["epithelial cell", "CELL", 73, 88], ["Viruses", "PROBLEM", 0, 7], ["influenza", "PROBLEM", 17, 26], ["excessive epithelial cell necrosis", "PROBLEM", 63, 97], ["inflammation", "PROBLEM", 102, 114], ["influenza", "OBSERVATION", 17, 26], ["may be", "UNCERTAINTY", 28, 34], ["excessive", "OBSERVATION_MODIFIER", 63, 72], ["epithelial cell necrosis", "OBSERVATION", 73, 97], ["inflammation", "OBSERVATION", 102, 114]]], ["However even rhinoviruses with milder pathogenicity, and less direct cellular necrosis, can lead to a marked symptomatic host response.", [["cellular", "ANATOMY", 69, 77], ["necrosis", "DISEASE", 78, 86], ["rhinoviruses", "ORGANISM", 13, 25], ["cellular", "CELL", 69, 77], ["rhinoviruses", "PROBLEM", 13, 25], ["milder pathogenicity", "PROBLEM", 31, 51], ["less direct cellular necrosis", "PROBLEM", 57, 86], ["a marked symptomatic host response", "PROBLEM", 100, 134], ["rhinoviruses", "OBSERVATION", 13, 25], ["milder", "OBSERVATION_MODIFIER", 31, 37], ["pathogenicity", "OBSERVATION", 38, 51], ["less", "OBSERVATION_MODIFIER", 57, 61], ["direct", "OBSERVATION_MODIFIER", 62, 68], ["cellular", "OBSERVATION_MODIFIER", 69, 77], ["necrosis", "OBSERVATION", 78, 86], ["marked", "OBSERVATION_MODIFIER", 102, 108], ["symptomatic", "OBSERVATION_MODIFIER", 109, 120], ["host response", "OBSERVATION", 121, 134]]], ["A virus infected epithelial cell releases a wide range of inflammatory cytokines including IL-1, TNF-a, IL-6 IL-8, GRO-a, IL-11, RANTES, GM-CSF and eotaxin.", [["epithelial cell", "ANATOMY", 17, 32], ["epithelial cell", "CELL", 17, 32], ["IL-1", "GENE_OR_GENE_PRODUCT", 91, 95], ["TNF-a", "GENE_OR_GENE_PRODUCT", 97, 102], ["IL-6", "GENE_OR_GENE_PRODUCT", 104, 108], ["IL-8", "GENE_OR_GENE_PRODUCT", 109, 113], ["GRO-a", "GENE_OR_GENE_PRODUCT", 115, 120], ["IL-11", "GENE_OR_GENE_PRODUCT", 122, 127], ["RANTES", "GENE_OR_GENE_PRODUCT", 129, 135], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 137, 143], ["eotaxin", "GENE_OR_GENE_PRODUCT", 148, 155], ["virus infected epithelial cell", "CELL_TYPE", 2, 32], ["inflammatory cytokines", "PROTEIN", 58, 80], ["IL", "PROTEIN", 91, 93], ["TNF", "PROTEIN", 97, 100], ["IL-6 IL-8", "PROTEIN", 104, 113], ["GRO", "PROTEIN", 115, 118], ["IL-11", "PROTEIN", 122, 127], ["RANTES", "PROTEIN", 129, 135], ["GM", "PROTEIN", 137, 139], ["CSF", "PROTEIN", 140, 143], ["eotaxin", "PROTEIN", 148, 155], ["A virus infected epithelial cell", "PROBLEM", 0, 32], ["inflammatory cytokines", "PROBLEM", 58, 80], ["IL", "TEST", 91, 93], ["TNF", "TEST", 97, 100], ["IL", "TEST", 104, 106], ["IL", "TEST", 109, 111], ["GRO", "TEST", 115, 118], ["IL", "TEST", 122, 124], ["RANTES", "TEST", 129, 135], ["GM", "TEST", 137, 139], ["CSF", "TEST", 140, 143], ["eotaxin", "TEST", 148, 155], ["virus", "OBSERVATION_MODIFIER", 2, 7], ["infected", "OBSERVATION_MODIFIER", 8, 16], ["epithelial cell", "OBSERVATION", 17, 32], ["wide", "OBSERVATION_MODIFIER", 44, 48], ["inflammatory", "OBSERVATION_MODIFIER", 58, 70]]], ["In addition the expression of growth factors, adhesion molecules and immunity related molecules is up-regulated by virus infection [19] .", [["infection", "DISEASE", 121, 130], ["growth factors", "PROTEIN", 30, 44], ["adhesion molecules", "PROTEIN", 46, 64], ["immunity related molecules", "PROTEIN", 69, 95], ["growth factors", "PROBLEM", 30, 44], ["adhesion molecules", "PROBLEM", 46, 64], ["immunity related molecules", "PROBLEM", 69, 95], ["virus infection", "PROBLEM", 115, 130]]], ["A recent longitudinal study of exacerbations in severe asthmatics identified increases in IL-13 and IFN-g producing T-cells during exacerbations; the deficiency of regulatory T cells found at baseline was also exaggerated during exacerbations [20] .", [["T-cells", "ANATOMY", 116, 123], ["regulatory T cells", "ANATOMY", 164, 182], ["IL-13", "GENE_OR_GENE_PRODUCT", 90, 95], ["IFN-g", "GENE_OR_GENE_PRODUCT", 100, 105], ["T-cells", "CELL", 116, 123], ["T cells", "CELL", 175, 182], ["IFN", "PROTEIN", 100, 103], ["T-cells", "CELL_TYPE", 116, 123], ["regulatory T cells", "CELL_TYPE", 164, 182], ["A recent longitudinal study", "TEST", 0, 27], ["exacerbations", "PROBLEM", 31, 44], ["severe asthmatics", "PROBLEM", 48, 65], ["IL", "TEST", 90, 92], ["IFN", "TEST", 100, 103], ["T-cells", "PROBLEM", 116, 123], ["exacerbations", "PROBLEM", 131, 144], ["the deficiency of regulatory T cells", "PROBLEM", 146, 182], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["asthmatics", "OBSERVATION", 55, 65], ["increases", "OBSERVATION_MODIFIER", 77, 86], ["exaggerated", "OBSERVATION_MODIFIER", 210, 221]]], ["This study offers new insight into the pathophysiology of asthma exacerbations, and although viruses were not investigated in this study future work should explore their role in these cellular changes.Increased neurotransmitter levelsVirus infection in the lung leads to an increase in airway neurotransmitters particularly the tachykinin substance P, through a variety of different mechanisms.", [["cellular", "ANATOMY", 184, 192], ["lung", "ANATOMY", 257, 261], ["airway", "ANATOMY", 286, 292], ["asthma", "DISEASE", 58, 64], ["Virus infection", "DISEASE", 234, 249], ["cellular", "CELL", 184, 192], ["Virus", "ORGANISM", 234, 239], ["lung", "ORGAN", 257, 261], ["airway", "MULTI-TISSUE_STRUCTURE", 286, 292], ["tachykinin substance P", "GENE_OR_GENE_PRODUCT", 328, 350], ["This study", "TEST", 0, 10], ["asthma exacerbations", "PROBLEM", 58, 78], ["viruses", "PROBLEM", 93, 100], ["this study", "TEST", 126, 136], ["Increased neurotransmitter levels", "PROBLEM", 201, 234], ["Virus infection in the lung", "PROBLEM", 234, 261], ["an increase in airway neurotransmitters", "PROBLEM", 271, 310], ["asthma", "OBSERVATION", 58, 64], ["cellular changes", "OBSERVATION", 184, 200], ["neurotransmitter levels", "OBSERVATION", 211, 234], ["infection", "OBSERVATION", 240, 249], ["lung", "ANATOMY", 257, 261], ["increase", "OBSERVATION_MODIFIER", 274, 282], ["airway", "ANATOMY", 286, 292]]], ["Tachykinins are neuro-excitatory molecules which act as potent vasodilators and cause contraction of airway smooth muscle and secretion of airway mucus.", [["airway smooth muscle", "ANATOMY", 101, 121], ["airway mucus", "ANATOMY", 139, 151], ["Tachykinins", "CHEMICAL", 0, 11], ["Tachykinins", "CHEMICAL", 0, 11], ["Tachykinins", "SIMPLE_CHEMICAL", 0, 11], ["airway smooth muscle", "TISSUE", 101, 121], ["airway mucus", "TISSUE", 139, 151], ["neuro-excitatory molecules", "PROTEIN", 16, 42], ["Tachykinins", "PROBLEM", 0, 11], ["neuro-excitatory molecules", "PROBLEM", 16, 42], ["potent vasodilators", "TREATMENT", 56, 75], ["contraction of airway smooth muscle", "PROBLEM", 86, 121], ["secretion of airway mucus", "PROBLEM", 126, 151], ["airway", "ANATOMY", 101, 107], ["smooth muscle", "OBSERVATION", 108, 121], ["airway", "ANATOMY", 139, 145], ["mucus", "OBSERVATION", 146, 151]]], ["Substance P was found to be elevated in bronchoalveolar lavage (BAL) fluid from RSV infected mice [21] and this has been implicated in the lymphocytic response [22] .", [["bronchoalveolar lavage (BAL) fluid", "ANATOMY", 40, 74], ["lymphocytic", "ANATOMY", 139, 150], ["RSV infected", "DISEASE", 80, 92], ["Substance P", "GENE_OR_GENE_PRODUCT", 0, 11], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 40, 62], ["BAL", "ORGANISM_SUBSTANCE", 64, 67], ["fluid", "ORGANISM_SUBSTANCE", 69, 74], ["RSV", "ORGANISM", 80, 83], ["mice", "ORGANISM", 93, 97], ["mice", "SPECIES", 93, 97], ["RSV", "SPECIES", 80, 83], ["mice", "SPECIES", 93, 97], ["bronchoalveolar lavage", "TEST", 40, 62], ["RSV infected mice", "PROBLEM", 80, 97], ["elevated", "OBSERVATION_MODIFIER", 28, 36], ["bronchoalveolar lavage", "OBSERVATION", 40, 62], ["lymphocytic response", "OBSERVATION", 139, 159]]], ["Further study in RSV infected mice again found elevated substance P levels, but also falls in the airway protective compound calcitonin gene-related peptide CGRP [23] .", [["airway", "ANATOMY", 98, 104], ["RSV infected", "DISEASE", 17, 29], ["calcitonin gene-related peptide", "CHEMICAL", 125, 156], ["CGRP", "CHEMICAL", 157, 161], ["RSV", "ORGANISM", 17, 20], ["mice", "ORGANISM", 30, 34], ["airway", "MULTI-TISSUE_STRUCTURE", 98, 104], ["calcitonin", "GENE_OR_GENE_PRODUCT", 125, 135], ["mice", "SPECIES", 30, 34], ["RSV", "SPECIES", 17, 20], ["mice", "SPECIES", 30, 34], ["Further study", "TEST", 0, 13], ["elevated substance P levels", "PROBLEM", 47, 74], ["the airway protective compound calcitonin gene", "TREATMENT", 94, 140], ["airway", "ANATOMY", 98, 104]]], ["CGRP, a neuropeptide with vasodilating effects, is constitutively found in the airway and when deficient airways were found to be inflamed and hyper-responsive [24] .", [["airway", "ANATOMY", 79, 85], ["airways", "ANATOMY", 105, 112], ["CGRP", "CHEMICAL", 0, 4], ["CGRP", "GENE_OR_GENE_PRODUCT", 0, 4], ["airway", "MULTI-TISSUE_STRUCTURE", 79, 85], ["airways", "MULTI-TISSUE_STRUCTURE", 105, 112], ["vasodilating effects", "TREATMENT", 26, 46], ["deficient airways", "PROBLEM", 95, 112], ["inflamed", "PROBLEM", 130, 138], ["hyper-responsive", "PROBLEM", 143, 159], ["airway", "ANATOMY", 79, 85], ["airways", "ANATOMY", 105, 112]]], ["The central role of substance P in virus induced airway dysfunction was confirmed when it was shown that selective blocking of the substance P receptor, neurokinin-1 (NK-1) receptor with Sendide abolished AHR [23] .Reduced neutral endopeptidasesVirus infection of the respiratory tract not only causes tachykinin release from Ad nerve fibres in guinea pigs [25] but also decreases the activity of neutral endopeptidases (NEs), important enzymes involved in degradation of airway tachykinins [26] .", [["airway", "ANATOMY", 49, 55], ["respiratory tract", "ANATOMY", 268, 285], ["nerve fibres", "ANATOMY", 329, 341], ["airway", "ANATOMY", 472, 478], ["airway dysfunction", "DISEASE", 49, 67], ["Virus infection", "DISEASE", 245, 260], ["tachykinin", "CHEMICAL", 302, 312], ["substance P", "GENE_OR_GENE_PRODUCT", 20, 31], ["airway", "MULTI-TISSUE_STRUCTURE", 49, 55], ["substance P receptor", "GENE_OR_GENE_PRODUCT", 131, 151], ["neurokinin-1", "GENE_OR_GENE_PRODUCT", 153, 165], ["NK-1) receptor", "GENE_OR_GENE_PRODUCT", 167, 181], ["Sendide", "SIMPLE_CHEMICAL", 187, 194], ["Virus", "ORGANISM", 245, 250], ["respiratory tract", "ORGANISM_SUBDIVISION", 268, 285], ["tachykinin", "GENE_OR_GENE_PRODUCT", 302, 312], ["Ad", "ORGANISM", 326, 328], ["nerve fibres", "TISSUE", 329, 341], ["guinea pigs", "ORGANISM", 345, 356], ["NEs", "GENE_OR_GENE_PRODUCT", 421, 424], ["substance P receptor", "PROTEIN", 131, 151], ["neurokinin-1 (NK-1) receptor", "PROTEIN", 153, 181], ["neutral endopeptidases", "PROTEIN", 223, 245], ["neutral endopeptidases", "PROTEIN", 397, 419], ["NEs", "PROTEIN", 421, 424], ["guinea pigs", "SPECIES", 345, 356], ["substance P in virus induced airway dysfunction", "PROBLEM", 20, 67], ["the substance P receptor", "TREATMENT", 127, 151], ["neurokinin", "TEST", 153, 163], ["AHR", "TEST", 205, 208], ["Reduced neutral endopeptidases", "PROBLEM", 215, 245], ["Virus infection of the respiratory tract", "PROBLEM", 245, 285], ["tachykinin release", "PROBLEM", 302, 320], ["Ad nerve fibres", "PROBLEM", 326, 341], ["important enzymes", "TEST", 427, 444], ["airway tachykinins", "PROBLEM", 472, 490], ["central", "OBSERVATION_MODIFIER", 4, 11], ["substance", "OBSERVATION", 20, 29], ["airway", "ANATOMY", 49, 55], ["dysfunction", "OBSERVATION", 56, 67], ["neutral endopeptidases", "OBSERVATION", 223, 245], ["infection", "OBSERVATION", 251, 260], ["respiratory tract", "ANATOMY", 268, 285], ["decreases", "OBSERVATION_MODIFIER", 371, 380], ["airway", "ANATOMY", 472, 478]]], ["A rat study using RSV demonstrated significantly higher levels of substance P in lung tissue following infection; additionally stimulation with capsaicin further increased substance P release in infected lungs compared to controls [27] .", [["lung tissue", "ANATOMY", 81, 92], ["lungs", "ANATOMY", 204, 209], ["infection", "DISEASE", 103, 112], ["capsaicin", "CHEMICAL", 144, 153], ["capsaicin", "CHEMICAL", 144, 153], ["rat", "ORGANISM", 2, 5], ["RSV", "ORGANISM", 18, 21], ["lung tissue", "TISSUE", 81, 92], ["capsaicin", "SIMPLE_CHEMICAL", 144, 153], ["substance P", "SIMPLE_CHEMICAL", 172, 183], ["lungs", "ORGAN", 204, 209], ["rat", "SPECIES", 2, 5], ["RSV", "SPECIES", 18, 21], ["A rat study", "TEST", 0, 11], ["RSV", "PROBLEM", 18, 21], ["substance P in lung tissue", "PROBLEM", 66, 92], ["infection", "PROBLEM", 103, 112], ["capsaicin further increased substance P release in infected lungs", "TREATMENT", 144, 209], ["lung", "ANATOMY", 81, 85], ["infection", "OBSERVATION", 103, 112], ["lungs", "ANATOMY", 204, 209]]], ["Work in guinea pigs confirmed the high potency of substance P in cough generation and the effect of NE to limit this [28] .", [["cough", "DISEASE", 65, 70], ["NE", "CHEMICAL", 100, 102], ["guinea pigs", "ORGANISM", 8, 19], ["NE", "SIMPLE_CHEMICAL", 100, 102], ["NE", "PROTEIN", 100, 102], ["guinea pigs", "SPECIES", 8, 19], ["cough generation", "PROBLEM", 65, 81], ["high potency", "OBSERVATION_MODIFIER", 34, 46]]], ["By inactivating cough generating tachykinins, NEs limit cough activity.", [["cough", "DISEASE", 16, 21], ["cough", "DISEASE", 56, 61], ["tachykinins", "GENE_OR_GENE_PRODUCT", 33, 44], ["NEs", "SIMPLE_CHEMICAL", 46, 49], ["inactivating cough generating tachykinins", "PROBLEM", 3, 44]]], ["Exogenous inhibitors of NE were able to increase the sensitivity to substance P with an increase in cough frequency and a lower dose response curve to capsaicin induced cough in guinea pigs [28] .Increased neural receptor levelsIn addition to a total increase in tachykinin levels in the lung, expression of NK-1 receptor is increased, further amplifying virus induced neuro-stimulatory signals [29] .", [["neural", "ANATOMY", 206, 212], ["lung", "ANATOMY", 288, 292], ["NK", "ANATOMY", 308, 310], ["NE", "CHEMICAL", 24, 26], ["cough", "DISEASE", 100, 105], ["capsaicin", "CHEMICAL", 151, 160], ["cough", "DISEASE", 169, 174], ["tachykinin", "CHEMICAL", 263, 273], ["capsaicin", "CHEMICAL", 151, 160], ["NE", "SIMPLE_CHEMICAL", 24, 26], ["capsaicin", "SIMPLE_CHEMICAL", 151, 160], ["guinea pigs", "ORGANISM", 178, 189], ["neural receptor", "GENE_OR_GENE_PRODUCT", 206, 221], ["tachykinin", "SIMPLE_CHEMICAL", 263, 273], ["lung", "ORGAN", 288, 292], ["NK-1 receptor", "GENE_OR_GENE_PRODUCT", 308, 321], ["NE", "PROTEIN", 24, 26], ["NK-1 receptor", "PROTEIN", 308, 321], ["guinea pigs", "SPECIES", 178, 189], ["Exogenous inhibitors of NE", "PROBLEM", 0, 26], ["an increase in cough frequency", "PROBLEM", 85, 115], ["a lower dose response curve", "TREATMENT", 120, 147], ["capsaicin induced cough", "PROBLEM", 151, 174], ["Increased neural receptor levels", "PROBLEM", 196, 228], ["a total increase in tachykinin levels in the lung", "PROBLEM", 243, 292], ["NK", "TEST", 308, 310], ["neural", "ANATOMY_MODIFIER", 206, 212], ["receptor levels", "OBSERVATION", 213, 228], ["total", "OBSERVATION_MODIFIER", 245, 250], ["increase", "OBSERVATION_MODIFIER", 251, 259], ["tachykinin levels", "OBSERVATION", 263, 280], ["lung", "ANATOMY", 288, 292], ["NK", "ANATOMY", 308, 310]]], ["This effect was shown in young rats to be dependent on nerve growth factors (NGF) as neutralising antibody to NGF abolished the effect and exogenous addition of NGF up-regulated NK-1 receptor levels.", [["NK", "ANATOMY", 178, 180], ["rats", "ORGANISM", 31, 35], ["nerve growth factors", "GENE_OR_GENE_PRODUCT", 55, 75], ["NGF", "GENE_OR_GENE_PRODUCT", 77, 80], ["NGF", "GENE_OR_GENE_PRODUCT", 110, 113], ["NGF", "GENE_OR_GENE_PRODUCT", 161, 164], ["NK-1 receptor", "GENE_OR_GENE_PRODUCT", 178, 191], ["nerve growth factors", "PROTEIN", 55, 75], ["NGF", "PROTEIN", 77, 80], ["neutralising antibody", "PROTEIN", 85, 106], ["NGF", "PROTEIN", 110, 113], ["NGF", "PROTEIN", 161, 164], ["NK-1 receptor", "PROTEIN", 178, 191], ["rats", "SPECIES", 31, 35], ["dependent on nerve growth factors", "PROBLEM", 42, 75], ["neutralising antibody to NGF", "TREATMENT", 85, 113], ["NGF", "TEST", 161, 164], ["nerve", "ANATOMY", 55, 60]]], ["Additionally levels of NGF fell with increasing age which may indicate a mechanism for exaggerated virus induced airway disease in the infant.Modulation of neural activitiesIn addition to increases in neurotransmitters and receptors following virus infection, it has been shown that qualitative changes in afferent nerves occur.", [["airway", "ANATOMY", 113, 119], ["neural", "ANATOMY", 156, 162], ["afferent nerves", "ANATOMY", 306, 321], ["airway disease", "DISEASE", 113, 127], ["infection", "DISEASE", 249, 258], ["NGF", "GENE_OR_GENE_PRODUCT", 23, 26], ["airway", "MULTI-TISSUE_STRUCTURE", 113, 119], ["infant", "ORGANISM", 135, 141], ["afferent nerves", "MULTI-TISSUE_STRUCTURE", 306, 321], ["NGF", "PROTEIN", 23, 26], ["infant", "SPECIES", 135, 141], ["Additionally levels of NGF", "PROBLEM", 0, 26], ["exaggerated virus induced airway disease in the infant", "PROBLEM", 87, 141], ["Modulation of neural activities", "PROBLEM", 142, 173], ["increases in neurotransmitters", "PROBLEM", 188, 218], ["virus infection", "PROBLEM", 243, 258], ["qualitative changes in afferent nerves", "PROBLEM", 283, 321], ["NGF fell", "OBSERVATION", 23, 31], ["virus", "OBSERVATION", 99, 104], ["airway disease", "OBSERVATION", 113, 127], ["neural activities", "OBSERVATION", 156, 173], ["increases", "OBSERVATION_MODIFIER", 188, 197], ["afferent nerves", "OBSERVATION", 306, 321]]], ["Experimental infection of guinea pigs with Sendai virus have shown that labelled afferent neurones from the trachea increased in size following virus infection and that this resolves in convalescence [25] .", [["afferent neurones", "ANATOMY", 81, 98], ["trachea", "ANATOMY", 108, 115], ["infection", "DISEASE", 13, 22], ["infection", "DISEASE", 150, 159], ["guinea pigs", "ORGANISM", 26, 37], ["Sendai virus", "ORGANISM", 43, 55], ["afferent neurones", "MULTI-TISSUE_STRUCTURE", 81, 98], ["trachea", "ORGAN", 108, 115], ["guinea pigs", "SPECIES", 26, 37], ["Sendai virus", "SPECIES", 43, 55], ["guinea pigs", "SPECIES", 26, 37], ["Sendai virus", "SPECIES", 43, 55], ["Experimental infection of guinea pigs", "PROBLEM", 0, 37], ["Sendai virus", "PROBLEM", 43, 55], ["labelled afferent neurones", "PROBLEM", 72, 98], ["virus infection", "PROBLEM", 144, 159], ["infection", "OBSERVATION", 13, 22], ["guinea pigs", "OBSERVATION", 26, 37], ["Sendai virus", "OBSERVATION", 43, 55], ["afferent neurones", "OBSERVATION", 81, 98], ["trachea", "ANATOMY", 108, 115], ["increased", "OBSERVATION_MODIFIER", 116, 125], ["size", "OBSERVATION_MODIFIER", 129, 133], ["virus infection", "OBSERVATION", 144, 159]]], ["Tachykinins are synthesised in the neuronal cell body; the diameter of which was increased during acute infection, suggesting that virus infection can lead to changes in the vagal afferent innervations of guinea pig airways such that both small diameter nociceptive-like neurons and large diameter nonnociceptive neurons express tachykinins.Cholinergic motor pathwaysDespite the significant impact that virus infection appears to have on cholinergic pathways no research specifically on cough has been undertaken in this area.", [["neuronal cell body", "ANATOMY", 35, 53], ["vagal afferent innervations", "ANATOMY", 174, 201], ["airways", "ANATOMY", 216, 223], ["nociceptive-like neurons", "ANATOMY", 254, 278], ["nonnociceptive neurons", "ANATOMY", 298, 320], ["Tachykinins", "CHEMICAL", 0, 11], ["infection", "DISEASE", 104, 113], ["infection", "DISEASE", 137, 146], ["infection", "DISEASE", 409, 418], ["cough", "DISEASE", 487, 492], ["Tachykinins", "CHEMICAL", 0, 11], ["Tachykinins", "GENE_OR_GENE_PRODUCT", 0, 11], ["neuronal cell body", "IMMATERIAL_ANATOMICAL_ENTITY", 35, 53], ["vagal afferent innervations", "MULTI-TISSUE_STRUCTURE", 174, 201], ["pig", "ORGANISM", 212, 215], ["airways", "MULTI-TISSUE_STRUCTURE", 216, 223], ["neurons", "CELL", 271, 278], ["neurons", "CELL", 313, 320], ["tachykinins", "GENE_OR_GENE_PRODUCT", 329, 340], ["Tachykinins", "PROTEIN", 0, 11], ["small diameter nociceptive-like neurons", "CELL_TYPE", 239, 278], ["large diameter nonnociceptive neurons", "CELL_TYPE", 283, 320], ["guinea pig", "SPECIES", 205, 215], ["guinea pig", "SPECIES", 205, 215], ["Tachykinins", "PROBLEM", 0, 11], ["acute infection", "PROBLEM", 98, 113], ["virus infection", "PROBLEM", 131, 146], ["the vagal afferent innervations", "PROBLEM", 170, 201], ["guinea pig airways", "PROBLEM", 205, 223], ["both small diameter nociceptive-like neurons", "PROBLEM", 234, 278], ["large diameter nonnociceptive neurons express tachykinins", "PROBLEM", 283, 340], ["virus infection", "PROBLEM", 403, 418], ["cough", "PROBLEM", 487, 492], ["neuronal cell body", "ANATOMY_MODIFIER", 35, 53], ["diameter", "OBSERVATION_MODIFIER", 59, 67], ["increased", "OBSERVATION_MODIFIER", 81, 90], ["acute", "OBSERVATION_MODIFIER", 98, 103], ["infection", "OBSERVATION", 104, 113], ["virus", "OBSERVATION_MODIFIER", 131, 136], ["infection", "OBSERVATION", 137, 146], ["vagal afferent", "OBSERVATION", 174, 188], ["guinea pig airways", "OBSERVATION", 205, 223], ["small", "OBSERVATION_MODIFIER", 239, 244], ["diameter", "OBSERVATION_MODIFIER", 245, 253], ["large", "OBSERVATION_MODIFIER", 283, 288], ["diameter", "OBSERVATION_MODIFIER", 289, 297], ["significant", "OBSERVATION_MODIFIER", 379, 390], ["virus", "OBSERVATION_MODIFIER", 403, 408], ["infection", "OBSERVATION", 409, 418]]], ["Surrogate markers such as bronchoconstriction and AHR have been used instead.", [["Surrogate markers", "TREATMENT", 0, 17], ["bronchoconstriction", "PROBLEM", 26, 45], ["AHR", "TREATMENT", 50, 53]]], ["Virus infection appears to activate bronchoconstriction through the vagus nerve.", [["vagus nerve", "ANATOMY", 68, 79], ["Virus infection", "DISEASE", 0, 15], ["Virus", "ORGANISM", 0, 5], ["vagus nerve", "MULTI-TISSUE_STRUCTURE", 68, 79], ["Virus infection", "PROBLEM", 0, 15], ["bronchoconstriction through the vagus nerve", "PROBLEM", 36, 79], ["infection", "OBSERVATION", 6, 15], ["bronchoconstriction", "OBSERVATION", 36, 55], ["vagus nerve", "ANATOMY", 68, 79]]], ["Acetylcholine levels are increased when the inhibitory effects of the muscarinic receptor (M2) are lost and virus infection has been shown to potentiate this [30] .", [["Acetylcholine", "CHEMICAL", 0, 13], ["infection", "DISEASE", 114, 123], ["Acetylcholine", "CHEMICAL", 0, 13], ["Acetylcholine", "SIMPLE_CHEMICAL", 0, 13], ["muscarinic receptor", "GENE_OR_GENE_PRODUCT", 70, 89], ["M2", "GENE_OR_GENE_PRODUCT", 91, 93], ["muscarinic receptor", "PROTEIN", 70, 89], ["M2", "PROTEIN", 91, 93], ["Acetylcholine levels", "TEST", 0, 20], ["the muscarinic receptor", "TREATMENT", 66, 89], ["virus infection", "PROBLEM", 108, 123], ["increased", "OBSERVATION_MODIFIER", 25, 34]]], ["Cells from animals infected with parainfluenza virus released more acetylcholine than non-infected cells and M2 receptor activity was disrupted by IFN-gamma (g) exposure suggesting a potential mechanism for virus induced cough and possible increased sensitivity of afferent nerves [31] .Cholinergic motor pathwaysMuscarinic receptors have also been shown to play a central role in airway vascular leakage and bronchoconstriction and mucus secretion; in a model of gastro-oesophageal reflux where cough may be a prominent feature, stimulation with acid activated muscarinic receptors (M1 and M3) and the effect was blocked with specific antagonists [32] .", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 99, 104], ["afferent nerves", "ANATOMY", 265, 280], ["airway vascular", "ANATOMY", 381, 396], ["mucus", "ANATOMY", 433, 438], ["gastro-oesophageal", "ANATOMY", 464, 482], ["parainfluenza", "DISEASE", 33, 46], ["acetylcholine", "CHEMICAL", 67, 80], ["cough", "DISEASE", 221, 226], ["gastro-oesophageal reflux", "DISEASE", 464, 489], ["cough", "DISEASE", 496, 501], ["acetylcholine", "CHEMICAL", 67, 80], ["Cells", "CELL", 0, 5], ["animals", "ORGANISM", 11, 18], ["parainfluenza virus", "ORGANISM", 33, 52], ["acetylcholine", "SIMPLE_CHEMICAL", 67, 80], ["cells", "CELL", 99, 104], ["M2 receptor", "GENE_OR_GENE_PRODUCT", 109, 120], ["IFN-gamma", "GENE_OR_GENE_PRODUCT", 147, 156], ["afferent nerves", "MULTI-TISSUE_STRUCTURE", 265, 280], ["Muscarinic receptors", "GENE_OR_GENE_PRODUCT", 313, 333], ["airway vascular", "MULTI-TISSUE_STRUCTURE", 381, 396], ["mucus", "ORGANISM_SUBSTANCE", 433, 438], ["non-infected cells", "CELL_TYPE", 86, 104], ["M2 receptor", "PROTEIN", 109, 120], ["IFN", "PROTEIN", 147, 150], ["Muscarinic receptors", "PROTEIN", 313, 333], ["acid activated muscarinic receptors", "PROTEIN", 547, 582], ["M1", "PROTEIN", 584, 586], ["M3", "PROTEIN", 591, 593], ["parainfluenza", "SPECIES", 33, 46], ["parainfluenza virus", "SPECIES", 33, 52], ["parainfluenza virus", "PROBLEM", 33, 52], ["non-infected cells", "PROBLEM", 86, 104], ["M2 receptor activity", "TEST", 109, 129], ["virus induced cough", "PROBLEM", 207, 226], ["increased sensitivity of afferent nerves", "PROBLEM", 240, 280], ["airway vascular leakage", "PROBLEM", 381, 404], ["bronchoconstriction", "PROBLEM", 409, 428], ["mucus secretion", "PROBLEM", 433, 448], ["gastro-oesophageal reflux", "PROBLEM", 464, 489], ["cough", "PROBLEM", 496, 501], ["a prominent feature", "PROBLEM", 509, 528], ["acid activated muscarinic receptors", "TREATMENT", 547, 582], ["parainfluenza virus", "OBSERVATION", 33, 52], ["afferent nerves", "OBSERVATION", 265, 280], ["central", "ANATOMY_MODIFIER", 365, 372], ["airway", "ANATOMY_MODIFIER", 381, 387], ["vascular", "ANATOMY", 388, 396], ["leakage", "OBSERVATION", 397, 404], ["bronchoconstriction", "OBSERVATION", 409, 428], ["mucus secretion", "OBSERVATION", 433, 448], ["gastro", "ANATOMY", 464, 470], ["oesophageal", "ANATOMY", 471, 482], ["reflux", "OBSERVATION", 483, 489]]], ["Again no studies have specifically investigated cough and mechanisms of cholinergic activation.LeukotrienesLeukotrienes (LT) are potent mediators of bronchoconstriction, vascular dilatation, mucus production and AHR which again are used as surrogate markers for cough.", [["vascular", "ANATOMY", 170, 178], ["mucus", "ANATOMY", 191, 196], ["cough", "DISEASE", 48, 53], ["LeukotrienesLeukotrienes", "CHEMICAL", 95, 119], ["LT", "CHEMICAL", 121, 123], ["cough", "DISEASE", 262, 267], ["LeukotrienesLeukotrienes", "CHEMICAL", 95, 119], ["LeukotrienesLeukotrienes", "SIMPLE_CHEMICAL", 95, 119], ["LT", "SIMPLE_CHEMICAL", 121, 123], ["vascular", "MULTI-TISSUE_STRUCTURE", 170, 178], ["mucus", "MULTI-TISSUE_STRUCTURE", 191, 196], ["cough", "PROBLEM", 48, 53], ["cholinergic activation", "PROBLEM", 72, 94], ["LeukotrienesLeukotrienes (LT)", "TREATMENT", 95, 124], ["bronchoconstriction", "PROBLEM", 149, 168], ["vascular dilatation", "PROBLEM", 170, 189], ["mucus production", "PROBLEM", 191, 207], ["AHR", "TREATMENT", 212, 215], ["cough", "PROBLEM", 262, 267], ["cholinergic activation", "OBSERVATION", 72, 94], ["bronchoconstriction", "OBSERVATION", 149, 168], ["vascular", "ANATOMY", 170, 178], ["dilatation", "OBSERVATION", 179, 189], ["mucus production", "OBSERVATION", 191, 207]]], ["They are produced from arachidonic acid by 5-lipoxygenase activating protein (FLAP) and 5lipoxygenase (5-LO) leading to production of the cysteinyl-LTs (specifically LTC4, D4 and E4) particularly in eosinophils and basophils.", [["eosinophils", "ANATOMY", 199, 210], ["basophils", "ANATOMY", 215, 224], ["arachidonic acid", "CHEMICAL", 23, 39], ["5-LO", "CHEMICAL", 103, 107], ["cysteinyl", "CHEMICAL", 138, 147], ["LTC4", "CHEMICAL", 166, 170], ["arachidonic acid", "CHEMICAL", 23, 39], ["cysteinyl", "CHEMICAL", 138, 147], ["arachidonic acid", "SIMPLE_CHEMICAL", 23, 39], ["5-lipoxygenase activating protein", "GENE_OR_GENE_PRODUCT", 43, 76], ["FLAP", "GENE_OR_GENE_PRODUCT", 78, 82], ["5lipoxygenase", "SIMPLE_CHEMICAL", 88, 101], ["5-LO", "SIMPLE_CHEMICAL", 103, 107], ["cysteinyl-LTs", "SIMPLE_CHEMICAL", 138, 151], ["LTC4", "SIMPLE_CHEMICAL", 166, 170], ["E4", "GENE_OR_GENE_PRODUCT", 179, 181], ["eosinophils", "CELL", 199, 210], ["basophils", "CELL", 215, 224], ["5-lipoxygenase activating protein", "PROTEIN", 43, 76], ["FLAP", "PROTEIN", 78, 82], ["5lipoxygenase", "PROTEIN", 88, 101], ["LO", "PROTEIN", 105, 107], ["E4", "PROTEIN", 179, 181], ["eosinophils", "CELL_TYPE", 199, 210], ["basophils", "CELL_TYPE", 215, 224], ["arachidonic acid", "TEST", 23, 39], ["lipoxygenase activating protein (FLAP", "TREATMENT", 45, 82], ["5lipoxygenase", "TREATMENT", 88, 101], ["the cysteinyl-LTs", "TEST", 134, 151], ["LTC4", "TEST", 166, 170], ["eosinophils", "TEST", 199, 210], ["basophils", "TEST", 215, 224], ["FLAP", "ANATOMY", 78, 82]]], ["These are potent mediators in bronchial asthma and in aspirin induced asthma, inhibition of COX-1 following administration of non-steroidal anti-inflammatory drugs produces an excess of LTs with consequent worsening AHR and bronchoconstriction.", [["bronchial", "ANATOMY", 30, 39], ["non-steroidal", "ANATOMY", 126, 139], ["bronchial asthma", "DISEASE", 30, 46], ["aspirin", "CHEMICAL", 54, 61], ["asthma", "DISEASE", 70, 76], ["aspirin", "CHEMICAL", 54, 61], ["aspirin", "SIMPLE_CHEMICAL", 54, 61], ["COX-1", "GENE_OR_GENE_PRODUCT", 92, 97], ["non-steroidal anti-inflammatory drugs", "SIMPLE_CHEMICAL", 126, 163], ["COX-1", "PROTEIN", 92, 97], ["bronchial asthma", "PROBLEM", 30, 46], ["aspirin induced asthma", "PROBLEM", 54, 76], ["inhibition of COX", "PROBLEM", 78, 95], ["non-steroidal anti-inflammatory drugs", "TREATMENT", 126, 163], ["an excess of LTs", "PROBLEM", 173, 189], ["consequent worsening AHR", "PROBLEM", 195, 219], ["bronchoconstriction", "PROBLEM", 224, 243], ["potent", "OBSERVATION_MODIFIER", 10, 16], ["bronchial", "ANATOMY", 30, 39], ["asthma", "OBSERVATION", 40, 46], ["aspirin induced", "OBSERVATION_MODIFIER", 54, 69], ["asthma", "OBSERVATION", 70, 76], ["worsening", "OBSERVATION_MODIFIER", 206, 215], ["AHR", "OBSERVATION", 216, 219], ["bronchoconstriction", "OBSERVATION", 224, 243]]], ["Attempts to specifically inhibit the activity of these compounds have led to new therapeutic agents, such as Montelukast and Zafirlukast [33] [34] [35] .LeukotrienesIn a study of non-atopic normal subjects using experimental rhinovirus infection; bronchoscopy was performed 2 weeks prior to infection and repeated 4 days after virus inoculation.", [["Montelukast", "CHEMICAL", 109, 120], ["Zafirlukast", "CHEMICAL", 125, 136], ["rhinovirus infection", "DISEASE", 225, 245], ["infection", "DISEASE", 291, 300], ["Montelukast", "CHEMICAL", 109, 120], ["Zafirlukast", "CHEMICAL", 125, 136], ["Montelukast", "SIMPLE_CHEMICAL", 109, 120], ["Zafirlukast [33] [34] [35]", "SIMPLE_CHEMICAL", 125, 151], ["Leukotrienes", "SIMPLE_CHEMICAL", 153, 165], ["rhinovirus", "ORGANISM", 225, 235], ["new therapeutic agents", "TREATMENT", 77, 99], ["Montelukast and Zafirlukast", "TREATMENT", 109, 136], ["Leukotrienes", "TREATMENT", 153, 165], ["a study", "TEST", 168, 175], ["experimental rhinovirus infection", "PROBLEM", 212, 245], ["bronchoscopy", "TREATMENT", 247, 259], ["infection", "PROBLEM", 291, 300], ["virus inoculation", "PROBLEM", 327, 344], ["rhinovirus infection", "OBSERVATION", 225, 245]]], ["This identified increased airway inflammation with increases in macrophages and mast cells in bronchial biopsies during acute infection.", [["airway", "ANATOMY", 26, 32], ["macrophages", "ANATOMY", 64, 75], ["mast cells", "ANATOMY", 80, 90], ["bronchial biopsies", "ANATOMY", 94, 112], ["airway inflammation", "DISEASE", 26, 45], ["acute infection", "DISEASE", 120, 135], ["airway", "MULTI-TISSUE_STRUCTURE", 26, 32], ["macrophages", "CELL", 64, 75], ["mast cells", "CELL", 80, 90], ["bronchial biopsies", "MULTI-TISSUE_STRUCTURE", 94, 112], ["macrophages", "CELL_TYPE", 64, 75], ["mast cells", "CELL_TYPE", 80, 90], ["increased airway inflammation", "PROBLEM", 16, 45], ["increases in macrophages", "PROBLEM", 51, 75], ["mast cells", "PROBLEM", 80, 90], ["bronchial biopsies", "TEST", 94, 112], ["acute infection", "PROBLEM", 120, 135], ["increased", "OBSERVATION_MODIFIER", 16, 25], ["airway", "ANATOMY", 26, 32], ["inflammation", "OBSERVATION", 33, 45], ["increases", "OBSERVATION_MODIFIER", 51, 60], ["macrophages", "OBSERVATION_MODIFIER", 64, 75], ["mast cells", "OBSERVATION", 80, 90], ["bronchial", "ANATOMY", 94, 103], ["biopsies", "OBSERVATION", 104, 112], ["acute", "OBSERVATION_MODIFIER", 120, 125], ["infection", "OBSERVATION", 126, 135]]], ["In biopsy samples there were 9 and 3.6 fold increases in cells counts staining positively for 5-LO and FLAP respectively.", [["biopsy samples", "ANATOMY", 3, 17], ["cells", "ANATOMY", 57, 62], ["biopsy samples", "CANCER", 3, 17], ["cells", "CELL", 57, 62], ["5-LO", "SIMPLE_CHEMICAL", 94, 98], ["FLAP", "GENE_OR_GENE_PRODUCT", 103, 107], ["LO", "PROTEIN", 96, 98], ["FLAP", "PROTEIN", 103, 107], ["biopsy samples", "TEST", 3, 17], ["3.6 fold increases in cells counts staining", "PROBLEM", 35, 78], ["FLAP", "TREATMENT", 103, 107], ["increases", "OBSERVATION_MODIFIER", 44, 53], ["cells counts", "OBSERVATION", 57, 69], ["FLAP", "ANATOMY", 103, 107]]], ["In addition staining for the inducible enzyme COX-2, which is responsible for prostaglandin (PG) synthesis, was significantly increased.", [["prostaglandin", "CHEMICAL", 78, 91], ["PG", "CHEMICAL", 93, 95], ["prostaglandin", "CHEMICAL", 78, 91], ["COX-2", "GENE_OR_GENE_PRODUCT", 46, 51], ["prostaglandin", "SIMPLE_CHEMICAL", 78, 91], ["PG", "SIMPLE_CHEMICAL", 93, 95], ["inducible enzyme", "PROTEIN", 29, 45], ["COX-2", "PROTEIN", 46, 51], ["the inducible enzyme COX", "TEST", 25, 49], ["prostaglandin (PG) synthesis", "TREATMENT", 78, 106], ["significantly", "OBSERVATION_MODIFIER", 112, 125], ["increased", "OBSERVATION_MODIFIER", 126, 135]]], ["This study demonstrated an increased capacity for the production of LT and PG [36] .", [["PG", "CHEMICAL", 75, 77], ["LT", "PROTEIN", 68, 70], ["This study", "TEST", 0, 10], ["an increased capacity", "PROBLEM", 24, 45], ["increased", "OBSERVATION_MODIFIER", 27, 36], ["capacity", "OBSERVATION_MODIFIER", 37, 45]]], ["Cold symptoms were assessed during the study using the Jackson cold scoring system; which includes cough as a symptom indicator and scores correlated with stained cell counts of FLAP, supporting a link between symptoms and virus induced LT.", [["cell", "ANATOMY", 163, 167], ["cough", "DISEASE", 99, 104], ["cell", "CELL", 163, 167], ["FLAP", "GENE_OR_GENE_PRODUCT", 178, 182], ["FLAP", "PROTEIN", 178, 182], ["Cold symptoms", "PROBLEM", 0, 13], ["the study", "TEST", 35, 44], ["cough", "PROBLEM", 99, 104], ["a symptom indicator", "PROBLEM", 108, 127], ["stained cell counts", "TEST", 155, 174], ["FLAP", "TREATMENT", 178, 182], ["a link between symptoms", "PROBLEM", 195, 218], ["virus induced LT", "PROBLEM", 223, 239], ["FLAP", "ANATOMY", 178, 182]]], ["LT levels have also been shown to increase after RSV infection and have a possible aetiological role in bronchiolitis, as a randomised control trial of the LT antagonist Montelukast found an improvement in lung symptom scores during RSV bronchiolitis [35] .", [["lung", "ANATOMY", 206, 210], ["RSV infection", "DISEASE", 49, 62], ["bronchiolitis", "DISEASE", 104, 117], ["Montelukast", "CHEMICAL", 170, 181], ["bronchiolitis", "DISEASE", 237, 250], ["Montelukast", "CHEMICAL", 170, 181], ["LT", "GENE_OR_GENE_PRODUCT", 0, 2], ["RSV", "ORGANISM", 49, 52], ["Montelukast", "SIMPLE_CHEMICAL", 170, 181], ["lung", "ORGAN", 206, 210], ["RSV", "ORGANISM", 233, 236], ["LT", "PROTEIN", 0, 2], ["RSV", "SPECIES", 49, 52], ["RSV", "SPECIES", 233, 236], ["LT levels", "TEST", 0, 9], ["RSV infection", "PROBLEM", 49, 62], ["bronchiolitis", "PROBLEM", 104, 117], ["a randomised control trial", "TREATMENT", 122, 148], ["the LT antagonist Montelukast", "TREATMENT", 152, 181], ["lung symptom scores", "PROBLEM", 206, 225], ["RSV bronchiolitis", "PROBLEM", 233, 250], ["increase", "OBSERVATION_MODIFIER", 34, 42], ["RSV", "OBSERVATION_MODIFIER", 49, 52], ["infection", "OBSERVATION", 53, 62], ["possible", "UNCERTAINTY", 74, 82], ["bronchiolitis", "OBSERVATION", 104, 117], ["improvement", "OBSERVATION_MODIFIER", 191, 202], ["lung", "ANATOMY", 206, 210], ["symptom", "OBSERVATION", 211, 218], ["RSV bronchiolitis", "OBSERVATION", 233, 250]]], ["Studies specifically investigating these pathways in cough would be of interest.Mucus production following viral infectionMucus hyper secretion is well recognised in diseases of the airway, particularly COPD where mucus production forms part of the definition of chronic bronchitis.", [["Mucus", "ANATOMY", 80, 85], ["airway", "ANATOMY", 182, 188], ["mucus", "ANATOMY", 214, 219], ["cough", "DISEASE", 53, 58], ["COPD", "DISEASE", 203, 207], ["bronchitis", "DISEASE", 271, 281], ["Mucus", "MULTI-TISSUE_STRUCTURE", 80, 85], ["airway", "MULTI-TISSUE_STRUCTURE", 182, 188], ["mucus", "MULTI-TISSUE_STRUCTURE", 214, 219], ["Studies", "TEST", 0, 7], ["cough", "PROBLEM", 53, 58], ["Mucus production", "PROBLEM", 80, 96], ["viral infectionMucus hyper secretion", "PROBLEM", 107, 143], ["diseases of the airway", "PROBLEM", 166, 188], ["COPD", "PROBLEM", 203, 207], ["mucus production", "PROBLEM", 214, 230], ["chronic bronchitis", "PROBLEM", 263, 281], ["cough", "OBSERVATION", 53, 58], ["viral", "OBSERVATION_MODIFIER", 107, 112], ["airway", "ANATOMY", 182, 188], ["COPD", "OBSERVATION", 203, 207], ["mucus production", "OBSERVATION", 214, 230], ["chronic", "OBSERVATION_MODIFIER", 263, 270], ["bronchitis", "OBSERVATION", 271, 281]]], ["Production is also stimulated by virus infection and so mucus is likely to be a significant inducer of cough, at least in part by direct airway irritation [10] .", [["mucus", "ANATOMY", 56, 61], ["airway", "ANATOMY", 137, 143], ["infection", "DISEASE", 39, 48], ["cough", "DISEASE", 103, 108], ["airway irritation", "DISEASE", 137, 154], ["mucus", "ORGANISM_SUBSTANCE", 56, 61], ["airway", "MULTI-TISSUE_STRUCTURE", 137, 143], ["virus infection", "PROBLEM", 33, 48], ["cough", "PROBLEM", 103, 108], ["direct airway irritation", "PROBLEM", 130, 154], ["likely to be", "UNCERTAINTY", 65, 77], ["significant", "OBSERVATION_MODIFIER", 80, 91], ["cough", "OBSERVATION", 103, 108], ["airway", "ANATOMY", 137, 143], ["irritation", "OBSERVATION", 144, 154]]], ["In vitro investigations of MUC5AC, a prominent airway mucin, have identified key signalling pathways and molecules [37] .", [["airway", "ANATOMY", 47, 53], ["MUC5AC", "GENE_OR_GENE_PRODUCT", 27, 33], ["airway mucin", "GENE_OR_GENE_PRODUCT", 47, 59], ["MUC5AC", "PROTEIN", 27, 33], ["MUC5AC", "PROBLEM", 27, 33], ["a prominent airway mucin", "PROBLEM", 35, 59], ["prominent", "OBSERVATION_MODIFIER", 37, 46], ["airway", "ANATOMY", 47, 53]]], ["Specifically the signalling for MUC5AC gene promoter is activated by the transcription factor SP1 following stimulation with the model inflammatory stimulus PMA.Mucus production following viral infectionSubsequently in vitro rhinovirus infection of human tracheal cells and submucosal glands demonstrated an up-regulation of mRNA for mucin producing genes.", [["Mucus", "ANATOMY", 161, 166], ["tracheal cells", "ANATOMY", 255, 269], ["submucosal glands", "ANATOMY", 274, 291], ["rhinovirus infection", "DISEASE", 225, 245], ["PMA", "CHEMICAL", 157, 160], ["MUC5AC", "GENE_OR_GENE_PRODUCT", 32, 38], ["SP1", "GENE_OR_GENE_PRODUCT", 94, 97], ["PMA", "SIMPLE_CHEMICAL", 157, 160], ["Mucus", "GENE_OR_GENE_PRODUCT", 161, 166], ["rhinovirus", "ORGANISM", 225, 235], ["human", "ORGANISM", 249, 254], ["tracheal cells", "CELL", 255, 269], ["submucosal glands", "ORGAN", 274, 291], ["mucin", "GENE_OR_GENE_PRODUCT", 334, 339], ["MUC5AC gene promoter", "DNA", 32, 52], ["transcription factor", "PROTEIN", 73, 93], ["SP1", "PROTEIN", 94, 97], ["human tracheal cells", "CELL_TYPE", 249, 269], ["mRNA", "RNA", 325, 329], ["mucin producing genes", "DNA", 334, 355], ["human", "SPECIES", 249, 254], ["human", "SPECIES", 249, 254], ["MUC5AC gene promoter", "TREATMENT", 32, 52], ["the model inflammatory stimulus PMA", "TREATMENT", 125, 160], ["Mucus production", "PROBLEM", 161, 177], ["viral infectionSubsequently", "PROBLEM", 188, 215], ["vitro rhinovirus infection of human tracheal cells", "PROBLEM", 219, 269], ["submucosal glands", "PROBLEM", 274, 291], ["mucin producing genes", "PROBLEM", 334, 355], ["inflammatory stimulus", "OBSERVATION", 135, 156], ["rhinovirus infection", "OBSERVATION", 225, 245], ["tracheal cells", "ANATOMY", 255, 269], ["submucosal glands", "ANATOMY", 274, 291]]], ["Levels of MUC5AC mRNA, protein and total mucin concentration were also elevated [10] .", [["MUC5AC", "GENE_OR_GENE_PRODUCT", 10, 16], ["mucin", "GENE_OR_GENE_PRODUCT", 41, 46], ["MUC5AC mRNA", "RNA", 10, 21], ["Levels", "TEST", 0, 6], ["MUC5AC mRNA", "TEST", 10, 21], ["protein", "TEST", 23, 30], ["total mucin concentration", "TEST", 35, 60]]], ["This effect was attenuated following addition of an NF-kB and mitogen activated protein (MAP)-kinase inhibitor, suggesting these signalling molecules are important for mucus hyper-secretion following virus infection and suggesting inhibitors of these as potential therapeutic targets.", [["mucus", "ANATOMY", 168, 173], ["infection", "DISEASE", 206, 215], ["NF-kB", "GENE_OR_GENE_PRODUCT", 52, 57], ["mitogen activated protein (MAP)-kinase", "GENE_OR_GENE_PRODUCT", 62, 100], ["mucus", "ORGANISM_SUBSTANCE", 168, 173], ["NF-kB", "PROTEIN", 52, 57], ["MAP", "PROTEIN", 89, 92], ["an NF-kB", "TREATMENT", 49, 57], ["mitogen activated protein (MAP)-kinase inhibitor", "TREATMENT", 62, 110], ["these signalling molecules", "PROBLEM", 123, 149], ["mucus hyper-secretion", "PROBLEM", 168, 189], ["virus infection", "PROBLEM", 200, 215], ["inhibitors", "TREATMENT", 231, 241]]], ["In vivo rhinovirus infection has been shown to induce MUC5AC levels in BAL and in vitro studies demonstrated that this occurs as a result of new mRNA synthesis.", [["BAL", "ANATOMY", 71, 74], ["rhinovirus infection", "DISEASE", 8, 28], ["rhinovirus", "ORGANISM", 8, 18], ["MUC5AC", "GENE_OR_GENE_PRODUCT", 54, 60], ["BAL", "CELL", 71, 74], ["MUC5AC", "PROTEIN", 54, 60], ["vivo rhinovirus infection", "PROBLEM", 3, 28], ["MUC5AC levels", "TEST", 54, 67], ["BAL", "TEST", 71, 74], ["vitro studies", "TEST", 82, 95], ["new mRNA synthesis", "PROBLEM", 141, 159], ["rhinovirus infection", "OBSERVATION", 8, 28], ["new", "OBSERVATION_MODIFIER", 141, 144], ["mRNA synthesis", "OBSERVATION", 145, 159]]], ["The signalling pathway has been characterised in detail and the transcription factors NF-kB and SP-1 were shown to be involved.", [["NF-kB", "GENE_OR_GENE_PRODUCT", 86, 91], ["SP-1", "GENE_OR_GENE_PRODUCT", 96, 100], ["transcription factors", "PROTEIN", 64, 85], ["NF-kB and SP-1", "PROTEIN", 86, 100]]], ["Following RV infection NF-kB is activated and matrix metalloproteinase mediated release of transforming growth factor (TGF) occurs.", [["RV infection", "DISEASE", 10, 22], ["NF-kB", "GENE_OR_GENE_PRODUCT", 23, 28], ["matrix metalloproteinase", "GENE_OR_GENE_PRODUCT", 46, 70], ["transforming growth factor", "GENE_OR_GENE_PRODUCT", 91, 117], ["TGF", "GENE_OR_GENE_PRODUCT", 119, 122], ["NF-kB", "PROTEIN", 23, 28], ["matrix metalloproteinase", "PROTEIN", 46, 70], ["transforming growth factor", "PROTEIN", 91, 117], ["TGF", "PROTEIN", 119, 122], ["RV infection NF", "PROBLEM", 10, 25], ["activated and matrix metalloproteinase mediated release", "TREATMENT", 32, 87], ["transforming growth factor", "PROBLEM", 91, 117], ["RV", "ANATOMY", 10, 12], ["infection", "OBSERVATION", 13, 22]]], ["This in turn activates the epidermal growth factor receptor leading to activation of protein kinase signalling (MAPK, MEK and ERK).", [["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 27, 59], ["MAPK", "GENE_OR_GENE_PRODUCT", 112, 116], ["MEK", "GENE_OR_GENE_PRODUCT", 118, 121], ["ERK", "GENE_OR_GENE_PRODUCT", 126, 129], ["epidermal growth factor receptor", "PROTEIN", 27, 59], ["protein kinase", "PROTEIN", 85, 99], ["MAPK", "PROTEIN", 112, 116], ["MEK", "PROTEIN", 118, 121], ["ERK", "PROTEIN", 126, 129], ["the epidermal growth factor receptor", "PROBLEM", 23, 59], ["protein kinase signalling", "TEST", 85, 110], ["MAPK", "TEST", 112, 116], ["MEK", "TEST", 118, 121], ["ERK", "TEST", 126, 129]]], ["Finally through SP-1 signalling the MUC5AC gene transcription is increased and hence protein levels elevated [37] (C.A. Hewson et al., unpublished results).Mouse model of RV infectionInvestigation of the mechanism of virus induced cough has suffered from the lack of a small animal model of virus induced cough, particularly for rhinovirus which is the most common virus infection in humans [38] and repeatedly indentified as the most frequent virus in acute exacerbations of airway disease [8, [14] [15] [16] .", [["RV", "ANATOMY", 171, 173], ["airway", "ANATOMY", 476, 482], ["RV infection", "DISEASE", 171, 183], ["cough", "DISEASE", 231, 236], ["cough", "DISEASE", 305, 310], ["infection", "DISEASE", 371, 380], ["airway disease", "DISEASE", 476, 490], ["SP-1", "GENE_OR_GENE_PRODUCT", 16, 20], ["MUC5AC", "GENE_OR_GENE_PRODUCT", 36, 42], ["Mouse", "ORGANISM", 156, 161], ["rhinovirus", "ORGANISM", 329, 339], ["humans", "ORGANISM", 384, 390], ["airway", "ORGAN", 476, 482], ["SP", "PROTEIN", 16, 18], ["MUC5AC gene", "DNA", 36, 47], ["Mouse", "SPECIES", 156, 161], ["humans", "SPECIES", 384, 390], ["RV", "SPECIES", 171, 173], ["humans", "SPECIES", 384, 390], ["the MUC5AC gene transcription", "TREATMENT", 32, 61], ["protein levels", "TEST", 85, 99], ["RV infection", "PROBLEM", 171, 183], ["virus induced cough", "PROBLEM", 217, 236], ["a small animal model of virus induced cough", "PROBLEM", 267, 310], ["rhinovirus", "PROBLEM", 329, 339], ["the most common virus infection", "PROBLEM", 349, 380], ["acute exacerbations of airway disease", "PROBLEM", 453, 490], ["increased", "OBSERVATION_MODIFIER", 65, 74], ["RV", "ANATOMY", 171, 173], ["infection", "OBSERVATION", 174, 183], ["small", "OBSERVATION_MODIFIER", 269, 274], ["most frequent", "OBSERVATION_MODIFIER", 430, 443], ["virus", "OBSERVATION", 444, 449], ["acute", "OBSERVATION_MODIFIER", 453, 458], ["exacerbations", "OBSERVATION", 459, 472], ["airway", "ANATOMY", 476, 482]]], ["Major group rhinoviruses (90% of serotypes) bind to the human intercellular adhesion molecule-1 (ICAM-1) as their cellular receptor.", [["cellular", "ANATOMY", 114, 122], ["rhinoviruses", "ORGANISM", 12, 24], ["human intercellular adhesion molecule-1", "GENE_OR_GENE_PRODUCT", 56, 95], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 97, 103], ["cellular", "CELL", 114, 122], ["human intercellular adhesion molecule-1 (ICAM-1", "PROTEIN", 56, 103], ["cellular receptor", "PROTEIN", 114, 131], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["Major group rhinoviruses", "PROBLEM", 0, 24], ["the human intercellular adhesion molecule", "TEST", 52, 93], ["ICAM", "TEST", 97, 101], ["rhinoviruses", "OBSERVATION", 12, 24]]], ["However they are unable to bind to mouse ICAM-1.", [["mouse", "ORGANISM", 35, 40], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 41, 47], ["mouse ICAM-1", "PROTEIN", 35, 47], ["mouse", "SPECIES", 35, 40], ["mouse", "SPECIES", 35, 40]]], ["The recent generation of a mouse-human ICAM-1 chimera has enabled a mouse model of rhinovirus infection to be created [39] .", [["rhinovirus infection", "DISEASE", 83, 103], ["mouse", "ORGANISM", 27, 32], ["human", "ORGANISM", 33, 38], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 39, 45], ["mouse", "ORGANISM", 68, 73], ["rhinovirus", "ORGANISM", 83, 93], ["mouse-human ICAM-1 chimera", "PROTEIN", 27, 53], ["mouse", "SPECIES", 27, 32], ["human", "SPECIES", 33, 38], ["mouse", "SPECIES", 68, 73], ["mouse", "SPECIES", 27, 32], ["human", "SPECIES", 33, 38], ["mouse", "SPECIES", 68, 73], ["a mouse-human ICAM", "TREATMENT", 25, 43], ["rhinovirus infection", "PROBLEM", 83, 103], ["rhinovirus", "OBSERVATION", 83, 93]]], ["In addition the model included sensitisation and subsequent re-challenge with ovalbumen to create features of atopy, which in combination with rhinovirus infection provides a model for asthma exacerbations.", [["ovalbumen", "CHEMICAL", 78, 87], ["atopy", "DISEASE", 110, 115], ["rhinovirus infection", "DISEASE", 143, 163], ["asthma exacerbations", "DISEASE", 185, 205], ["ovalbumen", "SIMPLE_CHEMICAL", 78, 87], ["rhinovirus", "ORGANISM", 143, 153], ["ovalbumen", "TREATMENT", 78, 87], ["atopy", "PROBLEM", 110, 115], ["rhinovirus infection", "PROBLEM", 143, 163], ["asthma exacerbations", "PROBLEM", 185, 205], ["rhinovirus", "OBSERVATION", 143, 153]]], ["In the absence of coughing in mice AHR would have to be used as surrogate for cough, however guinea pigs, which are able to cough, may prove a more useful model in the future.", [["coughing", "DISEASE", 18, 26], ["cough", "DISEASE", 78, 83], ["cough", "DISEASE", 124, 129], ["mice", "ORGANISM", 30, 34], ["guinea pigs", "ORGANISM", 93, 104], ["mice", "SPECIES", 30, 34], ["guinea pigs", "SPECIES", 93, 104], ["mice", "SPECIES", 30, 34], ["guinea pigs", "SPECIES", 93, 104], ["coughing in mice AHR", "PROBLEM", 18, 38], ["cough", "PROBLEM", 78, 83], ["guinea pigs", "TREATMENT", 93, 104], ["cough", "PROBLEM", 124, 129], ["coughing", "OBSERVATION", 18, 26]]], ["Sendai and RSV infection are established in guinea pigs but RV infection has not presently been attempted.", [["RSV infection", "DISEASE", 11, 24], ["RV infection", "DISEASE", 60, 72], ["Sendai", "ORGANISM", 0, 6], ["RSV", "ORGANISM", 11, 14], ["guinea pigs", "ORGANISM", 44, 55], ["RV", "ORGAN", 60, 62], ["RSV", "SPECIES", 11, 14], ["guinea pigs", "SPECIES", 44, 55], ["RSV", "SPECIES", 11, 14], ["guinea pigs", "SPECIES", 44, 55], ["RV", "SPECIES", 60, 62], ["Sendai", "PROBLEM", 0, 6], ["RSV infection", "PROBLEM", 11, 24], ["guinea pigs", "TREATMENT", 44, 55], ["RV infection", "PROBLEM", 60, 72], ["RSV infection", "OBSERVATION", 11, 24], ["RV", "ANATOMY", 60, 62], ["infection", "OBSERVATION", 63, 72]]], ["The availability of a small animal model will prove invaluable in the development of therapies for cough.Human studiesHuman challenge studies with rhinovirus have been performed in healthy subjects and in those with asthma and COPD [12, [40] [41] [42] .", [["cough", "DISEASE", 99, 104], ["asthma", "DISEASE", 216, 222], ["COPD", "DISEASE", 227, 231], ["Human", "ORGANISM", 105, 110], ["Human", "ORGANISM", 118, 123], ["rhinovirus", "ORGANISM", 147, 157], ["Human", "SPECIES", 105, 110], ["Human", "SPECIES", 118, 123], ["Human", "SPECIES", 105, 110], ["a small animal model", "TREATMENT", 20, 40], ["therapies", "TREATMENT", 85, 94], ["cough", "PROBLEM", 99, 104], ["Human studies", "TEST", 105, 118], ["Human challenge studies", "TEST", 118, 141], ["rhinovirus", "PROBLEM", 147, 157], ["asthma", "PROBLEM", 216, 222], ["COPD", "PROBLEM", 227, 231], ["COPD", "OBSERVATION", 227, 231]]], ["Experimental infection in humans allows investigation of the complete physiological system and detailed characterisation of subjects at baseline, prior to infection and at regular intervals throughout infection until convalescence.", [["infection", "DISEASE", 13, 22], ["infection", "DISEASE", 155, 164], ["infection", "DISEASE", 201, 210], ["humans", "ORGANISM", 26, 32], ["humans", "SPECIES", 26, 32], ["humans", "SPECIES", 26, 32], ["Experimental infection in humans", "PROBLEM", 0, 32], ["infection", "PROBLEM", 155, 164], ["infection", "OBSERVATION", 13, 22], ["infection", "OBSERVATION", 155, 164], ["infection", "OBSERVATION", 201, 210]]], ["This provides an opportunity for detailed investigation of cough symptoms throughout the full time-line of rhinovirus infection and the potential to further investigate in vivo mechanisms of virus induced cough in healthy subjects as well as those with airway disease.COPDCough is the most frequent symptom in COPD yet it is used surprisingly infrequently in the monitoring of the disease or assessment of treatment response.", [["airway", "ANATOMY", 253, 259], ["cough symptoms", "DISEASE", 59, 73], ["rhinovirus infection", "DISEASE", 107, 127], ["cough", "DISEASE", 205, 210], ["airway disease", "DISEASE", 253, 267], ["COPD", "DISEASE", 310, 314], ["rhinovirus", "ORGANISM", 107, 117], ["airway", "MULTI-TISSUE_STRUCTURE", 253, 259], ["cough symptoms", "PROBLEM", 59, 73], ["rhinovirus infection", "PROBLEM", 107, 127], ["virus induced cough", "PROBLEM", 191, 210], ["airway disease", "PROBLEM", 253, 267], ["the most frequent symptom", "PROBLEM", 281, 306], ["COPD", "PROBLEM", 310, 314], ["the disease", "PROBLEM", 377, 388], ["treatment response", "PROBLEM", 406, 424], ["rhinovirus", "OBSERVATION", 107, 117], ["airway", "ANATOMY", 253, 259], ["disease", "OBSERVATION", 260, 267], ["most frequent", "OBSERVATION_MODIFIER", 285, 298], ["COPD", "OBSERVATION", 310, 314], ["disease", "OBSERVATION", 381, 388]]], ["In an experimental challenge study RV infection was performed in patients with mild to moderate COPD and age and smoking matched, non-obstructed controls.", [["RV infection", "DISEASE", 35, 47], ["COPD", "DISEASE", 96, 100], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["RV", "SPECIES", 35, 37], ["an experimental challenge study", "TEST", 3, 34], ["RV infection", "PROBLEM", 35, 47], ["mild to moderate COPD", "PROBLEM", 79, 100], ["non-obstructed controls", "PROBLEM", 130, 153], ["RV", "ANATOMY", 35, 37], ["infection", "OBSERVATION", 38, 47], ["moderate", "OBSERVATION_MODIFIER", 87, 95], ["COPD", "OBSERVATION", 96, 100], ["non-obstructed", "OBSERVATION", 130, 144]]], ["The model was shown to be a safe and valid model for the study of COPD exacerbations [42] .", [["COPD", "DISEASE", 66, 70], ["the study", "TEST", 53, 62], ["COPD exacerbations", "PROBLEM", 66, 84], ["COPD", "OBSERVATION", 66, 70]]], ["Subjects kept symptom diary cards throughout the study; these revealed a significant increase in cough scores for both groups during acute viral infection when compared to their baseline scores [42] .", [["cough", "DISEASE", 97, 102], ["acute viral infection", "DISEASE", 133, 154], ["Subjects", "ORGANISM", 0, 8], ["the study", "TEST", 45, 54], ["a significant increase in cough scores", "PROBLEM", 71, 109], ["acute viral infection", "PROBLEM", 133, 154], ["significant", "OBSERVATION_MODIFIER", 73, 84], ["increase", "OBSERVATION_MODIFIER", 85, 93], ["cough", "OBSERVATION", 97, 102], ["acute", "OBSERVATION_MODIFIER", 133, 138], ["viral", "OBSERVATION_MODIFIER", 139, 144], ["infection", "OBSERVATION", 145, 154]]], ["This new model provides an exciting opportunity to investigate mechanisms of cough in COPD and future studies with a non-smoking control arm are awaited with interest in order to permit separation of the effects of smoking from those of COPD.Cough monitoringReporting of cough by patients is highly subjective; many factors such as mood, health belief and coexisting symptoms may bias reporting.", [["cough", "DISEASE", 77, 82], ["COPD", "DISEASE", 86, 90], ["smoking", "CHEMICAL", 215, 222], ["COPD", "DISEASE", 237, 241], ["cough", "DISEASE", 271, 276], ["patients", "ORGANISM", 280, 288], ["patients", "SPECIES", 280, 288], ["cough", "PROBLEM", 77, 82], ["COPD", "PROBLEM", 86, 90], ["future studies", "TEST", 95, 109], ["a non-smoking control arm", "TREATMENT", 115, 140], ["COPD", "PROBLEM", 237, 241], ["Cough monitoring", "TEST", 242, 258], ["cough", "PROBLEM", 271, 276], ["coexisting symptoms", "PROBLEM", 356, 375], ["cough", "OBSERVATION", 77, 82], ["COPD", "OBSERVATION", 86, 90], ["COPD", "OBSERVATION", 237, 241], ["cough", "OBSERVATION", 271, 276]]], ["Therefore more objective assessments of cough monitoring have been developed.", [["cough", "DISEASE", 40, 45], ["objective assessments", "TEST", 15, 36], ["cough monitoring", "TEST", 40, 56]]], ["In these, sound from coughing is recorded digitally and numbers of individual coughs and time spent coughing are calculated by investigators.", [["coughing", "PROBLEM", 21, 29], ["individual coughs", "PROBLEM", 67, 84], ["coughing", "PROBLEM", 100, 108], ["sound", "OBSERVATION_MODIFIER", 10, 15], ["coughing", "OBSERVATION", 21, 29]]], ["The system has been validated by correlation with video recordings and has been shown to be responsive to symptom changes following use in cystic fibrosis patients [43] .", [["cystic", "ANATOMY", 139, 145], ["fibrosis", "DISEASE", 146, 154], ["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 155, 163], ["video recordings", "TEST", 50, 66], ["symptom changes", "PROBLEM", 106, 121], ["cystic fibrosis", "PROBLEM", 139, 154], ["cystic", "OBSERVATION_MODIFIER", 139, 145], ["fibrosis", "OBSERVATION", 146, 154]]], ["Objective monitoring of cough in stable COPD has been performed [44] ; here it was shown that cough was more frequent during the day and did not correlate with lung function tests.", [["lung", "ANATOMY", 160, 164], ["cough", "DISEASE", 24, 29], ["COPD", "DISEASE", 40, 44], ["cough", "DISEASE", 94, 99], ["lung", "ORGAN", 160, 164], ["Objective monitoring", "TEST", 0, 20], ["cough", "PROBLEM", 24, 29], ["stable COPD", "PROBLEM", 33, 44], ["cough", "PROBLEM", 94, 99], ["lung function tests", "TEST", 160, 179], ["cough", "OBSERVATION", 24, 29], ["stable", "OBSERVATION_MODIFIER", 33, 39], ["COPD", "OBSERVATION", 40, 44], ["cough", "OBSERVATION", 94, 99], ["lung", "ANATOMY", 160, 164]]], ["Many different systems to measure cough have been developed for both research and commercial purposes.", [["cough", "DISEASE", 34, 39], ["cough", "PROBLEM", 34, 39]]], ["In addition to the system detailed above at least two other groups in the UK have developed cough monitoring systems [45, 46] .", [["cough", "DISEASE", 92, 97], ["cough monitoring systems", "TEST", 92, 116], ["cough", "OBSERVATION", 92, 97]]], ["Only moderate correlation with subjective scoring was observed.", [["subjective scoring", "PROBLEM", 31, 49], ["moderate", "OBSERVATION_MODIFIER", 5, 13]]], ["The opportunity to combine objective monitoring with experimental rhinovirus infection would provide a unique opportunity to study cough in controlled and well-defined populations; both those with and without airways disease.", [["airways", "ANATOMY", 209, 216], ["rhinovirus infection", "DISEASE", 66, 86], ["cough", "DISEASE", 131, 136], ["airways disease", "DISEASE", 209, 224], ["rhinovirus", "ORGANISM", 66, 76], ["airways", "MULTI-TISSUE_STRUCTURE", 209, 216], ["objective monitoring", "TEST", 27, 47], ["experimental rhinovirus infection", "PROBLEM", 53, 86], ["cough in controlled and well-defined populations", "PROBLEM", 131, 179], ["airways disease", "PROBLEM", 209, 224], ["rhinovirus", "OBSERVATION", 66, 76], ["without", "UNCERTAINTY", 201, 208], ["airways", "ANATOMY", 209, 216], ["disease", "OBSERVATION", 217, 224]]], ["Both COPD and asthma exacerbations could be studied which would provide data of the duration and severity of cough following viral infection.", [["COPD", "DISEASE", 5, 9], ["asthma", "DISEASE", 14, 20], ["cough", "DISEASE", 109, 114], ["viral infection", "DISEASE", 125, 140], ["Both COPD", "PROBLEM", 0, 9], ["asthma exacerbations", "PROBLEM", 14, 34], ["cough", "PROBLEM", 109, 114], ["viral infection", "PROBLEM", 125, 140], ["COPD", "OBSERVATION", 5, 9], ["asthma", "OBSERVATION", 14, 20], ["cough", "OBSERVATION", 109, 114], ["viral", "OBSERVATION_MODIFIER", 125, 130], ["infection", "OBSERVATION", 131, 140]]], ["Not only would this facilitate investigation of the mechanisms of cough but also provide the opportunity to test potential therapies.Potential therapiesFew effective antitussive medications are available for virus mediated cough and these are not often used clinically.", [["cough", "DISEASE", 66, 71], ["cough", "DISEASE", 223, 228], ["cough", "PROBLEM", 66, 71], ["Potential therapies", "TREATMENT", 133, 152], ["Few effective antitussive medications", "TREATMENT", 152, 189], ["virus mediated cough", "PROBLEM", 208, 228], ["cough", "OBSERVATION", 66, 71]]], ["Strategies have traditionally concentrated on symptom reduction but advances in antiviral therapy are likely to result in direct attempts to modulate virus replication.Potential therapiesA recent placebo controlled study of non-smokers with an URTI found that tiotropium, a long acting anticholinergic, was effective at reducing the cough reflex sensitivity following stimulation with capsaicin.", [["URTI", "DISEASE", 244, 248], ["tiotropium", "CHEMICAL", 260, 270], ["cough", "DISEASE", 333, 338], ["capsaicin", "CHEMICAL", 385, 394], ["tiotropium", "CHEMICAL", 260, 270], ["capsaicin", "CHEMICAL", 385, 394], ["non-smokers", "ORGANISM", 224, 235], ["tiotropium", "SIMPLE_CHEMICAL", 260, 270], ["capsaicin", "SIMPLE_CHEMICAL", 385, 394], ["symptom reduction", "TREATMENT", 46, 63], ["antiviral therapy", "TREATMENT", 80, 97], ["modulate virus replication", "TREATMENT", 141, 167], ["an URTI", "PROBLEM", 241, 248], ["tiotropium", "TREATMENT", 260, 270], ["a long acting anticholinergic", "TREATMENT", 272, 301], ["the cough reflex sensitivity", "PROBLEM", 329, 357], ["capsaicin", "TREATMENT", 385, 394]]], ["As there were no associated changes in lung function the authors suggest that the antitussive effects of tiotropium may be through a mechanism other than bronchodilation [47] .", [["lung", "ANATOMY", 39, 43], ["tiotropium", "CHEMICAL", 105, 115], ["tiotropium", "CHEMICAL", 105, 115], ["lung", "ORGAN", 39, 43], ["tiotropium", "SIMPLE_CHEMICAL", 105, 115], ["associated changes in lung function", "PROBLEM", 17, 52], ["tiotropium", "TREATMENT", 105, 115], ["no associated", "UNCERTAINTY", 14, 27], ["changes", "OBSERVATION_MODIFIER", 28, 35], ["lung", "ANATOMY", 39, 43]]], ["A double blind placebo controlled study of nasal ipratropium bromide reported decreased sneezing and rhinorrhea [48] , however cough was not investigated specifically in this study.Potential therapiesA reduction in cough was also achieved after double blind administration of pseudoephedrine and brompheniramine, a first generation antihistamine [49] , however this effect was not seen when newer non-sedating antihistamines were used [50] , which may have less anti-cholinergic activity.", [["nasal", "ANATOMY", 43, 48], ["ipratropium bromide", "CHEMICAL", 49, 68], ["decreased sneezing", "DISEASE", 78, 96], ["rhinorrhea", "DISEASE", 101, 111], ["cough", "DISEASE", 127, 132], ["cough", "DISEASE", 215, 220], ["pseudoephedrine", "CHEMICAL", 276, 291], ["brompheniramine", "CHEMICAL", 296, 311], ["antihistamine", "CHEMICAL", 332, 345], ["ipratropium bromide", "CHEMICAL", 49, 68], ["pseudoephedrine", "CHEMICAL", 276, 291], ["brompheniramine", "CHEMICAL", 296, 311], ["nasal ipratropium bromide", "SIMPLE_CHEMICAL", 43, 68], ["pseudoephedrine", "SIMPLE_CHEMICAL", 276, 291], ["brompheniramine", "SIMPLE_CHEMICAL", 296, 311], ["antihistamines", "SIMPLE_CHEMICAL", 410, 424], ["A double blind placebo", "TREATMENT", 0, 22], ["nasal ipratropium bromide", "TREATMENT", 43, 68], ["decreased sneezing", "PROBLEM", 78, 96], ["rhinorrhea", "PROBLEM", 101, 111], ["cough", "PROBLEM", 127, 132], ["this study", "TEST", 170, 180], ["Potential therapiesA reduction", "TREATMENT", 181, 211], ["cough", "PROBLEM", 215, 220], ["pseudoephedrine", "TREATMENT", 276, 291], ["brompheniramine", "TREATMENT", 296, 311], ["a first generation antihistamine", "TREATMENT", 313, 345], ["newer non-sedating antihistamines", "TREATMENT", 391, 424], ["nasal", "ANATOMY", 43, 48], ["reduction", "OBSERVATION_MODIFIER", 202, 211], ["cough", "OBSERVATION", 215, 220]]], ["Side effects are likely to limit the use of more sedating drugs in most routine practice, and particularly in children.Potential therapiesThe NSAID naproxen decreased cough and associated symptoms in a double blind placebo controlled study using experimental RV challenge [51] .", [["naproxen", "CHEMICAL", 148, 156], ["cough", "DISEASE", 167, 172], ["naproxen", "CHEMICAL", 148, 156], ["children", "ORGANISM", 110, 118], ["NSAID", "SIMPLE_CHEMICAL", 142, 147], ["naproxen", "SIMPLE_CHEMICAL", 148, 156], ["children", "SPECIES", 110, 118], ["more sedating drugs", "TREATMENT", 44, 63], ["Potential therapies", "TREATMENT", 119, 138], ["The NSAID naproxen", "TREATMENT", 138, 156], ["cough", "PROBLEM", 167, 172], ["associated symptoms", "PROBLEM", 177, 196], ["a double blind placebo", "TREATMENT", 200, 222], ["experimental RV challenge", "TREATMENT", 246, 271]]], ["It was concluded that prostaglandins are among the inflammatory mediators that play a role in RV induced cold symptoms including cough.Potential therapiesSpecific antiviral therapies have been studied but their use is likely to be limited by the wide variety of viruses responsible for URTI and the difficulty in prescribing appropriately in the absence of rapid accurate diagnostic testing.", [["RV", "ANATOMY", 94, 96], ["prostaglandins", "CHEMICAL", 22, 36], ["cough", "DISEASE", 129, 134], ["URTI", "DISEASE", 286, 290], ["prostaglandins", "CHEMICAL", 22, 36], ["prostaglandins", "SIMPLE_CHEMICAL", 22, 36], ["RV", "MULTI-TISSUE_STRUCTURE", 94, 96], ["inflammatory mediators", "PROTEIN", 51, 73], ["prostaglandins", "TREATMENT", 22, 36], ["the inflammatory mediators", "PROBLEM", 47, 73], ["RV induced cold symptoms", "PROBLEM", 94, 118], ["cough", "PROBLEM", 129, 134], ["Potential therapiesSpecific antiviral therapies", "TREATMENT", 135, 182], ["the wide variety of viruses", "PROBLEM", 242, 269], ["URTI", "PROBLEM", 286, 290], ["rapid accurate diagnostic testing", "TEST", 357, 390], ["cough", "OBSERVATION", 129, 134], ["antiviral therapies", "OBSERVATION", 163, 182], ["viruses", "OBSERVATION", 262, 269]]], ["The antiviral ruprintrivir was used in experimental RV colds and reduced the mean daily symptom score when given 24 hours after infection.", [["ruprintrivir", "CHEMICAL", 14, 26], ["RV colds", "DISEASE", 52, 60], ["infection", "DISEASE", 128, 137], ["ruprintrivir", "SIMPLE_CHEMICAL", 14, 26], ["RV", "SPECIES", 52, 54], ["The antiviral ruprintrivir", "TREATMENT", 0, 26], ["experimental RV colds", "TREATMENT", 39, 60], ["infection", "PROBLEM", 128, 137], ["RV", "ANATOMY", 52, 54], ["infection", "OBSERVATION", 128, 137]]], ["Prophylactic use reduced the viral load but did not reduce the frequency of colds [52] .", [["colds", "DISEASE", 76, 81], ["the viral load", "PROBLEM", 25, 39], ["colds", "PROBLEM", 76, 81], ["viral load", "OBSERVATION", 29, 39]]], ["A review of RV chemotherapy concluded that effective drugs were available but studying these in trials and their use clinically are difficult as almost immediate diagnosis and treatment of virus infection is required [53] .", [["infection", "DISEASE", 195, 204], ["RV chemotherapy", "TREATMENT", 12, 27], ["effective drugs", "TREATMENT", 43, 58], ["virus infection", "PROBLEM", 189, 204], ["RV", "ANATOMY", 12, 14]]], ["Ribavirin is an effective antiviral for RSV, but larger clinical studies have lacked the power to demonstrate a benefit in bronchiolitis, although there is conflicting evidence in the literature [54] [55] [56] and it has not been specifically shown to reduce cough symptoms.", [["Ribavirin", "CHEMICAL", 0, 9], ["RSV", "DISEASE", 40, 43], ["bronchiolitis", "DISEASE", 123, 136], ["cough", "DISEASE", 259, 264], ["Ribavirin", "CHEMICAL", 0, 9], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["RSV", "ORGANISM", 40, 43], ["RSV", "SPECIES", 40, 43], ["Ribavirin", "TREATMENT", 0, 9], ["an effective antiviral", "TREATMENT", 13, 35], ["RSV", "PROBLEM", 40, 43], ["larger clinical studies", "TEST", 49, 72], ["bronchiolitis", "PROBLEM", 123, 136], ["cough symptoms", "PROBLEM", 259, 273], ["bronchiolitis", "OBSERVATION", 123, 136]]], ["Centrally acting cough suppressors are not specific to virus induced cough and are generally avoided because of their side effect profile.", [["cough", "DISEASE", 69, 74], ["Centrally acting cough suppressors", "PROBLEM", 0, 34], ["virus induced cough", "PROBLEM", 55, 74], ["their side effect profile", "PROBLEM", 112, 137], ["cough suppressors", "OBSERVATION", 17, 34]]], ["A double blind placebo controlled study using both objective and subjective cough monitoring found very little support for conventional antitussives over placebo in an URTI associated cough [57] .", [["URTI", "DISEASE", 168, 172], ["cough", "DISEASE", 184, 189], ["A double blind placebo controlled study", "TREATMENT", 0, 39], ["subjective cough monitoring", "TEST", 65, 92], ["conventional antitussives over placebo", "TREATMENT", 123, 161], ["an URTI associated cough", "PROBLEM", 165, 189]]], ["Alternative therapies may be developed in the future, but these will need to have minimal side effects and a rapid onset of action if there are to be of use in URTI and control of cough.ConclusionAcute cough represents a highly significant burden to those with and without lung disease.ConclusionThe majority of episodes of cough are due to acute respiratory virus infections and presently therapies directly targeting this are sub-optimal.ConclusionOur present understanding is that virus infection likely generates cough by selectively altering neural signalling.", [["lung", "ANATOMY", 273, 277], ["neural", "ANATOMY", 547, 553], ["URTI", "DISEASE", 160, 164], ["cough", "DISEASE", 180, 185], ["cough", "DISEASE", 202, 207], ["lung disease", "DISEASE", 273, 285], ["cough", "DISEASE", 324, 329], ["acute respiratory virus infections", "DISEASE", 341, 375], ["infection", "DISEASE", 490, 499], ["cough", "DISEASE", 517, 522], ["lung", "ORGAN", 273, 277], ["neural", "CELL", 547, 553], ["Alternative therapies", "TREATMENT", 0, 21], ["minimal side effects", "PROBLEM", 82, 102], ["cough", "PROBLEM", 180, 185], ["ConclusionAcute cough", "PROBLEM", 186, 207], ["lung disease", "PROBLEM", 273, 285], ["cough", "PROBLEM", 324, 329], ["acute respiratory virus infections", "PROBLEM", 341, 375], ["therapies", "TREATMENT", 390, 399], ["virus infection", "PROBLEM", 484, 499], ["cough", "PROBLEM", 517, 522], ["selectively altering neural signalling", "PROBLEM", 526, 564], ["cough", "OBSERVATION", 180, 185], ["highly", "OBSERVATION_MODIFIER", 221, 227], ["significant", "OBSERVATION_MODIFIER", 228, 239], ["burden", "OBSERVATION", 240, 246], ["without", "UNCERTAINTY", 265, 272], ["lung", "ANATOMY", 273, 277], ["disease", "OBSERVATION", 278, 285], ["majority", "OBSERVATION_MODIFIER", 300, 308], ["cough", "OBSERVATION", 324, 329], ["acute", "OBSERVATION_MODIFIER", 341, 346], ["respiratory virus", "OBSERVATION", 347, 364], ["virus", "OBSERVATION", 484, 489], ["cough", "OBSERVATION", 517, 522], ["neural signalling", "OBSERVATION", 547, 564]]], ["Neurokinin levels and their specific receptors may be increased in addition to a reduction in their degrading enzyme.", [["Neurokinin", "GENE_OR_GENE_PRODUCT", 0, 10], ["Neurokinin", "PROTEIN", 0, 10], ["degrading enzyme", "PROTEIN", 100, 116], ["Neurokinin levels", "TEST", 0, 17], ["a reduction in their degrading enzyme", "PROBLEM", 79, 116]]], ["Cholinergic pathways appear to show promise as targets for future therapies.", [["future therapies", "TREATMENT", 59, 75]]], ["Drugs acting here have a favourable side effect profile and both short and long acting compounds have shown beneficial effects.ConclusionLeukotrienes also may play a mechanistic role by promoting cough and excess production of mucus in both healthy and diseased lungs.", [["mucus", "ANATOMY", 227, 232], ["lungs", "ANATOMY", 262, 267], ["ConclusionLeukotrienes", "CHEMICAL", 127, 149], ["cough", "DISEASE", 196, 201], ["ConclusionLeukotrienes", "CHEMICAL", 127, 149], ["ConclusionLeukotrienes", "SIMPLE_CHEMICAL", 127, 149], ["mucus", "ORGANISM_SUBSTANCE", 227, 232], ["lungs", "ORGAN", 262, 267], ["a favourable side effect profile", "PROBLEM", 23, 55], ["both short and long acting compounds", "PROBLEM", 60, 96], ["promoting cough", "PROBLEM", 186, 201], ["excess production of mucus in both healthy and diseased lungs", "PROBLEM", 206, 267], ["cough", "OBSERVATION", 196, 201], ["diseased", "OBSERVATION", 253, 261], ["lungs", "ANATOMY", 262, 267]]], ["They probably play a significant role in virus induced cough and this is an area which includes potentially promising therapeutic targets.", [["cough", "DISEASE", 55, 60], ["virus induced cough", "PROBLEM", 41, 60], ["significant", "OBSERVATION_MODIFIER", 21, 32], ["cough", "OBSERVATION", 55, 60]]], ["Inhibition of prostaglandin synthesis has been shown to be beneficial in symptom reduction.ConclusionOur understanding of the mechanisms by which acute virus infection generates cough is poor.", [["prostaglandin", "CHEMICAL", 14, 27], ["infection", "DISEASE", 158, 167], ["cough", "DISEASE", 178, 183], ["prostaglandin", "CHEMICAL", 14, 27], ["prostaglandin", "SIMPLE_CHEMICAL", 14, 27], ["prostaglandin synthesis", "TREATMENT", 14, 37], ["symptom reduction", "TREATMENT", 73, 90], ["acute virus infection", "PROBLEM", 146, 167], ["cough", "PROBLEM", 178, 183], ["prostaglandin synthesis", "OBSERVATION", 14, 37], ["acute", "OBSERVATION_MODIFIER", 146, 151], ["virus", "OBSERVATION", 152, 157]]], ["More research is required and the recent establishment of both human and animal experimental models will allow these to be adapted to specifically and objectively study cough, hopefully leading to a better understanding of the underlying mechanisms.", [["cough", "DISEASE", 169, 174], ["human", "ORGANISM", 63, 68], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["cough", "PROBLEM", 169, 174]]]], "PMC6965650": [["IntroductionEven before the era of microbiology, people adopted cooking, bathing and washing garments to reduce the devastating effects of disease caused by infectious pathogens1,2.", [["people", "ORGANISM", 49, 55], ["people", "SPECIES", 49, 55], ["bathing and washing garments", "TREATMENT", 73, 101], ["disease", "PROBLEM", 139, 146], ["infectious pathogens", "PROBLEM", 157, 177], ["disease", "OBSERVATION", 139, 146], ["infectious", "OBSERVATION_MODIFIER", 157, 167]]], ["Cleansing and purification of materials have been employed to improve human health since Roman times, but it was not until the 1800s when Louis Pasteur and William Henry explored pressurized steam for sterilization of contaminated clothing and materials that have been in contact with contagions3.", [["human", "ORGANISM", 70, 75], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75], ["Cleansing", "TREATMENT", 0, 9], ["purification of materials", "TREATMENT", 14, 39], ["pressurized steam", "TREATMENT", 179, 196], ["sterilization of contaminated clothing and materials", "TREATMENT", 201, 253]]], ["The ongoing co-evolution of pathogen and human has been described as an arms race, where new developments of antimicrobial medicines are overcome by microbes with newly evolved resistance to those drugs4\u20137.", [["human", "ORGANISM", 41, 46], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["pathogen", "PROBLEM", 28, 36], ["antimicrobial medicines", "TREATMENT", 109, 132], ["those drugs4\u20137", "TREATMENT", 191, 205], ["pathogen", "OBSERVATION", 28, 36]]], ["Indeed, as drug development fails to keep pace with increased microbial resistance, hygiene and monitoring of sterility assurance are becoming increasingly important.IntroductionBecause of the persistence of nosocomial infections and foodborne diseases, much attention in health care, food and pharmaceutical industries has focused on the need for appropriate surface cleaning, disinfection, and sterility assurance.", [["surface", "ANATOMY", 360, 367], ["nosocomial infections", "DISEASE", 208, 229], ["foodborne diseases", "DISEASE", 234, 252], ["increased microbial resistance", "TREATMENT", 52, 82], ["sterility assurance", "TREATMENT", 110, 129], ["nosocomial infections", "PROBLEM", 208, 229], ["foodborne diseases", "PROBLEM", 234, 252], ["appropriate surface cleaning", "TREATMENT", 348, 376], ["disinfection", "TREATMENT", 378, 390], ["sterility assurance", "TREATMENT", 396, 415], ["microbial resistance", "OBSERVATION", 62, 82], ["nosocomial", "OBSERVATION_MODIFIER", 208, 218], ["infections", "OBSERVATION", 219, 229], ["foodborne diseases", "OBSERVATION", 234, 252]]], ["The cleanliness of surfaces, such as walls, countertops, and floors, in hospitals have been shown to correlate with the occurrence of cross-contamination8\u201311.", [["\u201311", "GENE_OR_GENE_PRODUCT", 154, 157], ["cross-contamination8\u201311", "PROTEIN", 134, 157], ["cleanliness", "OBSERVATION_MODIFIER", 4, 15], ["surfaces", "OBSERVATION_MODIFIER", 19, 27]]], ["Inadequate cleaning and disinfection of these surfaces put consumers at risk, and leads to food spoilage or shortened shelf lives12,13.", [["Inadequate cleaning", "TREATMENT", 0, 19], ["disinfection", "TREATMENT", 24, 36], ["cleaning", "OBSERVATION", 11, 19], ["disinfection", "OBSERVATION_MODIFIER", 24, 36]]], ["Quality assurance methods in the pharmaceutical industry to prevent microbial contamination are also strictly regulated to ensure aseptic processing of products14,15.IntroductionSterility assurance is also important in space exploration, where nations are required by international law to ensure that interplanetary spacecraft destined to potentially habitable worlds in our solar system contain less than a specified bioburden16,17.", [["the pharmaceutical industry", "TREATMENT", 29, 56], ["microbial contamination", "PROBLEM", 68, 91], ["aseptic processing of products", "PROBLEM", 130, 160], ["IntroductionSterility assurance", "TREATMENT", 166, 197], ["space exploration", "TEST", 219, 236], ["interplanetary spacecraft", "PROBLEM", 301, 326], ["microbial contamination", "OBSERVATION", 68, 91], ["aseptic", "OBSERVATION_MODIFIER", 130, 137], ["interplanetary spacecraft", "OBSERVATION", 301, 326]]], ["Missions with life-detection experiments must undergo additional procedures to ensure that the total bioburden is even lower18.", [["additional procedures", "TREATMENT", 54, 75], ["the total bioburden", "TEST", 91, 110]]], ["The standards pertaining to bioburden use endospores (i.e., bacterial spores) as the indicator organisms to verify that bioburden thresholds are not exceeded.", [["spores", "ANATOMY", 70, 76], ["bioburden use endospores", "TREATMENT", 28, 52], ["bacterial spores", "PROBLEM", 60, 76], ["the indicator organisms", "PROBLEM", 81, 104], ["bioburden thresholds", "TEST", 120, 140]]], ["Endospores are ideal bioindicator organisms because they are the most resistant form of life towards various sterilization regimens, such as dry heat, steam, vaporized hydrogen peroxide, ethylene oxide, oxygen plasma and ultraviolet radiation19\u201323.IntroductionEvaluation of microbial contamination on work surfaces has relied on the swab and rinse sampling techniques and standard heterotrophic plate count (HPC), which have been widely practiced in hospitals, food processing plants, and by NASA for evaluating the bioburden level of flight hardware for planetary protection in robotic extraterrestrial missions24,25.", [["hydrogen peroxide", "CHEMICAL", 168, 185], ["ethylene oxide", "CHEMICAL", 187, 201], ["oxygen", "CHEMICAL", 203, 209], ["ultraviolet radiation19\u201323", "CHEMICAL", 221, 247], ["hydrogen peroxide", "CHEMICAL", 168, 185], ["ethylene oxide", "CHEMICAL", 187, 201], ["oxygen", "CHEMICAL", 203, 209], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 168, 185], ["ethylene oxide", "SIMPLE_CHEMICAL", 187, 201], ["oxygen", "SIMPLE_CHEMICAL", 203, 209], ["plasma", "ORGANISM_SUBSTANCE", 210, 216], ["Endospores", "PROBLEM", 0, 10], ["ideal bioindicator organisms", "PROBLEM", 15, 43], ["various sterilization regimens", "TREATMENT", 101, 131], ["vaporized hydrogen peroxide", "TREATMENT", 158, 185], ["ethylene oxide", "TREATMENT", 187, 201], ["oxygen plasma", "TREATMENT", 203, 216], ["ultraviolet radiation19", "TREATMENT", 221, 244], ["IntroductionEvaluation", "TEST", 248, 270], ["microbial contamination on work surfaces", "PROBLEM", 274, 314], ["the swab", "TEST", 329, 337], ["rinse sampling techniques", "TEST", 342, 367], ["standard heterotrophic plate count", "TEST", 372, 406], ["flight hardware", "TREATMENT", 535, 550], ["planetary protection", "TREATMENT", 555, 575], ["robotic extraterrestrial missions", "TREATMENT", 579, 612], ["microbial contamination", "OBSERVATION", 274, 297]]], ["The major drawback is that HPC usually requires several days for results.", [["HPC", "CELL_TYPE", 27, 30], ["HPC", "OBSERVATION", 27, 30]]], ["Faster and more efficient methods have been proposed in recent years to measure microbial contamination of surfaces, such as ATP bioluminescence, enzyme, and nucleic acid-based techniques26\u201330.", [["ATP", "CHEMICAL", 125, 128], ["nucleic acid", "CHEMICAL", 158, 170], ["ATP", "CHEMICAL", 125, 128], ["ATP", "SIMPLE_CHEMICAL", 125, 128], ["nucleic acid", "SIMPLE_CHEMICAL", 158, 170], ["microbial contamination of surfaces", "PROBLEM", 80, 115], ["ATP bioluminescence", "TEST", 125, 144], ["enzyme", "TEST", 146, 152], ["nucleic acid", "TEST", 158, 170]]], ["Yet, conventional cleaning practices of surfaces still largely do not include quantitative approaches for assessing the effectiveness of the cleaning regimen, because of cost, ease-of-use, or time-to-results.", [["the cleaning regimen", "TREATMENT", 137, 157]]], ["There is a need for fast, quantitative, cost effective and convenient methods to assess the level of contamination on surfaces in tracking routes of infection, surveillance of the environment and evaluation of decontamination protocols.", [["infection", "DISEASE", 149, 158], ["convenient methods", "TEST", 59, 77], ["contamination", "PROBLEM", 101, 114], ["infection", "PROBLEM", 149, 158], ["evaluation", "TEST", 196, 206], ["decontamination protocols", "TREATMENT", 210, 235], ["contamination", "OBSERVATION", 101, 114], ["infection", "OBSERVATION", 149, 158]]], ["The endospore germinability assay (EGA) addresses this need by enabling the fast measurement of germinable endospore populations, which serve as excellent indicators for measuring surface bioburden reduction, owing to their omnipresence in the environment, and because they are the hardiest microbial organisms.", [["endospore", "ANATOMY", 4, 13], ["surface", "ANATOMY", 180, 187], ["endospore populations", "CELL", 107, 128], ["germinable endospore populations", "CELL_TYPE", 96, 128], ["The endospore germinability assay", "TEST", 0, 33], ["germinable endospore populations", "PROBLEM", 96, 128], ["measuring surface bioburden reduction", "TREATMENT", 170, 207]]], ["Consequently, a reduction of viable endospores necessarily indicates an even greater reduction in non-spore forming microorganisms.IntroductionThe concept of endospores as bioindicators for monitoring sterilization effectiveness is extensively used in hospitals, where sterilization processes are monitored by using endospores as dosimeters (e.g., endospore test strips to verify autoclave compliance with regulatory requirements31).", [["a reduction of viable endospores", "PROBLEM", 14, 46], ["an even greater reduction in non-spore forming microorganisms", "PROBLEM", 69, 130], ["monitoring sterilization effectiveness", "TREATMENT", 190, 228], ["sterilization processes", "TREATMENT", 269, 292], ["endospore test strips", "TREATMENT", 348, 369], ["autoclave compliance", "TREATMENT", 380, 400], ["greater", "OBSERVATION_MODIFIER", 77, 84], ["reduction", "OBSERVATION_MODIFIER", 85, 94]]], ["Endospore producing genera include Geobacillus, Bacillus and Clostridium, which produce this dormant and resilient form during times of environmental stress.", [["Bacillus", "ORGANISM", 48, 56], ["Geobacillus", "PROBLEM", 35, 46], ["Bacillus", "PROBLEM", 48, 56], ["Clostridium", "PROBLEM", 61, 72], ["environmental stress", "PROBLEM", 136, 156], ["genera", "OBSERVATION_MODIFIER", 20, 26], ["Bacillus", "ANATOMY", 48, 56]]], ["They are protected from environmental extremes and sterilants by a series of protective layers, including spore coat, peptidoglycan cortex, and a core that includes high concentrations of calcium dipicolinate stores32\u201334.", [["peptidoglycan cortex", "ANATOMY", 118, 138], ["calcium", "CHEMICAL", 188, 195], ["calcium dipicolinate", "CHEMICAL", 188, 208], ["layers", "TISSUE", 88, 94], ["calcium dipicolinate", "SIMPLE_CHEMICAL", 188, 208], ["protective layers", "TREATMENT", 77, 94], ["spore coat, peptidoglycan cortex", "PROBLEM", 106, 138], ["calcium dipicolinate stores", "PROBLEM", 188, 215], ["peptidoglycan cortex", "ANATOMY", 118, 138]]], ["Endospores can remain dormant for many years35,36, and when more favorable conditions are signaled by the presence of water, nutrients, and germinants, endospores may germinate and become metabolically active22,37,38.", [["Endospores", "PROBLEM", 0, 10]]], ["In the context of human health, this enables endospore-forming pathogens (e.g., B. anthracis, C. botulinum, and C. difficile) to persist after cleaning regimens are applied, causing contamination, food spoilage, and disease.", [["food spoilage", "DISEASE", 197, 210], ["human", "ORGANISM", 18, 23], ["B. anthracis", "ORGANISM", 80, 92], ["C. botulinum", "ORGANISM", 94, 106], ["C. difficile", "ORGANISM", 112, 124], ["human", "SPECIES", 18, 23], ["B. anthracis", "SPECIES", 80, 92], ["C. botulinum", "SPECIES", 94, 106], ["C. difficile", "SPECIES", 112, 124], ["human", "SPECIES", 18, 23], ["B. anthracis", "SPECIES", 80, 92], ["C. botulinum", "SPECIES", 94, 106], ["C. difficile", "SPECIES", 112, 124], ["pathogens (e.g., B. anthracis", "PROBLEM", 63, 92], ["C. botulinum", "PROBLEM", 94, 106], ["C. difficile)", "PROBLEM", 112, 125], ["cleaning regimens", "TREATMENT", 143, 160], ["contamination", "PROBLEM", 182, 195], ["disease", "PROBLEM", 216, 223], ["food spoilage", "OBSERVATION", 197, 210]]], ["The remarkable resistance of endospores makes them ideal bioindicators for both sterility assurance of sterilizers and of surfaces in work environments of health care, food and pharmaceutical industries, and for planetary protection as humans continue to explore potentially habitable worlds in the solar systems.IntroductionWe have previously reported on germinable-endospore biodosimetry using EGA to achieve rapid validation of sterilization in aqueous suspensions39.", [["humans", "ORGANISM", 236, 242], ["humans", "SPECIES", 236, 242], ["humans", "SPECIES", 236, 242], ["both sterility assurance of sterilizers", "TREATMENT", 75, 114], ["planetary protection", "TREATMENT", 212, 232], ["sterilization in aqueous suspensions", "TREATMENT", 431, 467], ["remarkable", "OBSERVATION_MODIFIER", 4, 14], ["resistance", "OBSERVATION", 15, 25]]], ["DPA (dipicolinic acid, 2,6-pyridinedicarboxylic acid) naturally present in endospores can be released from the core by inducing germination (e.g., with L-alanine40,41) or physical lysis (e.g., autoclaving, microwaving42).", [["DPA", "CHEMICAL", 0, 3], ["dipicolinic acid", "CHEMICAL", 5, 21], ["2,6-pyridinedicarboxylic acid", "CHEMICAL", 23, 52], ["L-alanine40,41", "CHEMICAL", 152, 166], ["DPA", "CHEMICAL", 0, 3], ["dipicolinic acid", "CHEMICAL", 5, 21], ["2,6-pyridinedicarboxylic acid", "CHEMICAL", 23, 52], ["L-alanine", "CHEMICAL", 152, 161], ["DPA", "SIMPLE_CHEMICAL", 0, 3], ["dipicolinic acid", "SIMPLE_CHEMICAL", 5, 21], ["2,6-pyridinedicarboxylic acid", "SIMPLE_CHEMICAL", 23, 52], ["L-alanine", "SIMPLE_CHEMICAL", 152, 161], ["DPA (dipicolinic acid", "TREATMENT", 0, 21], ["2,6-pyridinedicarboxylic acid", "TREATMENT", 23, 52], ["L-alanine", "TEST", 152, 161], ["physical lysis", "TEST", 171, 185], ["lysis", "OBSERVATION", 180, 185]]], ["L-alanine is a general germinant for endospores, and the addition induces endospores to germinate and release approximately 108 DPA molecules per endospore.", [["L-alanine", "CHEMICAL", 0, 9], ["L-alanine", "CHEMICAL", 0, 9], ["DPA", "CHEMICAL", 128, 131], ["L-alanine", "SIMPLE_CHEMICAL", 0, 9], ["108 DPA molecules", "PROTEIN", 124, 141]]], ["When endospores germinate and release their Ca-DPA stores into the immediate surrounding volume, the resultant Tb-DPA luminescent complex surrounding the germinated endospore bodies, are imaged with a time-gated microscope.", [["endospore bodies", "ANATOMY", 165, 181], ["Tb-DPA", "CHEMICAL", 111, 117], ["Ca-DPA", "CHEMICAL", 44, 50], ["Tb-DPA", "CHEMICAL", 111, 117], ["Ca-DPA", "GENE_OR_GENE_PRODUCT", 44, 50], ["Ca-DPA", "PROTEIN", 44, 50], ["DPA luminescent complex", "PROTEIN", 114, 137], ["the resultant Tb-DPA luminescent complex", "PROBLEM", 97, 137], ["resultant", "OBSERVATION_MODIFIER", 101, 110], ["Tb", "OBSERVATION", 111, 113], ["complex", "OBSERVATION_MODIFIER", 130, 137], ["germinated", "OBSERVATION_MODIFIER", 154, 164], ["endospore bodies", "OBSERVATION", 165, 181]]], ["DPA acts as a light-harvesting antenna with a large extinction coefficient in the UV to transfer the energy to Tb3+ upon UV excitation43\u201346.", [["DPA", "CHEMICAL", 0, 3], ["Tb3", "CHEMICAL", 111, 114], ["DPA", "CHEMICAL", 0, 3], ["Tb3+", "CHEMICAL", 111, 115], ["DPA", "SIMPLE_CHEMICAL", 0, 3], ["Tb3+", "SIMPLE_CHEMICAL", 111, 115], ["Tb3", "PROTEIN", 111, 114], ["a light-harvesting antenna", "TREATMENT", 12, 38], ["a large extinction coefficient", "PROBLEM", 44, 74], ["UV excitation", "TEST", 121, 134], ["large", "OBSERVATION_MODIFIER", 46, 51], ["extinction", "OBSERVATION", 52, 62]]], ["An intensity profile can be recorded in accordance with the lag time and germination dynamics on a time scale of 15 minutes for most germinable spores in a population.", [["spores", "ANATOMY", 144, 150], ["An intensity profile", "TEST", 0, 20], ["germination dynamics", "TEST", 73, 93]]], ["Only a small subset of the germinable population germinates > 15 minutes, even for populations that have been exposed to inactivation regimens.", [["inactivation regimens", "TREATMENT", 121, 142], ["small", "OBSERVATION_MODIFIER", 7, 12], ["subset", "OBSERVATION_MODIFIER", 13, 19], ["germinable", "OBSERVATION_MODIFIER", 27, 37], ["population", "OBSERVATION_MODIFIER", 38, 48]]], ["Each Tb-DPA luminescent spot in the time-gated microscope field of view is assigned and enumerated as one germinable endospore.IntroductionIn this paper, we focus on the application of EGA for detecting germinable endospores on test surfaces, which involves a 4-step procedure consisting of (i) swab-rinse sampling, (ii) sample preparation, (iii) time-gated imaging with EGA, and (iv) enumeration of germinable endospores39,47.", [["endospore", "ANATOMY", 117, 126], ["sample", "ANATOMY", 321, 327], ["Tb-DPA", "CHEMICAL", 5, 11], ["Tb-DPA", "CHEMICAL", 5, 11], ["endospore", "CANCER", 117, 126], ["DPA luminescent spot", "TEST", 8, 28], ["germinable endospores on test surfaces", "PROBLEM", 203, 241], ["a 4-step procedure", "TREATMENT", 258, 276], ["gated imaging", "TEST", 352, 365], ["EGA", "TEST", 371, 374], ["germinable endospores", "PROBLEM", 400, 421]]], ["EGA has also been used to investigate germinable endospore populations within environmental samples, including ice cores39,48, desert soils39,48, and an Antarctic lake49, and has been adapted for Clostridium endospores48,50.", [["samples", "ANATOMY", 92, 99], ["endospore populations", "CELL", 49, 70], ["Clostridium endospores48,50", "SPECIES", 196, 223], ["germinable endospore populations", "PROBLEM", 38, 70], ["ice cores", "TEST", 111, 120], ["desert soils", "TEST", 127, 139], ["Clostridium endospores", "PROBLEM", 196, 218]]], ["The objectives of this investigation are to (1) validate the EGA methodology in comparison to standard HPC to assess the number of endospores sampled from nonporous stainless steel coupon surfaces, and (2) employ EGA in comparison to HPC for determination of the decimal reduction values of surface endospore populations inactivated by dry heat, ultraviolet radiation, vaporized hydrogen peroxide, and atmospheric pressure air plasma.Germination and culturing as a measure of endospore viability ::: Results and DiscussionThe Endospore Germinability Assay (EGA) is based on the earliest observable mechanistic steps of dormant endospores reentering the active life cycle as observed by DPA release during stage I germination.", [["surface endospore", "ANATOMY", 291, 308], ["plasma", "ANATOMY", 427, 433], ["endospore", "ANATOMY", 476, 485], ["hydrogen peroxide", "CHEMICAL", 379, 396], ["DPA", "CHEMICAL", 686, 689], ["hydrogen peroxide", "CHEMICAL", 379, 396], ["DPA", "CHEMICAL", 686, 689], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 379, 396], ["plasma", "ORGANISM_SUBSTANCE", 427, 433], ["DPA", "SIMPLE_CHEMICAL", 686, 689], ["HPC", "CELL_TYPE", 103, 106], ["HPC", "CELL_TYPE", 234, 237], ["surface endospore populations", "CELL_TYPE", 291, 320], ["the EGA methodology", "TEST", 57, 76], ["standard HPC", "TEST", 94, 106], ["endospores", "PROBLEM", 131, 141], ["nonporous stainless steel coupon surfaces", "TREATMENT", 155, 196], ["HPC", "TEST", 234, 237], ["the decimal reduction values", "TREATMENT", 259, 287], ["surface endospore populations", "TREATMENT", 291, 320], ["ultraviolet radiation", "TREATMENT", 346, 367], ["vaporized hydrogen peroxide", "TREATMENT", 369, 396], ["atmospheric pressure air plasma", "TEST", 402, 433], ["culturing", "TEST", 450, 459], ["The Endospore Germinability Assay", "TEST", 522, 555], ["nonporous stainless", "OBSERVATION_MODIFIER", 155, 174], ["active", "OBSERVATION_MODIFIER", 653, 659]]], ["By comparison, ATP assays probe at stage II germination and culturing probes after 20 or so replication cycles.", [["ATP", "CHEMICAL", 15, 18], ["ATP", "CHEMICAL", 15, 18], ["ATP", "SIMPLE_CHEMICAL", 15, 18], ["ATP assays", "TEST", 15, 25], ["stage II germination", "TREATMENT", 35, 55], ["culturing probes", "TEST", 60, 76], ["replication cycles", "TREATMENT", 92, 110]]], ["None of these methods directly probe the viable population.", [["viable", "OBSERVATION_MODIFIER", 41, 47], ["population", "OBSERVATION", 48, 58]]], ["Defining viability for microorganisms is neither simple nor straightforward51.", [["microorganisms", "PROBLEM", 23, 37]]], ["Endospores that give rise to colonies on growth media are clearly viable, and this is generally considered a reliable approach to demonstrating viability.", [["colonies", "ANATOMY", 29, 37], ["Endospores", "PROBLEM", 0, 10]]], ["However, culture-based methods often overlook more than 99% of the viable-but-not-culturable (VBNC) population of cells in environmental samples52\u201354, effectively representing a conservative lower limit estimate of viability.", [["cells", "ANATOMY", 114, 119], ["cells", "CELL", 114, 119], ["culture", "TEST", 9, 16], ["environmental samples", "TEST", 123, 144]]], ["In contrast, germination accounts for a greater fraction of viable organisms, but may include a subset population of germinable-but-not-viable endospores.", [["endospores", "ANATOMY", 143, 153], ["endospores", "CELL", 143, 153], ["a greater fraction of viable organisms", "PROBLEM", 38, 76], ["viable organisms", "OBSERVATION", 60, 76], ["may include", "UNCERTAINTY", 82, 93], ["subset", "OBSERVATION_MODIFIER", 96, 102], ["population", "OBSERVATION", 103, 113]]], ["As a complement to culturability, however, germination may be considered an upper limit on the viable number of endospores.", [["upper limit", "OBSERVATION_MODIFIER", 76, 87]]], ["While germination is a process that is nutrient-induced, and nutrients supplied may not cause all spores to germinate55,56, we have demonstrated the reproducible correlation of germination-capable populations to culturable populations within lab spore suspensions, and that this correlation can be extended to spore inactivation studies39,57.", [["spore inactivation studies", "TEST", 310, 336]]], ["Therefore, trends observed in germinability can be used as a good indication of trends in viability, along with assigning an upper limit to the viable population.Germination and culturing as a measure of endospore viability ::: Results and DiscussionQuantification of all viable biomass, as defined as having the ability for metabolic activity and reproduction, in an environmental sample, is currently difficult to achieve.", [["endospore", "ANATOMY", 204, 213], ["culturing", "TEST", 178, 187], ["upper limit", "OBSERVATION_MODIFIER", 125, 136]]], ["Nonetheless, the culture-based assays and the Endospore Germinability Assay may be used in parallel to map out upper and lower limits of viability, thus allowing a bounded estimate of viability.Germination and culturing as a measure of endospore viability ::: Results and DiscussionThe application of EGA for sterility assurance of surfaces may be implemented by measuring the reduction in germinable endospore populations before versus after surface sterilization regimen are applied, which provides a measure of sterility assurance level.", [["endospore", "ANATOMY", 236, 245], ["surface", "ANATOMY", 443, 450], ["upper", "ORGANISM_SUBDIVISION", 111, 116], ["endospore populations", "CELL", 401, 422], ["germinable endospore populations", "CELL_LINE", 390, 422], ["the culture", "TEST", 13, 24], ["based assays", "TEST", 25, 37], ["the Endospore Germinability Assay", "TEST", 42, 75], ["culturing", "TEST", 210, 219], ["sterility assurance of surfaces", "TREATMENT", 309, 340], ["the reduction in germinable endospore populations", "TREATMENT", 373, 422], ["surface sterilization regimen", "TREATMENT", 443, 472], ["sterility assurance level", "TEST", 514, 539], ["lower limits", "OBSERVATION_MODIFIER", 121, 133], ["reduction", "OBSERVATION_MODIFIER", 377, 386], ["germinable", "OBSERVATION_MODIFIER", 390, 400], ["endospore", "OBSERVATION_MODIFIER", 401, 410], ["populations", "OBSERVATION_MODIFIER", 411, 422]]], ["While endospore presence on surfaces are generally ubiquitous, a mixed population of environmental endospores may include species that are not readily germinable on the EGA experiment time scale with the germinants supplied.", [["endospore", "ANATOMY", 6, 15], ["a mixed population of environmental endospores", "PROBLEM", 63, 109], ["species", "PROBLEM", 122, 129], ["surfaces", "OBSERVATION_MODIFIER", 28, 36], ["mixed", "OBSERVATION_MODIFIER", 65, 70], ["population", "OBSERVATION_MODIFIER", 71, 81], ["environmental endospores", "OBSERVATION", 85, 109]]], ["This concern may be mitigated by a broad spectrum germinant solution and extending the EGA observation time.", [["a broad spectrum germinant solution", "TREATMENT", 33, 68]]], ["Alternatively, fully characterized, bioindicator endospore populations may be used on surfaces to assess sterilization effectiveness with EGA.", [["endospore populations", "CELL", 49, 70], ["bioindicator endospore populations", "CELL_LINE", 36, 70], ["bioindicator endospore populations", "TREATMENT", 36, 70], ["sterilization effectiveness", "TREATMENT", 105, 132]]], ["Additional characterization of EGA applied to surface sterility assurance with various sterilants and environments will provide improved guidelines for appropriate use of EGA for a range of applications.Recovery of endospores from test surface coupons of stainless steel ::: Results and DiscussionCoupon surfaces were inoculated with a range of total spore populations as determined by phase contrast microscopy (0, 0.3, 1, 3.2, 10, 31.6, 100, 317, 1000 spores/coupon), of which 48% were germinable and 28% were culturable.", [["surface", "ANATOMY", 46, 53], ["surface", "ANATOMY", 236, 243], ["EGA", "DNA", 31, 34], ["EGA", "TEST", 31, 34], ["surface sterility assurance", "TREATMENT", 46, 73], ["various sterilants and environments", "TREATMENT", 79, 114], ["phase contrast microscopy", "TEST", 386, 411], ["stainless steel", "OBSERVATION", 255, 270]]], ["The coupon surfaces were swabbed, rinsed and assayed by both EGA and HPC.", [["HPC", "CELL_TYPE", 69, 72], ["The coupon surfaces", "TREATMENT", 0, 19]]], ["Endospore recovery percentages (%R) were determined to be 36.3 \u00b1 7.6% for EGA (%REGA) and 19.8 \u00b1 7.2% for HPC (%RHPC) (Fig. 1a).", [["Endospore", "ANATOMY", 0, 9], ["HPC", "CELL_TYPE", 106, 109], ["Endospore recovery percentages", "TEST", 0, 30], ["EGA", "TEST", 74, 77], ["REGA", "TEST", 80, 84], ["HPC", "TEST", 106, 109], ["RHPC", "TEST", 112, 116]]], ["EGA and HPC results were strongly correlated as determined by Spearman rank correlation coefficient (rs = 0.9321, p < 0.0001) on the entire data set.", [["EGA and HPC", "TEST", 0, 11], ["rs", "TEST", 101, 103]]], ["A scatter plot of EGA-HPC results and pairwise regression analyses (Fig. 1b) revealed a correlation coefficient of 0.965 across almost four orders of magnitude in concentration, as well as a strong linear correlation.", [["A scatter plot of EGA", "TEST", 0, 21], ["pairwise regression analyses", "TEST", 38, 66]]], ["The limit of detection (LOD) for endospore detection by EGA was calculated to be single endospores based on the fact that all signals had a signal-to-noise ratio (S/N) greater than or equal to 3.", [["endospore detection", "TEST", 33, 52], ["EGA", "TEST", 56, 59], ["noise ratio", "TEST", 150, 161]]], ["No false positives were recorded by either assay, as all sterile coupons gave zero counts.Recovery of endospores from test surface coupons of stainless steel ::: Results and DiscussionThe swab-and-rinse procedure consists of two major steps, where Step 1 is the transfer of endospores from the coupon surface to the swab head, and Step 2 is the transfer of endospores from the swab head into aqueous suspension by a series of vortexing and sonication.", [["surface", "ANATOMY", 123, 130], ["surface", "ANATOMY", 301, 308], ["swab head", "ANATOMY", 316, 325], ["swab head", "ANATOMY", 377, 386], ["head", "ORGANISM_SUBDIVISION", 321, 325], ["swab", "ORGANISM_SUBSTANCE", 377, 381], ["head", "ORGANISM_SUBDIVISION", 382, 386], ["false positives", "PROBLEM", 3, 18], ["The swab", "TEST", 184, 192], ["-rinse procedure", "TREATMENT", 196, 212], ["the swab head", "TEST", 312, 325], ["vortexing and sonication", "TREATMENT", 426, 450], ["false positives", "OBSERVATION", 3, 18], ["stainless steel", "OBSERVATION", 142, 157]]], ["While step 1 is fundamentally difficult to assess empirically, we carried out an experiment on the recovery of endospores directly inoculated onto the cotton tip of a swab applicator.", [["a swab applicator", "TREATMENT", 165, 182], ["tip", "OBSERVATION_MODIFIER", 158, 161]]], ["The inoculum population was 1,000 \u00b1 67.5 endospores (n = 20, of which 48% were germinable and 28% were culturable).", [["The inoculum population", "TEST", 0, 23], ["inoculum", "OBSERVATION_MODIFIER", 4, 12]]], ["Table 1 shows that the recovery efficacies measured by EGA was 92.7 \u00b1 9.2% and TSA HPC was 86.8 \u00b1 13.8%.Thermal inactivation of B. atrophaeus endospores ::: Results and DiscussionFigure 2a shows semi-logarithmic survival graphs of B. atrophaeus endospores laden on stainless steel coupons subjected to dry heat inactivation at 105 \u00b0C as measured by EGA and HPC.", [["B. atrophaeus", "ORGANISM", 128, 141], ["HPC", "CELL_TYPE", 357, 360], ["B. atrophaeus", "SPECIES", 128, 141], ["B. atrophaeus", "SPECIES", 231, 244], ["B. atrophaeus", "SPECIES", 128, 141], ["B. atrophaeus", "SPECIES", 231, 244], ["EGA", "TEST", 55, 58], ["TSA HPC", "TEST", 79, 86], ["semi-logarithmic survival graphs", "PROBLEM", 195, 227], ["B. atrophaeus endospores", "PROBLEM", 231, 255], ["stainless steel coupons", "TREATMENT", 265, 288], ["dry heat inactivation", "PROBLEM", 302, 323], ["stainless steel", "OBSERVATION_MODIFIER", 265, 280]]], ["Survival graphs showed significant reduction of viable endospore counts with increasing thermal treatment time.", [["endospore", "ANATOMY", 55, 64], ["Survival graphs", "TEST", 0, 15], ["significant reduction of viable endospore counts", "PROBLEM", 23, 71], ["increasing thermal treatment time", "TREATMENT", 77, 110], ["significant", "OBSERVATION_MODIFIER", 23, 34], ["reduction", "OBSERVATION_MODIFIER", 35, 44], ["viable", "OBSERVATION_MODIFIER", 48, 54], ["endospore counts", "OBSERVATION", 55, 71], ["increasing", "OBSERVATION_MODIFIER", 77, 87], ["thermal treatment", "OBSERVATION_MODIFIER", 88, 105]]], ["The coupon was rendered sterile as measured by both EGA and HPC after 60 minutes at 105 \u00b0C (>7 log reduction).", [["HPC", "CELL_TYPE", 60, 63], ["The coupon", "TREATMENT", 0, 10]]], ["Survival graphs measured were fitted to both log-linear and Weibull distribution models.", [["Survival graphs", "TEST", 0, 15], ["Weibull distribution", "OBSERVATION", 60, 80]]], ["The survival graph measured by EGA showed a sigmoid curve with a noticeable 18-min shoulder and tail, while the HPC graph showed log linear decay of endospore viability.", [["tail", "ANATOMY", 96, 100], ["endospore", "ANATOMY", 149, 158], ["shoulder", "ORGANISM_SUBDIVISION", 83, 91], ["tail", "ORGANISM_SUBDIVISION", 96, 100], ["The survival graph", "TEST", 0, 18], ["a sigmoid curve", "TEST", 42, 57], ["the HPC graph", "TEST", 108, 121], ["endospore viability", "PROBLEM", 149, 168], ["sigmoid", "ANATOMY", 44, 51], ["shoulder", "ANATOMY", 83, 91], ["tail", "ANATOMY", 96, 100], ["log linear", "OBSERVATION_MODIFIER", 129, 139], ["endospore viability", "OBSERVATION", 149, 168]]], ["To verify the existence of shoulder on the EGA graph, 6 data points were taken within the initial 10 min.", [["shoulder", "ANATOMY", 27, 35], ["shoulder", "ORGANISM_SUBDIVISION", 27, 35], ["EGA graph", "DNA", 43, 52], ["the EGA graph", "TEST", 39, 52], ["shoulder", "ANATOMY", 27, 35]]], ["The EGA D-value was calculated based on the log-linear portion of the EGA sigmoidal inactivation graph, which yielded a D-value of 25.6 \u00b1 3.2 min and tC of 14.7 \u00b1 2.1 min.", [["EGA D", "DNA", 4, 9], ["The EGA D-value", "TEST", 0, 15], ["a D-value", "TEST", 118, 127], ["tC", "TEST", 150, 152], ["sigmoidal inactivation", "OBSERVATION", 74, 96]]], ["The HPC inactivation graph yielded a D-value of 3.4 \u00b1 0.6 min and tC of 2.64 \u00b1 0.3 min.", [["The HPC inactivation graph", "TEST", 0, 26], ["a D-value", "TEST", 35, 44], ["tC", "TEST", 66, 68]]], ["The HPC inactivation graph measured showed upward concavity, which indicates that at least two populations of endospores were present, with one that was inactivated at a relatively fast rate leaving behind survivors with a higher resistance.Ultraviolet inactivation of B. atrophaeus endospores ::: Results and DiscussionFigure 2b shows the inactivation graphs of B. atrophaeus endospores air-dried on stainless steel coupons, subjected to 254-nm irradiation with a power of 22.9 \u00b5W/cm2.", [["stainless steel", "CHEMICAL", 401, 416], ["B. atrophaeus", "ORGANISM", 269, 282], ["B. atrophaeus", "SPECIES", 269, 282], ["B. atrophaeus", "SPECIES", 363, 376], ["B. atrophaeus", "SPECIES", 269, 282], ["B. atrophaeus", "SPECIES", 363, 376], ["The HPC inactivation graph", "TEST", 0, 26], ["upward concavity", "PROBLEM", 43, 59], ["a higher resistance", "PROBLEM", 221, 240], ["Ultraviolet inactivation", "TREATMENT", 241, 265], ["the inactivation graphs", "PROBLEM", 336, 359], ["B. atrophaeus endospores air", "PROBLEM", 363, 391], ["stainless steel coupons", "TREATMENT", 401, 424], ["upward concavity", "OBSERVATION", 43, 59], ["higher resistance", "OBSERVATION", 223, 240], ["stainless steel", "OBSERVATION_MODIFIER", 401, 416]]], ["EGA and HPC were employed to enumerate the surviving endospore fractions.", [["endospore fractions", "ANATOMY", 53, 72], ["HPC", "CELL_TYPE", 8, 11], ["EGA", "TEST", 0, 3]]], ["Survival graphs were fitted to both the log-linear and Weibull models.", [["Survival graphs", "TEST", 0, 15]]], ["EGA measured an inactivation curve with downward concavity, while HPC generated an inactivation curve that followed a log-linear pattern with a slight upward concavity.", [["HPC", "CELL_TYPE", 66, 69], ["EGA", "TEST", 0, 3], ["an inactivation curve", "TEST", 13, 34], ["downward concavity", "PROBLEM", 40, 58], ["an inactivation curve", "TEST", 80, 101], ["a slight upward concavity", "PROBLEM", 142, 167], ["downward concavity", "OBSERVATION_MODIFIER", 40, 58], ["slight", "OBSERVATION_MODIFIER", 144, 150], ["upward concavity", "OBSERVATION", 151, 167]]], ["The EGA and HPC inactivation curves show substantial differences, which indicates that germination stage Imechanisms are less susceptible to UV inactivation than replication mechanisms.", [["The EGA and HPC inactivation curves", "TEST", 0, 35], ["germination stage Imechanisms", "PROBLEM", 87, 116], ["UV inactivation", "TREATMENT", 141, 156], ["substantial", "OBSERVATION_MODIFIER", 41, 52], ["UV inactivation", "OBSERVATION", 141, 156]]], ["Sterility was achieved after 80 min of ultraviolet irradiation as measured by both assays.", [["ultraviolet", "CHEMICAL", 39, 50], ["ultraviolet irradiation", "TREATMENT", 39, 62]]], ["EGA measured a D-value of 12.4 \u00b1 4.5 min and tC of 6.9 \u00b1 0.5 min.", [["EGA", "TEST", 0, 3], ["a D-value", "TEST", 13, 22], ["tC", "TEST", 45, 47]]], ["HPC measured a D-value of 11.6 \u00b1 3.8 min and tC of 6.1 \u00b1 0.3 min.Oxygen plasma inactivation of B. subtilis endospores ::: Results and DiscussionFigure 2c shows survival graphs of B. subtilis endospores inactivated by oxygen plasma.", [["plasma", "ANATOMY", 72, 78], ["plasma", "ANATOMY", 224, 230], ["Oxygen", "CHEMICAL", 65, 71], ["oxygen", "CHEMICAL", 217, 223], ["Oxygen", "CHEMICAL", 65, 71], ["oxygen", "CHEMICAL", 217, 223], ["Oxygen", "SIMPLE_CHEMICAL", 65, 71], ["plasma", "ORGANISM_SUBSTANCE", 72, 78], ["B. subtilis", "ORGANISM", 95, 106], ["B. subtilis", "ORGANISM", 179, 190], ["oxygen", "SIMPLE_CHEMICAL", 217, 223], ["plasma", "ORGANISM_SUBSTANCE", 224, 230], ["HPC", "CELL_TYPE", 0, 3], ["B. subtilis", "SPECIES", 95, 106], ["B. subtilis", "SPECIES", 179, 190], ["B. subtilis", "SPECIES", 95, 106], ["B. subtilis", "SPECIES", 179, 190], ["HPC", "TEST", 0, 3], ["a D-value", "TEST", 13, 22], ["tC", "TEST", 45, 47], ["Oxygen plasma inactivation", "TREATMENT", 65, 91], ["survival graphs of B. subtilis endospores", "PROBLEM", 160, 201], ["oxygen plasma", "TEST", 217, 230]]], ["EGA and HPC both yielded first-order exponential inactivation kinetics from 0 to 30 min with good fitting to both log-linear and Weibull distribution plots.", [["HPC", "CHEMICAL", 8, 11], ["HPC", "CELL_TYPE", 8, 11], ["EGA", "TEST", 0, 3], ["HPC", "TEST", 8, 11]]], ["A rapid loss in germinability and culturability was observed after 30 min of exposure.", [["A rapid loss in germinability", "PROBLEM", 0, 29], ["rapid", "OBSERVATION_MODIFIER", 2, 7], ["loss", "OBSERVATION_MODIFIER", 8, 12]]], ["The two methods were highly correlated with a correlation coefficient of 0.9997.", [["a correlation coefficient", "TEST", 44, 69]]], ["EGA measured a D-value of 14.0 \u00b1 1.6 min and tC of 14.2 \u00b1 1.2 min.", [["EGA", "TEST", 0, 3], ["a D-value", "TEST", 13, 22], ["tC", "TEST", 45, 47]]], ["HPC measured a D-value of 16.9 \u00b1 4.0 min and tC of 17.2 \u00b1 2.3 min.", [["HPC", "CELL_TYPE", 0, 3], ["HPC", "TEST", 0, 3], ["a D-value", "TEST", 13, 22], ["tC", "TEST", 45, 47]]], ["The survival curve showed a significant reduction of the viable endospore count for increasing plasma inactivation time.", [["endospore", "ANATOMY", 64, 73], ["plasma", "ANATOMY", 95, 101], ["plasma", "ORGANISM_SUBSTANCE", 95, 101], ["The survival curve", "TEST", 0, 18], ["the viable endospore count", "TEST", 53, 79], ["increasing plasma inactivation time", "TREATMENT", 84, 119], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["reduction", "OBSERVATION_MODIFIER", 40, 49], ["endospore count", "OBSERVATION", 64, 79], ["plasma inactivation", "OBSERVATION", 95, 114]]], ["The Weibull shape parameters, \u03b2, were very close to 1 in both cases because of the log-linear shape of the inactivation graphs.Vaporized hydrogen peroxide inactivation of G. stearothermophilus endospores ::: Results and DiscussionFigure 2d illustrates the inactivation data of G. stearothermophilus endospores as a function of vaporized hydrogen peroxide treatment time.", [["hydrogen peroxide", "CHEMICAL", 137, 154], ["hydrogen peroxide", "CHEMICAL", 337, 354], ["hydrogen peroxide", "CHEMICAL", 137, 154], ["hydrogen peroxide", "CHEMICAL", 337, 354], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 137, 154], ["G. stearothermophilus", "ORGANISM", 171, 192], ["G. stearothermophilus", "ORGANISM", 277, 298], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 337, 354], ["G. stearothermophilus", "SPECIES", 171, 192], ["G. stearothermophilus", "SPECIES", 277, 298], ["G. stearothermophilus", "SPECIES", 171, 192], ["G. stearothermophilus", "SPECIES", 277, 298], ["The Weibull shape parameters", "TEST", 0, 28], ["Vaporized hydrogen peroxide inactivation", "TREATMENT", 127, 167], ["G. stearothermophilus endospores", "PROBLEM", 277, 309], ["vaporized hydrogen peroxide treatment", "TREATMENT", 327, 364], ["shape", "OBSERVATION_MODIFIER", 12, 17], ["linear shape", "OBSERVATION_MODIFIER", 87, 99], ["inactivation graphs", "OBSERVATION", 107, 126], ["hydrogen peroxide", "OBSERVATION", 137, 154]]], ["Similar to the oxygen plasma inactivation case, the two inactivation graphs were both of a log-linear shape, sharing very similar model parameters.", [["plasma", "ANATOMY", 22, 28], ["oxygen", "CHEMICAL", 15, 21], ["oxygen", "CHEMICAL", 15, 21], ["oxygen", "SIMPLE_CHEMICAL", 15, 21], ["plasma", "ORGANISM_SUBSTANCE", 22, 28], ["the oxygen plasma inactivation", "TREATMENT", 11, 41], ["the two inactivation graphs", "PROBLEM", 48, 75], ["linear shape", "OBSERVATION_MODIFIER", 95, 107]]], ["The coefficients of determination values were both 0.99 and 0.99 for EGA and HPC, respectively.", [["determination values", "TEST", 20, 40], ["EGA", "TEST", 69, 72]]], ["EGA measured a D-value of 12.7 \u00b1 0.7 min and tC of 12.5 \u00b1 1.0 min.", [["EGA", "TEST", 0, 3], ["a D-value", "TEST", 13, 22], ["tC", "TEST", 45, 47]]], ["HPC measured a D-value of 13.4 \u00b1 0.8 min and tC of 13.2 \u00b1 1.1 min.Summary and Conclusions ::: Results and DiscussionWhen sterilization processes are evaluated using CFU inactivation of endospores (i.e., HPC), at least 2 days of incubation are required before results become available.", [["HPC", "CELL_TYPE", 0, 3], ["HPC", "TEST", 0, 3], ["a D-value", "TEST", 13, 22], ["tC", "TEST", 45, 47], ["DiscussionWhen sterilization processes", "TREATMENT", 106, 144], ["incubation", "TREATMENT", 228, 238]]], ["Such a gap between sampling and results is undesirable for bioburden reduction or sterility assurance applications58.", [["a gap between sampling", "TEST", 5, 27], ["bioburden reduction", "TREATMENT", 59, 78], ["sterility assurance", "TREATMENT", 82, 101]]], ["We showed that EGA and HPC are reproducibly correlated in measuring endospores recovery efficiency from stainless steel coupons, and for measuring inactivation of endospores attached on stainless steel coupons with heat, ultraviolet radiation, vaporized hydrogen peroxide and oxygen plasma.", [["plasma", "ANATOMY", 283, 289], ["ultraviolet", "CHEMICAL", 221, 232], ["hydrogen peroxide", "CHEMICAL", 254, 271], ["oxygen", "CHEMICAL", 276, 282], ["hydrogen peroxide", "CHEMICAL", 254, 271], ["oxygen", "CHEMICAL", 276, 282], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 254, 271], ["oxygen", "SIMPLE_CHEMICAL", 276, 282], ["plasma", "ORGANISM_SUBSTANCE", 283, 289], ["HPC", "CELL_TYPE", 23, 26], ["EGA", "PROBLEM", 15, 18], ["HPC", "PROBLEM", 23, 26], ["stainless steel coupons", "TREATMENT", 104, 127], ["endospores", "PROBLEM", 163, 173], ["stainless steel coupons", "TREATMENT", 186, 209], ["heat", "TREATMENT", 215, 219], ["ultraviolet radiation", "TREATMENT", 221, 242], ["vaporized hydrogen peroxide", "TREATMENT", 244, 271], ["oxygen plasma", "TREATMENT", 276, 289], ["stainless steel coupons", "OBSERVATION", 104, 127], ["stainless steel", "OBSERVATION_MODIFIER", 186, 201]]], ["EGA inherently measures a higher number of viable endospore than culture-based assays, because of the presence of germinable-but-not-culturable populations that are more resilient, which makes EGA a more conservative measure than HPC for sterility assurance.", [["endospore", "ANATOMY", 50, 59], ["endospore", "CELL", 50, 59], ["HPC", "CELL_TYPE", 230, 233], ["culture", "TEST", 65, 72], ["culturable populations", "PROBLEM", 133, 155], ["sterility assurance", "TREATMENT", 238, 257], ["more resilient", "OBSERVATION_MODIFIER", 165, 179]]], ["These populations arise because there are more mechanistic steps required in replication that can be targets for inactivation than those required for stage I germination.", [["inactivation", "PROBLEM", 113, 125], ["stage I germination", "PROBLEM", 150, 169]]], ["EGA is a fast, quantitative and complementary biodosimetry method to the traditional culture-based assays in sterility assurance testing of surfaces.Chemicals ::: MethodsThe methods used were described first in a Caltech thesis59.", [["the traditional culture", "TEST", 69, 92], ["sterility assurance testing", "TEST", 109, 136]]], ["Terbium (III) chloride hexahydrate, 99.999%, L-alanine, DPA, and other salts were purchased from Sigma (St. Louis, MO) and were used as received.", [["Terbium (III) chloride", "CHEMICAL", 0, 22], ["L-alanine", "CHEMICAL", 45, 54], ["DPA", "CHEMICAL", 56, 59], ["Terbium (III) chloride hexahydrate", "CHEMICAL", 0, 34], ["L-alanine", "CHEMICAL", 45, 54], ["DPA", "CHEMICAL", 56, 59], ["Terbium (III) chloride hexahydrate", "SIMPLE_CHEMICAL", 0, 34], ["L-alanine", "SIMPLE_CHEMICAL", 45, 54], ["DPA", "SIMPLE_CHEMICAL", 56, 59], ["salts", "SIMPLE_CHEMICAL", 71, 76], ["St. Louis", "ORGANISM", 104, 113], ["Terbium (III) chloride hexahydrate", "TREATMENT", 0, 34], ["L-alanine", "TREATMENT", 45, 54], ["other salts", "TREATMENT", 65, 76]]], ["Agarose (>90%) was purchased from Invitrogen (Carlsbad, CA).", [["Agarose", "SIMPLE_CHEMICAL", 0, 7], ["Agarose", "TEST", 0, 7]]], ["Tryptic soy agar (TSA), nutrient broth and agar were obtained from Becton, Dickinson and Company (Sparks, MD).", [["TSA", "CHEMICAL", 18, 21], ["TSA", "SIMPLE_CHEMICAL", 18, 21]]], ["Calcium dipicolinate was prepared as previously reported60.", [["Calcium dipicolinate", "CHEMICAL", 0, 20], ["Calcium dipicolinate", "CHEMICAL", 0, 20], ["Calcium dipicolinate", "SIMPLE_CHEMICAL", 0, 20], ["Calcium dipicolinate", "TREATMENT", 0, 20]]], ["Poly-dimethylsiloxane (PDMS) was obtained from Dow Corning (Edison, NJ).Endospore cultures ::: MethodsGeobacillus stearothermophilus ATCC 7953 was obtained in the form of filter paper inoculated with an endospore population of 1.8 \u00d7 106 CFU per strip from Steris Corporation (Mentor, OH).", [["Poly-dimethylsiloxane", "CHEMICAL", 0, 21], ["PDMS", "CHEMICAL", 23, 27], ["Poly-dimethylsiloxane", "CHEMICAL", 0, 21], ["PDMS", "CHEMICAL", 23, 27], ["Poly-dimethylsiloxane", "SIMPLE_CHEMICAL", 0, 21], ["PDMS", "SIMPLE_CHEMICAL", 23, 27], ["Geobacillus stearothermophilus ATCC 7953", "CELL", 102, 142], ["Endospore cultures", "CELL_LINE", 72, 90], ["Geobacillus stearothermophilus ATCC", "SPECIES", 102, 137], ["Geobacillus stearothermophilus ATCC 7953", "SPECIES", 102, 142], ["Poly-dimethylsiloxane (PDMS", "TREATMENT", 0, 27], ["Endospore cultures", "TEST", 72, 90], ["MethodsGeobacillus stearothermophilus ATCC", "TEST", 95, 137], ["an endospore population", "TEST", 200, 223], ["filter", "OBSERVATION", 171, 177], ["endospore", "OBSERVATION_MODIFIER", 203, 212]]], ["Bacillus subtilis ATCC 27370 endospores were prepared as previously described61.", [["Bacillus subtilis ATCC 27370", "ORGANISM", 0, 28], ["Bacillus subtilis ATCC", "SPECIES", 0, 22], ["Bacillus subtilis ATCC 27370", "SPECIES", 0, 28], ["Bacillus subtilis ATCC", "PROBLEM", 0, 22]]], ["B. subtilis was cultured in tryptic soy broth (TSB) at 37 \u00b0C for 36 h.", [["B. subtilis", "ORGANISM", 0, 11], ["B. subtilis", "SPECIES", 0, 11], ["B. subtilis", "SPECIES", 0, 11], ["TSB", "TEST", 47, 50]]], ["Vegetative cells in the exponential growth phase were inoculated into a sporulation medium consisting of 1.6% nutrient broth, 1.5% agar, 0.2% KCl and 0.05% MgSO4 with filter-sterilized 1 mmol l\u22121 Ca(NO3)2, 100 \u00b5mol l\u22121 MnCl2, 1 \u00b5mol l\u22121 FeSO4, and 0.1% glucose.", [["Vegetative cells", "ANATOMY", 0, 16], ["KCl", "CHEMICAL", 142, 145], ["MgSO4", "CHEMICAL", 156, 161], ["Ca", "CHEMICAL", 196, 198], ["MnCl2", "CHEMICAL", 219, 224], ["FeSO4", "CHEMICAL", 237, 242], ["glucose", "CHEMICAL", 253, 260], ["KCl", "CHEMICAL", 142, 145], ["MgSO4", "CHEMICAL", 156, 161], ["Ca(NO3)2", "CHEMICAL", 196, 204], ["MnCl2", "CHEMICAL", 219, 224], ["FeSO4", "CHEMICAL", 237, 242], ["glucose", "CHEMICAL", 253, 260], ["Vegetative cells", "CELL", 0, 16], ["KCl", "SIMPLE_CHEMICAL", 142, 145], ["MgSO4", "SIMPLE_CHEMICAL", 156, 161], ["Ca(NO3)2", "SIMPLE_CHEMICAL", 196, 204], ["MnCl2", "SIMPLE_CHEMICAL", 219, 224], ["FeSO4", "SIMPLE_CHEMICAL", 237, 242], ["glucose", "SIMPLE_CHEMICAL", 253, 260], ["Vegetative cells", "CELL_TYPE", 0, 16], ["Vegetative cells", "PROBLEM", 0, 16], ["a sporulation medium", "TREATMENT", 70, 90], ["KCl", "TREATMENT", 142, 145], ["MgSO4", "TREATMENT", 156, 161], ["filter", "TREATMENT", 167, 173], ["Ca(NO3)", "TREATMENT", 196, 203], ["MnCl2", "TEST", 219, 224], ["FeSO4", "TEST", 237, 242], ["exponential", "OBSERVATION_MODIFIER", 24, 35], ["growth", "OBSERVATION_MODIFIER", 36, 42], ["phase", "OBSERVATION_MODIFIER", 43, 48]]], ["The sporulating culture was incubated at 37 \u00b0C for 5 days.", [["The sporulating culture", "TEST", 0, 23]]], ["Following an overnight lysozyme digestion at 37 \u00b0C, endospores were purified from vegetative cell and cell debris by repeated centrifugation at 15,000 x g for 15 min at 4 \u00b0C and washing until 99.9% fully refractile bodies was obtained under phase contrast microscopy.Endospore cultures ::: MethodsBacillus atrophaeus ATCC 9372 was obtained in endospore suspension from Raven Biological Laboratories, Inc. (Omaha, NE; now Mesalabs, Inc.), with a concentration of 2.3 \u00d7 1010 CFU ml\u22121.", [["vegetative cell", "ANATOMY", 82, 97], ["cell debris", "ANATOMY", 102, 113], ["refractile bodies", "ANATOMY", 204, 221], ["MethodsBacillus atrophaeus ATCC 9372", "CHEMICAL", 290, 326], ["vegetative cell", "CELL", 82, 97], ["cell debris", "CELL", 102, 113], ["Endospore cultures", "CELL", 267, 285], ["MethodsBacillus atrophaeus ATCC 9372", "CELL", 290, 326], ["lysozyme", "PROTEIN", 23, 31], ["vegetative cell", "CELL_TYPE", 82, 97], ["Endospore cultures", "CELL_LINE", 267, 285], ["MethodsBacillus atrophaeus ATCC", "SPECIES", 290, 321], ["MethodsBacillus atrophaeus ATCC 9372", "SPECIES", 290, 326], ["an overnight lysozyme digestion", "TREATMENT", 10, 41], ["endospores", "PROBLEM", 52, 62], ["vegetative cell", "PROBLEM", 82, 97], ["cell debris", "PROBLEM", 102, 113], ["repeated centrifugation", "TREATMENT", 117, 140], ["washing", "TEST", 178, 185], ["phase contrast microscopy", "TEST", 241, 266], ["Endospore cultures", "TEST", 267, 285], ["MethodsBacillus atrophaeus ATCC", "TEST", 290, 321], ["Mesalabs", "TEST", 421, 429], ["a concentration", "TEST", 443, 458], ["vegetative cell", "OBSERVATION", 82, 97], ["cell debris", "OBSERVATION", 102, 113]]], ["Total endospore concentrations were determined using a Petroff-Hausser hemocytometer (Horsham, PA) and CFU concentrations were determined using TSA HPC in triplicate measurements.", [["endospore", "ANATOMY", 6, 15], ["TSA", "CHEMICAL", 144, 147], ["TSA", "CHEMICAL", 144, 147], ["TSA HPC", "CELL_LINE", 144, 151], ["Total endospore concentrations", "PROBLEM", 0, 30], ["a Petroff-Hausser hemocytometer", "TREATMENT", 53, 84], ["TSA HPC", "TEST", 144, 151]]], ["Endospore suspension was stored at 4 \u00b0C in the dark before use.", [["Endospore suspension", "TREATMENT", 0, 20], ["suspension", "OBSERVATION_MODIFIER", 10, 20]]], ["Before each germination experiment, endospore samples were centrifuged at 8000 \u00d7 g for 20 min and washed twice to remove excess dipicolinic acid in the supernatant.", [["endospore samples", "ANATOMY", 36, 53], ["supernatant", "ANATOMY", 152, 163], ["dipicolinic acid", "CHEMICAL", 128, 144], ["dipicolinic acid", "CHEMICAL", 128, 144], ["endospore samples", "ORGANISM_SUBSTANCE", 36, 53], ["dipicolinic acid", "SIMPLE_CHEMICAL", 128, 144], ["endospore samples", "TEST", 36, 53], ["excess dipicolinic acid", "TREATMENT", 121, 144]]], ["No significant difference in the stock CFU population was observed before and after heat shock treatment at 80 \u00b0C for 15 min.", [["shock", "DISEASE", 89, 94], ["heat shock treatment", "TREATMENT", 84, 104], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION_MODIFIER", 15, 25], ["stock CFU", "OBSERVATION", 33, 42]]], ["The heat shock process is a standard protocol for evaluating the bioburden level of flight hardware for planetary protection in NASA\u2019s robotic planetary missions as stated in the Handbook for the Microbial Examination of Space Hardware.", [["The heat shock process", "TREATMENT", 0, 22], ["a standard protocol", "TREATMENT", 26, 45], ["flight hardware", "TREATMENT", 84, 99], ["planetary protection", "TREATMENT", 104, 124], ["robotic planetary missions", "TREATMENT", 135, 161], ["the Microbial Examination", "TEST", 192, 217], ["Space Hardware", "TREATMENT", 221, 235], ["shock", "OBSERVATION", 9, 14], ["Space Hardware", "OBSERVATION", 221, 235]]], ["The heat shock is used to kill vegetative cells, if present, and to activate the spores for germination.Coupon preparation ::: MethodsStainless steel 316 sheets (40\u2033 \u00d7 80\u2033) were procured and cut into 2\u2033 \u00d7 2\u2033 coupons in the machine shop at the California Institute of Technology (Caltech).", [["vegetative cells", "ANATOMY", 31, 47], ["spores", "ANATOMY", 81, 87], ["shock", "DISEASE", 9, 14], ["vegetative cells", "CELL", 31, 47], ["vegetative cells", "CELL_TYPE", 31, 47], ["The heat shock", "TREATMENT", 0, 14], ["shock", "OBSERVATION", 9, 14]]], ["Cotton applicators (Puritan, Guilford, ME) of length 15 cm were used to swab the coupon surfaces.", [["Cotton applicators (Puritan, Guilford, ME) of length 15 cm", "TREATMENT", 0, 58]]], ["Coupons were rinsed with 18.2 M\u03a9-cm deionized water and acetone to remove surface impurities and stains.", [["surface", "ANATOMY", 74, 81], ["acetone", "CHEMICAL", 56, 63], ["acetone", "CHEMICAL", 56, 63], ["acetone", "SIMPLE_CHEMICAL", 56, 63], ["acetone", "TREATMENT", 56, 63], ["stains", "TEST", 97, 103]]], ["They were cleaned with clean-room grade polyester wipes (BD Consumer Healthcare, Franklin Lakes, NY) saturated with 70% isopropyl alcohol.", [["isopropyl alcohol", "CHEMICAL", 120, 137], ["polyester", "CHEMICAL", 40, 49], ["isopropyl alcohol", "CHEMICAL", 120, 137], ["isopropyl alcohol", "SIMPLE_CHEMICAL", 120, 137]]], ["Each coupon was autoclaved at 121 \u00b0C for 15 min inside a glass Petri dish before inoculation.", [["glass", "OBSERVATION", 57, 62], ["Petri dish", "OBSERVATION", 63, 73]]], ["Endospore suspensions of B. atrophaeus were added aseptically and evenly on the coupons. evaporation and deposition were observed under a microscope to ensure minimal clumping, even spread and formation of monolayers of endospores.", [["monolayers", "ANATOMY", 206, 216], ["B. atrophaeus", "ORGANISM", 25, 38], ["monolayers", "CELL", 206, 216], ["B. atrophaeus", "SPECIES", 25, 38], ["B. atrophaeus", "SPECIES", 25, 38], ["Endospore suspensions", "TREATMENT", 0, 21], ["B. atrophaeus", "PROBLEM", 25, 38], ["evaporation", "TREATMENT", 89, 100], ["a microscope", "TEST", 136, 148], ["minimal clumping", "PROBLEM", 159, 175], ["monolayers of endospores", "PROBLEM", 206, 230], ["suspensions", "OBSERVATION_MODIFIER", 10, 21], ["B. atrophaeus", "OBSERVATION", 25, 38], ["minimal", "OBSERVATION_MODIFIER", 159, 166], ["clumping", "OBSERVATION", 167, 175], ["spread", "OBSERVATION_MODIFIER", 182, 188], ["monolayers", "OBSERVATION_MODIFIER", 206, 216]]], ["Coupons were air dried at room temperature inside a biological safety cabinet for 2 h and then further dried inside a Petri dish in a desiccator for 12 h in the presence of silica gel, and were used within 24 hSurface sampling ::: MethodsEach coupon was swabbed three times using a moistened sterile cotton applicator at an angle of 30\u00b0 applying a firm pressure on the surface.", [["surface", "ANATOMY", 369, 376], ["silica gel", "CHEMICAL", 173, 183], ["silica gel", "CHEMICAL", 173, 183], ["silica", "SIMPLE_CHEMICAL", 173, 179], ["surface", "CELLULAR_COMPONENT", 369, 376], ["a Petri dish in a desiccator", "TREATMENT", 116, 144], ["silica gel", "TREATMENT", 173, 183], ["MethodsEach coupon", "TREATMENT", 231, 249], ["a moistened sterile cotton applicator", "TREATMENT", 280, 317], ["a firm pressure on the surface", "TREATMENT", 346, 376], ["air", "OBSERVATION", 13, 16], ["Petri dish", "OBSERVATION", 118, 128], ["firm", "OBSERVATION_MODIFIER", 348, 352], ["pressure", "OBSERVATION", 353, 361], ["surface", "OBSERVATION_MODIFIER", 369, 376]]], ["The same swabbing procedure was repeated two more times with a 90\u00b0 and 45\u00b0 rotation of the coupon, respectively.", [["The same swabbing procedure", "TREATMENT", 0, 27]]], ["Double swabbing is used to minimize variations in pressure, sampling time and moistening of cotton tip (Patterson, 1971).", [["Double swabbing", "TREATMENT", 0, 15], ["pressure", "TEST", 50, 58], ["pressure", "OBSERVATION_MODIFIER", 50, 58]]], ["The cotton head was aseptically broken off and placed into a tube containing 10 mL of sterile water.", [["head", "ANATOMY", 11, 15], ["head", "ORGANISM_SUBDIVISION", 11, 15], ["tube", "TISSUE", 61, 65], ["cotton", "SPECIES", 4, 10], ["The cotton head", "TREATMENT", 0, 15], ["a tube", "TREATMENT", 59, 65], ["sterile water", "TREATMENT", 86, 99], ["cotton", "OBSERVATION_MODIFIER", 4, 10], ["head", "ANATOMY", 11, 15], ["tube", "OBSERVATION", 61, 65]]], ["Cells were dislodged from the swab by 10 seconds of vortexing and 2 min of sonication at 25 kHz.", [["Cells", "ANATOMY", 0, 5], ["swab", "ANATOMY", 30, 34], ["Cells", "CELL", 0, 5], ["the swab", "TEST", 26, 34], ["vortexing", "TREATMENT", 52, 61]]], ["The sample underwent heat shock at 80 \u00b0C for 15 min.", [["sample", "ANATOMY", 4, 10], ["shock", "DISEASE", 26, 31], ["heat shock", "TREATMENT", 21, 31], ["shock", "OBSERVATION", 26, 31]]], ["Endospore strips of G. stearothermophilus and PDMS inoculated with B. subtilis were directly immersed into 10 mL of sterile water.", [["PDMS", "CHEMICAL", 46, 50], ["G. stearothermophilus", "ORGANISM", 20, 41], ["B. subtilis", "ORGANISM", 67, 78], ["G. stearothermophilus", "SPECIES", 20, 41], ["B. subtilis", "SPECIES", 67, 78], ["G. stearothermophilus", "SPECIES", 20, 41], ["B. subtilis", "SPECIES", 67, 78], ["Endospore strips", "TREATMENT", 0, 16], ["G. stearothermophilus and PDMS", "TREATMENT", 20, 50], ["B. subtilis", "TREATMENT", 67, 78], ["stearothermophilus", "ANATOMY", 23, 41]]], ["The subsequent extraction and analysis processes were the same.", [["The subsequent extraction", "TREATMENT", 0, 25], ["analysis processes", "TEST", 30, 48]]], ["A total of 30 samples at each inoculum population (0, 0.3, 1, 3.2, 10, 31.6, 100, 317, 1000 spore/coupon) were obtained on the stainless steel coupons.", [["samples", "ANATOMY", 14, 21], ["inoculum population", "TEST", 30, 49], ["the stainless steel coupons", "TREATMENT", 123, 150], ["stainless steel", "OBSERVATION_MODIFIER", 127, 142]]], ["Germinable EGA counts were determined in replicates of 8 per coupon and culturable counts were determined in replicates of 6 per coupon, i.e., a total of 240 EGA measurements and 180 samples for culture assay.Enumeration of germinable endospores ::: MethodsSamples were filtered onto 1.5-mm2 spots on 0.2-\u00b5m polycarbonate membrane filters (Whatman, Florham Park, NJ) using a 96-well micro-sample filtration manifold (Schleicher and Schuell, Keene, NH).", [["samples", "ANATOMY", 183, 190], ["membrane", "ANATOMY", 322, 330], ["polycarbonate", "CHEMICAL", 308, 321], ["Germinable EGA counts", "TEST", 0, 21], ["culturable counts", "TEST", 72, 89], ["EGA measurements", "TEST", 158, 174], ["culture assay", "TEST", 195, 208], ["MethodsSamples", "TEST", 250, 264], ["0.2-\u00b5m polycarbonate membrane filters", "TREATMENT", 301, 338], ["a 96-well micro-sample filtration manifold", "TREATMENT", 373, 415], ["germinable endospores", "OBSERVATION", 224, 245]]], ["Endospores concentrated on the filter were transferred to a ~0.5 mm thick, 9 mm diameter slab of 1.5% agarose substrate containing 100 \u00b5mol l\u22121 TbCl3 and 20 mmol l\u22121 L-alanine mounted in a silicone isolator (Molecular Probes, Eugene, OR) on a quartz microscope slide.", [["Endospores", "ANATOMY", 0, 10], ["l\u22121 L-alanine", "CHEMICAL", 162, 175], ["TbCl3", "CHEMICAL", 144, 149], ["l\u22121 L-alanine", "CHEMICAL", 162, 175], ["quartz", "CHEMICAL", 243, 249], ["agarose", "SIMPLE_CHEMICAL", 102, 109], ["TbCl3", "SIMPLE_CHEMICAL", 144, 149], ["mmol l\u22121 L-alanine", "SIMPLE_CHEMICAL", 157, 175], ["Endospores", "TREATMENT", 0, 10], ["the filter", "TREATMENT", 27, 37], ["a ~0.5 mm thick, 9 mm diameter slab of 1.5% agarose substrate", "TREATMENT", 58, 119], ["a silicone isolator", "TREATMENT", 187, 206], ["a quartz microscope slide", "TREATMENT", 241, 266], ["filter", "OBSERVATION", 31, 37], ["silicone isolator", "OBSERVATION", 189, 206]]], ["After transfer of endospores, the agarose surface was covered with a piece of 0.2-mm-thick PDMS (Dow Corning, Midland, MI), prepared by mixing the polymer base and curing agent in a 10 to 1 ratio by weight.", [["surface", "ANATOMY", 42, 49], ["PDMS", "CHEMICAL", 91, 95], ["agarose", "SIMPLE_CHEMICAL", 34, 41], ["the agarose surface", "TREATMENT", 30, 49], ["MI", "PROBLEM", 119, 121]]], ["After degassing, the mixture was casted over a 0.2-mm thick stainless steel mold and cured in an oven for 2 h at 65 \u00b0C. Agarose, silicone isolator and PDMS were autoclaved at 121 \u00b0C for 15 min before use.", [["PDMS", "CHEMICAL", 151, 155], ["Agarose", "SIMPLE_CHEMICAL", 120, 127], ["the mixture", "TREATMENT", 17, 28], ["a 0.2-mm thick stainless steel mold", "TREATMENT", 45, 80], ["Agarose, silicone isolator and PDMS", "TREATMENT", 120, 155], ["silicone isolator", "OBSERVATION", 129, 146]]], ["A piece of PDMS was peeled off and attached on top of an endospore-laden agarose surface aseptically for sealing.", [["surface", "ANATOMY", 81, 88], ["PDMS", "CHEMICAL", 11, 15], ["A piece of PDMS", "TREATMENT", 0, 15], ["an endospore-laden agarose surface", "TREATMENT", 54, 88], ["PDMS", "OBSERVATION", 11, 15], ["laden", "OBSERVATION_MODIFIER", 67, 72], ["agarose", "OBSERVATION_MODIFIER", 73, 80], ["surface", "OBSERVATION_MODIFIER", 81, 88], ["sealing", "OBSERVATION_MODIFIER", 105, 112]]], ["Time-lapse gated images were collected by real-time streaming with a delay of 100 \u00b5s and exposure time of 5 s in each frame using a previously reported EGA instrumentation39.Enumeration of culturable endospores ::: MethodsCulturable counts were determined by HPC on tryptic soy agar (TSA).", [["HPC", "CHEMICAL", 259, 262], ["EGA instrumentation39", "DNA", 152, 173], ["HPC", "CELL_TYPE", 259, 262], ["MethodsCulturable counts", "TEST", 215, 239], ["culturable endospores", "OBSERVATION", 189, 210]]], ["B. subtilis and B. atrophaeus endospores were incubated at 37 \u00b0C. G. stearothermophilus endospores were incubated at 55 \u00b0C, CFU counts were recorded after 72 h of incubation.Heat inactivation ::: MethodsIn the dry heat inactivation experiment, B. atrophaeus endospores inoculated on stainless steel coupons were heat treated in an oven at 105 \u00b1 0.5 \u00b0C. A beaker of silica gel was kept inside the oven.", [["silica gel", "CHEMICAL", 365, 375], ["silica", "CHEMICAL", 365, 371], ["B. subtilis", "ORGANISM", 0, 11], ["B. atrophaeus endospores", "ORGANISM", 16, 40], ["G. stearothermophilus", "ORGANISM", 66, 87], ["B. atrophaeus", "ORGANISM", 244, 257], ["silica", "SIMPLE_CHEMICAL", 365, 371], ["B. subtilis", "SPECIES", 0, 11], ["B. atrophaeus", "SPECIES", 16, 29], ["G. stearothermophilus", "SPECIES", 66, 87], ["B. atrophaeus", "SPECIES", 244, 257], ["B. subtilis", "SPECIES", 0, 11], ["B. atrophaeus", "SPECIES", 16, 29], ["G. stearothermophilus", "SPECIES", 66, 87], ["B. atrophaeus", "SPECIES", 244, 257], ["B. subtilis and B. atrophaeus endospores", "PROBLEM", 0, 40], ["G. stearothermophilus endospores", "PROBLEM", 66, 98], ["CFU counts", "TEST", 124, 134], ["Methods", "TREATMENT", 196, 203], ["the dry heat inactivation experiment", "PROBLEM", 206, 242], ["B. atrophaeus endospores", "PROBLEM", 244, 268], ["stainless steel coupons", "TREATMENT", 283, 306], ["A beaker of silica gel", "TREATMENT", 353, 375], ["dry heat", "OBSERVATION_MODIFIER", 210, 218], ["stainless steel", "OBSERVATION_MODIFIER", 283, 298], ["silica gel", "OBSERVATION", 365, 375]]], ["The time required to raise the coupon surface temperature to 105 \u00b0C was determined by a thermocouple and was added to each exposure cycle.", [["surface", "ANATOMY", 38, 45]]], ["Lethality of the process only included the holding period at 105 \u00b0C. Immediately after removal from the oven, each stainless steel coupon was chilled by ice.", [["Lethality of the process", "PROBLEM", 0, 24], ["removal", "TREATMENT", 87, 94], ["each stainless steel coupon", "TREATMENT", 110, 137]]], ["Endospores were sampled by the swab-rinse technique and enumerated by TSA HPC and EGA.", [["Endospores", "ANATOMY", 0, 10], ["TSA", "CHEMICAL", 70, 73], ["TSA", "CHEMICAL", 70, 73], ["Endospores", "PROBLEM", 0, 10]]], ["D105 \u00b0C was determined from a best-fit regression line of the data points by using a least square method.", [["a least square method", "TREATMENT", 83, 104]]], ["The variation of the data points around each regression line was measured by calculating the standard deviation of the estimate.UV inactivation ::: MethodsB. atrophaeus endospores laden on stainless steel coupons were contained in glass Petri dishes.", [["stainless steel", "CHEMICAL", 189, 204], ["MethodsB", "PROBLEM", 148, 156], ["atrophaeus endospores", "PROBLEM", 158, 179], ["stainless steel coupons", "TREATMENT", 189, 212], ["variation", "OBSERVATION_MODIFIER", 4, 13], ["regression line", "OBSERVATION", 45, 60], ["endospores", "OBSERVATION_MODIFIER", 169, 179], ["laden", "OBSERVATION_MODIFIER", 180, 185], ["stainless steel", "OBSERVATION_MODIFIER", 189, 204], ["coupons", "OBSERVATION", 205, 212], ["glass Petri dishes", "OBSERVATION", 231, 249]]], ["They were exposed to continuous irradiation of UV from a 4 W low-pressure mercury lamp (UVP, Upland, CA) with peak irradiance at 254 nm (UVC) coupled with a 0.7-neutral-density filter.", [["mercury", "CHEMICAL", 74, 81], ["mercury", "CHEMICAL", 74, 81], ["continuous irradiation of UV", "TREATMENT", 21, 49], ["a 4 W low-pressure mercury lamp", "TREATMENT", 55, 86], ["peak irradiance", "TEST", 110, 125], ["a 0.7-neutral-density filter", "TREATMENT", 155, 183], ["density filter", "OBSERVATION", 169, 183]]], ["The distance between the UV lamp and the surface of the stainless coupon was 10 cm.", [["surface", "ANATOMY", 41, 48], ["surface", "CELLULAR_COMPONENT", 41, 48], ["the UV lamp", "TREATMENT", 21, 32], ["the stainless coupon", "TREATMENT", 52, 72], ["distance", "OBSERVATION_MODIFIER", 4, 12], ["UV lamp", "OBSERVATION", 25, 32], ["surface", "OBSERVATION_MODIFIER", 41, 48], ["stainless", "OBSERVATION_MODIFIER", 56, 65], ["10 cm", "OBSERVATION_MODIFIER", 77, 82]]], ["The uniformity of the lamp source had a maximum variation of ~4% within the irradiation area.", [["the lamp source", "TEST", 18, 33], ["uniformity", "OBSERVATION_MODIFIER", 4, 14], ["lamp source", "OBSERVATION", 22, 33], ["maximum", "OBSERVATION_MODIFIER", 40, 47], ["variation", "OBSERVATION_MODIFIER", 48, 57], ["irradiation", "OBSERVATION_MODIFIER", 76, 87], ["area", "OBSERVATION_MODIFIER", 88, 92]]], ["The lamp was switched on 20 min before the start of the inactivation to stabilize the emission power and spectrum.", [["The lamp", "TREATMENT", 0, 8], ["the inactivation", "TREATMENT", 52, 68]]], ["Irradiation experiments were performed in a dark environment at room temperature without controlling the relative humidity.", [["Irradiation experiments", "TREATMENT", 0, 23]]], ["After irradiation, the samples were immediately chilled by ice at 0 \u00b0C. The swab-rinse method was used to suspend sampled populations, and the endospore surface concentration was determined by EGA and CFU enumeration.", [["samples", "ANATOMY", 23, 30], ["endospore surface", "ANATOMY", 143, 160], ["irradiation", "TREATMENT", 6, 17], ["the samples", "TEST", 19, 30], ["The swab-rinse method", "TREATMENT", 72, 93], ["the endospore surface concentration", "TEST", 139, 174], ["CFU enumeration", "OBSERVATION", 201, 216]]], ["The protocol for monitoring UV inactivation of B. atrophaeus endospores in suspension was previously reported39.Plasma inactivation ::: MethodsB. subtilis endospores were inoculated onto a 2 mm \u00d7 2 mm piece of PDMS placed on a glass microscope slide.", [["B. atrophaeus", "ORGANISM", 47, 60], ["Plasma", "ORGANISM_SUBSTANCE", 112, 118], ["B. atrophaeus", "SPECIES", 47, 60], ["subtilis", "SPECIES", 146, 154], ["B. atrophaeus", "SPECIES", 47, 60], ["subtilis", "SPECIES", 146, 154], ["The protocol", "TREATMENT", 0, 12], ["monitoring UV inactivation", "TREATMENT", 17, 43], ["B. atrophaeus endospores", "PROBLEM", 47, 71], ["MethodsB", "PROBLEM", 136, 144], ["subtilis endospores", "PROBLEM", 146, 165], ["a 2 mm \u00d7 2 mm piece of PDMS", "TREATMENT", 187, 214], ["a glass microscope slide", "TREATMENT", 225, 249], ["endospores", "OBSERVATION_MODIFIER", 155, 165]]], ["The sample slide was placed within a glass vacuum chamber (150 mm radius and 300 mm length) at room temperature of a plasma system (Diener Electronics GmbH + Co., Germany).", [["plasma", "ANATOMY", 117, 123], ["plasma", "ORGANISM_SUBSTANCE", 117, 123], ["The sample slide", "TREATMENT", 0, 16], ["a glass vacuum chamber", "TREATMENT", 35, 57], ["glass vacuum chamber", "OBSERVATION", 37, 57]]], ["Low pressure was achieved using a vacuum pump.", [["Low pressure", "TREATMENT", 0, 12], ["a vacuum pump", "TREATMENT", 32, 45], ["pressure", "OBSERVATION_MODIFIER", 4, 12], ["vacuum pump", "OBSERVATION", 34, 45]]], ["A radio frequency of 13.6 MHz was used to sustain the plasma.", [["plasma", "ANATOMY", 54, 60], ["plasma", "ORGANISM_SUBSTANCE", 54, 60], ["the plasma", "TEST", 50, 60]]], ["The endospore-inoculated glass slides were exposed to glow discharge at 100 W power for 0, 15, 30, 45, and 60 min.", [["The endospore-inoculated glass slides", "TREATMENT", 0, 37], ["inoculated glass slides", "OBSERVATION", 14, 37]]], ["The RF generator was turned off immediately at the end of the inactivation process.Vaporized hydrogen peroxide inactivation ::: MethodsVaporized hydrogen peroxide (VHP) resistance of G. stearothermophilus ATCC 7953 (mean population = 1.8 \u00d7 106 CFU/coupon) on metal coupons was measured by EGA and culturability (colony formation on TSA).", [["colony", "ANATOMY", 312, 318], ["hydrogen peroxide", "CHEMICAL", 93, 110], ["hydrogen peroxide", "CHEMICAL", 145, 162], ["VHP", "CHEMICAL", 164, 167], ["hydrogen peroxide", "CHEMICAL", 93, 110], ["hydrogen peroxide", "CHEMICAL", 145, 162], ["VHP", "CHEMICAL", 164, 167], ["TSA", "CHEMICAL", 332, 335], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 93, 110], ["MethodsVaporized hydrogen peroxide", "SIMPLE_CHEMICAL", 128, 162], ["VHP", "SIMPLE_CHEMICAL", 164, 167], ["G. stearothermophilus ATCC 7953", "ORGANISM", 183, 214], ["G. stearothermophilus ATCC", "SPECIES", 183, 209], ["G. stearothermophilus ATCC 7953", "SPECIES", 183, 214], ["The RF generator", "TREATMENT", 0, 16], ["the inactivation process", "TREATMENT", 58, 82], ["MethodsVaporized hydrogen peroxide", "TREATMENT", 128, 162], ["G. stearothermophilus ATCC", "TEST", 183, 209], ["mean population", "TEST", 216, 231], ["metal coupons", "TREATMENT", 259, 272], ["TSA", "TEST", 332, 335], ["hydrogen peroxide", "OBSERVATION", 93, 110]]], ["In a preliminary test, 0.5 mL of hydrogen peroxide was vaporized at 45 \u00b0C for 3 min in a chamber at Jet Propulsion Laboratory.", [["hydrogen peroxide", "CHEMICAL", 33, 50], ["hydrogen peroxide", "CHEMICAL", 33, 50], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 33, 50], ["hydrogen peroxide", "TREATMENT", 33, 50]]], ["107B. atrophaeus endospore/coupon and 1.8 \u00d7 106 G. stearothermophilus endospore/coupon were placed inside sterilization pouches and subjected to vaporized H2O2 inactivation.", [["pouches", "ANATOMY", 120, 127], ["107B", "CHEMICAL", 0, 4], ["H2O2", "CHEMICAL", 155, 159], ["H2O2", "CHEMICAL", 155, 159], ["atrophaeus endospore", "ORGANISM", 6, 26], ["stearothermophilus", "ORGANISM", 51, 69], ["pouches", "ORGAN", 120, 127], ["H2O2", "SIMPLE_CHEMICAL", 155, 159], ["107B", "PROTEIN", 0, 4], ["G. stearothermophilus endospore", "SPECIES", 48, 79], ["atrophaeus endospore", "TEST", 6, 26], ["coupon", "TEST", 27, 33], ["stearothermophilus endospore/coupon", "TREATMENT", 51, 86], ["sterilization pouches", "TREATMENT", 106, 127], ["vaporized H2O2 inactivation", "TREATMENT", 145, 172], ["H2O2 inactivation", "OBSERVATION", 155, 172]]], ["In the VHP experiment, G. stearothermophilus endospores strips with different durations of vaporized H2O2 inactivation treatment (0, 15, 30, 45, 60 min) were obtained from Steris Corporation using a LaCalhene two-glove isolator connected to a VHP1000ED system.", [["H2O2", "CHEMICAL", 101, 105], ["H2O2", "CHEMICAL", 101, 105], ["G. stearothermophilus", "ORGANISM", 23, 44], ["H2O2", "SIMPLE_CHEMICAL", 101, 105], ["G. stearothermophilus", "SPECIES", 23, 44], ["G. stearothermophilus", "SPECIES", 23, 44], ["G. stearothermophilus endospores strips", "TREATMENT", 23, 62], ["vaporized H2O2 inactivation treatment", "TREATMENT", 91, 128], ["a LaCalhene two-glove isolator", "TREATMENT", 197, 227], ["a VHP1000ED system", "TREATMENT", 241, 259]]], ["G. stearothermophilus endospores were incubated and germinated at 37 \u00b0C and 55 \u00b0C, respectively.Data analysis ::: MethodsPhase contrast microscopy (PCM), Endospore Germinability Assay (EGA), and heterotrophic plate counts (HPC) were used to determine total endospore populations (PPCM), germinable populations (PEGA) and culturable populations (PHPC), respectively, and these were used to derive the germinable fractions (PEGA/PPCM) and culturable fractions (PCFU/PPCM).", [["PPCM", "DISEASE", 280, 284], ["PPCM", "DISEASE", 427, 431], ["PPCM", "DISEASE", 464, 468], ["G. stearothermophilus", "ORGANISM", 0, 21], ["G. stearothermophilus", "SPECIES", 0, 21], ["G. stearothermophilus", "SPECIES", 0, 21], ["G. stearothermophilus endospores", "TEST", 0, 32], ["Data analysis", "TEST", 96, 109], ["MethodsPhase contrast microscopy", "TEST", 114, 146], ["PCM", "TEST", 148, 151], ["Endospore Germinability Assay", "TEST", 154, 183], ["EGA", "TEST", 185, 188], ["heterotrophic plate counts", "TEST", 195, 221], ["total endospore populations", "PROBLEM", 251, 278], ["PPCM", "PROBLEM", 280, 284], ["germinable populations", "PROBLEM", 287, 309], ["PEGA", "TEST", 311, 315], ["culturable populations", "TEST", 321, 343], ["PEGA/PPCM", "TREATMENT", 422, 431], ["culturable fractions", "TEST", 437, 457]]]], "b33eaa2a57ec25b18ffc91be9fe42e94bd22d474": [["We thank the authors for their response and welcome critical discussion on the potential of LDRT as a treatment for COVID-19 pneumonia.", [["pneumonia", "DISEASE", 125, 134], ["LDRT", "SIMPLE_CHEMICAL", 92, 96], ["LDRT", "TREATMENT", 92, 96], ["a treatment", "TREATMENT", 100, 111], ["COVID", "TEST", 116, 121], ["pneumonia", "PROBLEM", 125, 134], ["pneumonia", "OBSERVATION", 125, 134]]], ["Kefayat and Ghahremani raise several valid points in their letter.", [["Kefayat", "TREATMENT", 0, 7]]], ["Certainly further study on the matter is warranted.", [["further study", "TEST", 10, 23]]], ["Based on historical evidence in the literature and the current pandemic status, the radiation therapy community would be justified in designing both pre-clinical and clinical trials to modern standards to investigate the effectiveness of LDRT against COVID-19 pneumonia using end points such as progression to the need for ventilator support, duration of hospitalisation, length of intensive care, and overall mortality rates.", [["pneumonia", "DISEASE", 260, 269], ["LDRT", "SIMPLE_CHEMICAL", 238, 242], ["the radiation therapy", "TREATMENT", 80, 101], ["modern standards", "TREATMENT", 185, 201], ["LDRT", "TREATMENT", 238, 242], ["COVID", "TEST", 251, 256], ["pneumonia", "PROBLEM", 260, 269], ["ventilator support", "TREATMENT", 323, 341], ["intensive care", "TREATMENT", 382, 396], ["pneumonia", "OBSERVATION", 260, 269]]], ["We agree that the timing of the irradiation in relation to disease progression is likely to influence treatment outcomes.", [["the irradiation", "TREATMENT", 28, 43], ["disease progression", "PROBLEM", 59, 78], ["disease", "OBSERVATION", 59, 66]]], ["As such the treatment should be designed to emulate fast-track, palliative treatments with minimal planning and complexity in order to easily adapt to treating large numbers of patients in rapid response to a localized outbreak (e.g. parallel opposed pair chest treatments with standard linear accelerators).", [["chest", "ANATOMY", 256, 261], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 177, 185], ["the treatment", "TREATMENT", 8, 21], ["palliative treatments", "TREATMENT", 64, 85], ["a localized outbreak", "PROBLEM", 207, 227], ["parallel opposed pair chest treatments", "TREATMENT", 234, 272], ["standard linear accelerators", "TREATMENT", 278, 306], ["chest", "ANATOMY", 256, 261]]], ["This constraint may challenge the authors' proposition of TBI-type treatment which often requires specialized facilities and increases the plan complexity, although whole lung fields would still irradiate large volumes in order to encompass both lungs simultaneously.", [["lung", "ANATOMY", 171, 175], ["lungs", "ANATOMY", 246, 251], ["TBI", "DISEASE", 58, 61], ["lung", "ORGAN", 171, 175], ["lungs", "ORGAN", 246, 251], ["TBI-type treatment", "TREATMENT", 58, 76], ["whole lung fields", "PROBLEM", 165, 182], ["lung", "ANATOMY", 171, 175], ["fields", "ANATOMY_MODIFIER", 176, 182], ["large", "OBSERVATION_MODIFIER", 205, 210], ["volumes", "OBSERVATION", 211, 218], ["both", "ANATOMY_MODIFIER", 241, 245], ["lungs", "ANATOMY", 246, 251]]]], "f6de88d3372bcb0a2a68d4a19ddf7e7aef79b3d0": [["L'identit\u00e9 modifi\u00e9e \u00ab Ne plus sortir revient \u00e0 perdre un support essentiel de l'identit\u00e9 de l'individu contemporain \u00e0 savoir sa composition multidimensionnelle ou plurielle \u00bb [3] .", [["Ne plus sortir revient", "TREATMENT", 22, 44]]], ["La libert\u00e9 entrav\u00e9e au nom de la crise sanitaire L'article que j'ai choisi s'interroge justement sur la perte des libert\u00e9s de chacun \u00e0 cause du coronavirus et du confinement.", [["du coronavirus", "OBSERVATION", 141, 155]]], ["En effet, elle dit qu'\u00eatre limit\u00e9 dans nos actions, nous permet de nous rendre compte \u00e0 quel point nous sommes libres habituellement \u00ab Notre libert\u00e9 ne nous appara\u00eet jamais avec autant d'acuit\u00e9 que le jour o\u00f9 nous en sommes priv\u00e9s \u00bb.", [["Notre libert\u00e9 ne nous appara\u00eet jamais avec autant d'acuit\u00e9 que le jour o\u00f9 nous en sommes priv\u00e9s", "SPECIES", 135, 230]]], ["En effet, cette p\u00e9riode de pand\u00e9mie nous offre le temps de (re)faire des choses simples, des petits riens de la vie : \u00ab red\u00e9couvrir le go\u00fbt du caf\u00e9 le matin, ce caf\u00e9 d'habitude si vite aval\u00e9, ouvrir ce livre abandonn\u00e9, apprendre \u00e0 faire son pain, etc. \u00bb.", [["pain", "DISEASE", 241, 245], ["son pain", "PROBLEM", 237, 245]]], ["Cela fait rappel au TD pratique de la ph\u00e9nom\u00e9nologie de M. Fiorletta.", [["Cela", "TEST", 0, 4]]], ["De m\u00eame, je fais le lien avec les cours de M. Boudrahem, qui parlait des rituels en s'appuyant sur la d\u00e9finition d'Arnold Van Gennep [10] : \u00ab l'ensemble des recettes qui permet d'apprivoiser le temps qui passe, de d\u00e9passer, canaliser l'angoisse qui accompagne tout changement d\u00e9cisif dans l'existence humaine \u00bb.", [["\u00ab l'ensemble des", "TREATMENT", 140, 156]]], ["Florian Ferrisse Le rapport aux dimensions spatio-temporelles Plusieurs \u00e9tudiants dont Thomas Boisson rel\u00e8vent l'\u00e0-propos de cette citation de Blaise Pascal dans le contexte du confinement : \u00ab Tout le malheur des hommes vient d'une seule chose, qui est de ne savoir pas demeurer en repos dans une chambre. \u00bb", [["Tout le malheur des hommes vient d'une seule chose, qui est de ne savoir pas demeurer en repos dans une chambre", "SPECIES", 193, 304], ["Le rapport", "TEST", 17, 27]]], ["Ainsi, comme le r\u00e9sume si bien l'article : \u00ab Pour celles qui ne contracteront pas le virus, un autre danger mortel plane aussi, celui de mourir de tristesse et de solitude \u00bb.", [["Pour celles qui ne contracteront pas le virus", "SPECIES", 45, 90], ["Pour celles", "TEST", 45, 56], ["le virus", "ANATOMY", 82, 90]]], ["Dans nos cours de Sciences humaines, on apprend que l'humain a des besoins fondamentaux qui le d\u00e9finissent dont celui de vivre en communaut\u00e9, en \u00e9tant en contact avec les autres humains, ce qui n'est plus possible pendant le confinement.", [["pendant le confinement", "PROBLEM", 214, 236]]], ["Les conditions particuli\u00e8res dans lesquelles les mesures de confinement doivent \u00eatre appliqu\u00e9es dans ces \u00e9tablissements ont un impact sur les soignants qui se voient forc\u00e9s de s'adapter \u00e0 une situation \u00e0 laquelle ils n'\u00e9taient pas pr\u00e9par\u00e9s et qui peut \u00eatre source de malaise quand les actions \u00e0 effectuer leur paraissent trop s'\u00e9loigner de leurs fonctions.", [["les actions", "TEST", 281, 292], ["effectuer", "TEST", 295, 304], ["leur paraissent trop s", "PROBLEM", 305, 327], ["leurs fonctions", "OBSERVATION", 340, 355]]], ["Ceci est en rapport avec les enseignements d'UE2 et notamment dans la probl\u00e9matique de l'identit\u00e9 car l'adaptation rapide \u00e0 cette situation qui n'a pas \u00e9t\u00e9 pr\u00e9vue bouleverse le quotidien des soignants et l'image qu'ils avaient de leur m\u00e9tier.", [["Ceci est", "TEST", 0, 8], ["le quotidien des", "TREATMENT", 174, 190]]], ["D'autres \u00e9tudiants sont affect\u00e9s par les violences infantiles L\u00e9a Cioni choisit l'article \u00e9crit par Naomi Titti pour France Culture [16] : L'auteure tente de lever le tabou sur la maltraitance infantile.", [["maltraitance infantile", "DISEASE", 180, 202], ["L\u00e9a", "TEST", 62, 65], ["Cioni", "TEST", 66, 71], ["choisit", "TEST", 72, 79], ["l'article", "TEST", 80, 89], ["pour France Culture", "TEST", 112, 131]]]], "PMC7112423": [["A new disease entity known as severe acute respiratory syndrome (SARS) appeared in Guangdong Province, People's Republic of China, in late 2002, and then in Hong Kong, Vietnam, Singapore, and Canada, in March, 2003.1 A novel coronavirus, SARS-associated coronavirus, was identified as the putative cause.2 This disease proved to be highly infectious with respiratory droplets suspected as the main route of transmission.3 However, faeces were also suggested to have an important role in some outbreaks.3 Therefore, viral shedding patterns in different body fluids and secretions are important, to know which are the most appropriate specimens for diagnosis and how to institute appropriate infection control measures.", [["respiratory", "ANATOMY", 355, 366], ["faeces", "ANATOMY", 431, 437], ["body fluids", "ANATOMY", 552, 563], ["secretions", "ANATOMY", 568, 578], ["specimens", "ANATOMY", 633, 642], ["acute respiratory syndrome", "DISEASE", 37, 63], ["SARS", "DISEASE", 65, 69], ["SARS-associated coronavirus", "DISEASE", 238, 265], ["infection", "DISEASE", 690, 699], ["coronavirus", "ORGANISM", 225, 236], ["SARS-associated coronavirus", "ORGANISM", 238, 265], ["faeces", "ORGANISM_SUBSTANCE", 431, 437], ["body", "ORGANISM_SUBDIVISION", 552, 556], ["secretions", "ORGANISM_SUBSTANCE", 568, 578], ["A new disease entity", "PROBLEM", 0, 20], ["severe acute respiratory syndrome", "PROBLEM", 30, 63], ["A novel coronavirus", "PROBLEM", 217, 236], ["SARS", "PROBLEM", 238, 242], ["coronavirus", "PROBLEM", 254, 265], ["This disease", "PROBLEM", 306, 318], ["respiratory droplets", "PROBLEM", 355, 375], ["viral shedding patterns", "PROBLEM", 515, 538], ["different body fluids", "TREATMENT", 542, 563], ["secretions", "PROBLEM", 568, 578], ["appropriate infection control measures", "TREATMENT", 678, 716], ["new", "OBSERVATION_MODIFIER", 2, 5], ["disease", "OBSERVATION", 6, 13], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["acute", "OBSERVATION_MODIFIER", 37, 42], ["respiratory syndrome", "OBSERVATION", 43, 63], ["coronavirus", "OBSERVATION", 225, 236], ["coronavirus", "OBSERVATION", 254, 265], ["disease", "OBSERVATION", 311, 318], ["highly", "OBSERVATION_MODIFIER", 332, 338], ["infectious", "OBSERVATION", 339, 349], ["respiratory droplets", "OBSERVATION", 355, 375], ["main", "OBSERVATION_MODIFIER", 393, 397], ["viral", "OBSERVATION", 515, 520], ["infection", "OBSERVATION", 690, 699]]]], "093daa3ff0fb6f613aa0dff9edd31e530f1ebc52": [["Wuhan, the capital city of Hubei province with a population of more than 11 million people, is the largest city and the most important traffic hub in Central China.", [["people", "ORGANISM", 84, 90], ["people", "SPECIES", 84, 90], ["largest", "OBSERVATION_MODIFIER", 99, 106], ["Central", "ANATOMY_MODIFIER", 150, 157]]], ["Since December 2019, the outbreak of coronavirus disease 2019 (COVID-19) hit the Wuhan city [1] .", [["coronavirus disease", "DISEASE", 37, 56], ["coronavirus", "ORGANISM", 37, 48], ["coronavirus", "SPECIES", 37, 48], ["coronavirus disease", "PROBLEM", 37, 56], ["COVID", "TEST", 63, 68], ["coronavirus disease", "OBSERVATION", 37, 56]]], ["The time of the outbreak coincided with the Chinese Spring Festival, when the largest annual population movement began.", [["largest", "OBSERVATION_MODIFIER", 78, 85], ["population movement", "OBSERVATION", 93, 112]]], ["The infected people in incubation period had brought the virus to other cities and person-to-person transmission of the new coronavirus caused the spread of infections across the country.", [["coronavirus", "DISEASE", 124, 135], ["infections", "DISEASE", 157, 167], ["people", "ORGANISM", 13, 19], ["coronavirus", "ORGANISM", 124, 135], ["people", "SPECIES", 13, 19], ["person", "SPECIES", 83, 89], ["person", "SPECIES", 93, 99], ["the virus", "PROBLEM", 53, 62], ["the new coronavirus", "PROBLEM", 116, 135], ["infected", "OBSERVATION_MODIFIER", 4, 12], ["people", "OBSERVATION", 13, 19], ["infections", "OBSERVATION", 157, 167]]]], "PMC7437108": [["IntroductionIt is announced by the World Health Organization (WHO) that the novel coronavirus (COVID-19) has become a pandemic in recent times.", [["coronavirus", "DISEASE", 82, 93], ["COVID-19", "CHEMICAL", 95, 103], ["coronavirus", "ORGANISM", 82, 93], ["COVID-19", "ORGANISM", 95, 103], ["the novel coronavirus", "PROBLEM", 72, 93], ["COVID", "TEST", 95, 100], ["pandemic", "OBSERVATION", 118, 126]]], ["The severity of this pandemic is increased from day to day and created new records almost every day.", [["this pandemic", "PROBLEM", 16, 29], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["pandemic", "OBSERVATION", 21, 29], ["increased", "OBSERVATION_MODIFIER", 33, 42]]], ["The infected, death and recovered cases for this disease are 18,514,884, 699,027, and 11,731,138, respectively, around the world [1].", [["death", "DISEASE", 14, 19], ["this disease", "PROBLEM", 44, 56], ["infected", "OBSERVATION_MODIFIER", 4, 12]]], ["Due to this pandemic, almost all the sectors including the healthcare system [2] are facing a serious crisis of infrastructure both in developed and developing countries.IntroductionThere are several types of diseases such as heart disease [3], breast cancer [4, 5], liver disorder [6], diabetes [7] available in medical science that causes a lot of problems in human health but the current pandemic is COVID-19 [8, 9].", [["heart", "ANATOMY", 226, 231], ["breast cancer", "ANATOMY", 245, 258], ["liver", "ANATOMY", 267, 272], ["heart disease", "DISEASE", 226, 239], ["breast cancer", "DISEASE", 245, 258], ["liver disorder", "DISEASE", 267, 281], ["diabetes", "DISEASE", 287, 295], ["heart", "ORGAN", 226, 231], ["breast cancer", "CANCER", 245, 258], ["liver", "ORGAN", 267, 272], ["human", "ORGANISM", 362, 367], ["human", "SPECIES", 362, 367], ["human", "SPECIES", 362, 367], ["this pandemic", "PROBLEM", 7, 20], ["a serious crisis of infrastructure", "PROBLEM", 92, 126], ["diseases", "PROBLEM", 209, 217], ["heart disease", "PROBLEM", 226, 239], ["breast cancer", "PROBLEM", 245, 258], ["liver disorder", "PROBLEM", 267, 281], ["diabetes", "PROBLEM", 287, 295], ["COVID", "TEST", 403, 408], ["serious", "OBSERVATION_MODIFIER", 94, 101], ["crisis", "OBSERVATION", 102, 108], ["diseases", "OBSERVATION", 209, 217], ["heart", "ANATOMY", 226, 231], ["disease", "OBSERVATION", 232, 239], ["breast", "ANATOMY", 245, 251], ["cancer", "OBSERVATION", 252, 258], ["liver", "ANATOMY", 267, 272]]], ["The major symptoms for COVID-19 are fever, tiredness, breathing difficulties, and dry cough [10].", [["fever", "DISEASE", 36, 41], ["tiredness", "DISEASE", 43, 52], ["breathing difficulties", "DISEASE", 54, 76], ["dry cough", "DISEASE", 82, 91], ["The major symptoms", "PROBLEM", 0, 18], ["COVID", "TEST", 23, 28], ["fever", "PROBLEM", 36, 41], ["tiredness", "PROBLEM", 43, 52], ["breathing difficulties", "PROBLEM", 54, 76], ["dry cough", "PROBLEM", 82, 91]]], ["Among these symptoms, the respiration problem is more severe and acute [11].", [["these symptoms", "PROBLEM", 6, 20], ["the respiration problem", "PROBLEM", 22, 45], ["severe", "OBSERVATION_MODIFIER", 54, 60], ["acute", "OBSERVATION_MODIFIER", 65, 70]]], ["There are crucial devices [12, 13] usually available within the healthcare technology [14, 15], but they simply do not occur in a high sufficient density to deal with the increased number of patients related to epidemics.", [["patients", "ORGANISM", 191, 199], ["patients", "SPECIES", 191, 199], ["epidemics", "PROBLEM", 211, 220], ["crucial devices", "OBSERVATION", 10, 25], ["high sufficient density", "OBSERVATION_MODIFIER", 130, 153], ["increased", "OBSERVATION_MODIFIER", 171, 180], ["number", "OBSERVATION_MODIFIER", 181, 187]]], ["Various assistant devices [16\u201319] are developed to support humanity in different applications like fall detection for elderly [20, 21], staircase detection [22, 23], path hole as well as road surface smoothness detection [24\u201327], and any types of hindrances detection [28, 29] using modern technologies.", [["surface", "ANATOMY", 192, 199], ["fall detection", "TEST", 99, 113], ["staircase detection", "TEST", 136, 155], ["road surface smoothness detection", "TEST", 187, 220], ["hindrances detection", "TEST", 247, 267], ["modern technologies", "TREATMENT", 283, 302]]], ["The recent development of respiratory support systems assists infected patients for initial treatment.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["respiratory support systems", "TREATMENT", 26, 53], ["initial treatment", "TREATMENT", 84, 101], ["respiratory support", "OBSERVATION", 26, 45]]], ["Oxygen therapy devices [30, 31] are an appropriate solution for the COVID-19 patients, generally available in hospitals as well as ambulance.", [["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["Oxygen therapy devices", "TREATMENT", 0, 22]]], ["Ventilators both invasive and non-invasive are mostly used devices for breathing assistance in the hospital environment [32, 33].", [["Ventilators", "TREATMENT", 0, 11], ["breathing assistance", "TREATMENT", 71, 91]]], ["The recent deployment of CPAP devices [34, 35] has emerged a direction for the patients having breathing problem.IntroductionThe paper aims to overview the recent technologies that are evolved for the COVID-19 infected patients for breathing assistant.", [["patients", "ORGANISM", 79, 87], ["patients", "ORGANISM", 219, 227], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 219, 227], ["CPAP devices", "TREATMENT", 25, 37], ["breathing problem", "PROBLEM", 95, 112], ["the COVID", "TEST", 197, 206], ["CPAP devices", "OBSERVATION", 25, 37]]], ["The review described breathing aid devices like oxygen therapy devices, ventilators, and CPAP devices.", [["oxygen", "CHEMICAL", 48, 54], ["oxygen", "CHEMICAL", 48, 54], ["oxygen", "SIMPLE_CHEMICAL", 48, 54], ["breathing aid devices", "TREATMENT", 21, 42], ["oxygen therapy devices", "TREATMENT", 48, 70], ["ventilators", "TREATMENT", 72, 83], ["CPAP devices", "TREATMENT", 89, 101], ["oxygen therapy", "OBSERVATION", 48, 62], ["CPAP devices", "OBSERVATION", 89, 101]]], ["The developed systems are demonstrated in terms of the working principle, the construction procedure, the used hardware components, cost analysis, and comparative advantages and disadvantages.", [["the construction procedure", "TREATMENT", 74, 100], ["the used hardware components", "TREATMENT", 102, 130], ["cost analysis", "TEST", 132, 145], ["hardware", "OBSERVATION", 111, 119]]], ["To find the best technology, a comparative analysis among the available devices with challenges and possible future trends are outlined in the review.IntroductionThe rest of the paper is organized as follows.", [["a comparative analysis", "TEST", 29, 51], ["the available devices", "TREATMENT", 58, 79]]], ["Section \u201cBreathing Aid Devices for COVID-19 Patients\u201d describes the existing technologies for breathing support for the patients infected with COVID-19.", [["COVID-19", "CHEMICAL", 143, 151], ["patients", "ORGANISM", 120, 128], ["Patients", "SPECIES", 44, 52], ["patients", "SPECIES", 120, 128], ["Breathing Aid Devices", "TREATMENT", 9, 30], ["COVID", "TEST", 35, 40], ["breathing support", "TREATMENT", 94, 111], ["COVID", "TEST", 143, 148]]], ["A relative analysis among the available technologies with the necessary challenges and possible future directions are described in Section \u201cDiscussions\u201d.", [["A relative analysis", "TEST", 0, 19]]], ["Section \u201cConclusion\u201d concludes the paper lastly.Oxygen Therapy Device ::: Breathing Aid Devices for COVID-19 PatientsOxygen gas which is found in the air is necessary for human life for breathing.", [["Oxygen", "CHEMICAL", 48, 54], ["Oxygen", "CHEMICAL", 117, 123], ["Oxygen", "CHEMICAL", 48, 54], ["COVID-19", "CHEMICAL", 100, 108], ["Oxygen", "CHEMICAL", 117, 123], ["Oxygen", "SIMPLE_CHEMICAL", 48, 54], ["Patients", "ORGANISM", 109, 117], ["Oxygen", "SIMPLE_CHEMICAL", 117, 123], ["human", "ORGANISM", 171, 176], ["Patients", "SPECIES", 109, 117], ["human", "SPECIES", 171, 176], ["human", "SPECIES", 171, 176], ["Oxygen Therapy", "TREATMENT", 48, 62], ["Breathing Aid Devices", "TREATMENT", 74, 95], ["COVID", "TEST", 100, 105], ["PatientsOxygen gas", "TEST", 109, 127], ["human life", "TREATMENT", 171, 181]]], ["While one feels short of breath and the level of oxygen being very low than supplemental oxygen, oxygen therapy is needed as a breathing aid.", [["oxygen", "CHEMICAL", 49, 55], ["oxygen", "CHEMICAL", 89, 95], ["oxygen", "CHEMICAL", 97, 103], ["oxygen", "CHEMICAL", 49, 55], ["oxygen", "CHEMICAL", 89, 95], ["oxygen", "CHEMICAL", 97, 103], ["oxygen", "SIMPLE_CHEMICAL", 49, 55], ["oxygen", "SIMPLE_CHEMICAL", 89, 95], ["oxygen", "SIMPLE_CHEMICAL", 97, 103], ["short of breath", "PROBLEM", 16, 31], ["oxygen", "TREATMENT", 49, 55], ["very low", "PROBLEM", 62, 70], ["supplemental oxygen", "TREATMENT", 76, 95], ["oxygen therapy", "TREATMENT", 97, 111], ["a breathing aid", "TREATMENT", 125, 140]]], ["Oxygen therapy is generally received using tubes wearing in nose or trachea, face mask, or windpipe.", [["tubes", "ANATOMY", 43, 48], ["nose", "ANATOMY", 60, 64], ["trachea", "ANATOMY", 68, 75], ["face", "ANATOMY", 77, 81], ["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["nose", "ORGANISM_SUBDIVISION", 60, 64], ["trachea", "MULTI-TISSUE_STRUCTURE", 68, 75], ["Oxygen therapy", "TREATMENT", 0, 14], ["tubes wearing in nose", "TREATMENT", 43, 64], ["trachea", "TREATMENT", 68, 75], ["face mask", "TREATMENT", 77, 86], ["windpipe", "TREATMENT", 91, 99], ["trachea", "ANATOMY", 68, 75]]], ["From various kinds of oxygen therapy, direct oxygen gas, or liquid stored in a portable tank is used widely all over the world.", [["oxygen", "CHEMICAL", 22, 28], ["oxygen", "CHEMICAL", 45, 51], ["oxygen", "CHEMICAL", 22, 28], ["oxygen", "CHEMICAL", 45, 51], ["oxygen", "SIMPLE_CHEMICAL", 22, 28], ["oxygen", "SIMPLE_CHEMICAL", 45, 51], ["oxygen therapy", "TREATMENT", 22, 36], ["direct oxygen gas", "TEST", 38, 55], ["a portable tank", "TREATMENT", 77, 92], ["oxygen therapy", "OBSERVATION", 22, 36]]], ["Besides, oxygen concentrators that take oxygen from the room and another device named hyperbaric oxygen therapy in which oxygen gas is pressurized in a room or chamber are used mostly.", [["oxygen", "CHEMICAL", 9, 15], ["oxygen", "CHEMICAL", 40, 46], ["oxygen", "CHEMICAL", 97, 103], ["oxygen", "CHEMICAL", 121, 127], ["oxygen", "CHEMICAL", 9, 15], ["oxygen", "CHEMICAL", 40, 46], ["oxygen", "CHEMICAL", 97, 103], ["oxygen", "CHEMICAL", 121, 127], ["oxygen", "SIMPLE_CHEMICAL", 9, 15], ["oxygen", "SIMPLE_CHEMICAL", 40, 46], ["oxygen", "SIMPLE_CHEMICAL", 97, 103], ["oxygen", "SIMPLE_CHEMICAL", 121, 127], ["oxygen concentrators", "TREATMENT", 9, 29], ["oxygen", "TREATMENT", 40, 46], ["another device", "TREATMENT", 65, 79], ["hyperbaric oxygen therapy", "TREATMENT", 86, 111], ["oxygen gas", "TEST", 121, 131], ["oxygen concentrators", "OBSERVATION", 9, 29], ["hyperbaric", "OBSERVATION", 86, 96], ["oxygen therapy", "OBSERVATION", 97, 111]]], ["Though oxygen has a fire risk, this therapy is normally safe and can improve survival rates [36].", [["oxygen", "CHEMICAL", 7, 13], ["oxygen", "CHEMICAL", 7, 13], ["oxygen", "SIMPLE_CHEMICAL", 7, 13], ["this therapy", "TREATMENT", 31, 43], ["survival rates", "TEST", 77, 91]]], ["Oxygen therapy can play an important role in COVID-19 patients like other breathing-related diseases including pneumonia and asthma.Oxygen Therapy Device ::: Breathing Aid Devices for COVID-19 PatientsOxygen therapy by nasal cannula is a well-known procedure in controlling and preventing respiratory diseases like COVID-19.", [["nasal", "ANATOMY", 219, 224], ["respiratory", "ANATOMY", 289, 300], ["Oxygen", "CHEMICAL", 0, 6], ["pneumonia", "DISEASE", 111, 120], ["asthma", "DISEASE", 125, 131], ["Oxygen", "CHEMICAL", 132, 138], ["Oxygen", "CHEMICAL", 201, 207], ["respiratory diseases", "DISEASE", 289, 309], ["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "CHEMICAL", 132, 138], ["Oxygen", "CHEMICAL", 201, 207], ["COVID-19", "CHEMICAL", 315, 323], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["patients", "ORGANISM", 54, 62], ["Oxygen", "SIMPLE_CHEMICAL", 132, 138], ["Patients", "ORGANISM", 193, 201], ["Oxygen", "SIMPLE_CHEMICAL", 201, 207], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 219, 232], ["patients", "SPECIES", 54, 62], ["Patients", "SPECIES", 193, 201], ["Oxygen therapy", "TREATMENT", 0, 14], ["related diseases", "PROBLEM", 84, 100], ["pneumonia", "PROBLEM", 111, 120], ["asthma", "PROBLEM", 125, 131], ["Oxygen Therapy", "TREATMENT", 132, 146], ["Breathing Aid Devices", "TREATMENT", 158, 179], ["COVID", "TEST", 184, 189], ["PatientsOxygen therapy", "TREATMENT", 193, 215], ["nasal cannula", "TREATMENT", 219, 232], ["a well-known procedure", "TREATMENT", 236, 258], ["respiratory diseases", "PROBLEM", 289, 309], ["COVID", "TEST", 315, 320], ["pneumonia", "OBSERVATION", 111, 120], ["asthma", "OBSERVATION", 125, 131], ["Oxygen therapy", "OBSERVATION", 201, 215], ["respiratory", "ANATOMY", 289, 300], ["diseases", "OBSERVATION", 301, 309]]], ["It provides 5\u20136 L of oxygen flow per minute [37].", [["oxygen", "CHEMICAL", 21, 27], ["oxygen", "CHEMICAL", 21, 27], ["oxygen", "SIMPLE_CHEMICAL", 21, 27], ["oxygen flow", "TEST", 21, 32]]], ["In the nasal cannula system, a small amount of air is continuously vacuumed and transferred to a sensor located on the display [38].", [["nasal", "ANATOMY", 7, 12], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 7, 20], ["the nasal cannula system", "TREATMENT", 3, 27], ["a small amount of air", "PROBLEM", 29, 50], ["nasal cannula", "ANATOMY", 7, 20], ["small", "OBSERVATION_MODIFIER", 31, 36], ["amount", "OBSERVATION_MODIFIER", 37, 43], ["air", "OBSERVATION", 47, 50]]], ["A face mask is also used as an oxygen serving system.", [["oxygen", "CHEMICAL", 31, 37], ["oxygen", "CHEMICAL", 31, 37], ["oxygen", "SIMPLE_CHEMICAL", 31, 37], ["A face mask", "TREATMENT", 0, 11], ["an oxygen serving system", "TREATMENT", 28, 52], ["face mask", "OBSERVATION", 2, 11]]], ["This mask is fitted with one unidirectional valve for inspiration and two unidirectional valves for expiration.", [["This mask", "TREATMENT", 0, 9], ["one unidirectional valve", "TREATMENT", 25, 49], ["two unidirectional valves", "TREATMENT", 70, 95], ["unidirectional valves", "OBSERVATION", 74, 95]]], ["A high oxygen flow is provided to the mask continuously that dilutes the carbon dioxide exhaled by the patient [39].", [["oxygen", "CHEMICAL", 7, 13], ["carbon dioxide", "CHEMICAL", 73, 87], ["oxygen", "CHEMICAL", 7, 13], ["carbon dioxide", "CHEMICAL", 73, 87], ["oxygen", "SIMPLE_CHEMICAL", 7, 13], ["carbon dioxide", "SIMPLE_CHEMICAL", 73, 87], ["patient", "ORGANISM", 103, 110], ["patient", "SPECIES", 103, 110], ["A high oxygen flow", "TREATMENT", 0, 18], ["the mask", "TREATMENT", 34, 42], ["the carbon dioxide exhaled", "TREATMENT", 69, 95], ["high", "OBSERVATION_MODIFIER", 2, 6], ["oxygen flow", "OBSERVATION", 7, 18]]], ["There are two types of face mask which are used to deliver inspired oxygen (FiO2) flow.", [["oxygen", "CHEMICAL", 68, 74], ["oxygen", "CHEMICAL", 68, 74], ["FiO2", "CHEMICAL", 76, 80], ["oxygen", "SIMPLE_CHEMICAL", 68, 74], ["FiO2", "SIMPLE_CHEMICAL", 76, 80], ["face mask", "TREATMENT", 23, 32], ["inspired oxygen (FiO2) flow", "TREATMENT", 59, 86], ["two", "OBSERVATION_MODIFIER", 10, 13], ["types", "OBSERVATION_MODIFIER", 14, 19], ["face mask", "OBSERVATION", 23, 32]]], ["Non-Rebreathing Mask (NRM) provides supplemental oxygen with the rates of approximately 5\u201310 L/min; while, Partial Rebreathing Mask (PRM) can provide a flow rate of 90% of 15 L/min [40].", [["oxygen", "CHEMICAL", 49, 55], ["oxygen", "CHEMICAL", 49, 55], ["oxygen", "SIMPLE_CHEMICAL", 49, 55], ["Non-Rebreathing Mask", "TREATMENT", 0, 20], ["supplemental oxygen", "TREATMENT", 36, 55], ["Partial Rebreathing Mask", "TREATMENT", 107, 131], ["a flow rate", "TEST", 150, 161]]], ["Farias et al. [41] described a system in their study that PRM can deliver high oxygen flow than NRM.", [["oxygen", "CHEMICAL", 79, 85], ["oxygen", "CHEMICAL", 79, 85], ["oxygen", "SIMPLE_CHEMICAL", 79, 85], ["their study", "TEST", 41, 52], ["high oxygen flow than NRM", "TREATMENT", 74, 99]]], ["Nasal cannulas and face masks can be used for COVID-19 patients in low-risk cases.", [["Nasal", "ANATOMY", 0, 5], ["face", "ANATOMY", 19, 23], ["Nasal cannulas", "MULTI-TISSUE_STRUCTURE", 0, 14], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["Nasal cannulas", "TREATMENT", 0, 14], ["face masks", "TREATMENT", 19, 29], ["COVID", "TEST", 46, 51], ["cannulas", "OBSERVATION", 6, 14]]], ["In serious respiratory failure, high-flow nasal cannula (HFNC) is used for its safety and efficacy.", [["respiratory", "ANATOMY", 11, 22], ["nasal", "ANATOMY", 42, 47], ["respiratory failure", "DISEASE", 11, 30], ["HFNC", "CHEMICAL", 57, 61], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 42, 55], ["serious respiratory failure", "PROBLEM", 3, 30], ["high-flow nasal cannula (HFNC", "TREATMENT", 32, 61], ["serious", "OBSERVATION_MODIFIER", 3, 10], ["respiratory failure", "OBSERVATION", 11, 30], ["high", "OBSERVATION_MODIFIER", 32, 36], ["flow", "OBSERVATION_MODIFIER", 37, 41], ["nasal cannula", "OBSERVATION", 42, 55]]], ["It consists of an air/oxygen blender, a nasal cannula, a single heated tube, and an active humidifier [42].", [["nasal", "ANATOMY", 40, 45], ["oxygen", "CHEMICAL", 22, 28], ["oxygen", "CHEMICAL", 22, 28], ["oxygen", "SIMPLE_CHEMICAL", 22, 28], ["tube", "TISSUE", 71, 75], ["an air/oxygen blender", "TREATMENT", 15, 36], ["a nasal cannula", "TREATMENT", 38, 53], ["a single heated tube", "TREATMENT", 55, 75], ["an active humidifier", "TREATMENT", 81, 101], ["air", "OBSERVATION", 18, 21], ["oxygen blender", "OBSERVATION", 22, 36], ["nasal cannula", "ANATOMY", 40, 53]]], ["It can deliver about 60 L/min oxygen flow.", [["oxygen", "CHEMICAL", 30, 36], ["oxygen", "CHEMICAL", 30, 36], ["oxygen", "SIMPLE_CHEMICAL", 30, 36], ["oxygen flow", "TEST", 30, 41]]], ["The use of HFNC limited the mortality in hypoxemic respiratory failure.", [["respiratory", "ANATOMY", 51, 62], ["HFNC", "CHEMICAL", 11, 15], ["hypoxemic respiratory failure", "DISEASE", 41, 70], ["HFNC", "TREATMENT", 11, 15], ["hypoxemic respiratory failure", "PROBLEM", 41, 70], ["hypoxemic", "OBSERVATION_MODIFIER", 41, 50], ["respiratory failure", "OBSERVATION", 51, 70]]], ["In addition, it can decrease the risk of subsequent intubation and the need for Intensive Care Unit (ICU) admission [43\u201345].", [["subsequent intubation", "TREATMENT", 41, 62], ["intubation", "OBSERVATION", 52, 62]]], ["It can be commonly used in COVID-19 patients having respiratory failure as a method to administer high concentrations of oxygen.Oxygen Therapy Device ::: Breathing Aid Devices for COVID-19 PatientsAnother type of oxygen serving device is Hyperbaric Oxygen Therapy (HBOT) [46] in which patients are entered in a special chamber or room to breathe in 100% oxygen in air pressure.", [["respiratory", "ANATOMY", 52, 63], ["respiratory failure", "DISEASE", 52, 71], ["oxygen", "CHEMICAL", 121, 127], ["Oxygen", "CHEMICAL", 128, 134], ["oxygen", "CHEMICAL", 213, 219], ["Oxygen", "CHEMICAL", 249, 255], ["oxygen", "CHEMICAL", 354, 360], ["oxygen", "CHEMICAL", 121, 127], ["Oxygen", "CHEMICAL", 128, 134], ["oxygen", "CHEMICAL", 213, 219], ["Oxygen", "CHEMICAL", 249, 255], ["oxygen", "CHEMICAL", 354, 360], ["patients", "ORGANISM", 36, 44], ["oxygen", "SIMPLE_CHEMICAL", 121, 127], ["Oxygen", "SIMPLE_CHEMICAL", 128, 134], ["Patients", "ORGANISM", 189, 197], ["oxygen", "SIMPLE_CHEMICAL", 213, 219], ["Oxygen", "SIMPLE_CHEMICAL", 249, 255], ["patients", "ORGANISM", 285, 293], ["oxygen", "SIMPLE_CHEMICAL", 354, 360], ["patients", "SPECIES", 36, 44], ["Patients", "SPECIES", 189, 197], ["patients", "SPECIES", 285, 293], ["respiratory failure", "PROBLEM", 52, 71], ["a method", "TREATMENT", 75, 83], ["high concentrations of oxygen", "TREATMENT", 98, 127], ["Oxygen Therapy", "TREATMENT", 128, 142], ["Breathing Aid Devices", "TREATMENT", 154, 175], ["COVID", "TEST", 180, 185], ["oxygen serving device", "TREATMENT", 213, 234], ["Hyperbaric Oxygen Therapy", "TREATMENT", 238, 263], ["air pressure", "TEST", 364, 376], ["respiratory", "ANATOMY", 52, 63], ["failure", "OBSERVATION", 64, 71], ["Hyperbaric", "OBSERVATION", 238, 248], ["Oxygen Therapy", "OBSERVATION", 249, 263], ["air pressure", "OBSERVATION", 364, 376]]], ["The target of this device is to repair and restore normal body function by filling the blood with adequate oxygen.", [["body", "ANATOMY", 58, 62], ["blood", "ANATOMY", 87, 92], ["oxygen", "CHEMICAL", 107, 113], ["oxygen", "CHEMICAL", 107, 113], ["body", "ORGANISM_SUBDIVISION", 58, 62], ["blood", "ORGANISM_SUBSTANCE", 87, 92], ["oxygen", "SIMPLE_CHEMICAL", 107, 113], ["this device", "TREATMENT", 14, 25], ["repair", "TREATMENT", 32, 38], ["adequate oxygen", "TREATMENT", 98, 113], ["normal body function", "OBSERVATION", 51, 71], ["oxygen", "OBSERVATION_MODIFIER", 107, 113]]], ["Air pressure is raised 1.5\u20133 times from the normal air pressure in a hyperbaric oxygen treatment chamber.", [["oxygen", "CHEMICAL", 80, 86], ["oxygen", "CHEMICAL", 80, 86], ["oxygen", "SIMPLE_CHEMICAL", 80, 86], ["Air pressure", "TEST", 0, 12], ["a hyperbaric oxygen treatment chamber", "TREATMENT", 67, 104], ["pressure", "OBSERVATION_MODIFIER", 4, 12], ["normal", "OBSERVATION", 44, 50], ["air pressure", "OBSERVATION", 51, 63], ["hyperbaric", "OBSERVATION", 69, 79], ["oxygen treatment", "OBSERVATION", 80, 96]]], ["In such circumstances, patients\u2019 lungs could collect more oxygen than normal air pressure to breathe pure oxygen.", [["lungs", "ANATOMY", 33, 38], ["oxygen", "CHEMICAL", 58, 64], ["oxygen", "CHEMICAL", 106, 112], ["oxygen", "CHEMICAL", 58, 64], ["oxygen", "CHEMICAL", 106, 112], ["patients", "ORGANISM", 23, 31], ["lungs", "ORGAN", 33, 38], ["oxygen", "SIMPLE_CHEMICAL", 58, 64], ["oxygen", "SIMPLE_CHEMICAL", 106, 112], ["patients", "SPECIES", 23, 31], ["lungs", "ANATOMY", 33, 38], ["air pressure", "OBSERVATION", 77, 89]]], ["This oxygen transports blood all over the body.", [["blood", "ANATOMY", 23, 28], ["body", "ANATOMY", 42, 46], ["oxygen", "CHEMICAL", 5, 11], ["oxygen", "CHEMICAL", 5, 11], ["oxygen", "SIMPLE_CHEMICAL", 5, 11], ["blood", "ORGANISM_SUBSTANCE", 23, 28], ["body", "ORGANISM_SUBDIVISION", 42, 46], ["This oxygen transports blood", "TREATMENT", 0, 28], ["body", "ANATOMY", 42, 46]]], ["This helps to kill bacteria and encourages the release of cures of substances such as growth factors and stem cells.", [["stem cells", "ANATOMY", 105, 115], ["stem cells", "CELL", 105, 115], ["growth factors", "PROTEIN", 86, 100], ["stem cells", "CELL_TYPE", 105, 115], ["kill bacteria", "PROBLEM", 14, 27], ["cures of substances", "TREATMENT", 58, 77], ["stem cells", "OBSERVATION", 105, 115]]], ["There are two types of HBOT (1) Monoplace chamber, (2) Multiplace chamber.", [["HBOT (1) Monoplace chamber", "TREATMENT", 23, 49], ["two", "OBSERVATION_MODIFIER", 10, 13], ["types", "OBSERVATION_MODIFIER", 14, 19], ["HBOT", "OBSERVATION", 23, 27]]], ["Monoplace unit is designed for one person where the patient lies down on a table.", [["patient", "ORGANISM", 52, 59], ["person", "SPECIES", 35, 41], ["patient", "SPECIES", 52, 59]]], ["It is like a Magnetic resonance imaging (MRI) machine with a long plastic tube.", [["tube", "TISSUE", 74, 78], ["a Magnetic resonance imaging", "TEST", 11, 39], ["MRI", "TEST", 41, 44], ["a long plastic tube", "TREATMENT", 59, 78], ["tube", "OBSERVATION", 74, 78]]], ["With 100% oxygen, it is slowly pressurized.", [["oxygen", "CHEMICAL", 10, 16], ["oxygen", "CHEMICAL", 10, 16], ["oxygen", "SIMPLE_CHEMICAL", 10, 16], ["100% oxygen", "TREATMENT", 5, 16]]], ["In contrast, a room designed for several persons is called multiplace chamber.", [["persons", "ORGANISM", 41, 48], ["persons", "SPECIES", 41, 48]]], ["This chamber usually looks like a large room in the hospital where a patient can sit down or lie down.", [["patient", "ORGANISM", 69, 76], ["patient", "SPECIES", 69, 76], ["large", "OBSERVATION_MODIFIER", 34, 39]]], ["In this case, the oxygen is normally supplied with a thin, transparent hood.", [["oxygen", "CHEMICAL", 18, 24], ["oxygen", "CHEMICAL", 18, 24], ["oxygen", "SIMPLE_CHEMICAL", 18, 24], ["oxygen", "OBSERVATION_MODIFIER", 18, 24]]], ["Though this therapy is normally a safe procedure, it carries some risk.", [["this therapy", "TREATMENT", 7, 19], ["a safe procedure", "TREATMENT", 32, 48]]], ["In certain situations, fire may trigger due to the oxygen-rich atmosphere in the treatment chamber.", [["oxygen", "CHEMICAL", 51, 57], ["oxygen", "CHEMICAL", 51, 57], ["oxygen", "SIMPLE_CHEMICAL", 51, 57], ["the oxygen-rich atmosphere", "TREATMENT", 47, 73], ["the treatment chamber", "TREATMENT", 77, 98]]], ["In addition, a lung may collapse due to certain changes in air pressure [47, 48].", [["lung", "ANATOMY", 15, 19], ["lung", "ORGAN", 15, 19], ["a lung may collapse", "PROBLEM", 13, 32], ["air pressure", "TEST", 59, 71], ["lung", "ANATOMY", 15, 19], ["collapse", "OBSERVATION", 24, 32], ["air pressure", "OBSERVATION", 59, 71]]], ["A recent study [49] shows that using additional oxygen up to certain concentrations can improve mortality in certain populations.", [["oxygen", "CHEMICAL", 48, 54], ["oxygen", "CHEMICAL", 48, 54], ["oxygen", "SIMPLE_CHEMICAL", 48, 54], ["A recent study", "TEST", 0, 14], ["additional oxygen", "TREATMENT", 37, 54]]], ["The oxygen therapy devices which are frequently used are shown in Fig. 2.Ventilator ::: Breathing Aid Devices for COVID-19 PatientsVentilator known as a mechanical ventilator is widely used as a breathing aid tool while a disease makes the respiration difficult or can not bring enough oxygen into the blood.", [["blood", "ANATOMY", 302, 307], ["oxygen", "CHEMICAL", 4, 10], ["Ventilator", "DISEASE", 131, 141], ["oxygen", "CHEMICAL", 286, 292], ["oxygen", "CHEMICAL", 4, 10], ["oxygen", "CHEMICAL", 286, 292], ["oxygen", "SIMPLE_CHEMICAL", 4, 10], ["Patients", "ORGANISM", 123, 131], ["oxygen", "SIMPLE_CHEMICAL", 286, 292], ["blood", "ORGANISM_SUBSTANCE", 302, 307], ["Patients", "SPECIES", 123, 131], ["The oxygen therapy devices", "TREATMENT", 0, 26], ["Breathing Aid Devices", "TREATMENT", 88, 109], ["COVID", "TEST", 114, 119], ["PatientsVentilator", "TREATMENT", 123, 141], ["a mechanical ventilator", "TREATMENT", 151, 174], ["a breathing aid tool", "PROBLEM", 193, 213], ["a disease", "PROBLEM", 220, 229], ["oxygen therapy", "OBSERVATION", 4, 18], ["mechanical ventilator", "OBSERVATION", 153, 174]]], ["It works like a bellow for moving air in (oxygen) and out (Carbon Dioxide) of the lungs.", [["lungs", "ANATOMY", 82, 87], ["oxygen", "CHEMICAL", 42, 48], ["Carbon Dioxide", "CHEMICAL", 59, 73], ["oxygen", "CHEMICAL", 42, 48], ["Carbon Dioxide", "CHEMICAL", 59, 73], ["oxygen", "SIMPLE_CHEMICAL", 42, 48], ["Carbon Dioxide", "SIMPLE_CHEMICAL", 59, 73], ["lungs", "ORGAN", 82, 87], ["moving air in (oxygen)", "TREATMENT", 27, 49], ["Carbon Dioxide)", "TREATMENT", 59, 74], ["lungs", "ANATOMY", 82, 87]]], ["It can be fitted with a mask, a helmet, or a breathing tube if the respiration problem is more serious to get air into the lungs.", [["lungs", "ANATOMY", 123, 128], ["lungs", "ORGAN", 123, 128], ["a mask", "TREATMENT", 22, 28], ["a helmet", "TREATMENT", 30, 38], ["a breathing tube", "TREATMENT", 43, 59], ["the respiration problem", "PROBLEM", 63, 86], ["lungs", "ANATOMY", 123, 128]]], ["The major advantages of the use of a ventilator are no trouble occurs in respiring because the muscles are relaxing in the patients\u2019 breathing.", [["muscles", "ANATOMY", 95, 102], ["muscles", "ORGAN", 95, 102], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["a ventilator", "TREATMENT", 35, 47], ["trouble", "PROBLEM", 55, 62], ["muscles", "ANATOMY", 95, 102]]], ["In addition, the patient will recover from the failure of normal breathing.", [["patient", "ORGANISM", 17, 24], ["patient", "SPECIES", 17, 24], ["normal breathing", "OBSERVATION", 58, 74]]], ["Ventilators can play a significant role for COVID-19 patients having acute respiratory distress syndrome (ARDS) and pneumonia.Ventilator ::: Breathing Aid Devices for COVID-19 PatientsRecently, a new high-pressure ventilator called Ventilator Intervention Technology Accessible Locally (VITAL) is developed by NASA engineers which is approved by the Food and Drug Administration (FDA) for emergency treatment of COVID-19 patients [50].", [["respiratory", "ANATOMY", 75, 86], ["Ventilators", "DISEASE", 0, 11], ["acute respiratory distress syndrome", "DISEASE", 69, 104], ["ARDS", "DISEASE", 106, 110], ["pneumonia", "DISEASE", 116, 125], ["patients", "ORGANISM", 53, 61], ["Patients", "ORGANISM", 176, 184], ["patients", "ORGANISM", 421, 429], ["patients", "SPECIES", 53, 61], ["Patients", "SPECIES", 176, 184], ["patients", "SPECIES", 421, 429], ["Ventilators", "TREATMENT", 0, 11], ["acute respiratory distress syndrome", "PROBLEM", 69, 104], ["ARDS)", "PROBLEM", 106, 111], ["pneumonia", "PROBLEM", 116, 125], ["a new high-pressure ventilator", "TREATMENT", 194, 224], ["Ventilator Intervention", "TREATMENT", 232, 255], ["emergency treatment", "TREATMENT", 389, 408], ["COVID", "TEST", 412, 417], ["acute", "OBSERVATION_MODIFIER", 69, 74], ["respiratory", "ANATOMY", 75, 86], ["distress", "OBSERVATION", 87, 95], ["ARDS", "OBSERVATION", 106, 110], ["pneumonia", "OBSERVATION", 116, 125], ["pressure ventilator", "OBSERVATION", 205, 224]]], ["Like other ventilators, this ventilator also requires sedation in patients and insertion in their airways of an oxygen tube to breathe.", [["airways", "ANATOMY", 98, 105], ["oxygen", "CHEMICAL", 112, 118], ["oxygen", "CHEMICAL", 112, 118], ["patients", "ORGANISM", 66, 74], ["airways", "MULTI-TISSUE_STRUCTURE", 98, 105], ["oxygen", "SIMPLE_CHEMICAL", 112, 118], ["tube", "TISSUE", 119, 123], ["patients", "SPECIES", 66, 74], ["other ventilators", "TREATMENT", 5, 22], ["this ventilator", "TREATMENT", 24, 39], ["sedation", "TREATMENT", 54, 62], ["insertion", "TREATMENT", 79, 88], ["an oxygen tube", "TREATMENT", 109, 123], ["airways", "ANATOMY", 98, 105], ["oxygen tube", "OBSERVATION", 112, 123]]], ["Before the FDA review, on 21 April at the Icahn School of Medicine at Mount Sinai, NY, a critical test was performed with the VITAL prototype.", [["a critical test", "TEST", 87, 102]]], ["The important benefit of this device is it can be faster designed and easier to maintain than a conventional ventilator and consists of far fewer components.", [["this device", "TREATMENT", 25, 36], ["a conventional ventilator", "TREATMENT", 94, 119], ["far fewer components", "PROBLEM", 136, 156]]], ["\u201cAmboVent\u201d [51] is the bag valve mask (BVM)-type ventilator that provides breathing speed, volume controls, and maximum peak pressure controls of an emergency patient.", [["patient", "ORGANISM", 159, 166], ["patient", "SPECIES", 159, 166], ["the bag valve mask", "TREATMENT", 19, 37], ["type ventilator", "TREATMENT", 44, 59], ["breathing speed", "TEST", 74, 89], ["volume controls", "TREATMENT", 91, 106], ["maximum peak pressure controls", "TREATMENT", 112, 142], ["bag valve", "OBSERVATION", 23, 32]]], ["This device is developed with a Volume control ventilation (VCV) machine, BVM, Positive end-expiratory pressure (PEEP) adapter, PEEP valve, Heat and moisture exchanger (HME) filter, oxygen reservoir bag.", [["oxygen", "CHEMICAL", 182, 188], ["oxygen", "CHEMICAL", 182, 188], ["oxygen", "SIMPLE_CHEMICAL", 182, 188], ["This device", "TREATMENT", 0, 11], ["a Volume control ventilation", "TREATMENT", 30, 58], ["BVM", "TEST", 74, 77], ["Positive end-expiratory pressure", "TREATMENT", 79, 111], ["PEEP", "TREATMENT", 113, 117], ["PEEP valve", "TREATMENT", 128, 138], ["Heat and moisture exchanger (HME) filter", "TREATMENT", 140, 180], ["oxygen reservoir bag", "TREATMENT", 182, 202], ["PEEP valve", "OBSERVATION", 128, 138], ["oxygen", "OBSERVATION", 182, 188], ["reservoir bag", "OBSERVATION", 189, 202]]], ["The main features of this device are it has a big range of tidal scale, varying from 30 to 100% of maximum tidal capacity, and large rates of ventilation of 6\u201324 cycles per minute.", [["this device", "TREATMENT", 21, 32], ["tidal scale", "TEST", 59, 70], ["maximum tidal capacity", "TEST", 99, 121], ["large rates of ventilation", "TREATMENT", 127, 153], ["main", "OBSERVATION_MODIFIER", 4, 8], ["device", "OBSERVATION", 26, 32], ["big", "OBSERVATION_MODIFIER", 46, 49], ["tidal scale", "OBSERVATION", 59, 70], ["varying", "OBSERVATION_MODIFIER", 72, 79], ["tidal capacity", "OBSERVATION", 107, 121], ["large", "OBSERVATION_MODIFIER", 127, 132], ["rates", "OBSERVATION_MODIFIER", 133, 138]]], ["MIT Emergency Ventilator (E-Vent) [52], which is formed on March 12, 2020, designed a simple ventilator in response to the rapid spread of the COVID-19 pandemic.", [["a simple ventilator", "TREATMENT", 84, 103], ["the COVID", "TEST", 139, 148], ["pandemic", "PROBLEM", 152, 160]]], ["This new system fits into an Ambu bag that is already used in many hospitals.", [["an Ambu bag", "TREATMENT", 26, 37], ["Ambu bag", "OBSERVATION", 29, 37]]], ["These types of bags are designed to be manually operated by a doctor or emergency nurse in circumstances such as a heart attack to breathe of a patient.", [["heart", "ANATOMY", 115, 120], ["heart", "ORGAN", 115, 120], ["patient", "ORGANISM", 144, 151], ["patient", "SPECIES", 144, 151], ["bags", "TREATMENT", 15, 19], ["bags", "OBSERVATION", 15, 19], ["heart", "ANATOMY", 115, 120]]], ["But in MIT E-Vent, a mechanical system is developed to perform squeezing and releasing of the Ambu bag.", [["Vent", "TREATMENT", 13, 17], ["a mechanical system", "TREATMENT", 19, 38], ["the Ambu bag", "TREATMENT", 90, 102], ["Ambu bag", "OBSERVATION", 94, 102]]], ["This leads air through a tube in the airway of the patient.", [["airway", "ANATOMY", 37, 43], ["tube", "TISSUE", 25, 29], ["airway", "MULTI-TISSUE_STRUCTURE", 37, 43], ["patient", "ORGANISM", 51, 58], ["patient", "SPECIES", 51, 58], ["a tube in the airway", "TREATMENT", 23, 43], ["air", "OBSERVATION", 11, 14], ["tube", "OBSERVATION", 25, 29], ["airway", "ANATOMY", 37, 43]]], ["The developed device is very reliable and handled manually immediately.Ventilator ::: Breathing Aid Devices for COVID-19 PatientsLu et al. [53] designed a portable high-frequency ventilator which is low cost, portable, and light weight.", [["Patients", "SPECIES", 121, 129], ["device", "TREATMENT", 14, 20], ["Breathing Aid Devices", "TREATMENT", 86, 107], ["COVID", "TEST", 112, 117], ["a portable high-frequency ventilator", "TREATMENT", 153, 189], ["light weight", "TEST", 223, 235], ["device", "OBSERVATION", 14, 20], ["low", "OBSERVATION_MODIFIER", 199, 202]]], ["As a mechanical instrument, two check valves, two flow meters, two flow control valves, one pressure sensor, one solenoid valve, and one gas chamber are used to regulate the airflow.", [["a mechanical instrument", "TREATMENT", 3, 26], ["two check valves", "TREATMENT", 28, 44], ["two flow meters", "TREATMENT", 46, 61], ["two flow control valves", "TREATMENT", 63, 86], ["one pressure sensor", "TREATMENT", 88, 107], ["one solenoid valve", "TREATMENT", 109, 127], ["one gas chamber", "TREATMENT", 133, 148], ["mechanical instrument", "OBSERVATION", 5, 26], ["valves", "OBSERVATION", 38, 44], ["flow control valves", "OBSERVATION", 67, 86], ["solenoid valve", "OBSERVATION", 113, 127], ["gas chamber", "OBSERVATION", 137, 148], ["airflow", "OBSERVATION_MODIFIER", 174, 181]]], ["Multiplexer, comparator, oscillator, capacitor, Digital to Analog (D/A) converter, MOSFET, and voltage converter are utilized as electronic instrument in the control circuit board to control the frequency.", [["Analog (D/A) converter, MOSFET, and voltage converter", "TREATMENT", 59, 112], ["electronic instrument in the control circuit board", "TREATMENT", 129, 179]]], ["The measurable parameters of this device are shown on a digital display as flow per minute (0\u201340 L/min), output frequency (2\u20134 Hz), oxygen concentration flow per once (0\u2013160 mL).", [["oxygen", "CHEMICAL", 132, 138], ["oxygen", "CHEMICAL", 132, 138], ["oxygen", "SIMPLE_CHEMICAL", 132, 138], ["this device", "TREATMENT", 29, 40], ["output frequency", "TEST", 105, 121], ["oxygen concentration flow", "TREATMENT", 132, 157], ["measurable", "OBSERVATION_MODIFIER", 4, 14]]], ["The main advantages of this device are its small size, configurable features, and instant feedback control.", [["this device", "TREATMENT", 23, 34], ["instant feedback control", "TREATMENT", 82, 106], ["main", "OBSERVATION_MODIFIER", 4, 8], ["device", "OBSERVATION", 28, 34], ["small", "OBSERVATION_MODIFIER", 43, 48], ["size", "OBSERVATION_MODIFIER", 49, 53], ["configurable", "OBSERVATION_MODIFIER", 55, 67], ["feedback control", "OBSERVATION", 90, 106]]], ["Using the concept Artificial Manual Breathing Unit (AMBU) bag, Shahid [54] proposed a cost-effective prototype of a ventilator.", [["Artificial Manual Breathing Unit (AMBU) bag", "TREATMENT", 18, 61], ["a ventilator", "TREATMENT", 114, 126]]], ["The main components of this prototype are microcontroller, pressure sensor, breath detection elements (Thermistor and CO2 sensor), and mechanical mechanism (chained plank mechanism and cam shaft mechanism).", [["CO2", "CHEMICAL", 118, 121], ["CO2", "SIMPLE_CHEMICAL", 118, 121], ["pressure sensor", "TEST", 59, 74], ["Thermistor and CO2 sensor)", "TREATMENT", 103, 129], ["mechanical mechanism (chained plank mechanism", "TREATMENT", 135, 180], ["cam shaft mechanism", "TREATMENT", 185, 204], ["main", "OBSERVATION_MODIFIER", 4, 8], ["components", "OBSERVATION_MODIFIER", 9, 19]]], ["Moreover, the key features of this prototype are that various parameters like Breaths Per Minute (BPM), delivered air volume by this ventilator, peep rate and inspiration to expiration ratio can be regulated or adjustable.", [["this ventilator", "TREATMENT", 128, 143], ["peep rate", "TEST", 145, 154], ["expiration ratio", "TEST", 174, 190], ["air volume", "OBSERVATION", 114, 124]]], ["The considerable cost of this proposed prototype is less than $80.Ventilator ::: Breathing Aid Devices for COVID-19 PatientsIslam and Ahmad [55] developed a microcontroller-based mechanical ventilator using BVM ventilation mechanism and AMBU bag.", [["BVM", "SIMPLE_CHEMICAL", 207, 210], ["Breathing Aid Devices", "TREATMENT", 81, 102], ["COVID", "TEST", 107, 112], ["a microcontroller", "TREATMENT", 155, 172], ["mechanical ventilator", "TREATMENT", 179, 200], ["BVM ventilation mechanism", "TREATMENT", 207, 232], ["AMBU bag", "TREATMENT", 237, 245], ["mechanical ventilator", "OBSERVATION", 179, 200], ["AMBU bag", "OBSERVATION", 237, 245]]], ["Here, this AMBU bag is operated (compressed and decompressed) with computer-aided manufacturing (CAM) arm which is controlled via a control signal sent from microcontroller.", [["CAM", "MULTI-TISSUE_STRUCTURE", 97, 100], ["this AMBU bag", "TREATMENT", 6, 19], ["computer-aided manufacturing (CAM) arm", "TREATMENT", 67, 105], ["a control signal", "TEST", 130, 146], ["decompressed", "OBSERVATION", 48, 60], ["arm", "ANATOMY", 102, 105]]], ["The main merits of this device are its portability, compact design, light weight, and easily performable.", [["this device", "TREATMENT", 19, 30], ["light weight", "TEST", 68, 80], ["main", "OBSERVATION_MODIFIER", 4, 8], ["device", "OBSERVATION", 24, 30]]], ["This repairable and riskless device serves 90% accuracy in respiratory measurement.", [["respiratory", "ANATOMY", 59, 70], ["This repairable", "TREATMENT", 0, 15], ["riskless device", "TREATMENT", 20, 35], ["respiratory measurement", "TEST", 59, 82]]], ["J\u00fcr\u00df and Degner [56] described a concept of compact and low-cost ventilator having the blower unit and an integrated sensor unit.", [["low-cost ventilator", "TREATMENT", 56, 75], ["the blower unit", "TREATMENT", 83, 98], ["an integrated sensor unit", "TREATMENT", 103, 128]]], ["The key feature of this study is that without any respiration tubes, the proposed device can provide necessary ventilation to the patient\u2019s lungs with the blower unit.", [["lungs", "ANATOMY", 140, 145], ["patient", "ORGANISM", 130, 137], ["lungs", "ORGAN", 140, 145], ["patient", "SPECIES", 130, 137], ["this study", "TEST", 19, 29], ["any respiration tubes", "TREATMENT", 46, 67], ["the proposed device", "TREATMENT", 69, 88], ["ventilation", "TREATMENT", 111, 122], ["respiration tubes", "OBSERVATION", 50, 67], ["lungs", "ANATOMY", 140, 145]]], ["In addition, the relevant respiration data can be monitored with the sensor unit.", [["the relevant respiration data", "TEST", 13, 42]]], ["In another work, a low-cost ventilator is proposed by Garmendia et al. [57].", [["a low-cost ventilator", "TREATMENT", 17, 38]]], ["The major components of the developed system are Arduino Nano as a controlling device, high-pressure blower, and two pressure transducers.", [["Arduino Nano", "TREATMENT", 49, 61], ["a controlling device", "TREATMENT", 65, 85], ["high-pressure blower", "TREATMENT", 87, 107], ["two pressure transducers", "TREATMENT", 113, 137], ["major", "OBSERVATION_MODIFIER", 4, 9], ["components", "OBSERVATION_MODIFIER", 10, 20], ["pressure", "OBSERVATION_MODIFIER", 92, 100], ["blower", "OBSERVATION_MODIFIER", 101, 107], ["pressure", "OBSERVATION_MODIFIER", 117, 125], ["transducers", "OBSERVATION_MODIFIER", 126, 137]]], ["This non-invasive high commercial device is low cost as the authors declare the fabrication cost is less than $75.", [["This non-invasive high commercial device", "TREATMENT", 0, 40]]], ["Further, a portable ventilator is described in [58] based on BVM and cam arm operated by an electric motor.", [["BVM", "MULTI-TISSUE_STRUCTURE", 61, 64], ["a portable ventilator", "TEST", 9, 30], ["BVM", "TEST", 61, 64], ["an electric motor", "TEST", 89, 106]]], ["Though it serves a short time solution, it delivers the essential features of conventional ventilators at low cost, low power, and easy portability.", [["a short time solution", "TREATMENT", 17, 38], ["conventional ventilators", "TREATMENT", 78, 102], ["low power", "OBSERVATION_MODIFIER", 116, 125]]], ["The estimated price of manufacturing this device is less than $200.", [["manufacturing this device", "TREATMENT", 23, 48]]], ["A pre-stage public access ventilator (PAV) [59] is designed with a turbine and sensors.", [["A pre-stage public access ventilator", "TREATMENT", 0, 36], ["a turbine and sensors", "TREATMENT", 65, 86]]], ["The developed prototype can detect leakage and airway occlusion using the signals from sensors.", [["airway", "ANATOMY", 47, 53], ["airway", "MULTI-TISSUE_STRUCTURE", 47, 53], ["leakage", "PROBLEM", 35, 42], ["airway occlusion", "PROBLEM", 47, 63], ["leakage", "OBSERVATION", 35, 42], ["airway", "ANATOMY", 47, 53], ["occlusion", "OBSERVATION", 54, 63]]], ["The PAV was verified under three conditions 1) pressure-controlled ventilation (PCV), 2) PCV with controlled leakage and 3) PCV with simulated airway occlusion.", [["airway", "ANATOMY", 143, 149], ["airway occlusion", "DISEASE", 143, 159], ["airway", "MULTI-TISSUE_STRUCTURE", 143, 149], ["The PAV", "TREATMENT", 0, 7], ["pressure-controlled ventilation (PCV)", "TREATMENT", 47, 84], ["PCV", "TREATMENT", 89, 92], ["controlled leakage", "PROBLEM", 98, 116], ["PCV", "TREATMENT", 124, 127], ["simulated airway occlusion", "TREATMENT", 133, 159], ["leakage", "OBSERVATION", 109, 116], ["airway occlusion", "OBSERVATION", 143, 159]]], ["Also, there a proposal is available for Cardiopulmonary resuscitation (CPR) victim by Fogarty et al. [60] using an electric blower ventilator in replace of traditional BVM.", [["Cardiopulmonary", "ANATOMY", 40, 55], ["BVM", "CANCER", 168, 171], ["Cardiopulmonary resuscitation", "TREATMENT", 40, 69], ["an electric blower ventilator", "TREATMENT", 112, 141], ["traditional BVM", "TREATMENT", 156, 171]]], ["The proposed work can reduce the chance of injury from ventilation of the BVM.", [["BVM", "ANATOMY", 74, 77], ["BVM", "CANCER", 74, 77], ["injury", "PROBLEM", 43, 49], ["ventilation", "TREATMENT", 55, 66], ["the BVM", "TREATMENT", 70, 77], ["injury", "OBSERVATION", 43, 49]]], ["The available ventilators for breathing assistant are shown in Fig. 3.Continuous Positive Airway Pressure (CPAP) ::: Breathing Aid Devices for COVID-19 PatientsContinuous Positive Airway Pressure is a well-known device that is used for breathing assistant for the treatment of patients having a mild respiratory problem.", [["Airway", "ANATOMY", 180, 186], ["respiratory", "ANATOMY", 300, 311], ["Patients", "ORGANISM", 152, 160], ["patients", "ORGANISM", 277, 285], ["Patients", "SPECIES", 152, 160], ["patients", "SPECIES", 277, 285], ["The available ventilators", "TREATMENT", 0, 25], ["Continuous Positive Airway Pressure (CPAP", "TREATMENT", 70, 111], ["Breathing Aid Devices", "TREATMENT", 117, 138], ["COVID", "TEST", 143, 148], ["Continuous Positive Airway Pressure", "TREATMENT", 160, 195], ["a well-known device", "TREATMENT", 199, 218], ["breathing assistant", "TREATMENT", 236, 255], ["the treatment", "TREATMENT", 260, 273], ["a mild respiratory problem", "PROBLEM", 293, 319], ["Airway Pressure", "OBSERVATION", 90, 105], ["Airway Pressure", "OBSERVATION", 180, 195], ["mild", "OBSERVATION_MODIFIER", 295, 299], ["respiratory problem", "OBSERVATION", 300, 319]]], ["The positive airway pressure is delivered through a tight face or nasal mask in CPAP device.", [["airway", "ANATOMY", 13, 19], ["face", "ANATOMY", 58, 62], ["nasal", "ANATOMY", 66, 71], ["airway", "MULTI-TISSUE_STRUCTURE", 13, 19], ["nasal", "ORGANISM_SUBDIVISION", 66, 71], ["The positive airway pressure", "TREATMENT", 0, 28], ["a tight face", "TREATMENT", 50, 62], ["nasal mask", "TREATMENT", 66, 76], ["CPAP device", "TREATMENT", 80, 91], ["positive airway pressure", "OBSERVATION", 4, 28], ["nasal mask", "OBSERVATION", 66, 76], ["CPAP device", "OBSERVATION", 80, 91]]], ["The main advantage of CPAP device is that it can deliver positive pressure in each cycle of respiration.", [["CPAP device", "TREATMENT", 22, 33], ["positive pressure", "TREATMENT", 57, 74], ["main", "OBSERVATION_MODIFIER", 4, 8], ["CPAP device", "OBSERVATION", 22, 33], ["pressure", "OBSERVATION_MODIFIER", 66, 74]]], ["The pressure facilitates the alveoli to remain open during the breathing out of patients that is very helpful for oxygenation and easy breathing.", [["alveoli", "ANATOMY", 29, 36], ["alveoli", "MULTI-TISSUE_STRUCTURE", 29, 36], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["easy breathing", "PROBLEM", 130, 144], ["pressure", "OBSERVATION_MODIFIER", 4, 12]]], ["The device is proper suited for the patients having pneumonia related problems like COVID-19 for initial treatment.Continuous Positive Airway Pressure (CPAP) ::: Breathing Aid Devices for COVID-19 PatientsThere are several CPAP devices already developed for breathing aid of the coronavirus infected patients.", [["pneumonia", "DISEASE", 52, 61], ["COVID-19", "CHEMICAL", 84, 92], ["coronavirus infected", "DISEASE", 279, 299], ["patients", "ORGANISM", 36, 44], ["Patients", "ORGANISM", 197, 205], ["coronavirus", "ORGANISM", 279, 290], ["patients", "ORGANISM", 300, 308], ["patients", "SPECIES", 36, 44], ["Patients", "SPECIES", 197, 205], ["coronavirus", "SPECIES", 279, 290], ["patients", "SPECIES", 300, 308], ["The device", "TREATMENT", 0, 10], ["pneumonia", "PROBLEM", 52, 61], ["initial treatment", "TREATMENT", 97, 114], ["Continuous Positive Airway Pressure (CPAP", "TREATMENT", 115, 156], ["Breathing Aid Devices", "TREATMENT", 162, 183], ["COVID", "TEST", 188, 193], ["several CPAP devices", "TREATMENT", 215, 235], ["the coronavirus infected patients", "PROBLEM", 275, 308], ["pneumonia", "OBSERVATION", 52, 61], ["Airway Pressure", "OBSERVATION", 135, 150]]], ["A low-cost, microcontroller controlled electro-mechanical device is developed in [61] for the respiratory support of COVID-19 infected patients.", [["respiratory", "ANATOMY", 94, 105], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["A low-cost", "TREATMENT", 0, 10], ["microcontroller controlled electro-mechanical device", "TREATMENT", 12, 64], ["the respiratory support", "TREATMENT", 90, 113], ["COVID", "TEST", 117, 122], ["low", "OBSERVATION_MODIFIER", 2, 5], ["mechanical device", "OBSERVATION", 47, 64], ["infected", "OBSERVATION", 126, 134]]], ["The developed system consists of a control unit, a power supply with battery backup, a digital display (LCD), an air pump, and a nasal mask.", [["nasal", "ANATOMY", 129, 134], ["nasal", "ORGANISM_SUBDIVISION", 129, 134], ["battery backup", "TREATMENT", 69, 83], ["an air pump", "TREATMENT", 110, 121], ["a nasal mask", "TREATMENT", 127, 139], ["air pump", "OBSERVATION", 113, 121], ["nasal mask", "OBSERVATION", 129, 139]]], ["The main unit is here the air pump that is utilized for making pressurized air.", [["the air pump", "TREATMENT", 22, 34], ["main", "OBSERVATION_MODIFIER", 4, 8], ["air pump", "OBSERVATION", 26, 34], ["pressurized air", "OBSERVATION", 63, 78]]], ["An open-source breathing aid device is under development in [62] which is low cost.", [["An open-source breathing aid device", "TREATMENT", 0, 35], ["low cost", "OBSERVATION_MODIFIER", 74, 82]]], ["The developed system used an Arduino Nano as a microcontroller, DC motor, power supply, inflator pump, facial mask, and some 3D-printed parts.", [["DC", "ANATOMY", 64, 66], ["facial", "ANATOMY", 103, 109], ["an Arduino Nano", "TREATMENT", 26, 41], ["a microcontroller", "TREATMENT", 45, 62], ["inflator pump", "TREATMENT", 88, 101], ["facial mask", "TREATMENT", 103, 114], ["facial mask", "ANATOMY", 103, 114]]], ["However, the prototype is not recommended for medical applications due to the lack of enough tests with targeted people.", [["people", "ORGANISM", 113, 119], ["people", "SPECIES", 113, 119], ["medical applications", "TREATMENT", 46, 66]]], ["In another research, a bubble CPAP is introduced that provides a combined oxygen supply and space air to the respiratory-depressed babies [63].", [["oxygen", "CHEMICAL", 74, 80], ["depressed", "DISEASE", 121, 130], ["CPAP", "CHEMICAL", 30, 34], ["oxygen", "CHEMICAL", 74, 80], ["oxygen", "SIMPLE_CHEMICAL", 74, 80], ["a bubble CPAP", "TREATMENT", 21, 34], ["a combined oxygen supply", "TREATMENT", 63, 87], ["bubble CPAP", "OBSERVATION", 23, 34]]], ["The developed system is a cost-effective device with high durability and provides easy-to-use facility with a simple design.", [["a cost-effective device", "TREATMENT", 24, 47]]], ["Dundek et al. [64] developed a low cost bubble CPAP with the use of limited resources.", [["a low cost bubble CPAP", "TREATMENT", 29, 51], ["limited resources", "TREATMENT", 68, 85]]], ["The main component which is used here is an air blender where pressurized oxygen is delivered as input and the output is the combination of air and oxygen.", [["oxygen", "CHEMICAL", 74, 80], ["oxygen", "CHEMICAL", 148, 154], ["oxygen", "CHEMICAL", 74, 80], ["oxygen", "CHEMICAL", 148, 154], ["oxygen", "SIMPLE_CHEMICAL", 74, 80], ["oxygen", "SIMPLE_CHEMICAL", 148, 154], ["an air blender", "TREATMENT", 41, 55], ["pressurized oxygen", "TREATMENT", 62, 80], ["the output", "TEST", 107, 117], ["air and oxygen", "TREATMENT", 140, 154], ["main", "OBSERVATION_MODIFIER", 4, 8], ["component", "OBSERVATION_MODIFIER", 9, 18], ["air blender", "OBSERVATION", 44, 55], ["pressurized", "OBSERVATION_MODIFIER", 62, 73], ["oxygen", "OBSERVATION_MODIFIER", 74, 80], ["output", "OBSERVATION_MODIFIER", 111, 117], ["air", "OBSERVATION", 140, 143], ["oxygen", "OBSERVATION_MODIFIER", 148, 154]]], ["The prototype was developed with the combination of several parts printed in a 3D printer.", [["a 3D printer", "TREATMENT", 77, 89]]], ["Although the actual cost is not mentioned here, it is noted that the cost is 1% less than the gold standard device.", [["the gold standard device", "TREATMENT", 90, 114]]], ["Gehlot et al. [65] introduced a multi-power breathing aid device named as \u2018Saans\u2019 for the infants having severe respiration problem.", [["infants", "ORGANISM", 90, 97], ["infants", "SPECIES", 90, 97], ["a multi-power breathing aid device", "TREATMENT", 30, 64], ["severe respiration problem", "PROBLEM", 105, 131], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["respiration", "OBSERVATION", 112, 123]]], ["The prototype is comprised of battery-powered air pump, bubble jar, heated humidifier, and resuscitation circuit.", [["powered air pump", "TREATMENT", 38, 54], ["bubble jar", "TREATMENT", 56, 66], ["heated humidifier", "TREATMENT", 68, 85], ["resuscitation circuit", "TREATMENT", 91, 112], ["air pump", "OBSERVATION", 46, 54], ["bubble jar", "OBSERVATION", 56, 66]]], ["The developed device is tested with targeted people (newborn baby).", [["people", "ORGANISM", 45, 51], ["baby", "ORGANISM_SUBDIVISION", 61, 65], ["people", "SPECIES", 45, 51], ["device", "OBSERVATION", 14, 20]]], ["Further, Mukkundi et al. [66] proposed a multi-powered CPAP device for respiratory support for the patients having a breathing problem.", [["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["a multi-powered CPAP device", "TREATMENT", 39, 66], ["respiratory support", "TREATMENT", 71, 90], ["a breathing problem", "PROBLEM", 115, 134]]], ["In this system, two flow meters are used to control air and oxygen.", [["oxygen", "CHEMICAL", 60, 66], ["oxygen", "CHEMICAL", 60, 66], ["oxygen", "SIMPLE_CHEMICAL", 60, 66], ["two flow meters", "TREATMENT", 16, 31], ["oxygen", "TREATMENT", 60, 66], ["two", "OBSERVATION_MODIFIER", 16, 19], ["flow meters", "OBSERVATION", 20, 31], ["air", "OBSERVATION", 52, 55], ["oxygen", "OBSERVATION_MODIFIER", 60, 66]]], ["The popular CPAP devices that are extensively used or under development are shown in Fig. 4.DiscussionsIn this review, a comparative analysis among various breathing assistant devices supporting the COVID-19 pandemic situation is described.", [["The popular CPAP devices", "TREATMENT", 0, 24], ["a comparative analysis", "TEST", 119, 141], ["various breathing assistant devices", "TREATMENT", 148, 183], ["the COVID-19 pandemic situation", "TREATMENT", 195, 226], ["popular", "OBSERVATION_MODIFIER", 4, 11], ["CPAP devices", "OBSERVATION", 12, 24]]], ["All of the necessary features of the reviewed technologies are depicted in Table 1.DiscussionsAmong the reviewed systems, ventilators and CPAP devices are comparatively low cost.", [["ventilators", "TREATMENT", 122, 133], ["CPAP devices", "TREATMENT", 138, 150]]], ["Some study shows their cost less than $100 in [54, 57, 62] and higher than $100 in [58, 61].", [["Some study", "TEST", 0, 10]]], ["In contrast, oxygen therapy has a relatively higher cost than others [46].", [["oxygen", "CHEMICAL", 13, 19], ["oxygen", "CHEMICAL", 13, 19], ["oxygen", "SIMPLE_CHEMICAL", 13, 19], ["oxygen therapy", "TREATMENT", 13, 27], ["oxygen therapy", "OBSERVATION", 13, 27]]], ["Similarly, both ventilator and CPAP are light weight [53, 55, 58] where oxygen therapy device has heavy weight as it consists of many complex parts [48].", [["oxygen", "CHEMICAL", 72, 78], ["oxygen", "CHEMICAL", 72, 78], ["oxygen", "SIMPLE_CHEMICAL", 72, 78], ["CPAP", "TREATMENT", 31, 35], ["light weight", "TEST", 40, 52], ["oxygen therapy device", "TREATMENT", 72, 93], ["ventilator", "OBSERVATION_MODIFIER", 16, 26]]], ["Except medical technologies, there are several technologies that are used to develop these devices such as microcontroller, CAM, electronics, and mechanical.", [["CAM", "MULTI-TISSUE_STRUCTURE", 124, 127], ["these devices", "TREATMENT", 85, 98], ["microcontroller, CAM, electronics", "TREATMENT", 107, 140]]], ["Arduino Nano is frequently used in many breathing aid systems [55, 57, 61, 62] to control the signal received from other equipment.", [["Arduino Nano", "TREATMENT", 0, 12]]], ["Different electronic devices sucg as multiplexer, comparator, oscillator, capacitor, D/A converter, MOSFET, 3D printer, digital display are used in oxygen therapy devices [38], ventilators [53, 54, 58], and CPAP devices [61].", [["oxygen", "CHEMICAL", 148, 154], ["oxygen", "CHEMICAL", 148, 154], ["oxygen", "SIMPLE_CHEMICAL", 148, 154], ["Different electronic devices sucg", "TREATMENT", 0, 33], ["MOSFET, 3D printer", "TREATMENT", 100, 118], ["oxygen therapy devices", "TREATMENT", 148, 170], ["ventilators", "TEST", 177, 188], ["CPAP devices", "TREATMENT", 207, 219]]], ["AMBU bag is normally designed to be operated manually, but in some devices, it is operated mechanically or using CAM arm [52, 55].", [["AMBU bag", "TREATMENT", 0, 8]]], ["Almost all of the devices can be used in a different environment like home, hospital, and ambulance.", [["the devices", "TREATMENT", 14, 25]]], ["But some devices are specially developed for the hospital environment [46], and ambulance [51].", [["some devices", "TREATMENT", 4, 16], ["devices", "OBSERVATION", 9, 16]]], ["In COVID-19 disease, oxygen therapy and ventilator can provide better treatment in acute respiratory problems where CPAP is commonly used in mild cases as preliminary treatment.", [["respiratory", "ANATOMY", 89, 100], ["oxygen", "CHEMICAL", 21, 27], ["oxygen", "CHEMICAL", 21, 27], ["CPAP", "CHEMICAL", 116, 120], ["oxygen", "SIMPLE_CHEMICAL", 21, 27], ["disease", "PROBLEM", 12, 19], ["oxygen therapy", "TREATMENT", 21, 35], ["ventilator", "TREATMENT", 40, 50], ["acute respiratory problems", "PROBLEM", 83, 109], ["CPAP", "TREATMENT", 116, 120], ["preliminary treatment", "TREATMENT", 155, 176], ["19 disease", "OBSERVATION", 9, 19], ["oxygen therapy", "OBSERVATION", 21, 35], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["respiratory", "ANATOMY", 89, 100]]], ["Recently several devices are developed only for handling COVID-19 patients [50\u201352, 61].", [["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["several devices", "TREATMENT", 9, 24], ["handling COVID", "TEST", 48, 62], ["devices", "OBSERVATION", 17, 24]]], ["Oxygen therapy is used to improve survival rate [36] of patients though it has fire risk in contact with flame or smoke [48].", [["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["Oxygen therapy", "TREATMENT", 0, 14], ["survival rate", "TEST", 34, 47]]], ["Among all of them, CPAP devices can provide emergency support in the primary stage of respiratory problems and a ventilator is the most comfortable device for use [52].DiscussionsIn this study, sufficient breathing aid devices are reviewed for COVID-19 patients.", [["respiratory", "ANATOMY", 86, 97], ["respiratory problems", "DISEASE", 86, 106], ["CPAP", "CHEMICAL", 19, 23], ["patients", "ORGANISM", 253, 261], ["patients", "SPECIES", 253, 261], ["CPAP devices", "TREATMENT", 19, 31], ["emergency support", "TREATMENT", 44, 61], ["respiratory problems", "PROBLEM", 86, 106], ["a ventilator", "TREATMENT", 111, 123], ["this study", "TEST", 182, 192], ["sufficient breathing aid devices", "TREATMENT", 194, 226], ["respiratory problems", "OBSERVATION", 86, 106]]], ["Besides, in electronic-based devices there are much instrumental errors in providing original signal or result.", [["electronic-based devices", "TREATMENT", 12, 36], ["much instrumental errors", "PROBLEM", 47, 71]]], ["A proper selection of electronic devices may overcome this type of problem.", [["A proper selection of electronic devices", "TREATMENT", 0, 40], ["electronic devices", "OBSERVATION", 22, 40]]], ["In addition, it is important to produce more breathing supporting devices in a short time in this pandemic situation.", [["breathing supporting devices", "TREATMENT", 45, 73]]], ["In this circumstance, 3D-printing technology can play an important role in the mass production of such breathing aid devices.ConclusionThe COVID-19 is still an ongoing pandemic that is creating a lot of crisis in all sectors for humanity all over the world.", [["such breathing aid devices", "TREATMENT", 98, 124], ["The COVID", "TEST", 135, 144], ["mass", "OBSERVATION", 79, 83], ["pandemic", "OBSERVATION", 168, 176], ["lot", "OBSERVATION_MODIFIER", 196, 199], ["crisis", "OBSERVATION", 203, 209]]], ["This outbreak aims at increasing the threat\u2013benefit investigation of assessing the modality of breathing assistant for the infected patients.", [["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140]]], ["This paper overviews the recent available technologies that are frequently used for COVID-19 patients in hospitals, homes as well as the ambulance.", [["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101]]], ["The existing breathing aid devices are categorized into oxygen therapy devices, ventilators, and CPAP devices for proper demonstration.", [["oxygen", "CHEMICAL", 56, 62], ["oxygen", "CHEMICAL", 56, 62], ["oxygen", "SIMPLE_CHEMICAL", 56, 62], ["The existing breathing aid devices", "TREATMENT", 0, 34], ["oxygen therapy devices", "TREATMENT", 56, 78], ["ventilators", "TREATMENT", 80, 91], ["CPAP devices", "TREATMENT", 97, 109], ["oxygen therapy", "OBSERVATION", 56, 70]]], ["The devices are described in terms of working principle with construction, the equipment and technology used, cost, and relative analysis of merits and demerits throughout the paper.", [["The devices", "TREATMENT", 0, 11]]], ["The current challenges of existing technologies with possible future trends are also outlined in this review.", [["existing technologies", "TREATMENT", 26, 47]]], ["In this and future epidemics, there is a strong technological ability to mitigate respiratory support devices by utilizing modern small-scale technologies.", [["respiratory", "ANATOMY", 82, 93], ["respiratory support devices", "TREATMENT", 82, 109], ["modern small-scale technologies", "TREATMENT", 123, 154]]], ["The researchers with medical practitioners would provide an appropriate solution by developing necessary tools for the patients having breathing-related problems.", [["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["medical practitioners", "TREATMENT", 21, 42], ["an appropriate solution", "TREATMENT", 57, 80], ["related problems", "PROBLEM", 145, 161]]]], "5cb2a747c5ab924cd2f6e3aea2c521b5046c141b": [["EDITORIALIt's always about numerators and denominators (N/D) A both fundamental and seemingly simple methodological requirement in clinical epidemiology, and more generally in research and care, is the adequate handling of numerators, denominators, and their interrelationship N/ D. This implies not just good arithmetic, but primarily conceptual understanding.", [["simple", "OBSERVATION_MODIFIER", 94, 100]]], ["This is self-evident in the analysis of quantitative data.", [["quantitative data", "TEST", 40, 57]]], ["Also in N of 1 trials [1] the point is clear, with the nominators being events or scores during exposure versus non-exposure, and the denominators being time of exposure versus non-exposure, respectively.EDITORIALBut also in design development consistent 'N/D thinking' is essential to avoid bias.", [["clear", "OBSERVATION", 39, 44]]], ["For example, in effectiveness or etiological studies this implies ensuring that, when comparing the occurrence of events in two or more groups, the denominators are comparable, for example, by randomization in trials or adjustment in observational studies.", [["etiological studies", "TEST", 33, 52], ["observational studies", "TEST", 234, 255]]], ["In addition, N/D thinking is crucial is designing interventions and measurements and in preventing and handling missing data: is there any indication that one or more of such building blocks of good research is at risk of causing selection or observation bias by affecting the comparison, and how can this be addressed?EDITORIALNot always recognized is the importance of N/D thinking in (more) qualitative clinical research.", [["D", "SIMPLE_CHEMICAL", 15, 16]]], ["Also here the question must be asked to what extent N/D results could be influenced by the way the study is designed.EDITORIALIn healthcare, N/D awareness can help physicians understand that differences in clinical results can sometimes be explained by differences between practice populations, or recognize that patients who return to say they feel better may not be representative of the full denominator of the patients treated.", [["patients", "ORGANISM", 313, 321], ["patients", "ORGANISM", 414, 422], ["patients", "SPECIES", 313, 321], ["patients", "SPECIES", 414, 422], ["the study", "TEST", 95, 104]]], ["N/D thinking can also help understand patients' misconceptions of proportions, and making clear to them, for example, that hearing at age 55 about having a 2/3 risk of myocardial infarction does not refer to today's risk but to the average risk throughout further life [2] .", [["myocardial", "ANATOMY", 168, 178], ["myocardial infarction", "DISEASE", 168, 189], ["patients", "ORGANISM", 38, 46], ["myocardial", "MULTI-TISSUE_STRUCTURE", 168, 178], ["patients", "SPECIES", 38, 46], ["myocardial infarction", "PROBLEM", 168, 189], ["myocardial", "ANATOMY", 168, 178], ["infarction", "OBSERVATION", 179, 189]]], ["Such insights are fundamental for health communication with patients and the public [3] .", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68]]], ["A topical example is talking about the most affected country in the COVID-19 pandemic without mentioning whether this applies to the absolute number of cases or deaths, incidence rate, or death rate, which of course makes a huge difference [4] .EDITORIALA basic N/D issue in research is whether, in studying phenomena of interest, representative denominators are used.", [["deaths", "DISEASE", 161, 167], ["death", "DISEASE", 188, 193], ["incidence rate", "TEST", 169, 183], ["death rate", "TEST", 188, 198]]], ["This was addressed by Antequera c.s., who, in a bibliometric study, assessed female (under)representation in primary studies underpinning clinical guideline recommendations and systematic reviews for sepsis treatment.", [["sepsis", "DISEASE", 200, 206], ["a bibliometric study", "TEST", 46, 66], ["systematic reviews", "TEST", 177, 195], ["sepsis treatment", "TREATMENT", 200, 216], ["sepsis", "OBSERVATION", 200, 206]]], ["They found that female participation in these primary studies is below their representation in the sepsis population.", [["sepsis", "DISEASE", 99, 105], ["these primary studies", "TEST", 40, 61], ["the sepsis population", "PROBLEM", 95, 116], ["sepsis", "OBSERVATION", 99, 105]]], ["According to the authors, sex-based participation disparities and lack of sex-related analyses and reporting limit the generalizability of research findings and hamper the external validity of the effectiveness of interventions.", [["interventions", "TREATMENT", 214, 227]]], ["They make recommendations to all stakeholders in research to report disaggregated data, discuss the influence of sex and gender on research findings, and address diversity of patient populations.EDITORIALA good example of the need to make an appropriate match between numerators and denominators is subgroup analysis, which is intended, in the end, to better reflect individual patients in practice.", [["patient", "ORGANISM", 175, 182], ["patients", "ORGANISM", 378, 386], ["patient", "SPECIES", 175, 182], ["patients", "SPECIES", 378, 386], ["subgroup analysis", "TEST", 299, 316]]], ["In a systematic review Yu et al. evaluated the degree of personalization of benefit and harm results of RCTs of pharmacological therapy published in the McMaster Premium LiteratUre Service (PLUS) database [5] , with the proportion of trials reporting subgroup analyses of a combined benefit-harm outcome as primary outcome and the proportion of trials reporting subgroup analyses or clinical prediction guides for benefits or harms as secondary outcomes.", [["RCTs", "TREATMENT", 104, 108], ["pharmacological therapy", "TREATMENT", 112, 135], ["subgroup analyses", "TEST", 362, 379]]], ["While in aImost 60% of the RCTs subgroup analyses were performed, their overall methodological quality was low.", [["the RCTs subgroup analyses", "TEST", 23, 49]]], ["It was concluded that, despite great interest in the personalization of treatments, this is rarely reported in high-profile trials, and that there is a need for methods development for personalization of research results.", [["treatments", "TREATMENT", 72, 82], ["methods development", "TREATMENT", 161, 180]]], ["Webster-Clark c.s., considering that effect estimates from prespecified subgroups may not apply to corresponding subgroups in the source population, studied whether systematic or structural sources of misleading subgroup estimates could play a role here by using directed acyclic graphs to evaluate selection bias.", [["directed acyclic graphs", "TREATMENT", 263, 286]]], ["They recommend that researchers examine multiple potential modifiers of treatment effect at once, rather than conduct multiple crude subgroup analyses, to identify heterogeneous treatment effects.", [["treatment effect", "TREATMENT", 72, 88], ["multiple crude subgroup analyses", "TEST", 118, 150], ["heterogeneous treatment effects", "PROBLEM", 164, 195], ["heterogeneous", "OBSERVATION_MODIFIER", 164, 177], ["treatment", "OBSERVATION", 178, 187]]], ["A form of very focused subgroup analysis, evaluated by Swift and co-authors, is relating prognosis to tumor heterogeneity (TH) in order to promote precision medicine.", [["tumor", "ANATOMY", 102, 107], ["tumor", "DISEASE", 102, 107], ["tumor", "CANCER", 102, 107], ["subgroup analysis", "TEST", 23, 40], ["tumor heterogeneity", "PROBLEM", 102, 121], ["precision medicine", "TREATMENT", 147, 165], ["tumor", "OBSERVATION", 102, 107]]], ["They conducted a systematic review to identify guidelines to assist systematic reviewers or clinical researchers in identifying sampling bias due to tumor heterogeneity, and performed a post hoc analysis of prostate tumor somatic mutation data from a previous systematic review to evaluate reporting on TH.", [["tumor", "ANATOMY", 149, 154], ["prostate tumor", "ANATOMY", 207, 221], ["tumor", "DISEASE", 149, 154], ["prostate tumor", "DISEASE", 207, 221], ["tumor", "CANCER", 149, 154], ["prostate tumor", "CANCER", 207, 221], ["TH", "GENE_OR_GENE_PRODUCT", 303, 305], ["sampling bias", "TEST", 128, 141], ["tumor heterogeneity", "PROBLEM", 149, 168], ["a post hoc analysis", "TEST", 184, 203], ["prostate tumor somatic mutation data", "PROBLEM", 207, 243], ["tumor", "OBSERVATION", 149, 154], ["prostate", "ANATOMY", 207, 215], ["tumor", "OBSERVATION", 216, 221]]], ["The investigators found no formal guidelines, and methods or results to address tumor heterogeneity are insufficiently reported by most authors.", [["tumor", "ANATOMY", 80, 85], ["tumor", "DISEASE", 80, 85], ["tumor", "CANCER", 80, 85], ["tumor heterogeneity", "PROBLEM", 80, 99], ["no", "UNCERTAINTY", 24, 26], ["tumor", "OBSERVATION", 80, 85]]], ["They conclude that formal guidelines are required to help evidence-based decision makers to understand TH-related sample bias, and that primary authors need to clearly report tissue sample pathology methods, results, and tumor purity.EDITORIALAnother N/D challenge is whether a comprehensive or representative set of primary studies is retrieved in systematic reviews or meta-analyses.", [["tissue sample", "ANATOMY", 175, 188], ["tumor", "ANATOMY", 221, 226], ["tumor", "DISEASE", 221, 226], ["TH", "GENE_OR_GENE_PRODUCT", 103, 105], ["tissue", "TISSUE", 175, 181], ["tumor", "CANCER", 221, 226], ["tumor purity", "PROBLEM", 221, 233], ["primary studies", "TEST", 317, 332]]], ["For a random selection of studies they compared the DTA studies found by researchers with those that were identified by using this term.", [["a random selection of studies", "TEST", 4, 33], ["the DTA studies", "TEST", 48, 63]]], ["The Emtree term turned out to have a sensitivity of 42.4% and a specificity of 99.5%, while 30% of the studies were incorrectly labeled as being a DTA study.", [["a sensitivity", "TEST", 35, 48], ["a specificity", "TEST", 62, 75], ["the studies", "TEST", 99, 110], ["a DTA study", "TEST", 145, 156]]], ["The conclusion was that the Emtree DTA label failed to find most of the DTA studies and is not helpful to retrieve DTA studies accurately.", [["the DTA studies", "TEST", 68, 83], ["DTA studies", "TEST", 115, 126]]], ["Page c.s. point at the enormous importance of synthesizing the continuous and rapidly expanding volume of research literature in relation to the COVID-19 outbreak.", [["the COVID", "TEST", 141, 150]]], ["Rapid reviews [6] can inform policy making under urgent circumstances while living systematic reviews [7] will provide up-to-date evidence synthesis.", [["synthesis", "PROBLEM", 139, 148]]], ["To help identify, map, and synthesize the denominator of relevant research output as it emerges, online collaborative tools and virtual workspaces are crucial, but this faces major challenges such as: duplication of efforts leading to research waste, inefficiency in conducting research, and missing the opportunity to address important questions.", [["map", "TEST", 18, 21]]], ["The authors therefore elaborate and apply the principles of Open Synthesis to highlight its potential benefits, particularly in global crises such as the current COVID-19 pandemic.", [["Open Synthesis", "TREATMENT", 60, 74], ["global crises", "PROBLEM", 128, 141], ["the current COVID", "TEST", 150, 167], ["pandemic", "PROBLEM", 171, 179]]], ["Also these authors make a plea for international coordination to reduce the risk of duplication, and to effectively use global collective evidence synthesis resources.", [["duplication", "PROBLEM", 84, 95], ["synthesis resources", "TREATMENT", 147, 166]]], ["They outline several relevant methodological challenges to the conduct of rapid reviews that have become apparent during the COVID-19 pandemic, using an 8-step framework that follows the knowledge synthesis process and is also useful for future research.EDITORIALDeMets and Fleming make clear that independent oversight of (the denominator of) the numerous clinical trials being concurrently conducted, as provided by Data Monitoring Committees (DMCs), is particularly important in public health emergencies such as the coronavirus epidemic.", [["coronavirus", "DISEASE", 520, 531], ["coronavirus", "ORGANISM", 520, 531], ["the COVID", "TEST", 121, 130], ["an 8-step framework", "TREATMENT", 150, 169], ["the coronavirus epidemic", "PROBLEM", 516, 540]]], ["One of the issues they address is concurrently conducted trials on closely related scientific questions in related clinical settings, often individually underpowered for safety and having separate DMCs.", [["DMCs", "CANCER", 197, 201]]], ["As the authors say, ideally a single DMC would monitor a portfolio of clinical trials or a trial with multiple arms, such as a platform trial [8] .EDITORIALIn a commentary on the methodological challenges regarding the testing of COVID-19 tests for identification of infected persons and for revealing a previous infection, Bossuyt addresses several key problems, such as: the absence of an independent reference standard for the clinical evaluation of tests for viral RNA, lack of rigor in the recruitment of study participants, insufficiently informative study reports with failure to adhere to reporting guidelines, difficulty to assess the applicability of study findings, and single estimates of clinical sensitivity despite relevant heterogeneity.", [["DMC", "CHEMICAL", 37, 40], ["infection", "DISEASE", 313, 322], ["persons", "ORGANISM", 276, 283], ["viral RNA", "RNA", 463, 472], ["persons", "SPECIES", 276, 283], ["participants", "SPECIES", 516, 528], ["a trial with multiple arms", "TREATMENT", 89, 115], ["a platform trial", "TREATMENT", 125, 141], ["the testing", "TEST", 215, 226], ["COVID", "TEST", 230, 235], ["infected persons", "PROBLEM", 267, 283], ["a previous infection", "PROBLEM", 302, 322], ["the clinical evaluation", "TEST", 426, 449], ["tests", "TEST", 453, 458], ["viral RNA", "PROBLEM", 463, 472], ["rigor", "PROBLEM", 482, 487], ["study findings", "TEST", 661, 675], ["clinical sensitivity", "PROBLEM", 701, 721], ["infected", "OBSERVATION", 267, 275], ["infection", "OBSERVATION", 313, 322], ["heterogeneity", "OBSERVATION", 739, 752]]], ["Among these N/D issues are prominent, such as the requirement that participants and samples should be collected in the target population and that test performance should not be summarized in a single number, as that can be misleadingly ignore the variability in relation to, for example, target population and setting.EDITORIALIn an overarching commentary on evidence-based medicine in times of crisis, Djulbegovic and Guyatt stress that, in the face of the COVID-19 pandemic threat and the related challenges in research, society and policy making, applying evidence-based medicine (EBM) and associated GRADE [9] principles is crucial.", [["participants", "SPECIES", 67, 79], ["test performance", "TEST", 146, 162], ["crisis", "PROBLEM", 395, 401], ["Guyatt stress", "PROBLEM", 419, 432], ["associated GRADE [9] principles", "PROBLEM", 593, 624], ["prominent", "OBSERVATION_MODIFIER", 27, 36]]], ["This is in fact a matter of differentiating the full denominator of available studies according to quality, as GRADE classifies evidence from high quality to very low quality with categories of moderate and low in-between.", [["available studies", "TEST", 68, 85], ["high", "OBSERVATION_MODIFIER", 142, 146], ["moderate", "OBSERVATION_MODIFIER", 194, 202], ["low", "OBSERVATION_MODIFIER", 207, 210]]], ["When, in response to COVID-19, making recommendations regarding issues such as use of masks or hydroxychloroquine, implementing interventions based on high-quality evidence of substantial effectiveness can be expected to result in net benefit, whereas adopting interventions based on very low quality evidence runs a high risk of net harm.", [["hydroxychloroquine", "CHEMICAL", 95, 113], ["hydroxychloroquine", "CHEMICAL", 95, 113], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 95, 113], ["COVID", "TEST", 21, 26], ["masks", "TREATMENT", 86, 91], ["hydroxychloroquine", "TREATMENT", 95, 113], ["implementing interventions", "TREATMENT", 115, 141], ["adopting interventions", "TREATMENT", 252, 274], ["net harm", "PROBLEM", 330, 338], ["net harm", "OBSERVATION", 330, 338]]], ["Indeed, as these authors write, 'appropriate application of EBM and GRADE is never more important than in times of health crisis affecting millions of people'.", [["people", "ORGANISM", 151, 157], ["people", "SPECIES", 151, 157]]]], "649d38a5d9193f1070c4c27575c583a46a739e23": [["In BriefZika virus (ZIKV) is a mosquitotransmitted flavivirus that can cause severe neurological defects in humans.", [["neurological", "ANATOMY", 84, 96], ["flavivirus", "DISEASE", 51, 61], ["neurological defects", "DISEASE", 84, 104], ["BriefZika virus", "ORGANISM", 3, 18], ["ZIKV", "ORGANISM", 20, 24], ["humans", "ORGANISM", 108, 114], ["BriefZika virus", "SPECIES", 3, 18], ["humans", "SPECIES", 108, 114], ["BriefZika virus", "SPECIES", 3, 18], ["ZIKV", "SPECIES", 20, 24], ["humans", "SPECIES", 108, 114], ["BriefZika virus", "PROBLEM", 3, 18], ["a mosquitotransmitted flavivirus", "PROBLEM", 29, 61], ["severe neurological defects in humans", "PROBLEM", 77, 114], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["neurological defects", "OBSERVATION", 84, 104]]], ["Li et al. have identified a human monoclonal antibody capable of protection against ZIKV infection and related diseases when tested in mouse models.", [["Li", "CHEMICAL", 0, 2], ["ZIKV infection", "DISEASE", 84, 98], ["human", "ORGANISM", 28, 33], ["ZIKV", "ORGANISM", 84, 88], ["mouse", "ORGANISM", 135, 140], ["human monoclonal antibody", "PROTEIN", 28, 53], ["human", "SPECIES", 28, 33], ["mouse", "SPECIES", 135, 140], ["human", "SPECIES", 28, 33], ["ZIKV", "SPECIES", 84, 88], ["mouse", "SPECIES", 135, 140], ["a human monoclonal antibody", "TREATMENT", 26, 53], ["ZIKV infection", "PROBLEM", 84, 98], ["related diseases", "PROBLEM", 103, 119]]], ["This antibody serves as a promising candidate for clinical development against ZIKV.INTRODUCTIONThe recent, widespread neurological deficits caused by an emergent strain of Zika virus (ZIKV) have caught the world off guard Wikan and Smith, 2016) .", [["neurological", "ANATOMY", 119, 131], ["neurological deficits", "DISEASE", 119, 140], ["Zika virus", "ORGANISM", 173, 183], ["Zika virus", "SPECIES", 173, 183], ["Zika virus", "SPECIES", 173, 183], ["ZIKV", "SPECIES", 185, 189], ["widespread neurological deficits", "PROBLEM", 108, 140], ["Zika virus", "PROBLEM", 173, 183]]], ["ZIKV was first identified in the forests of Uganda, and infection was generally benign in humans (Dick et al., 1952) .", [["infection", "DISEASE", 56, 65], ["ZIKV", "GENE_OR_GENE_PRODUCT", 0, 4], ["humans", "ORGANISM", 90, 96], ["humans", "SPECIES", 90, 96], ["ZIKV", "SPECIES", 0, 4], ["humans", "SPECIES", 90, 96], ["ZIKV", "PROBLEM", 0, 4], ["infection", "PROBLEM", 56, 65], ["infection", "OBSERVATION", 56, 65], ["benign", "OBSERVATION_MODIFIER", 80, 86]]], ["However, this new strain of ZIKV is far more virulent and causes a range of clinical anomalies Rasmussen et al., 2016; Wikan and Smith, 2016) .", [["ZIKV", "GENE_OR_GENE_PRODUCT", 28, 32], ["ZIKV", "SPECIES", 28, 32], ["ZIKV", "PROBLEM", 28, 32], ["ZIKV", "OBSERVATION", 28, 32]]], ["Most notable are microcephaly and other congenital defects in infants born to mothers infected with ZIKV during pregnancy (Mlakar et al., 2016; Petersen et al., 2016; Rasmussen et al., 2016; Wikan and Smith, 2016) .", [["microcephaly", "DISEASE", 17, 29], ["congenital defects", "DISEASE", 40, 58], ["ZIKV", "CHEMICAL", 100, 104], ["infants", "ORGANISM", 62, 69], ["mothers", "ORGANISM", 78, 85], ["infants", "SPECIES", 62, 69], ["ZIKV", "SPECIES", 100, 104], ["microcephaly", "PROBLEM", 17, 29], ["other congenital defects", "PROBLEM", 34, 58], ["ZIKV during pregnancy", "PROBLEM", 100, 121], ["microcephaly", "OBSERVATION", 17, 29], ["congenital defects", "OBSERVATION", 40, 58]]], ["Although the exact mech-anism of neuropathogenesis remains uncertain, clinical abnormalities have been linked to the aberrant development and loss of neural progenitor cells (NPCs) (Cugola et al., 2016; Gabriel et al., 2017; Garcez et al., 2016; Li et al., 2016a Li et al., , 2016b Tang et al., 2016) .", [["neural progenitor cells", "ANATOMY", 150, 173], ["NPCs", "ANATOMY", 175, 179], ["neuropathogenesis", "DISEASE", 33, 50], ["neural progenitor cells", "CELL", 150, 173], ["NPCs", "CELL", 175, 179], ["neural progenitor cells", "CELL_TYPE", 150, 173], ["NPCs", "CELL_TYPE", 175, 179], ["neuropathogenesis", "PROBLEM", 33, 50], ["clinical abnormalities", "PROBLEM", 70, 92], ["loss of neural progenitor cells", "PROBLEM", 142, 173], ["loss", "OBSERVATION_MODIFIER", 142, 146], ["neural progenitor cells", "OBSERVATION", 150, 173]]], ["The contemporary strain of ZIKV has enhanced replication capacity and a specialized tropism for NPCs (Cugola et al., 2016; Dang et al., 2016; Garcez et al., 2016; Li et al., 2016b; Tang et al., 2016) , although other types of cells are susceptible (Tabata et al., 2016; Weisblum et al., 2017) .", [["NPCs", "ANATOMY", 96, 100], ["cells", "ANATOMY", 226, 231], ["ZIKV", "CHEMICAL", 27, 31], ["ZIKV", "GENE_OR_GENE_PRODUCT", 27, 31], ["NPCs", "CELL", 96, 100], ["cells", "CELL", 226, 231], ["NPCs", "CELL_TYPE", 96, 100], ["ZIKV", "SPECIES", 27, 31], ["enhanced replication capacity", "PROBLEM", 36, 65], ["ZIKV", "OBSERVATION", 27, 31]]], ["The infection inhibits NPC proliferation and differentiation and can trigger apoptosis or autophagy.", [["NPC", "ANATOMY", 23, 26], ["infection", "DISEASE", 4, 13], ["NPC", "CELL", 23, 26], ["The infection", "PROBLEM", 0, 13], ["NPC proliferation", "PROBLEM", 23, 40], ["apoptosis", "PROBLEM", 77, 86], ["autophagy", "PROBLEM", 90, 99], ["infection", "OBSERVATION", 4, 13], ["NPC proliferation", "OBSERVATION", 23, 40]]], ["Critically, the highest rates of birth defects occur in pregnant mothers who are infected during their first and second trimesters.", [["birth defects", "DISEASE", 33, 46], ["mothers", "ORGANISM", 65, 72], ["birth defects", "PROBLEM", 33, 46], ["highest", "OBSERVATION_MODIFIER", 16, 23], ["rates", "OBSERVATION_MODIFIER", 24, 29], ["defects", "OBSERVATION", 39, 46], ["infected", "OBSERVATION", 81, 89]]], ["This is presumably because, during the early stages of gestation, NPCs have a greater susceptibility to ZIKV infection, and there is more viral transfer across the placental barrier (Mlakar et al., 2016; Petersen et al., 2016; Rasmussen et al., 2016; Wikan and Smith, 2016) .", [["NPCs", "ANATOMY", 66, 70], ["placental barrier", "ANATOMY", 164, 181], ["infection", "DISEASE", 109, 118], ["NPCs", "CELL", 66, 70], ["ZIKV", "GENE_OR_GENE_PRODUCT", 104, 108], ["placental barrier", "TISSUE", 164, 181], ["NPCs", "CELL_TYPE", 66, 70], ["ZIKV", "SPECIES", 104, 108], ["NPCs", "PROBLEM", 66, 70], ["a greater susceptibility to ZIKV infection", "PROBLEM", 76, 118], ["presumably because", "UNCERTAINTY", 8, 26], ["greater susceptibility", "OBSERVATION_MODIFIER", 78, 100], ["ZIKV", "OBSERVATION_MODIFIER", 104, 108], ["infection", "OBSERVATION", 109, 118], ["viral", "OBSERVATION", 138, 143], ["placental", "ANATOMY", 164, 173]]], ["To fully protect the developing fetuses, an intervention must occur before this period or, ideally, prior to infection (Marston et al., 2016) .INTRODUCTIONNeutralizing antibodies are the essential mediator of immunity against viral infection (Burton and Hangartner, 2016; Corti and Lanzavecchia, 2013) .", [["fetuses", "ANATOMY", 32, 39], ["infection", "DISEASE", 109, 118], ["viral infection", "DISEASE", 226, 241], ["fetuses", "ORGANISM", 32, 39], [".INTRODUCTIONNeutralizing antibodies", "GENE_OR_GENE_PRODUCT", 142, 178], ["the developing fetuses", "PROBLEM", 17, 39], ["an intervention", "TREATMENT", 41, 56], ["infection", "PROBLEM", 109, 118], ["viral infection", "PROBLEM", 226, 241], ["fetuses", "OBSERVATION", 32, 39], ["infection", "OBSERVATION", 232, 241]]], ["For ZIKV and other flaviviruses, human neutralizing monoclonal antibodies target the surface envelope glycoprotein (E) that facilitates infection (Dejnirattisai et al., 2015; Fernandez et al., 2017; Fibriansah et al., 2015; Heinz and Stiasny, 2012; Magnani et al., 2017; Pierson and Diamond, 2008; Pierson and Graham, 2016; Robbiani et al., 2017; Rogers et al., 2017; Sapparapu et al., 2016; Stettler et al., 2016; Wang et al., 2016 Wang et al., , 2017b Zhao et al., 2016) .", [["surface", "ANATOMY", 85, 92], ["infection", "DISEASE", 136, 145], ["human", "ORGANISM", 33, 38], ["human neutralizing monoclonal antibodies", "PROTEIN", 33, 73], ["surface envelope glycoprotein", "PROTEIN", 85, 114], ["E", "PROTEIN", 116, 117], ["human", "SPECIES", 33, 38], ["ZIKV", "SPECIES", 4, 8], ["human", "SPECIES", 33, 38], ["ZIKV", "PROBLEM", 4, 8], ["other flaviviruses", "PROBLEM", 13, 31], ["human neutralizing monoclonal antibodies", "TREATMENT", 33, 73], ["infection", "OBSERVATION", 136, 145]]], ["We previously reported on a panel of monoclonal antibodies (mAbs) derived from the longitudinal samples of a ZIKV-convalescent individual and characterized their neutralizing activities, epitope specificities, and development timeline over the course of infection .", [["samples", "ANATOMY", 96, 103], ["infection", "DISEASE", 254, 263], ["monoclonal antibodies", "PROTEIN", 37, 58], ["mAbs", "PROTEIN", 60, 64], ["ZIKV", "SPECIES", 109, 113], ["a panel", "TEST", 26, 33], ["monoclonal antibodies", "TEST", 37, 58], ["epitope specificities", "PROBLEM", 187, 208], ["infection", "PROBLEM", 254, 263], ["neutralizing activities", "OBSERVATION", 162, 185], ["infection", "OBSERVATION", 254, 263]]], ["We also reported on mouse models of ZIKV infection and microcephaly, with enhanced specificity for neurological infection Figure 1 .", [["neurological", "ANATOMY", 99, 111], ["ZIKV infection", "DISEASE", 36, 50], ["microcephaly", "DISEASE", 55, 67], ["neurological infection", "DISEASE", 99, 121], ["mouse", "ORGANISM", 20, 25], ["ZIKV", "ORGANISM", 36, 40], ["mouse", "SPECIES", 20, 25], ["mouse", "SPECIES", 20, 25], ["ZIKV", "SPECIES", 36, 40], ["ZIKV infection", "PROBLEM", 36, 50], ["microcephaly", "PROBLEM", 55, 67], ["neurological infection Figure", "PROBLEM", 99, 128], ["ZIKV infection", "OBSERVATION", 36, 50], ["microcephaly", "OBSERVATION", 55, 67], ["infection", "OBSERVATION", 112, 121]]], ["Experimental Design to Evaluate the Prophylactic Potential of Six Human mAbs against ZIKV Infection in Developing Fetuses and AG6 Mice (A) Timeline for mAb injection, ZIKV inoculation, infant delivery, and the monitoring of a complementary set of clinical, virological, and neuropathological outcomes from embryonic day 14.5 to P28.", [["Fetuses", "ANATOMY", 114, 121], ["ZIKV Infection", "DISEASE", 85, 99], ["ZIKV", "CHEMICAL", 167, 171], ["Human", "ORGANISM", 66, 71], ["ZIKV", "ORGANISM", 85, 89], ["Fetuses", "ORGANISM", 114, 121], ["Mice", "ORGANISM", 130, 134], ["mAb", "GENE_OR_GENE_PRODUCT", 152, 155], ["Human", "SPECIES", 66, 71], ["Mice", "SPECIES", 130, 134], ["infant", "SPECIES", 185, 191], ["Human", "SPECIES", 66, 71], ["ZIKV", "SPECIES", 85, 89], ["ZIKV", "SPECIES", 167, 171], ["Six Human mAbs", "TREATMENT", 62, 76], ["ZIKV Infection", "PROBLEM", 85, 99], ["mAb injection", "TREATMENT", 152, 165], ["ZIKV inoculation", "TREATMENT", 167, 183], ["infant delivery", "TREATMENT", 185, 200], ["the monitoring", "TEST", 206, 220]]], ["The six mAbs tested are shown alongside their IC 50 values and epitope specificities.", [["mAbs", "PROTEIN", 8, 12], ["The six mAbs", "TEST", 0, 12], ["epitope specificities", "TEST", 63, 84]]], ["ZIKV-inoculated fetuses and neonates are indicated by ZIKV + in red; those left unexposed are indicated by ZIKV \u00c0 in blue.", [["fetuses", "ANATOMY", 16, 23], ["ZIKV", "CHEMICAL", 0, 4], ["ZIKV", "GENE_OR_GENE_PRODUCT", 0, 4], ["fetuses", "ORGANISM", 16, 23], ["neonates", "ORGANISM", 28, 36], ["ZIKV", "ORGANISM", 54, 58], ["ZIKV", "SPECIES", 0, 4], ["ZIKV", "SPECIES", 107, 111], ["ZIKV", "PROBLEM", 0, 4], ["inoculated fetuses", "PROBLEM", 5, 23], ["neonates", "TREATMENT", 28, 36], ["ZIKV", "PROBLEM", 54, 58], ["inoculated fetuses", "OBSERVATION", 5, 23], ["left", "ANATOMY_MODIFIER", 75, 79], ["ZIKV", "OBSERVATION", 107, 111]]], ["The cartoon mice on P3 include ZIKV + (small and large indicated in red) and ZIKV \u00c0 (large indicated in blue); the size representations reflect potential body weight outcomes.", [["body", "ANATOMY", 154, 158], ["mice", "ORGANISM", 12, 16], ["body", "ORGANISM_SUBDIVISION", 154, 158], ["mice", "SPECIES", 12, 16], ["ZIKV", "SPECIES", 77, 81], ["ZIKV", "PROBLEM", 31, 35], ["ZIKV \u00c0", "PROBLEM", 77, 83], ["potential body weight outcomes", "PROBLEM", 144, 174], ["small", "OBSERVATION_MODIFIER", 39, 44], ["large", "OBSERVATION_MODIFIER", 49, 54], ["size", "OBSERVATION_MODIFIER", 115, 119]]], ["Each mAb was tested, and the outcomes were monitored in three littermate neonates of three pregnant mice on P3 and P28.", [["mAb", "GENE_OR_GENE_PRODUCT", 5, 8], ["neonates", "ORGANISM", 73, 81], ["mice", "ORGANISM", 100, 104], ["mAb", "PROTEIN", 5, 8], ["mice", "SPECIES", 100, 104], ["mice", "SPECIES", 100, 104], ["Each mAb", "TREATMENT", 0, 8]]], ["(B) Different levels of protection conferred by the six mAbs, shown with the number (n) of neonates monitored for survival in each mAb treatment group.", [["neonates", "ORGANISM", 91, 99], ["mAbs", "PROTEIN", 56, 60], ["protection", "TREATMENT", 24, 34], ["neonates", "TREATMENT", 91, 99], ["survival in each mAb treatment group", "TREATMENT", 114, 150]]], ["(C) The body weight of neonates among the different mAb groups.", [["body", "ANATOMY", 8, 12], ["body", "ORGANISM_SUBDIVISION", 8, 12], ["neonates", "ORGANISM", 23, 31], ["The body weight", "TEST", 4, 19]]], ["ZIKV + neonates indicated in red are presented as a percentage of the blue ZIKV \u00c0 littermates.", [["ZIKV + neonates", "ORGANISM", 0, 15], ["blue ZIKV \u00c0 littermates", "ORGANISM", 70, 93], ["ZIKV", "SPECIES", 0, 4], ["blue ZIKV", "OBSERVATION", 70, 79]]], ["The ZK2B10-treated group had no discernable differences between the ZIKV + and ZIKV \u00c0 littermates and is, therefore, shown as a single red/blue checkered bar.", [["ZK2B10", "CHEMICAL", 4, 10], ["ZK2B10", "CHEMICAL", 4, 10], ["ZK2B10", "SIMPLE_CHEMICAL", 4, 10], ["ZIKV", "ORGANISM", 68, 72], ["ZIKV \u00c0 littermates", "ORGANISM", 79, 97], ["ZK2B10", "PROTEIN", 4, 10], ["ZIKV", "SPECIES", 79, 83], ["red/blue checkered bar", "SPECIES", 135, 157], ["The ZK2B10", "TEST", 0, 10], ["discernable differences", "PROBLEM", 32, 55], ["a single red/blue checkered bar", "TREATMENT", 126, 157], ["ZIKV", "OBSERVATION", 68, 72]]], ["The number of neonates for each analysis is indicated above the respective mAb, with ZIKV + in red and ZIKV \u00c0 in blue.INTRODUCTION(legend continued on next page) using a contemporary ZIKV Asian strain (GZ01).", [["neonates", "ORGANISM", 14, 22], ["mAb", "GENE_OR_GENE_PRODUCT", 75, 78], ["ZIKV \u00c0", "ORGANISM", 103, 109], ["mAb", "PROTEIN", 75, 78], ["ZIKV", "PROTEIN", 85, 89], ["ZIKV", "SPECIES", 103, 107], ["each analysis", "TEST", 27, 40], ["the respective mAb", "TREATMENT", 60, 78], ["ZIKV", "PROBLEM", 85, 89], ["a contemporary ZIKV Asian strain (GZ01)", "TREATMENT", 168, 207]]], ["In the model of microcephaly, the virus was inoculated directly into the lateral ventricles of the fetal mouse brain (Li et al., 2016a) .", [["lateral ventricles", "ANATOMY", 73, 91], ["fetal", "ANATOMY", 99, 104], ["brain", "ANATOMY", 111, 116], ["microcephaly", "DISEASE", 16, 28], ["lateral ventricles", "MULTI-TISSUE_STRUCTURE", 73, 91], ["mouse", "ORGANISM", 105, 110], ["brain", "ORGAN", 111, 116], ["mouse", "SPECIES", 105, 110], ["mouse", "SPECIES", 105, 110], ["microcephaly", "PROBLEM", 16, 28], ["the virus", "PROBLEM", 30, 39], ["microcephaly", "OBSERVATION", 16, 28], ["virus", "OBSERVATION", 34, 39], ["lateral", "ANATOMY_MODIFIER", 73, 80], ["ventricles", "ANATOMY", 81, 91], ["fetal", "ANATOMY_MODIFIER", 99, 104], ["mouse brain", "ANATOMY", 105, 116]]], ["ZIKV replicated in the fetal brain, with preferential infection of NPCs.", [["fetal brain", "ANATOMY", 23, 34], ["NPCs", "ANATOMY", 67, 71], ["infection", "DISEASE", 54, 63], ["ZIKV", "GENE_OR_GENE_PRODUCT", 0, 4], ["fetal brain", "ORGAN", 23, 34], ["NPCs", "CELL", 67, 71], ["ZIKV", "PROTEIN", 0, 4], ["NPCs", "CELL_TYPE", 67, 71], ["ZIKV", "SPECIES", 0, 4], ["ZIKV", "PROBLEM", 0, 4], ["preferential infection of NPCs", "PROBLEM", 41, 71], ["fetal brain", "ANATOMY", 23, 34], ["preferential", "OBSERVATION_MODIFIER", 41, 53], ["infection", "OBSERVATION", 54, 63]]], ["Infection resulted in cell-cycle arrest, differentiation defects, and a large number of cell deaths, as well as clinical presentations of microcephaly (Li et al., 2016a) .", [["cell", "ANATOMY", 22, 26], ["cell", "ANATOMY", 88, 92], ["deaths", "DISEASE", 93, 99], ["microcephaly", "DISEASE", 138, 150], ["cell", "CELL", 22, 26], ["cell", "CELL", 88, 92], ["Infection", "PROBLEM", 0, 9], ["cell-cycle arrest", "PROBLEM", 22, 39], ["differentiation defects", "PROBLEM", 41, 64], ["cell deaths", "PROBLEM", 88, 99], ["microcephaly", "PROBLEM", 138, 150], ["cell-cycle arrest", "OBSERVATION", 22, 39], ["differentiation defects", "OBSERVATION", 41, 64], ["large", "OBSERVATION_MODIFIER", 72, 77], ["number", "OBSERVATION_MODIFIER", 78, 84], ["cell deaths", "OBSERVATION", 88, 99]]], ["Here, we use the mouse models of ZIKV infection and microcephaly to analyze the in vivo protective activities of six human mAbs and compare the findings with our reported in vitro neutralization activity, as measured by plaque reduction neutralization test (PRNT).", [["plaque", "ANATOMY", 220, 226], ["ZIKV infection", "DISEASE", 33, 47], ["microcephaly", "DISEASE", 52, 64], ["mouse", "ORGANISM", 17, 22], ["ZIKV", "ORGANISM", 33, 37], ["human", "ORGANISM", 117, 122], ["human mAbs", "PROTEIN", 117, 127], ["mouse", "SPECIES", 17, 22], ["human", "SPECIES", 117, 122], ["mouse", "SPECIES", 17, 22], ["ZIKV", "SPECIES", 33, 37], ["human", "SPECIES", 117, 122], ["ZIKV infection", "PROBLEM", 33, 47], ["microcephaly", "PROBLEM", 52, 64], ["plaque reduction neutralization test", "TEST", 220, 256], ["neutralization activity", "OBSERVATION", 180, 203]]], ["Our results offer compelling evidence that the in vivo protection is directly associated with in vitro neutralization.", [["neutralization", "OBSERVATION", 103, 117]]], ["One antibody, ZK2B10, provides complete protection in pre-exposure treatment and partial protection in post-exposure therapy, with markedly reduced tissue pathology.", [["tissue", "ANATOMY", 148, 154], ["ZK2B10", "CHEMICAL", 14, 20], ["ZK2B10", "SIMPLE_CHEMICAL", 14, 20], ["tissue", "TISSUE", 148, 154], ["ZK2B10", "PROTEIN", 14, 20], ["One antibody", "TEST", 0, 12], ["ZK2B10", "TREATMENT", 14, 20], ["pre-exposure treatment", "TREATMENT", 54, 76], ["partial protection", "TREATMENT", 81, 99], ["post-exposure therapy", "TREATMENT", 103, 124], ["markedly reduced tissue pathology", "PROBLEM", 131, 164], ["markedly", "OBSERVATION_MODIFIER", 131, 139], ["reduced tissue", "OBSERVATION_MODIFIER", 140, 154], ["pathology", "OBSERVATION", 155, 164]]], ["We believe that ZK2B10 is a promising candidate for the development of antibody-based interventions and informs vaccine design specific to ZIKV infection.RESULTSIn Vivo Protection Correlates with In Vitro Neutralizing Activity of mAbs We evaluated and compared the protective potential of six representative human mAbs following the protocol highlighted in Figure 1A .", [["ZK2B10", "CHEMICAL", 16, 22], ["infection", "DISEASE", 144, 153], ["ZK2B10", "GENE_OR_GENE_PRODUCT", 16, 22], ["ZIKV", "ORGANISM", 139, 143], ["human", "ORGANISM", 308, 313], ["mAbs", "CELL", 314, 318], ["mAbs", "PROTEIN", 230, 234], ["human mAbs", "PROTEIN", 308, 318], ["human", "SPECIES", 308, 313], ["ZIKV", "SPECIES", 139, 143], ["human", "SPECIES", 308, 313], ["ZK2B10", "TREATMENT", 16, 22], ["antibody-based interventions", "TREATMENT", 71, 99], ["vaccine", "TREATMENT", 112, 119], ["ZIKV infection", "PROBLEM", 139, 153], ["Vivo Protection", "TREATMENT", 164, 179], ["the protocol", "TREATMENT", 329, 341]]], ["All these (ZK8-4, ZK5-2, ZK22F6, ZK2C2, ZK7C3, and ZK2B10) were isolated by our team.", [["ZK8-4", "GENE_OR_GENE_PRODUCT", 11, 16], ["ZK5-2", "GENE_OR_GENE_PRODUCT", 18, 23], ["ZK22F6", "GENE_OR_GENE_PRODUCT", 25, 31], ["ZK2C2", "GENE_OR_GENE_PRODUCT", 33, 38], ["ZK7C3", "GENE_OR_GENE_PRODUCT", 40, 45], ["ZK2B10", "GENE_OR_GENE_PRODUCT", 51, 57], ["ZK22F6", "DNA", 25, 31], ["ZK2C2", "DNA", 33, 38], ["ZK7C3", "DNA", 40, 45], ["ZK2B10", "DNA", 51, 57], ["ZK8", "TEST", 11, 14], ["ZK5", "TEST", 18, 21], ["ZK22F6", "TEST", 25, 31], ["ZK2C2", "TEST", 33, 38], ["ZK7C3", "TREATMENT", 40, 45]]], ["Two additional ZIKV Domain III (DIII)-specific mAbs (ZV67 and Z006) isolated by others were included for comparative analysis (Robbiani et al., 2017; Zhao et al., 2016) .", [["ZIKV Domain III", "GENE_OR_GENE_PRODUCT", 15, 30], ["DIII", "GENE_OR_GENE_PRODUCT", 32, 36], ["ZIKV Domain III", "PROTEIN", 15, 30], ["DIII", "PROTEIN", 32, 36], ["mAbs", "PROTEIN", 47, 51], ["ZV67", "PROTEIN", 53, 57], ["Z006", "PROTEIN", 62, 66], ["specific mAbs", "TEST", 38, 51], ["comparative analysis", "TEST", 105, 125], ["ZIKV", "OBSERVATION", 15, 19]]], ["A human antibody, Middle East respiratory syndrome-4 (MERS-4), targeting the Middle East respiratory syndrome coronavirus (MERS-CoV), was used as a negative control.", [["respiratory syndrome coronavirus", "DISEASE", 89, 121], ["human", "ORGANISM", 2, 7], ["Middle East respiratory syndrome-4", "ORGANISM", 18, 52], ["MERS-4", "ORGANISM", 54, 60], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 77, 121], ["MERS-CoV", "ORGANISM", 123, 131], ["human antibody", "PROTEIN", 2, 16], ["human", "SPECIES", 2, 7], ["human", "SPECIES", 2, 7], ["Middle East respiratory syndrome-4", "SPECIES", 18, 52], ["Middle East respiratory syndrome coronavirus", "SPECIES", 77, 121], ["MERS-CoV", "SPECIES", 123, 131], ["A human antibody", "TEST", 0, 16], ["Middle East respiratory syndrome", "PROBLEM", 18, 50], ["MERS", "TEST", 54, 58], ["the Middle East respiratory syndrome coronavirus", "PROBLEM", 73, 121], ["Middle", "ANATOMY_MODIFIER", 18, 24], ["respiratory syndrome", "OBSERVATION", 30, 50], ["Middle", "ANATOMY_MODIFIER", 77, 83], ["respiratory syndrome", "OBSERVATION", 89, 109]]], ["Our mAbs were initially isolated from the peripheral B cells of a convalescent Chinese man who acquired ZIKV while traveling to Venezuela during the outbreak in 2016 .", [["peripheral B cells", "ANATOMY", 42, 60], ["mAbs", "GENE_OR_GENE_PRODUCT", 4, 8], ["peripheral B cells", "CELL", 42, 60], ["man", "ORGANISM", 87, 90], ["mAbs", "PROTEIN", 4, 8], ["peripheral B cells", "CELL_TYPE", 42, 60], ["man", "SPECIES", 87, 90], ["ZIKV", "SPECIES", 104, 108], ["Our mAbs", "TEST", 0, 8], ["ZIKV", "PROBLEM", 104, 108], ["peripheral B cells", "OBSERVATION", 42, 60]]], ["Specimens were derived from sequential blood samples collected on day 4 (ZK8-4), day 7 (ZK5-2), day 15 (ZK22F6), or day 106 (ZK2C2, ZK7C3, and ZK2B10) after symptom onset.", [["Specimens", "ANATOMY", 0, 9], ["blood samples", "ANATOMY", 39, 52], ["blood samples", "ORGANISM_SUBSTANCE", 39, 52], ["Specimens", "TEST", 0, 9], ["sequential blood samples", "TEST", 28, 52], ["ZK8", "TEST", 73, 76], ["ZK5", "TEST", 88, 91], ["ZK2C2", "TEST", 125, 130], ["ZK7C3", "TREATMENT", 132, 137], ["ZK2B10", "TREATMENT", 143, 149], ["symptom onset", "PROBLEM", 157, 170]]], ["They targeted the ZIKV E with varying degrees of binding and neutralizing activities and epitope specificities .", [["ZIKV E", "DNA", 18, 24], ["varying degrees of binding", "PROBLEM", 30, 56], ["neutralizing activities", "PROBLEM", 61, 84], ["epitope specificities", "PROBLEM", 89, 110]]], ["For example, ZK2B10 and ZK7C3 were strictly ZIKV specific and demonstrated the most potent neutralizing activities, as measured by PRNT.", [["ZK2B10", "GENE_OR_GENE_PRODUCT", 13, 19], ["ZK7C3", "GENE_OR_GENE_PRODUCT", 24, 29], ["ZK2B10", "PROTEIN", 13, 19], ["ZK7C3", "PROTEIN", 24, 29], ["PRNT", "PROTEIN", 131, 135], ["ZK2B10", "TREATMENT", 13, 19], ["ZK7C3", "TREATMENT", 24, 29], ["most potent", "OBSERVATION_MODIFIER", 79, 90], ["neutralizing activities", "OBSERVATION", 91, 114]]], ["Of these, ZK2B10 recognized DIII, while ZK7C3 was specific for Domain I/Domain II (DI/DII).", [["ZK2B10", "GENE_OR_GENE_PRODUCT", 10, 16], ["DIII", "GENE_OR_GENE_PRODUCT", 28, 32], ["ZK7C3", "GENE_OR_GENE_PRODUCT", 40, 45], ["Domain I/Domain II", "GENE_OR_GENE_PRODUCT", 63, 81], ["ZK2B10", "PROTEIN", 10, 16], ["DIII", "PROTEIN", 28, 32], ["ZK7C3", "PROTEIN", 40, 45], ["Domain I", "PROTEIN", 63, 71], ["Domain II", "PROTEIN", 72, 81], ["DI", "PROTEIN", 83, 85], ["DII", "PROTEIN", 86, 89], ["Domain I/Domain II (DI/DII)", "PROBLEM", 63, 90]]], ["In comparison, ZK8-4, ZK5-2, ZK22F6, and ZK2C2 were much less potent against ZIKV but cross-neutralized other members of the flavivirus family, such as dengue virus serotypes DENV1 and DENV2.", [["dengue", "DISEASE", 152, 158], ["ZK8-4", "GENE_OR_GENE_PRODUCT", 15, 20], ["ZK5-2", "GENE_OR_GENE_PRODUCT", 22, 27], ["ZK22F6", "GENE_OR_GENE_PRODUCT", 29, 35], ["ZK2C2", "GENE_OR_GENE_PRODUCT", 41, 46], ["ZIKV", "ORGANISM", 77, 81], ["dengue virus serotypes DENV1", "ORGANISM", 152, 180], ["DENV2", "ORGANISM", 185, 190], ["dengue virus", "SPECIES", 152, 164], ["ZIKV", "SPECIES", 77, 81], ["dengue virus", "SPECIES", 152, 164], ["DENV2", "SPECIES", 185, 190], ["ZK8", "TEST", 15, 18], ["ZK5", "TEST", 22, 25], ["ZK22F6", "TEST", 29, 35], ["ZK2C2", "TEST", 41, 46], ["ZIKV", "PROBLEM", 77, 81], ["dengue virus serotypes", "PROBLEM", 152, 174], ["DENV2", "PROBLEM", 185, 190]]], ["On the ZIKV envelope, they targeted either DI/DII (ZK8-4, ZK5-2, and ZK22F6) or DI/DII/DIII (ZK2C2).", [["DII", "GENE_OR_GENE_PRODUCT", 46, 49], ["ZK8-4", "GENE_OR_GENE_PRODUCT", 51, 56], ["ZK5-2", "GENE_OR_GENE_PRODUCT", 58, 63], ["ZK22F6", "GENE_OR_GENE_PRODUCT", 69, 75], ["DII", "GENE_OR_GENE_PRODUCT", 83, 86], ["DIII", "GENE_OR_GENE_PRODUCT", 87, 91], ["ZK2C2", "GENE_OR_GENE_PRODUCT", 93, 98], ["DII", "PROTEIN", 46, 49], ["ZK8", "PROTEIN", 51, 54], ["ZK5", "PROTEIN", 58, 61], ["ZK22F6", "DNA", 69, 75], ["DI", "DNA", 80, 82], ["DII", "DNA", 83, 86], ["DIII", "DNA", 87, 91], ["ZK2C2", "DNA", 93, 98], ["ZK8", "TEST", 51, 54], ["ZK5", "TEST", 58, 61]]], ["In terms of genetic analyses, these antibodies demonstrated diverse heavy-chain variable regions.", [["antibodies", "PROTEIN", 36, 46], ["heavy-chain variable regions", "PROTEIN", 68, 96], ["genetic analyses", "TEST", 12, 28], ["these antibodies", "TEST", 30, 46], ["diverse heavy-chain variable regions", "PROBLEM", 60, 96], ["diverse", "OBSERVATION_MODIFIER", 60, 67], ["heavy", "OBSERVATION", 68, 73]]], ["Two, ZK8-4 and ZK22F6, fell into the immunoglobulinheavy variable (IGHV)4-39 family, while ZK5-2 and ZK7C3 belonged to the IGHV3-23 family.", [["ZK8-4", "GENE_OR_GENE_PRODUCT", 5, 10], ["ZK22F6", "GENE_OR_GENE_PRODUCT", 15, 21], ["immunoglobulinheavy variable (IGHV)4-39", "GENE_OR_GENE_PRODUCT", 37, 76], ["ZK5-2", "GENE_OR_GENE_PRODUCT", 91, 96], ["ZK7C3", "GENE_OR_GENE_PRODUCT", 101, 106], ["IGHV3-23", "GENE_OR_GENE_PRODUCT", 123, 131], ["ZK8", "PROTEIN", 5, 8], ["ZK22F6", "DNA", 15, 21], ["immunoglobulinheavy variable (IGHV)4-39 family", "DNA", 37, 83], ["ZK5-2", "DNA", 91, 96], ["ZK7C3", "DNA", 101, 106], ["IGHV3-23 family", "PROTEIN", 123, 138], ["ZK8", "TEST", 5, 8], ["ZK22F6", "TEST", 15, 21], ["ZK5", "TEST", 91, 94], ["ZK7C3", "TREATMENT", 101, 106]]], ["Finally, ZK2B10 and ZK2C2 belonged to the IGHV1-8 and IGHV3-30 families, respectively.RESULTSTo test prophylactic activity against ZIKV infection, 5 mg/kg of each mAb was administered intraperitoneally to a group of three pregnant mice on embryonic day 14.5 ( Figure 1A ).", [["embryonic", "ANATOMY", 239, 248], ["ZIKV infection", "DISEASE", 131, 145], ["ZK2B10", "GENE_OR_GENE_PRODUCT", 9, 15], ["ZK2C2", "GENE_OR_GENE_PRODUCT", 20, 25], ["IGHV1-8", "GENE_OR_GENE_PRODUCT", 42, 49], ["ZIKV", "ORGANISM", 131, 135], ["mAb", "GENE_OR_GENE_PRODUCT", 163, 166], ["mice", "ORGANISM", 231, 235], ["ZK2B10", "PROTEIN", 9, 15], ["ZK2C2", "PROTEIN", 20, 25], ["IGHV1-8 and IGHV3-30 families", "DNA", 42, 71], ["mAb", "PROTEIN", 163, 166], ["mice", "SPECIES", 231, 235], ["ZIKV", "SPECIES", 131, 135], ["mice", "SPECIES", 231, 235], ["ZK2B10", "TREATMENT", 9, 15], ["ZK2C2", "TREATMENT", 20, 25], ["RESULTSTo test", "TEST", 86, 100], ["ZIKV infection", "PROBLEM", 131, 145], ["each mAb", "TREATMENT", 158, 166]]], ["The following day (E15.5), the developing littermate fetuses in each pregnant mouse were either left untouched (ZIKV \u00c0 ; Figure 1A , blue) or inoculated with 350 plaque-forming units (PFUs) of ZIKV Asian strain GZ01 directly into the lateral ventricles of the brain (ZIKV + ; Figure 1A , red).", [["fetuses", "ANATOMY", 53, 60], ["plaque", "ANATOMY", 162, 168], ["lateral ventricles", "ANATOMY", 234, 252], ["brain", "ANATOMY", 260, 265], ["littermate fetuses", "ORGAN", 42, 60], ["mouse", "ORGANISM", 78, 83], ["lateral ventricles", "MULTI-TISSUE_STRUCTURE", 234, 252], ["brain", "ORGAN", 260, 265], ["mouse", "SPECIES", 78, 83], ["mouse", "SPECIES", 78, 83], ["ZIKV Asian strain GZ01", "SPECIES", 193, 215], ["littermate fetuses", "PROBLEM", 42, 60], ["ZIKV Asian strain GZ01", "PROBLEM", 193, 215], ["littermate fetuses", "OBSERVATION", 42, 60], ["left", "ANATOMY_MODIFIER", 96, 100], ["lateral", "ANATOMY_MODIFIER", 234, 241], ["ventricles", "ANATOMY", 242, 252], ["brain", "ANATOMY", 260, 265]]], ["The neonates were closely monitored after delivery and analyzed for a complementary set of clinical, virological, and neuropathological outcomes on post-natal day (P)3 and for survival up to P28.", [["neonates", "ORGANISM", 4, 12], ["delivery", "TREATMENT", 42, 50], ["survival", "TREATMENT", 176, 184]]], ["As shown in Figure 1B , the levels of protection conferred by the different mAbs varied considerably but clearly correlated with their neutralizing activities, as measured by half-maximal inhibitory concentrations (ICs 50 ) in the PRNT .", [["mAbs", "PROTEIN", 76, 80], ["PRNT", "PROTEIN", 231, 235], ["protection", "TREATMENT", 38, 48], ["ICs", "TEST", 215, 218]]], ["The most potently neutralizing mAb, ZK2B10, conferred complete protection.", [["ZK2B10", "CHEMICAL", 36, 42], ["ZK2B10", "SIMPLE_CHEMICAL", 36, 42], ["neutralizing mAb", "PROTEIN", 18, 34], ["ZK2B10", "PROTEIN", 36, 42], ["neutralizing mAb", "TREATMENT", 18, 34], ["ZK2B10", "TREATMENT", 36, 42]]], ["Survival rates of infected fetuses were as high as 100% on P28.", [["fetuses", "ANATOMY", 27, 34], ["fetuses", "ORGANISM", 27, 34], ["infected fetuses", "PROBLEM", 18, 34], ["infected fetuses", "OBSERVATION", 18, 34], ["high", "OBSERVATION_MODIFIER", 43, 47]]], ["The next potent, ZK7C3, however, conferred only partial protection with median survival of 16 days.", [["ZK7C3", "CHEMICAL", 17, 22], ["ZK7C3", "SIMPLE_CHEMICAL", 17, 22], ["ZK7C3", "TREATMENT", 17, 22], ["median survival", "TREATMENT", 72, 87]]], ["The two antibodies (ZV67 and Z006) isolated by others, together with the rest of the mAbs isolated by us, offered negligible protection and were virtually similar to the isotype control MERS-4.", [["antibodies", "PROTEIN", 8, 18], ["ZV67", "PROTEIN", 20, 24], ["Z006", "PROTEIN", 29, 33], ["mAbs", "PROTEIN", 85, 89], ["isotype control MERS-4", "PROTEIN", 170, 192], ["The two antibodies", "TEST", 0, 18], ["ZV67", "TEST", 20, 24], ["the mAbs", "TREATMENT", 81, 89]]], ["We also assessed impact on developing body weights and found weights measured on P3 closely correlated with the neutralizing activity.", [["body", "ANATOMY", 38, 42], ["body", "ORGANISM_SUBDIVISION", 38, 42], ["developing body weights", "PROBLEM", 27, 50], ["weights", "TEST", 61, 68], ["neutralizing activity", "OBSERVATION", 112, 133]]], ["The ZIKV + neonates treated with the most potent mAbs, ZK2B10 and ZK7C3, had weight gain similar to that of their ZIKV \u00c0 littermates.", [["weight gain", "DISEASE", 77, 88], ["ZIKV + neonates", "ORGANISM", 4, 19], ["mAbs", "GENE_OR_GENE_PRODUCT", 49, 53], ["ZK2B10", "GENE_OR_GENE_PRODUCT", 55, 61], ["ZK7C3", "GENE_OR_GENE_PRODUCT", 66, 71], ["ZIKV \u00c0 littermates", "ORGANISM", 114, 132], ["mAbs", "PROTEIN", 49, 53], ["ZK2B10", "PROTEIN", 55, 61], ["ZK7C3", "PROTEIN", 66, 71], ["the most potent mAbs", "TREATMENT", 33, 53], ["ZK2B10", "TREATMENT", 55, 61], ["ZK7C3", "TREATMENT", 66, 71], ["weight gain", "PROBLEM", 77, 88], ["ZIKV", "OBSERVATION", 4, 8], ["neonates", "OBSERVATION", 11, 19]]], ["The ZIKV + neonates treated with ZV67, Z006, and the remaining mAbs failed to do so.", [["ZV67", "CHEMICAL", 33, 37], ["Z006", "CHEMICAL", 39, 43], ["neonates", "ORGANISM", 11, 19], ["mAbs", "PROTEIN", 63, 67], ["ZV67", "TREATMENT", 33, 37], ["Z006", "TREATMENT", 39, 43], ["the remaining mAbs", "TREATMENT", 49, 67], ["ZIKV", "OBSERVATION", 4, 8], ["neonates", "OBSERVATION", 11, 19]]], ["The control ZIKV + MERS-4 group had the greatest loss in body weight.RESULTSNext, we studied whether the protection pattern observed in the pregnant mice also occurred in non-pregnant mice.", [["body", "ANATOMY", 57, 61], ["MERS-4", "CELL", 19, 25], ["body", "ORGANISM_SUBDIVISION", 57, 61], ["mice", "ORGANISM", 149, 153], ["mice", "ORGANISM", 184, 188], ["mice", "SPECIES", 149, 153], ["mice", "SPECIES", 184, 188], ["mice", "SPECIES", 149, 153], ["mice", "SPECIES", 184, 188], ["the greatest loss in body weight", "PROBLEM", 36, 68], ["greatest", "OBSERVATION_MODIFIER", 40, 48], ["loss", "OBSERVATION", 49, 53]]], ["We administered 300 mg of each mAb (ZK8-4, ZK5-2, ZK22F6, ZK2C2, ZK7C3, ZK2B10, ZV67, and Z006) or isotype control MERS-4 to a group of four 4-to 6-week-old AG6 mice via the intraperitoneal (i.p.) route.", [["intraperitoneal", "ANATOMY", 174, 189], ["ZK5-2", "CELL", 43, 48], ["ZK22F6", "SIMPLE_CHEMICAL", 50, 56], ["ZK2C2", "SIMPLE_CHEMICAL", 58, 63], ["ZV67", "CELL", 80, 84], ["Z006", "CELL", 90, 94], ["AG6", "ORGANISM", 157, 160], ["mice", "ORGANISM", 161, 165], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 174, 189], ["mice", "SPECIES", 161, 165], ["mice", "SPECIES", 161, 165], ["each mAb", "TREATMENT", 26, 34], ["ZK8", "TEST", 36, 39], ["ZK5", "TREATMENT", 43, 46], ["ZK22F6", "TREATMENT", 50, 56], ["ZK2C2", "TREATMENT", 58, 63], ["ZK7C3", "TREATMENT", 65, 70], ["ZK2B10", "TREATMENT", 72, 78], ["ZV67", "TREATMENT", 80, 84], ["Z006", "TREATMENT", 90, 94], ["isotype control MERS", "TREATMENT", 99, 119], ["intraperitoneal", "ANATOMY", 174, 189]]], ["The following day, animals were challenged with 10 4 PFUs of ZIKV Asian strain GZ01 via the i.p. route.", [["GZ01", "CHEMICAL", 79, 83], ["animals", "ORGANISM", 19, 26], ["GZ01", "SIMPLE_CHEMICAL", 79, 83], ["ZIKV Asian strain GZ01", "SPECIES", 61, 83], ["ZIKV Asian strain GZ01", "TREATMENT", 61, 83]]], ["Survival rates, body weight, and viral RNA copies in the blood were monitored for up to 14 days ( Figure 1D ).", [["body", "ANATOMY", 16, 20], ["blood", "ANATOMY", 57, 62], ["body", "ORGANISM_SUBDIVISION", 16, 20], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["viral RNA", "RNA", 33, 42], ["Survival rates", "TEST", 0, 14], ["body weight", "TEST", 16, 27], ["viral RNA copies", "PROBLEM", 33, 49], ["the blood", "TEST", 53, 62], ["viral RNA", "OBSERVATION", 33, 42]]], ["Consistent with the outcomes for pregnant mice, the level of protection in nonpregnant mice correlated with antibody neutralizing activities as measured by half-maximal inhibitory concentrations (ICs 50 ) in the PRNT ( Figure 1E ).", [["mice", "ORGANISM", 42, 46], ["mice", "ORGANISM", 87, 91], ["mice", "SPECIES", 42, 46], ["mice", "SPECIES", 87, 91], ["mice", "SPECIES", 42, 46], ["mice", "SPECIES", 87, 91], ["pregnant mice", "TREATMENT", 33, 46], ["antibody neutralizing activities", "TREATMENT", 108, 140], ["ICs", "TEST", 196, 199]]], ["For example, the most potent and protective mAb in pregnant mice, ZK2B10, provided complete protection in non-pregnant mice, with survival rates of 100% 14 days after the challenge.", [["ZK2B10", "CHEMICAL", 66, 72], ["mAb", "GENE_OR_GENE_PRODUCT", 44, 47], ["mice", "ORGANISM", 60, 64], ["ZK2B10", "CELL", 66, 72], ["mice", "ORGANISM", 119, 123], ["protective mAb", "PROTEIN", 33, 47], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 119, 123], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 119, 123], ["protective mAb", "TREATMENT", 33, 47], ["ZK2B10", "TREATMENT", 66, 72], ["survival rates", "TEST", 130, 144], ["most potent", "OBSERVATION_MODIFIER", 17, 28]]], ["The next potent and protective, ZK7C3, conferred only partial protection, with median survival of 13 days.", [["ZK7C3", "CHEMICAL", 32, 37], ["ZK7C3", "SIMPLE_CHEMICAL", 32, 37], ["ZK7C3", "TREATMENT", 32, 37]]], ["The rest of the tested mAbs, including the DIII-specific ones (ZV67 and Z006) isolated by others (Robbiani et al., 2017; Zhao et al., 2016) , offered even lower levels of protection.", [["mAbs", "GENE_OR_GENE_PRODUCT", 23, 27], ["DIII", "GENE_OR_GENE_PRODUCT", 43, 47], ["mAbs", "PROTEIN", 23, 27], ["DIII", "PROTEIN", 43, 47], ["the tested mAbs", "TEST", 12, 27]]], ["ZK8-4 was virtually identical to the isotype control MERS-4.RESULTS(D-G) Shown here: (D) timeline for mAb injection, ZIKV inoculation, and monitoring for (E) survival, (F) body weight, and (G) blood ZIKV RNA up to 14 days in AG6 mice.", [["body", "ANATOMY", 172, 176], ["blood", "ANATOMY", 193, 198], ["ZIKV", "CHEMICAL", 117, 121], ["ZK8-4", "GENE_OR_GENE_PRODUCT", 0, 5], ["MERS-4", "GENE_OR_GENE_PRODUCT", 53, 59], ["mAb", "GENE_OR_GENE_PRODUCT", 102, 105], ["body", "ORGANISM_SUBDIVISION", 172, 176], ["blood", "ORGANISM_SUBSTANCE", 193, 198], ["mice", "ORGANISM", 229, 233], ["ZK8-4", "DNA", 0, 5], ["isotype control MERS-4", "DNA", 37, 59], ["mAb", "PROTEIN", 102, 105], ["ZIKV RNA", "RNA", 199, 207], ["mice", "SPECIES", 229, 233], ["ZIKV", "SPECIES", 117, 121], ["mice", "SPECIES", 229, 233], ["ZK8", "TEST", 0, 3], ["mAb injection", "TREATMENT", 102, 115], ["ZIKV inoculation", "TREATMENT", 117, 133], ["body weight", "TEST", 172, 183]]], ["The body weight and ZIKV RNA in the whole blood derived from a single measurement showed distinct results among the study groups.", [["body", "ANATOMY", 4, 8], ["whole blood", "ANATOMY", 36, 47], ["body", "ORGANISM_SUBDIVISION", 4, 8], ["blood", "ORGANISM_SUBSTANCE", 42, 47], ["ZIKV RNA", "RNA", 20, 28], ["ZIKV", "SPECIES", 20, 24], ["The body weight", "TEST", 0, 15], ["ZIKV RNA", "TEST", 20, 28], ["a single measurement", "TEST", 61, 81], ["body", "ANATOMY_MODIFIER", 4, 8], ["ZIKV RNA", "OBSERVATION", 20, 28]]], ["All data are presented as mean \u00b1 SEM. p < 0.001; ns, no significant.RESULTSSimilarly, changes in body weight measured over the 14-day follow-up also correlated with the neutralizing activities.", [["body", "ANATOMY", 97, 101], ["body", "ORGANISM_SUBDIVISION", 97, 101], ["All data", "TEST", 0, 8], ["ns", "TREATMENT", 49, 51], ["body weight", "TEST", 97, 108], ["no", "UNCERTAINTY", 53, 55], ["significant", "OBSERVATION_MODIFIER", 56, 67], ["body", "OBSERVATION_MODIFIER", 97, 101]]], ["The ZIKV + mice treated with ZK2B10 maintained relatively stable body weight throughout the study, although there was a noticeable decline after the first blood sample collection on day 5 (Figure 1F ).", [["body", "ANATOMY", 65, 69], ["blood sample", "ANATOMY", 155, 167], ["ZK2B10", "CHEMICAL", 29, 35], ["ZK2B10", "CHEMICAL", 29, 35], ["ZIKV + mice", "ORGANISM", 4, 15], ["ZK2B10", "SIMPLE_CHEMICAL", 29, 35], ["body", "ORGANISM_SUBDIVISION", 65, 69], ["blood", "ORGANISM_SUBSTANCE", 155, 160], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 11, 15], ["ZK2B10", "TREATMENT", 29, 35], ["the study", "TEST", 88, 97], ["a noticeable decline", "PROBLEM", 118, 138], ["the first blood sample collection", "PROBLEM", 145, 178], ["stable", "OBSERVATION", 58, 64], ["noticeable", "OBSERVATION_MODIFIER", 120, 130], ["decline", "OBSERVATION", 131, 138]]], ["In contrast, ZIKV + mice treated with ZK7C3 lost substantial body weight beginning on day 9 post-challenge.", [["body", "ANATOMY", 61, 65], ["ZK7C3", "CHEMICAL", 38, 43], ["ZIKV + mice", "ORGANISM", 13, 24], ["ZK7C3", "GENE_OR_GENE_PRODUCT", 38, 43], ["body", "ORGANISM_SUBDIVISION", 61, 65], ["ZIKV", "PROTEIN", 13, 17], ["mice", "SPECIES", 20, 24], ["ZIKV", "SPECIES", 13, 17], ["mice", "SPECIES", 20, 24], ["ZK7C3", "TREATMENT", 38, 43]]], ["Animals treated with the remaining mAbs had severe and rapid losses in body weight that coincided with a clinical deterioration (Figure 1E) .", [["body", "ANATOMY", 71, 75], ["Animals", "ORGANISM", 0, 7], ["body", "ORGANISM_SUBDIVISION", 71, 75], ["mAbs", "PROTEIN", 35, 39], ["severe and rapid losses in body weight", "PROBLEM", 44, 82], ["a clinical deterioration", "PROBLEM", 103, 127], ["severe", "OBSERVATION_MODIFIER", 44, 50], ["rapid", "OBSERVATION_MODIFIER", 55, 60], ["losses", "OBSERVATION", 61, 67]]], ["Lastly, for ZIKV + mice treated with ZK2B10, blood levels of viral RNA were indistinguishable from those measured in uninfected animals on both day 5 (2.23 \u00b1 0.16 versus 2.54 \u00b1 0.13) and day 13 (2.88 \u00b1 0.34 versus 2.65 \u00b1 0.13) after challenge ( Figure 1G ).", [["blood", "ANATOMY", 45, 50], ["ZIKV + mice", "ORGANISM", 12, 23], ["ZK2B10", "GENE_OR_GENE_PRODUCT", 37, 43], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["ZIKV", "PROTEIN", 12, 16], ["viral RNA", "RNA", 61, 70], ["mice", "SPECIES", 19, 23], ["ZIKV", "SPECIES", 12, 16], ["mice", "SPECIES", 19, 23], ["ZIKV", "PROBLEM", 12, 16], ["ZK2B10", "TREATMENT", 37, 43], ["blood levels", "TEST", 45, 57], ["viral RNA", "PROBLEM", 61, 70], ["viral RNA", "OBSERVATION", 61, 70]]], ["However, RNA levels measured in ZK7C3-treated mice were, on average, 1 log greater on day 5 (3.29 \u00b1 0.17 versus 2.23 \u00b1 0.16) and more than 3 logs greater on day 13 (6.30 \u00b1 0.06 versus 2.88 \u00b1 0.34), compared to ZK2B10.", [["ZK7C3", "CHEMICAL", 32, 37], ["ZK7C3", "SIMPLE_CHEMICAL", 32, 37], ["mice", "ORGANISM", 46, 50], ["ZK7C3", "PROTEIN", 32, 37], ["ZK2B10", "PROTEIN", 210, 216], ["mice", "SPECIES", 46, 50], ["mice", "SPECIES", 46, 50], ["RNA levels", "TEST", 9, 19], ["ZK7C3", "TEST", 32, 37]]], ["The remaining mAbs failed to suppress viral replication.", [["mAbs", "GENE_OR_GENE_PRODUCT", 14, 18], ["mAbs", "PROTEIN", 14, 18], ["The remaining mAbs", "TREATMENT", 0, 18], ["viral replication", "TREATMENT", 38, 55]]], ["The measured ZIKV RNA load on day 5 ranged from 3.82 to 5.16 logs higher than that of ZK2B10, depending on the mAb used ( Figure 1G ).", [["ZIKV RNA", "RNA", 13, 21], ["mAb", "PROTEIN", 111, 114], ["ZIKV", "SPECIES", 13, 17], ["The measured ZIKV RNA load", "TEST", 0, 26], ["ZK2B10", "TREATMENT", 86, 92], ["the mAb", "TREATMENT", 107, 114], ["ZIKV", "OBSERVATION", 13, 17]]], ["Taken together, these results demonstrated that the protective patterns of each mAb were similar in both pregnant and non-pregnant mice and closely mirrored their respective in vitro neutralizing activities.Marked Improvement in Virological and Neuropathological Outcomes in the Protected AnimalsThe protective effects of each mAb on body weight and overall survival mirrored their respective virological and neuropathological outcomes in treated mice.", [["body", "ANATOMY", 334, 338], ["mAb", "GENE_OR_GENE_PRODUCT", 80, 83], ["mice", "ORGANISM", 131, 135], ["body", "ORGANISM_SUBDIVISION", 334, 338], ["mice", "ORGANISM", 447, 451], ["mAb", "PROTEIN", 80, 83], ["mAb", "PROTEIN", 327, 330], ["mice", "SPECIES", 131, 135], ["mice", "SPECIES", 447, 451], ["mice", "SPECIES", 131, 135], ["mice", "SPECIES", 447, 451], ["each mAb", "TREATMENT", 75, 83], ["each mAb on body weight", "TREATMENT", 322, 345], ["neutralizing activities", "OBSERVATION", 183, 206], ["Improvement", "OBSERVATION_MODIFIER", 214, 225], ["Virological", "OBSERVATION_MODIFIER", 229, 240]]], ["For instance, RNA loads measured in ZIKV + neonates treated with ZK2B10 were suppressed in the blood (2.16 \u00b1 0.12 log 10 copies per milliliter) and the brain (2.18 \u00b1 0.20 log 10 copies per gram) to levels indistinguishable from those in ZIKV \u00c0 littermates.", [["blood", "ANATOMY", 95, 100], ["brain", "ANATOMY", 152, 157], ["ZK2B10", "CHEMICAL", 65, 71], ["ZIKV + neonates", "ORGANISM", 36, 51], ["ZK2B10", "GENE_OR_GENE_PRODUCT", 65, 71], ["blood", "ORGANISM_SUBSTANCE", 95, 100], ["brain", "ORGAN", 152, 157], ["ZIKV \u00c0 littermates", "ORGANISM", 237, 255], ["ZIKV", "SPECIES", 36, 40], ["ZIKV", "SPECIES", 237, 241], ["RNA loads", "TEST", 14, 23], ["ZIKV + neonates", "PROBLEM", 36, 51], ["ZK2B10", "TREATMENT", 65, 71], ["RNA loads", "OBSERVATION", 14, 23], ["brain", "ANATOMY", 152, 157]]], ["In fact, ZK2B10 was able to reduce the ZIKV RNA by 3.77 logs in the blood and 6.86 logs in the brain, relative to that in the ZIKV + MERS-4 group (Figures 2A and 2B ).", [["blood", "ANATOMY", 68, 73], ["brain", "ANATOMY", 95, 100], ["ZK2B10", "CHEMICAL", 9, 15], ["ZK2B10", "CHEMICAL", 9, 15], ["ZK2B10", "GENE_OR_GENE_PRODUCT", 9, 15], ["ZIKV", "GENE_OR_GENE_PRODUCT", 39, 43], ["blood", "ORGANISM_SUBSTANCE", 68, 73], ["brain", "ORGAN", 95, 100], ["ZIKV RNA", "RNA", 39, 47], ["ZIKV", "SPECIES", 39, 43], ["ZK2B10", "TREATMENT", 9, 15], ["the ZIKV RNA", "PROBLEM", 35, 47], ["the blood", "TEST", 64, 73], ["blood", "ANATOMY", 68, 73], ["brain", "ANATOMY", 95, 100]]], ["In comparison, ZK7C3 was equally effective at suppressing replication in blood (2.18 \u00b1 0.12 log 10 copies per milliliter) but only moderately protective in the brain (6.41 \u00b1 0.28 log 10 copies per gram).", [["blood", "ANATOMY", 73, 78], ["brain", "ANATOMY", 160, 165], ["ZK7C3", "CHEMICAL", 15, 20], ["ZK7C3", "CHEMICAL", 15, 20], ["ZK7C3", "SIMPLE_CHEMICAL", 15, 20], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["brain", "ORGAN", 160, 165], ["ZK7C3", "TREATMENT", 15, 20], ["blood", "TEST", 73, 78], ["moderately protective in the brain", "PROBLEM", 131, 165], ["moderately", "OBSERVATION_MODIFIER", 131, 141], ["protective", "OBSERVATION", 142, 152], ["brain", "ANATOMY", 160, 165]]], ["The mAbs ZV67 and Z006 only moderately suppressed ZIKV replication in the blood (5.53 \u00b1 0.14 and 5.53 \u00b1 0.17 log 10 copies per milliliter, respectively) and the brain (8.09 \u00b1 0.09 and 8.25 \u00b1 0.08 log 10 copies per gram, respectively).", [["ZIKV", "ANATOMY", 50, 54], ["blood", "ANATOMY", 74, 79], ["brain", "ANATOMY", 161, 166], ["ZV67", "CHEMICAL", 9, 13], ["Z006", "CHEMICAL", 18, 22], ["Z006", "SIMPLE_CHEMICAL", 18, 22], ["ZIKV", "GENE_OR_GENE_PRODUCT", 50, 54], ["blood", "ORGANISM_SUBSTANCE", 74, 79], ["brain", "ORGAN", 161, 166], ["mAbs", "PROTEIN", 4, 8], ["ZIKV", "SPECIES", 50, 54], ["The mAbs ZV67", "TEST", 0, 13], ["Z006", "TREATMENT", 18, 22], ["moderately suppressed ZIKV replication", "PROBLEM", 28, 66], ["the brain", "TEST", 157, 166], ["moderately", "OBSERVATION_MODIFIER", 28, 38], ["suppressed", "OBSERVATION_MODIFIER", 39, 49], ["ZIKV", "OBSERVATION", 50, 54], ["brain", "ANATOMY", 161, 166]]], ["None of the remaining mAbs notably suppressed replication in either blood or brain tissue.", [["blood", "ANATOMY", 68, 73], ["brain tissue", "ANATOMY", 77, 89], ["mAbs", "GENE_OR_GENE_PRODUCT", 22, 26], ["blood", "ORGANISM_SUBSTANCE", 68, 73], ["brain tissue", "TISSUE", 77, 89], ["mAbs", "PROTEIN", 22, 26], ["either blood or brain tissue", "PROBLEM", 61, 89], ["suppressed", "OBSERVATION_MODIFIER", 35, 45], ["replication", "OBSERVATION", 46, 57], ["blood", "ANATOMY", 68, 73], ["brain tissue", "ANATOMY", 77, 89]]], ["All of the ZIKV + neonates treated with these mAbs had high levels of ZIKV RNA, which were similar to levels in the ZIKV + MERS-4 control group and significantly higher than those in their ZIKV \u00c0 littermates (Figures 2A and 2B ).", [["ZIKV + neonates", "ORGANISM", 11, 26], ["mAbs", "GENE_OR_GENE_PRODUCT", 46, 50], ["ZIKV", "GENE_OR_GENE_PRODUCT", 70, 74], ["ZIKV + MERS-4 control", "ORGANISM", 116, 137], ["ZIKV \u00c0 littermates", "ORGANISM", 189, 207], ["mAbs", "PROTEIN", 46, 50], ["ZIKV RNA", "RNA", 70, 78], ["ZIKV", "SPECIES", 11, 15], ["ZIKV", "SPECIES", 70, 74], ["these mAbs", "TREATMENT", 40, 50], ["high levels of ZIKV RNA", "PROBLEM", 55, 78], ["ZIKV", "OBSERVATION", 11, 15], ["ZIKV RNA", "OBSERVATION", 70, 78]]], ["Importantly, low levels of ZIKV RNA were associated with the healthier development of the neonatal brains.", [["brains", "ANATOMY", 99, 105], ["ZIKV", "GENE_OR_GENE_PRODUCT", 27, 31], ["brains", "ORGAN", 99, 105], ["ZIKV RNA", "RNA", 27, 35], ["ZIKV", "SPECIES", 27, 31], ["low levels of ZIKV RNA", "PROBLEM", 13, 35], ["low levels", "OBSERVATION_MODIFIER", 13, 23], ["ZIKV RNA", "OBSERVATION", 27, 35], ["neonatal brains", "ANATOMY", 90, 105]]], ["Of the six representative mAbs selected for in-depth neuropathological study, ZIKV + mice treated with either ZK2B10 or ZK7C3 maintained normal brain growth and structure.", [["brain", "ANATOMY", 144, 149], ["ZK2B10", "CHEMICAL", 110, 116], ["ZK7C3", "CHEMICAL", 120, 125], ["mAbs", "GENE_OR_GENE_PRODUCT", 26, 30], ["ZIKV", "ORGANISM", 78, 82], ["mice", "ORGANISM", 85, 89], ["ZK2B10", "GENE_OR_GENE_PRODUCT", 110, 116], ["ZK7C3", "GENE_OR_GENE_PRODUCT", 120, 125], ["brain", "ORGAN", 144, 149], ["mAbs", "PROTEIN", 26, 30], ["ZK7C3", "PROTEIN", 120, 125], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 85, 89], ["neuropathological study", "TEST", 53, 76], ["ZK2B10", "TREATMENT", 110, 116], ["ZK7C3", "TREATMENT", 120, 125], ["normal", "OBSERVATION", 137, 143], ["brain", "ANATOMY", 144, 149], ["growth", "OBSERVATION_MODIFIER", 150, 156]]], ["There were no notable differences in cerebral size, cortical thickness, or lateral ventricle area between these ZIKV + neonates and their ZIKV \u00c0 littermates ( Figures 2D-2H ).", [["cerebral", "ANATOMY", 37, 45], ["cortical", "ANATOMY", 52, 60], ["lateral ventricle area", "ANATOMY", 75, 97], ["cerebral", "ORGAN", 37, 45], ["cortical", "TISSUE", 52, 60], ["lateral ventricle", "MULTI-TISSUE_STRUCTURE", 75, 92], ["ZIKV \u00c0 littermates", "ORGANISM", 138, 156], ["notable differences in cerebral size", "PROBLEM", 14, 50], ["cortical thickness, or lateral ventricle area", "PROBLEM", 52, 97], ["no", "UNCERTAINTY", 11, 13], ["notable", "OBSERVATION_MODIFIER", 14, 21], ["differences", "OBSERVATION_MODIFIER", 22, 33], ["cerebral", "ANATOMY", 37, 45], ["size", "OBSERVATION_MODIFIER", 46, 50], ["cortical thickness", "OBSERVATION", 52, 70], ["lateral ventricle", "ANATOMY", 75, 92], ["area", "ANATOMY_MODIFIER", 93, 97], ["ZIKV", "OBSERVATION", 112, 116]]], ["However, ZIKV + mice treated with ZV67 and Z006 received only moderate protection, while ZK22F6 and MERS-4 failed to provide any protection.", [["ZV67", "CHEMICAL", 34, 38], ["Z006", "CHEMICAL", 43, 47], ["MERS-4", "CHEMICAL", 100, 106], ["ZV67", "CHEMICAL", 34, 38], ["Z006", "CHEMICAL", 43, 47], ["ZIKV + mice", "ORGANISM", 9, 20], ["Z006", "SIMPLE_CHEMICAL", 43, 47], ["MERS-4", "CELL", 100, 106], ["ZIKV", "PROTEIN", 9, 13], ["mice", "SPECIES", 16, 20], ["ZIKV", "SPECIES", 9, 13], ["mice", "SPECIES", 16, 20], ["ZV67", "TREATMENT", 34, 38], ["Z006", "TREATMENT", 43, 47], ["moderate", "OBSERVATION_MODIFIER", 62, 70]]], ["Low protection was measured by reduced cerebral size, thinner cortices, and enlarged lateral ventricles in ZIKV + neonates compared to their ZIKV \u00c0 littermates ( Figures 2D-2H ).", [["cerebral", "ANATOMY", 39, 47], ["cortices", "ANATOMY", 62, 70], ["lateral ventricles", "ANATOMY", 85, 103], ["cerebral", "ORGAN", 39, 47], ["cortices", "MULTI-TISSUE_STRUCTURE", 62, 70], ["lateral ventricles", "MULTI-TISSUE_STRUCTURE", 85, 103], ["ZIKV \u00c0 littermates", "ORGANISM", 141, 159], ["Low protection", "TREATMENT", 0, 14], ["reduced cerebral size, thinner cortices", "PROBLEM", 31, 70], ["enlarged lateral ventricles in ZIKV + neonates", "PROBLEM", 76, 122], ["reduced", "OBSERVATION_MODIFIER", 31, 38], ["cerebral", "OBSERVATION_MODIFIER", 39, 47], ["size", "OBSERVATION_MODIFIER", 48, 52], ["thinner cortices", "OBSERVATION", 54, 70], ["enlarged", "OBSERVATION_MODIFIER", 76, 84], ["lateral", "ANATOMY_MODIFIER", 85, 92], ["ventricles", "ANATOMY", 93, 103], ["ZIKV", "OBSERVATION", 107, 111], ["neonates", "OBSERVATION", 114, 122]]], ["It is interesting to note that the E-specific human immunoglobulin G (IgG) levels in the brain were higher in mice treated with ZK2B10 and ZK7C3 compared to the other mAb groups.", [["brain", "ANATOMY", 89, 94], ["ZK7C3", "CHEMICAL", 139, 144], ["human", "ORGANISM", 46, 51], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 52, 68], ["IgG", "GENE_OR_GENE_PRODUCT", 70, 73], ["brain", "ORGAN", 89, 94], ["mice", "ORGANISM", 110, 114], ["ZK2B10", "GENE_OR_GENE_PRODUCT", 128, 134], ["ZK7C3", "GENE_OR_GENE_PRODUCT", 139, 144], ["E-specific human immunoglobulin G", "PROTEIN", 35, 68], ["IgG", "PROTEIN", 70, 73], ["human", "SPECIES", 46, 51], ["mice", "SPECIES", 110, 114], ["human", "SPECIES", 46, 51], ["mice", "SPECIES", 110, 114], ["the E-specific human immunoglobulin G (IgG) levels", "TEST", 31, 81], ["ZK2B10", "TREATMENT", 128, 134], ["ZK7C3", "TREATMENT", 139, 144], ["brain", "ANATOMY", 89, 94], ["higher", "OBSERVATION_MODIFIER", 100, 106]]], ["In particular, the levels of ZK2B10 (0.55 \u00b1 0.11 mg/kg, which is translated into 0.09 \u00b1 0.02 mg/mL) in ZIKV + neonates were well above the IC 50 neutralization values measured in the PRNT, whereas IgG levels in the other mAb groups measured less than or similar to those in the negative control PBS group ( Figures 1A and 2C) .", [["ZK2B10", "CHEMICAL", 29, 35], ["ZK2B10", "CHEMICAL", 29, 35], ["ZK2B10", "GENE_OR_GENE_PRODUCT", 29, 35], ["neonates", "ORGANISM", 110, 118], ["PRNT", "CANCER", 183, 187], ["IgG", "GENE_OR_GENE_PRODUCT", 197, 200], ["IgG", "PROTEIN", 197, 200], ["mAb", "PROTEIN", 221, 224], ["ZIKV", "SPECIES", 103, 107], ["ZK2B10", "TREATMENT", 29, 35], ["neutralization values", "TEST", 145, 166], ["the PRNT", "TEST", 179, 187], ["IgG levels", "TEST", 197, 207], ["the other mAb groups", "TEST", 211, 231]]], ["These results indicate that the tested mAbs were able to transport across both the maternal-fetal placental barrier and the primitive blood-brain barrier of developing fetuses (Saunders et al., 2014) .Marked Reduction in Cell and Tissue Damages to the Brain in the Protected AnimalsWe also conducted immunohistochemical analyses of brain sections collected from P3 neonates in each group.", [["fetal placental barrier", "ANATOMY", 92, 115], ["blood", "ANATOMY", 134, 139], ["brain", "ANATOMY", 140, 145], ["fetuses", "ANATOMY", 168, 175], ["Cell", "ANATOMY", 221, 225], ["Tissue", "ANATOMY", 230, 236], ["Brain", "ANATOMY", 252, 257], ["brain sections", "ANATOMY", 332, 346], ["mAbs", "GENE_OR_GENE_PRODUCT", 39, 43], ["fetal placental barrier", "TISSUE", 92, 115], ["blood-brain barrier", "TISSUE", 134, 153], ["fetuses", "ORGAN", 168, 175], ["Cell", "CELL", 221, 225], ["Tissue", "TISSUE", 230, 236], ["Brain", "ORGAN", 252, 257], ["brain sections", "MULTI-TISSUE_STRUCTURE", 332, 346], ["mAbs", "PROTEIN", 39, 43], ["the tested mAbs", "PROBLEM", 28, 43], ["fetal placental barrier", "TREATMENT", 92, 115], ["Marked Reduction in Cell and Tissue Damages to the Brain", "PROBLEM", 201, 257], ["brain sections", "TEST", 332, 346], ["fetal placental", "ANATOMY", 92, 107], ["brain", "ANATOMY", 140, 145], ["Reduction", "OBSERVATION_MODIFIER", 208, 217], ["Cell", "OBSERVATION", 221, 225], ["Tissue Damages", "OBSERVATION", 230, 244], ["Brain", "ANATOMY", 252, 257]]], ["As shown in Figure 3A , in ZK2B10 and ZK7C3 groups, no ZIKV-infected cells (green) or apoptotic cells (Cas3 + , red) were detected in the cortices of either ZIKV + neonates or their ZIKV \u00c0 littermates.", [["cells", "ANATOMY", 69, 74], ["cells", "ANATOMY", 96, 101], ["cortices", "ANATOMY", 138, 146], ["ZK2B10", "CELL", 27, 33], ["ZIKV", "GENE_OR_GENE_PRODUCT", 55, 59], ["cells", "CELL", 69, 74], ["cells", "CELL", 96, 101], ["Cas3 + , red)", "GENE_OR_GENE_PRODUCT", 103, 116], ["cortices", "MULTI-TISSUE_STRUCTURE", 138, 146], ["ZIKV + neonates", "ORGANISM", 157, 172], ["ZIKV \u00c0 littermates", "ORGANISM", 182, 200], ["ZK2B10 and ZK7C3 groups", "CELL_LINE", 27, 50], ["ZIKV-infected cells", "CELL_LINE", 55, 74], ["apoptotic cells", "CELL_TYPE", 86, 101], ["Cas3", "PROTEIN", 103, 107], ["ZIKV", "SPECIES", 55, 59], ["ZIKV", "SPECIES", 182, 186], ["ZK2B10", "TEST", 27, 33], ["ZIKV", "PROBLEM", 55, 59], ["infected cells", "PROBLEM", 60, 74], ["apoptotic cells", "PROBLEM", 86, 101], ["Cas3", "TEST", 103, 107], ["no", "UNCERTAINTY", 52, 54], ["infected cells", "OBSERVATION", 60, 74], ["apoptotic cells", "OBSERVATION", 86, 101], ["ZIKV", "OBSERVATION", 157, 161]]], ["The mature neurons (NeuN; Figure 3A , gray) and nuclei (DAPI; Figure 3A , blue) appeared healthy, with a tightly packed structure throughout the tissue sections.", [["neurons", "ANATOMY", 11, 18], ["nuclei", "ANATOMY", 48, 54], ["tissue sections", "ANATOMY", 145, 160], ["neurons", "CELL", 11, 18], ["NeuN; Figure 3A", "GENE_OR_GENE_PRODUCT", 20, 35], ["nuclei", "CELLULAR_COMPONENT", 48, 54], ["DAPI", "CELLULAR_COMPONENT", 56, 60], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 145, 160], ["mature neurons", "CELL_TYPE", 4, 18], ["NeuN", "PROTEIN", 20, 24], ["a tightly packed structure throughout the tissue sections", "PROBLEM", 103, 160], ["mature", "OBSERVATION_MODIFIER", 4, 10], ["neurons", "ANATOMY", 11, 18], ["nuclei", "ANATOMY", 48, 54], ["tightly packed", "OBSERVATION_MODIFIER", 105, 119], ["tissue", "ANATOMY", 145, 151]]], ["In distinct contrast, a large number of ZIKV-positive cells were identified throughout the cortices of the ZIKV + neonates in ZV67, Z006, ZK22F6, and MERS-4 groups.", [["ZIKV-positive cells", "ANATOMY", 40, 59], ["cortices", "ANATOMY", 91, 99], ["ZK22F6", "ANATOMY", 138, 144], ["ZIKV", "GENE_OR_GENE_PRODUCT", 40, 44], ["cells", "CELL", 54, 59], ["cortices", "CANCER", 91, 99], ["ZIKV", "ORGANISM", 107, 111], ["neonates", "ORGANISM", 114, 122], ["ZV67", "CELL", 126, 130], ["Z006", "CELL", 132, 136], ["ZK22F6", "CELL", 138, 144], ["MERS-4", "CELL", 150, 156], ["ZIKV-positive cells", "CELL_LINE", 40, 59], ["ZIKV-positive cells", "PROBLEM", 40, 59], ["ZV67", "TEST", 126, 130], ["Z006", "TEST", 132, 136], ["ZK22F6", "TEST", 138, 144], ["MERS", "TEST", 150, 154], ["distinct", "OBSERVATION_MODIFIER", 3, 11], ["contrast", "OBSERVATION", 12, 20], ["large", "OBSERVATION_MODIFIER", 24, 29], ["number", "OBSERVATION_MODIFIER", 30, 36], ["ZIKV", "OBSERVATION", 40, 44], ["positive cells", "OBSERVATION", 45, 59], ["cortices", "ANATOMY_MODIFIER", 91, 99], ["ZIKV", "OBSERVATION", 107, 111], ["neonates", "OBSERVATION", 114, 122]]], ["This high prevalence of infection was associated with significant cell death ( Figure 3A , red) and degradation of the cortical structure ( Figure 3A , gray and blue).", [["cell", "ANATOMY", 66, 70], ["cortical structure", "ANATOMY", 119, 137], ["infection", "DISEASE", 24, 33], ["death", "DISEASE", 71, 76], ["cell", "CELL", 66, 70], ["cortical", "MULTI-TISSUE_STRUCTURE", 119, 127], ["infection", "PROBLEM", 24, 33], ["significant cell death", "PROBLEM", 54, 76], ["degradation of the cortical structure", "PROBLEM", 100, 137], ["infection", "OBSERVATION", 24, 33], ["significant", "OBSERVATION_MODIFIER", 54, 65], ["cell death", "OBSERVATION", 66, 76], ["cortical structure", "OBSERVATION", 119, 137]]], ["We also quantitatively assessed the protective activity of ZK2B10 and ZK7C3 using marker cells from multiple tissue sections.", [["cells", "ANATOMY", 89, 94], ["tissue sections", "ANATOMY", 109, 124], ["ZK2B10", "SIMPLE_CHEMICAL", 59, 65], ["ZK7C3", "SIMPLE_CHEMICAL", 70, 75], ["cells", "CELL", 89, 94], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 109, 124], ["ZK2B10", "PROTEIN", 59, 65], ["ZK7C3", "PROTEIN", 70, 75], ["marker cells", "CELL_TYPE", 82, 94], ["ZK2B10", "TREATMENT", 59, 65], ["ZK7C3", "TREATMENT", 70, 75], ["marker cells", "TREATMENT", 82, 94], ["multiple tissue sections", "TREATMENT", 100, 124], ["multiple tissue", "OBSERVATION_MODIFIER", 100, 115]]], ["As shown in Figures 3B and 3C , treatment with ZK2B10 and ZK7C3 in ZIKV + neonates reduced ZIKV infection and cell death to levels indistinguishable from those of their ZIKV \u00c0 littermates.", [["ZIKV", "ANATOMY", 91, 95], ["cell", "ANATOMY", 110, 114], ["ZK2B10", "CHEMICAL", 47, 53], ["ZK7C3", "CHEMICAL", 58, 63], ["infection", "DISEASE", 96, 105], ["death", "DISEASE", 115, 120], ["ZK2B10", "GENE_OR_GENE_PRODUCT", 47, 53], ["ZK7C3", "GENE_OR_GENE_PRODUCT", 58, 63], ["ZIKV + neonates", "ORGANISM", 67, 82], ["ZIKV", "ORGANISM", 91, 95], ["cell", "CELL", 110, 114], ["ZIKV \u00c0 littermates", "ORGANISM", 169, 187], ["ZK2B10", "PROTEIN", 47, 53], ["ZK7C3", "PROTEIN", 58, 63], ["ZIKV", "SPECIES", 67, 71], ["ZIKV", "SPECIES", 91, 95], ["treatment", "TREATMENT", 32, 41], ["ZK2B10", "TREATMENT", 47, 53], ["ZK7C3", "TREATMENT", 58, 63], ["ZIKV", "TREATMENT", 67, 71], ["neonates", "PROBLEM", 74, 82], ["ZIKV infection", "PROBLEM", 91, 105], ["cell death", "PROBLEM", 110, 120]]], ["Furthermore, in the ZK2B10 and ZK7C3 groups, counts of mature neurons were equivalent between ZIKV + neonates and their ZIKV \u00c0 littermates ( Figure 3D ).", [["ZK2B10", "ANATOMY", 20, 26], ["neurons", "ANATOMY", 62, 69], ["ZK2B10", "CELL", 20, 26], ["neurons", "CELL", 62, 69], ["ZIKV \u00c0 littermates", "ORGANISM", 120, 138], ["mature neurons", "CELL_TYPE", 55, 69], ["the ZK2B10 and ZK7C3 groups", "TREATMENT", 16, 43], ["mature neurons", "PROBLEM", 55, 69]]], ["However, for the ZIKV + neonates treated with either ZV76, Z006, ZK22F6, or MERS-4, ZIKV-positive cell and apoptotic cell counts were as high as 7,500 cells and 5,600 cells, on average, per square-millimeter tissue section, respectively ( Figures 3B and 3C) .", [["cell", "ANATOMY", 98, 102], ["cell", "ANATOMY", 117, 121], ["cells", "ANATOMY", 151, 156], ["cells", "ANATOMY", 167, 172], ["tissue section", "ANATOMY", 208, 222], ["ZIKV + neonates", "ORGANISM", 17, 32], ["MERS-4", "GENE_OR_GENE_PRODUCT", 76, 82], ["ZIKV", "GENE_OR_GENE_PRODUCT", 84, 88], ["cell", "CELL", 98, 102], ["apoptotic cell", "CELL", 107, 121], ["cells", "CELL", 151, 156], ["cells", "CELL", 167, 172], ["tissue", "TISSUE", 208, 214], ["ZIKV", "PROTEIN", 84, 88], ["5,600 cells", "CELL_LINE", 161, 172], ["ZIKV", "SPECIES", 17, 21], ["the ZIKV + neonates", "PROBLEM", 13, 32], ["ZV76", "TREATMENT", 53, 57], ["ZK22F6", "TREATMENT", 65, 71], ["MERS", "TEST", 76, 80], ["ZIKV", "TEST", 84, 88], ["apoptotic cell counts", "TEST", 107, 128], ["positive cell", "OBSERVATION", 89, 102], ["apoptotic cell counts", "OBSERVATION", 107, 128]]], ["Counts of mature neurons were also significantly reduced in these groups ( Figure 3D ).", [["neurons", "ANATOMY", 17, 24], ["neurons", "CELL", 17, 24], ["mature neurons", "CELL_TYPE", 10, 24], ["mature neurons", "PROBLEM", 10, 24], ["mature", "OBSERVATION_MODIFIER", 10, 16], ["neurons", "ANATOMY", 17, 24], ["significantly", "OBSERVATION_MODIFIER", 35, 48], ["reduced", "OBSERVATION_MODIFIER", 49, 56]]], ["These results support the enhanced therapeutic activity of ZK2B10 and ZK7C3 at the cellular and tissue levels relative to ZV67, ZV006, ZK22F6, and MERS-4 and also offer an explanation for their impressive in vivo protection of developing fetuses.Treatment with ZK2B10 Attenuates Disease ProgressionAs ZK2B10 demonstrated the greatest prophylactic efficacy against ZIKV infection, we went on to evaluate its treatment efficacy after ZIKV infection of the developing fetuses.", [["cellular", "ANATOMY", 83, 91], ["tissue", "ANATOMY", 96, 102], ["fetuses", "ANATOMY", 238, 245], ["fetuses", "ANATOMY", 465, 472], ["ZK2B10", "CHEMICAL", 261, 267], ["ZIKV infection", "DISEASE", 364, 378], ["infection", "DISEASE", 437, 446], ["ZK2B10", "CHEMICAL", 261, 267], ["ZK2B10", "GENE_OR_GENE_PRODUCT", 59, 65], ["ZK7C3", "GENE_OR_GENE_PRODUCT", 70, 75], ["cellular", "CELL", 83, 91], ["tissue", "TISSUE", 96, 102], ["ZV67", "CELL", 122, 126], ["ZV006", "GENE_OR_GENE_PRODUCT", 128, 133], ["ZK22F6", "CELL", 135, 141], ["MERS-4", "GENE_OR_GENE_PRODUCT", 147, 153], ["fetuses", "ORGANISM", 238, 245], ["ZK2B10", "SIMPLE_CHEMICAL", 261, 267], ["ZIKV", "ORGANISM", 364, 368], ["ZIKV", "ORGANISM", 432, 436], ["fetuses", "ORGANISM", 465, 472], ["ZK2B10", "PROTEIN", 59, 65], ["ZIKV", "SPECIES", 364, 368], ["ZIKV", "SPECIES", 432, 436], ["ZK2B10", "TREATMENT", 59, 65], ["ZK7C3", "TREATMENT", 70, 75], ["ZV67", "TREATMENT", 122, 126], ["ZV006", "TREATMENT", 128, 133], ["ZK22F6", "TREATMENT", 135, 141], ["developing fetuses", "PROBLEM", 227, 245], ["Treatment", "TREATMENT", 246, 255], ["ZK2B10", "TREATMENT", 261, 267], ["Attenuates Disease Progression", "PROBLEM", 268, 298], ["ZK2B10", "TREATMENT", 301, 307], ["ZIKV infection", "PROBLEM", 364, 378], ["its treatment efficacy", "TREATMENT", 403, 425], ["ZIKV infection", "PROBLEM", 432, 446], ["the developing fetuses", "PROBLEM", 450, 472], ["fetuses", "OBSERVATION", 238, 245], ["fetuses", "OBSERVATION", 465, 472]]], ["Specifically, after the littermate fetuses were either left untouched (ZIKV \u00c0 ) or inoculated with 350 PFUs of ZIKV GZ01 in the lateral ventricle (ZIKV + ) on E15.5, we administered 5 mg/kg ZK2B10 i.p. to the pregnant mice.", [["fetuses", "ANATOMY", 35, 42], ["lateral ventricle", "ANATOMY", 128, 145], ["ZK2B10", "CHEMICAL", 190, 196], ["fetuses", "ORGANISM", 35, 42], ["lateral ventricle", "MULTI-TISSUE_STRUCTURE", 128, 145], ["E15.5", "ORGAN", 159, 164], ["mice", "ORGANISM", 218, 222], ["ZIKV GZ01", "PROTEIN", 111, 120], ["mice", "SPECIES", 218, 222], ["ZIKV", "SPECIES", 111, 115], ["mice", "SPECIES", 218, 222], ["the littermate fetuses", "PROBLEM", 20, 42], ["left", "ANATOMY_MODIFIER", 55, 59], ["ZIKV", "OBSERVATION", 111, 115], ["lateral ventricle", "ANATOMY", 128, 145]]], ["This was done either on the same day (E15.5, day 0), 1 day later (E16.5, day 1), or 2 days later (E17.5, day 2).Treatment with ZK2B10 Attenuates Disease ProgressionThe littermate neonates were closely monitored after delivery and analyzed for the same outcomes measured in the prevention experiments ( Figure 1A ).", [["ZK2B10", "CHEMICAL", 127, 133], ["ZK2B10", "CHEMICAL", 127, 133], ["ZK2B10", "SIMPLE_CHEMICAL", 127, 133], ["neonates", "ORGANISM", 179, 187], ["Treatment", "TREATMENT", 112, 121], ["ZK2B10", "TREATMENT", 127, 133], ["Attenuates Disease Progression", "PROBLEM", 134, 164], ["The littermate neonates", "TREATMENT", 164, 187], ["delivery", "TREATMENT", 217, 225]]], ["Treatment on day 0 offered the most effective treatment, with a median survival of about 19 days.", [["a median survival", "TREATMENT", 62, 79]]], ["This is signif-icantly higher than that of mice treated on either day 1 (11 days) or day 2 (13 days).", [["mice", "ORGANISM", 43, 47], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 43, 47], ["signif", "OBSERVATION_MODIFIER", 8, 14], ["icantly", "OBSERVATION_MODIFIER", 15, 22], ["higher", "OBSERVATION_MODIFIER", 23, 29]]], ["The survival advantage conferred by treatment on day 0 corresponded with a clear reduction of viral load in the brain ( Figure 4D ) and less damage to the cortical thickness and lateral ventricles (Figures 4F and 4G) .", [["brain", "ANATOMY", 112, 117], ["cortical", "ANATOMY", 155, 163], ["lateral ventricles", "ANATOMY", 178, 196], ["brain", "ORGAN", 112, 117], ["cortical", "TISSUE", 155, 163], ["lateral ventricles", "MULTI-TISSUE_STRUCTURE", 178, 196], ["viral load in the brain", "PROBLEM", 94, 117], ["viral load", "OBSERVATION", 94, 104], ["brain", "ANATOMY", 112, 117], ["cortical", "ANATOMY_MODIFIER", 155, 163], ["thickness", "ANATOMY_MODIFIER", 164, 173], ["lateral ventricles", "ANATOMY", 178, 196]]], ["However, the effect was less obvious when measured by body weight or Each red dot represents a ZIKV + ; each blue dot represents a ZIKV \u00c0 neonate.", [["body", "ANATOMY", 54, 58], ["body", "ORGANISM_SUBDIVISION", 54, 58], ["neonate", "ORGANISM", 138, 145], ["ZIKV", "SPECIES", 131, 135], ["a ZIKV +", "PROBLEM", 93, 101], ["ZIKV", "OBSERVATION", 131, 135]]], ["The red dots with blue coating represent no discernable differences between ZIKV + and ZIKV \u00c0 littermates in ZK2B10-and ZK7C3-treated groups.", [["ZK7C3", "CHEMICAL", 120, 125], ["ZIKV", "GENE_OR_GENE_PRODUCT", 76, 80], ["ZIKV \u00c0 littermates", "ORGANISM", 87, 105], ["ZK2B10", "CELL", 109, 115], ["ZK7C3", "CELL", 120, 125], ["ZIKV", "SPECIES", 87, 91], ["The red dots with blue coating", "TREATMENT", 0, 30], ["discernable differences between ZIKV", "PROBLEM", 44, 80], ["ZK2B10", "TEST", 109, 115], ["ZK7C3", "TREATMENT", 120, 125], ["no", "UNCERTAINTY", 41, 43]]], ["The numbers of neonates for each mAb analyses are indicated above each group, with ZIKV + in red and ZIKV \u00c0 in blue.", [["neonates", "ORGANISM", 15, 23], ["mAb", "PROTEIN", 33, 36], ["ZIKV", "SPECIES", 101, 105], ["neonates", "TREATMENT", 15, 23], ["each mAb analyses", "TEST", 28, 45], ["ZIKV", "PROBLEM", 83, 87]]], ["In (G) and (H), each dot represents the mean value of at least two slices from one neonate.", [["slices", "ANATOMY", 67, 73]]], ["All data are presented as mean \u00b1 SEM. p < 0.001; ns, no significant.Treatment with ZK2B10 Attenuates Disease Progressionblood serum viral loads on P3 (Figures 4B and 4C ).", [["serum", "ANATOMY", 126, 131], ["ZK2B10", "CHEMICAL", 83, 89], ["ZK2B10", "CHEMICAL", 83, 89], ["ZK2B10", "SIMPLE_CHEMICAL", 83, 89], ["serum", "ORGANISM_SUBSTANCE", 126, 131], ["All data", "TEST", 0, 8], ["ns", "TREATMENT", 49, 51], ["Treatment", "TREATMENT", 68, 77], ["ZK2B10", "TREATMENT", 83, 89], ["Attenuates Disease", "PROBLEM", 90, 108], ["serum viral loads", "TEST", 126, 143], ["P3", "TEST", 147, 149], ["Figures", "TEST", 151, 158], ["no", "UNCERTAINTY", 53, 55], ["significant", "OBSERVATION_MODIFIER", 56, 67]]], ["Considering that, in our mouse model, the brain is the initial and active site of viral replication, we expected that antibody treatment effects would be more sensitive and immediate in this organ and would be apparent before effects on other organs and body weight as a whole.", [["brain", "ANATOMY", 42, 47], ["organ", "ANATOMY", 191, 196], ["organs", "ANATOMY", 243, 249], ["body", "ANATOMY", 254, 258], ["mouse", "ORGANISM", 25, 30], ["brain", "ORGAN", 42, 47], ["organ", "ORGAN", 191, 196], ["organs", "ORGAN", 243, 249], ["body", "ORGANISM_SUBDIVISION", 254, 258], ["mouse", "SPECIES", 25, 30], ["mouse", "SPECIES", 25, 30], ["viral replication", "TREATMENT", 82, 99], ["antibody treatment", "TREATMENT", 118, 136], ["brain", "ANATOMY", 42, 47], ["active", "OBSERVATION_MODIFIER", 67, 73], ["viral replication", "OBSERVATION", 82, 99]]], ["This hypothesis was supported by immunohistochemical analyses of brain sections derived from P3 neonates.", [["brain sections", "ANATOMY", 65, 79], ["brain sections", "MULTI-TISSUE_STRUCTURE", 65, 79], ["neonates", "ORGANISM", 96, 104], ["immunohistochemical analyses", "TEST", 33, 61], ["brain sections", "TEST", 65, 79], ["P3 neonates", "PROBLEM", 93, 104]]], ["As shown in Figure 5A , ZIKV-positive cells (green) were only sporadically detected in the day-0 treatment group.", [["ZIKV-positive cells", "ANATOMY", 24, 43], ["ZIKV", "GENE_OR_GENE_PRODUCT", 24, 28], ["cells", "CELL", 38, 43], ["ZIKV-positive cells", "CELL_LINE", 24, 43], ["ZIKV-positive cells", "PROBLEM", 24, 43]]], ["However, they were detected throughout the cortices if treatment was delayed to day 1 or day 2.", [["cortices", "ANATOMY", 43, 51], ["cortices", "MULTI-TISSUE_STRUCTURE", 43, 51]]], ["A greater level of infection was associated with increased cell death ( Figure 5A , red) and cortical abnormalities ( Figure 5A , gray and blue).", [["cell", "ANATOMY", 59, 63], ["cortical", "ANATOMY", 93, 101], ["infection", "DISEASE", 19, 28], ["death", "DISEASE", 64, 69], ["cortical abnormalities", "DISEASE", 93, 115], ["cell", "CELL", 59, 63], ["cortical", "MULTI-TISSUE_STRUCTURE", 93, 101], ["A greater level of infection", "PROBLEM", 0, 28], ["increased cell death", "PROBLEM", 49, 69], ["cortical abnormalities", "PROBLEM", 93, 115], ["greater", "OBSERVATION_MODIFIER", 2, 9], ["infection", "OBSERVATION", 19, 28], ["increased", "OBSERVATION_MODIFIER", 49, 58], ["cell death", "OBSERVATION", 59, 69], ["cortical", "ANATOMY_MODIFIER", 93, 101], ["abnormalities", "OBSERVATION", 102, 115]]], ["In particular, the tightly packed and well-organized structure of matured neurons in the cortices became loosely connected and disorganized.", [["neurons", "ANATOMY", 74, 81], ["cortices", "ANATOMY", 89, 97], ["neurons", "CELL", 74, 81], ["cortices", "MULTI-TISSUE_STRUCTURE", 89, 97], ["matured neurons", "CELL_TYPE", 66, 81], ["tightly", "OBSERVATION_MODIFIER", 19, 26], ["packed", "OBSERVATION_MODIFIER", 27, 33], ["well-organized", "OBSERVATION_MODIFIER", 38, 52], ["matured neurons", "OBSERVATION", 66, 81], ["cortices", "ANATOMY_MODIFIER", 89, 97], ["disorganized", "OBSERVATION_MODIFIER", 127, 139]]], ["Furthermore, a quantitative assessment of marker cells derived from multiple Each red dot represents a ZIKV + neonate; each blue dot represents a ZIKV \u00c0 littermate.", [["marker cells", "ANATOMY", 42, 54], ["cells", "CELL", 49, 54], ["ZIKV", "ORGANISM", 103, 107], ["neonate", "ORGANISM", 110, 117], ["ZIKV \u00c0 littermate", "ORGANISM", 146, 163], ["marker cells", "CELL_TYPE", 42, 54], ["a quantitative assessment", "TEST", 13, 38], ["marker cells", "PROBLEM", 42, 54], ["a ZIKV + neonate", "PROBLEM", 101, 117]]], ["Red dots with blue coating represent no discernable differences between ZIKV + and ZIKV \u00c0 littermates in ZK2B10-and ZK7C3treated groups.", [["ZIKV", "GENE_OR_GENE_PRODUCT", 72, 76], ["ZIKV \u00c0 littermates", "ORGANISM", 83, 101], ["ZK2B10", "CELL", 105, 111], ["ZIKV", "SPECIES", 83, 87], ["Red dots with blue coating", "TREATMENT", 0, 26], ["discernable differences", "PROBLEM", 40, 63], ["ZIKV", "PROBLEM", 72, 76], ["ZK2B10", "TREATMENT", 105, 111], ["ZK7C3treated groups", "TREATMENT", 116, 135], ["blue coating", "OBSERVATION", 14, 26], ["no", "UNCERTAINTY", 37, 39], ["discernable", "OBSERVATION_MODIFIER", 40, 51]]], ["Each dot represents the mean value of at least two slices from one neonate analyzed.", [["slices", "ANATOMY", 51, 57]]], ["The numbers of neonates for each analysis are indicated above each group, with ZIKV + in red and ZIKV \u00c0 in blue.", [["neonates", "ORGANISM", 15, 23], ["ZIKV", "SPECIES", 97, 101], ["each analysis", "TEST", 28, 41], ["ZIKV", "PROBLEM", 79, 83]]], ["Scale bar, 300 mm.", [["300 mm", "OBSERVATION_MODIFIER", 11, 17]]], ["All data are presented as mean \u00b1 SEM. p < 0.001. tissue sections supported the evidence that the time of treatment administration impacted treatment efficacy.", [["tissue sections", "ANATOMY", 49, 64], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 49, 64], ["All data", "TEST", 0, 8], ["tissue sections", "TEST", 49, 64], ["treatment administration impacted treatment efficacy", "TREATMENT", 105, 157]]], ["For instance, in the ZIKV + neonate group, treatment on day 0 significantly suppressed the number of ZIKV-positive cells to 5 \u00b1 3 and apoptotic cells to 6 \u00b1 4 per square millimeter of tissue section.", [["ZIKV-positive cells", "ANATOMY", 101, 120], ["cells", "ANATOMY", 144, 149], ["tissue section", "ANATOMY", 184, 198], ["ZIKV + neonate", "ORGANISM", 21, 35], ["ZIKV", "GENE_OR_GENE_PRODUCT", 101, 105], ["cells", "CELL", 115, 120], ["cells", "CELL", 144, 149], ["tissue", "TISSUE", 184, 190], ["ZIKV-positive cells", "CELL_LINE", 101, 120], ["apoptotic cells", "CELL_TYPE", 134, 149], ["ZIKV", "TEST", 101, 105], ["positive cells", "PROBLEM", 106, 120], ["apoptotic cells", "TEST", 134, 149], ["tissue section", "TEST", 184, 198], ["positive cells", "OBSERVATION", 106, 120], ["tissue section", "OBSERVATION", 184, 198]]], ["Treatment on day 2, however, allowed widespread cell infection and cell death counts as high as 3,323 \u00b1 1,971 and 399 \u00b1 329 per square-millimeter tissue section, respectively ( Figures 5B and 5C ).", [["cell", "ANATOMY", 48, 52], ["cell", "ANATOMY", 67, 71], ["tissue section", "ANATOMY", 146, 160], ["infection", "DISEASE", 53, 62], ["death", "DISEASE", 72, 77], ["cell", "CELL", 48, 52], ["cell", "CELL", 67, 71], ["tissue", "TISSUE", 146, 152], ["widespread cell infection", "PROBLEM", 37, 62], ["cell death counts", "TEST", 67, 84], ["tissue section", "TEST", 146, 160], ["Figures 5B", "TEST", 177, 187], ["widespread", "OBSERVATION_MODIFIER", 37, 47], ["cell infection", "OBSERVATION", 48, 62], ["cell", "OBSERVATION", 67, 71]]], ["However, although tissue samples from all three temporal treatment groups showed structural abnormalities in the cortices, there were no obvious reductions in the total number of mature neurons ( Figure 5D ).", [["tissue samples", "ANATOMY", 18, 32], ["cortices", "ANATOMY", 113, 121], ["neurons", "ANATOMY", 186, 193], ["tissue samples", "CANCER", 18, 32], ["cortices", "MULTI-TISSUE_STRUCTURE", 113, 121], ["neurons", "CELL", 186, 193], ["mature neurons", "CELL_TYPE", 179, 193], ["tissue samples", "TEST", 18, 32], ["structural abnormalities in the cortices", "PROBLEM", 81, 121], ["obvious reductions", "PROBLEM", 137, 155], ["abnormalities", "OBSERVATION", 92, 105], ["cortices", "ANATOMY_MODIFIER", 113, 121], ["no", "UNCERTAINTY", 134, 136], ["obvious", "OBSERVATION_MODIFIER", 137, 144], ["reductions", "OBSERVATION_MODIFIER", 145, 155], ["total", "OBSERVATION_MODIFIER", 163, 168]]], ["Treatment with the isotype MERS-4 control was worst among all groups, with no signs of Figure 4 .", [["Treatment", "TREATMENT", 0, 9], ["the isotype MERS", "TREATMENT", 15, 31]]], ["Evidence of Therapeutic Potential of ZK2B10 against ZIKV Infection in Developing Fetuses (A) Decreased survival when treatment administration is delayed from day 0 (E15.5) to day 1 (E16.5) or to day 2 (E17.5).", [["ZK2B10", "CHEMICAL", 37, 43], ["ZIKV Infection", "DISEASE", 52, 66], ["ZK2B10", "SIMPLE_CHEMICAL", 37, 43], ["ZIKV", "ORGANISM", 52, 56], ["ZIKV", "SPECIES", 52, 56], ["ZK2B10", "TREATMENT", 37, 43], ["ZIKV Infection", "PROBLEM", 52, 66], ["treatment administration", "TREATMENT", 117, 141], ["Therapeutic", "OBSERVATION_MODIFIER", 12, 23]]], ["The number (n) of neonates monitored for survival is indicated.", [["neonates", "ORGANISM", 18, 26], ["neonates", "TREATMENT", 18, 26], ["survival", "TREATMENT", 41, 49]]], ["(B-D) After treatment with ZK2B10 on day 0, day 1, or day 2, we analyzed ZIKV + neonates (indicated in red) and ZIKV \u00c0 littermates (indicated in blue) at P3 for (B) body weight, (C) ZIKV RNA copies in the blood, and (D) ZIVK RNA copies in the brain.", [["body", "ANATOMY", 165, 169], ["blood", "ANATOMY", 205, 210], ["brain", "ANATOMY", 243, 248], ["ZK2B10", "CHEMICAL", 27, 33], ["ZK2B10", "CHEMICAL", 27, 33], ["B-D", "GENE_OR_GENE_PRODUCT", 1, 4], ["ZK2B10", "SIMPLE_CHEMICAL", 27, 33], ["ZIKV + neonates", "ORGANISM", 73, 88], ["ZIKV \u00c0 littermates", "ORGANISM", 112, 130], ["body", "ORGANISM_SUBDIVISION", 165, 169], ["blood", "ORGANISM_SUBSTANCE", 205, 210], ["brain", "ORGAN", 243, 248], ["ZK2B10", "PROTEIN", 27, 33], ["B) body weight, (C) ZIKV RNA copies", "RNA", 162, 197], ["blood, and (D) ZIVK RNA copies", "RNA", 205, 235], ["ZIKV", "SPECIES", 112, 116], ["treatment", "TREATMENT", 12, 21], ["ZK2B10", "TREATMENT", 27, 33], ["body weight", "TEST", 165, 176], ["(C) ZIKV RNA copies", "PROBLEM", 178, 197], ["the blood", "TEST", 201, 210], ["ZIVK RNA copies in the brain", "PROBLEM", 220, 248], ["blood", "ANATOMY", 205, 210], ["brain", "ANATOMY", 243, 248]]], ["The number of neonates analyzed for each treatment time point is indicated above each group.", [["neonates", "ORGANISM", 14, 22], ["neonates", "TREATMENT", 14, 22]]], ["(E-G) Shown here: (E) the representative coronal sections of the neonatal brains at P3 was visualized with Nissl staining and analyzed for (F) cortex thickness and (G) ventricular area.", [["coronal sections", "ANATOMY", 41, 57], ["brains", "ANATOMY", 74, 80], ["F) cortex", "ANATOMY", 140, 149], ["ventricular area", "ANATOMY", 168, 184], ["coronal sections", "MULTI-TISSUE_STRUCTURE", 41, 57], ["brains", "ORGAN", 74, 80], ["ventricular area", "MULTI-TISSUE_STRUCTURE", 168, 184], ["P3", "DNA", 84, 86], ["Nissl staining", "TEST", 107, 121], ["(F) cortex thickness and (G) ventricular area", "PROBLEM", 139, 184], ["neonatal brains", "ANATOMY", 65, 80], ["ventricular", "ANATOMY", 168, 179], ["area", "ANATOMY_MODIFIER", 180, 184]]], ["The total numbers of slices analyzed for ZIKV \u00c0 , day 0, day 1, day 2, and MERS-4 were 8, 11, 8, 13, and 8, respectively.", [["slices", "ANATOMY", 21, 27], ["ZIKV", "PROTEIN", 41, 45], ["ZIKV", "SPECIES", 41, 45], ["The total numbers of slices", "TREATMENT", 0, 27], ["ZIKV", "PROBLEM", 41, 45], ["MERS", "TEST", 75, 79]]], ["The number of neonates analyzed for each treatment time point is indicated above each group.", [["neonates", "ORGANISM", 14, 22], ["neonates", "TREATMENT", 14, 22]]], ["Scale bar, 1 mm.", [["1 mm", "OBSERVATION_MODIFIER", 11, 15]]], ["All data are presented as mean \u00b1 SEM. p < 0.001; ns, no significant. protection (Figures 4 and 5) .", [["All data", "TEST", 0, 8], ["ns", "TREATMENT", 49, 51], ["no", "UNCERTAINTY", 53, 55], ["significant", "OBSERVATION_MODIFIER", 56, 67]]], ["These results highlight the critical role of ZK2B10 in attenuating disease progression by inhibiting cell infection and death at the cellular and tissue levels.", [["cell", "ANATOMY", 101, 105], ["cellular", "ANATOMY", 133, 141], ["tissue", "ANATOMY", 146, 152], ["ZK2B10", "CHEMICAL", 45, 51], ["infection", "DISEASE", 106, 115], ["death", "DISEASE", 120, 125], ["ZK2B10", "GENE_OR_GENE_PRODUCT", 45, 51], ["cell", "CELL", 101, 105], ["cellular", "CELL", 133, 141], ["tissue", "TISSUE", 146, 152], ["ZK2B10", "PROTEIN", 45, 51], ["ZK2B10", "TREATMENT", 45, 51], ["attenuating disease progression", "PROBLEM", 55, 86], ["inhibiting cell infection", "PROBLEM", 90, 115], ["attenuating", "OBSERVATION_MODIFIER", 55, 66], ["disease", "OBSERVATION", 67, 74], ["inhibiting cell infection", "OBSERVATION", 90, 115], ["tissue", "OBSERVATION_MODIFIER", 146, 152], ["levels", "OBSERVATION_MODIFIER", 153, 159]]], ["Furthermore, the time of administration relative to infection impacts efficacy.", [["infection", "DISEASE", 52, 61], ["administration", "TREATMENT", 25, 39], ["infection impacts efficacy", "PROBLEM", 52, 78], ["infection", "OBSERVATION", 52, 61]]], ["Treatment has the greatest protective effect when initiated immediately after infection.DISCUSSIONWe report here the systematic analyses of the prophylactic and therapeutic potential of a panel of human mAbs against ZIKV infection in a mouse model of microcephaly and non-pregnant AG6 mice.", [["infection", "DISEASE", 78, 87], ["ZIKV infection", "DISEASE", 216, 230], ["microcephaly", "DISEASE", 251, 263], ["human", "ORGANISM", 197, 202], ["mAbs", "GENE_OR_GENE_PRODUCT", 203, 207], ["ZIKV", "GENE_OR_GENE_PRODUCT", 216, 220], ["mouse", "ORGANISM", 236, 241], ["AG6 mice", "ORGANISM", 281, 289], ["human mAbs", "PROTEIN", 197, 207], ["human", "SPECIES", 197, 202], ["mouse", "SPECIES", 236, 241], ["mice", "SPECIES", 285, 289], ["human", "SPECIES", 197, 202], ["ZIKV", "SPECIES", 216, 220], ["mouse", "SPECIES", 236, 241], ["mice", "SPECIES", 285, 289], ["Treatment", "TREATMENT", 0, 9], ["infection", "PROBLEM", 78, 87], ["the prophylactic", "TREATMENT", 140, 156], ["a panel", "TEST", 186, 193], ["human mAbs", "TREATMENT", 197, 207], ["ZIKV infection", "PROBLEM", 216, 230], ["microcephaly", "PROBLEM", 251, 263], ["greatest", "OBSERVATION_MODIFIER", 18, 26], ["protective effect", "OBSERVATION_MODIFIER", 27, 44], ["infection", "OBSERVATION", 78, 87]]], ["We showed that different mAbs demonstrated distinct protective activity against ZIKV infection and that the major determinant of efficacy is their intrinsic neutralizing activities.", [["ZIKV infection", "DISEASE", 80, 94], ["ZIKV", "ORGANISM", 80, 84], ["mAbs", "PROTEIN", 25, 29], ["ZIKV", "SPECIES", 80, 84], ["different mAbs", "TREATMENT", 15, 29], ["ZIKV infection", "PROBLEM", 80, 94], ["distinct", "OBSERVATION_MODIFIER", 43, 51], ["protective activity", "OBSERVATION_MODIFIER", 52, 71], ["neutralizing activities", "OBSERVATION", 157, 180]]], ["A single i.p. injection of pregnant and non-pregnant mice with the most potent mAb, ZK2B10, provided developing fetuses and adult animals with a complete protection against ZIKV infection.", [["fetuses", "ANATOMY", 112, 119], ["ZK2B10", "CHEMICAL", 84, 90], ["ZIKV infection", "DISEASE", 173, 187], ["mice", "ORGANISM", 53, 57], ["mAb", "GENE_OR_GENE_PRODUCT", 79, 82], ["ZK2B10", "GENE_OR_GENE_PRODUCT", 84, 90], ["fetuses", "ORGANISM", 112, 119], ["ZIKV", "ORGANISM", 173, 177], ["mAb", "PROTEIN", 79, 82], ["ZK2B10", "PROTEIN", 84, 90], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 53, 57], ["ZIKV", "SPECIES", 173, 177], ["A single i.p. injection of pregnant", "TREATMENT", 0, 35], ["non-pregnant mice", "TREATMENT", 40, 57], ["the most potent mAb", "TREATMENT", 63, 82], ["ZK2B10", "TREATMENT", 84, 90], ["developing fetuses", "PROBLEM", 101, 119], ["adult animals", "PROBLEM", 124, 137], ["ZIKV infection", "PROBLEM", 173, 187], ["fetuses", "OBSERVATION", 112, 119]]], ["Treatment with ZK2B10 markedly reduced fetal infection and tissue pathology and significantly delayed mortality.", [["fetal", "ANATOMY", 39, 44], ["tissue", "ANATOMY", 59, 65], ["ZK2B10", "CHEMICAL", 15, 21], ["fetal infection", "DISEASE", 39, 54], ["ZK2B10", "CHEMICAL", 15, 21], ["ZK2B10", "SIMPLE_CHEMICAL", 15, 21], ["fetal", "ANATOMICAL_SYSTEM", 39, 44], ["tissue", "TISSUE", 59, 65], ["Treatment", "TREATMENT", 0, 9], ["ZK2B10", "TREATMENT", 15, 21], ["fetal infection", "PROBLEM", 39, 54], ["tissue pathology", "PROBLEM", 59, 75], ["significantly delayed mortality", "PROBLEM", 80, 111], ["reduced", "OBSERVATION_MODIFIER", 31, 38], ["infection", "OBSERVATION", 45, 54]]], ["Thus, ZK2B10 is a promising candidate for the development of antibody-based intervention and informs rational design of ZIKV vaccine.DISCUSSIONTwo unique aspects of our study are worth highlighting here.", [["ZK2B10", "CHEMICAL", 6, 12], ["ZIKV", "CHEMICAL", 120, 124], ["ZK2B10", "GENE_OR_GENE_PRODUCT", 6, 12], ["ZIKV", "ORGANISM", 120, 124], ["ZK2B10", "PROTEIN", 6, 12], ["ZIKV", "SPECIES", 120, 124], ["ZK2B10", "TREATMENT", 6, 12], ["antibody-based intervention", "TREATMENT", 61, 88], ["ZIKV vaccine", "TREATMENT", 120, 132], ["our study", "TEST", 165, 174]]], ["One is based in the tested mAbs that are all derived from the same ZIKV convalescent individual at different time points in the course of natural infection.", [["infection", "DISEASE", 146, 155], ["mAbs", "GENE_OR_GENE_PRODUCT", 27, 31], ["mAbs", "PROTEIN", 27, 31], ["ZIKV", "SPECIES", 67, 71], ["natural infection", "PROBLEM", 138, 155], ["ZIKV", "OBSERVATION", 67, 71], ["natural", "OBSERVATION_MODIFIER", 138, 145], ["infection", "OBSERVATION", 146, 155]]], ["Each has distinct neutralizing activity, epitope specificity, and lineage ancestry .", [["distinct neutralizing activity", "PROBLEM", 9, 39], ["distinct", "OBSERVATION_MODIFIER", 9, 17], ["neutralizing activity", "OBSERVATION", 18, 39], ["lineage ancestry", "OBSERVATION", 66, 82]]], ["This diversity not only allows us to pinpoint the major determinants of protection in the mouse model but also provides evidence for when protective potential arises during the course of a natural infection in humans.", [["infection", "DISEASE", 197, 206], ["mouse", "ORGANISM", 90, 95], ["humans", "ORGANISM", 210, 216], ["mouse", "SPECIES", 90, 95], ["humans", "SPECIES", 210, 216], ["mouse", "SPECIES", 90, 95], ["humans", "SPECIES", 210, 216], ["a natural infection in humans", "PROBLEM", 187, 216], ["infection", "OBSERVATION", 197, 206]]], ["Our results clearly show that neutralizing activity, rather than other features, is the critical biomarker for protection against ZIKV infection, although the role of Fc-mediated antiviral functions still need further investigation (Dejnirattisai et al., 2016; Pierson and Graham, 2016; Sapparapu et al., 2016; Stettler et al., 2016 ).", [["infection", "DISEASE", 135, 144], ["ZIKV", "ORGANISM", 130, 134], ["Fc", "GENE_OR_GENE_PRODUCT", 167, 169], ["Fc", "PROTEIN", 167, 169], ["ZIKV", "SPECIES", 130, 134], ["neutralizing activity", "PROBLEM", 30, 51], ["ZIKV infection", "PROBLEM", 130, 144], ["further investigation", "TEST", 210, 231], ["neutralizing activity", "OBSERVATION", 30, 51]]], ["Among the mAbs tested here, ZK2B10 is the most potent, and its epitope is located in the lateral ridge region within the DIII of E . mAbs that target DIII with potent neutralizing activity have also been isolated by other groups, derived from either infected humans or mice, and have been shown to be effective in various models of ZIKV pathogenesis (Fernandez et al., 2017; Magnani et al., 2017; Robbiani et al., 2017; Stettler et al., 2016; Wang et al., 2017b; Zhao et al., 2016) .", [["lateral ridge region", "ANATOMY", 89, 109], ["ZK2B10", "CHEMICAL", 28, 34], ["ZK2B10", "GENE_OR_GENE_PRODUCT", 28, 34], ["DIII", "GENE_OR_GENE_PRODUCT", 150, 154], ["humans", "ORGANISM", 259, 265], ["mice", "ORGANISM", 269, 273], ["ZIKV", "ORGANISM", 332, 336], ["mAbs", "PROTEIN", 10, 14], ["ZK2B10", "PROTEIN", 28, 34], ["lateral ridge region", "PROTEIN", 89, 109], ["DIII", "PROTEIN", 121, 125], ["mAbs", "PROTEIN", 133, 137], ["DIII", "PROTEIN", 150, 154], ["humans", "SPECIES", 259, 265], ["mice", "SPECIES", 269, 273], ["humans", "SPECIES", 259, 265], ["mice", "SPECIES", 269, 273], ["ZIKV", "SPECIES", 332, 336], ["the mAbs", "TEST", 6, 14], ["ZK2B10", "TEST", 28, 34], ["its epitope", "PROBLEM", 59, 70], ["potent neutralizing activity", "PROBLEM", 160, 188], ["most potent", "OBSERVATION_MODIFIER", 42, 53], ["epitope", "OBSERVATION", 63, 70], ["lateral", "ANATOMY_MODIFIER", 89, 96], ["ridge", "ANATOMY_MODIFIER", 97, 102], ["region", "ANATOMY_MODIFIER", 103, 109], ["infected", "OBSERVATION", 250, 258]]], ["Some weakly neutralizing mAbs have also been reported against the same domain (Robbiani et al., 2017; Sapparapu et al., 2016; Stettler et al., 2016; Zhao et al., 2016) .", [["mAbs", "PROTEIN", 25, 29], ["Some weakly neutralizing mAbs", "PROBLEM", 0, 29], ["weakly", "OBSERVATION_MODIFIER", 5, 11], ["neutralizing", "OBSERVATION", 12, 24]]], ["It would be hard to determine whether this convergence on DIII is a purely random event or whether DIII epitopes are somehow more exposed and, therefore, more accessible by the mAbs.", [["DIII", "GENE_OR_GENE_PRODUCT", 58, 62], ["DIII", "GENE_OR_GENE_PRODUCT", 99, 103], ["mAbs", "GENE_OR_GENE_PRODUCT", 177, 181], ["DIII", "PROTEIN", 58, 62], ["DIII epitopes", "PROTEIN", 99, 112], ["mAbs", "PROTEIN", 177, 181], ["a purely random event", "PROBLEM", 66, 87], ["DIII epitopes", "PROBLEM", 99, 112]]], ["It would be interesting to compare the exact epitopes of the highly potent mAbs to see whether the vulnerable spots are widely spread or confined to restricted regions on the DIII.", [["DIII", "GENE_OR_GENE_PRODUCT", 175, 179], ["mAbs", "PROTEIN", 75, 79], ["DIII", "PROTEIN", 175, 179], ["the vulnerable spots", "PROBLEM", 95, 115], ["vulnerable", "OBSERVATION_MODIFIER", 99, 109], ["spots", "OBSERVATION", 110, 115], ["widely", "OBSERVATION_MODIFIER", 120, 126], ["spread", "OBSERVATION", 127, 133]]], ["This information would undoubtedly contribute to our understanding of the immune recognition mechanisms and assist in the rational design of vaccines against ZIKV infection.", [["ZIKV infection", "DISEASE", 158, 172], ["ZIKV", "ORGANISM", 158, 162], ["ZIKV", "SPECIES", 158, 162], ["vaccines", "TREATMENT", 141, 149], ["ZIKV infection", "PROBLEM", 158, 172]]], ["Similar to other reported DIII-specific mAbs, ZK2B10 was isolated late after the onset of symptoms (106 days), when the production of DIII-specific antibodies had become more prevalent The total numbers of slices analyzed for ZIKV \u00c0 , day 0, day 1, day 2, and MERS-4 were 10, 8, 6, 10, and 8 in (B) and (D), and 10, 8, 6, 8, and 8 in (C), respectively.", [["slices", "ANATOMY", 206, 212], ["DIII", "GENE_OR_GENE_PRODUCT", 26, 30], ["mAbs", "GENE_OR_GENE_PRODUCT", 40, 44], ["ZK2B10", "GENE_OR_GENE_PRODUCT", 46, 52], ["DIII", "GENE_OR_GENE_PRODUCT", 134, 138], ["DIII", "PROTEIN", 26, 30], ["mAbs", "PROTEIN", 40, 44], ["ZK2B10", "PROTEIN", 46, 52], ["DIII", "PROTEIN", 134, 138], ["specific antibodies", "PROTEIN", 139, 158], ["ZIKV", "PROTEIN", 226, 230], ["ZIKV", "SPECIES", 226, 230], ["ZK2B10", "TREATMENT", 46, 52], ["symptoms", "PROBLEM", 90, 98], ["the production of DIII-specific antibodies", "PROBLEM", 116, 158], ["The total numbers of slices", "TREATMENT", 185, 212], ["ZIKV", "PROBLEM", 226, 230], ["MERS", "TEST", 260, 264]]], ["The total number of neonates analyzed is indicated above each group.", [["neonates", "ORGANISM", 20, 28], ["neonates", "TREATMENT", 20, 28], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["All data are presented as mean \u00b1 SEM. p < 0.05; *p < 0.001.", [["All data", "TEST", 0, 8]]]]}